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Abstract 
 
The analysis of volatile organic compounds (VOCs) in breath may be a useful 
non-invasive tool in the Intensive Care Unit (ICU) to monitor metabolic and 
oxidative stress or diagnose pulmonary infection. Acetone is produced during 
starvation and metabolic stress, hydrogen sulphide (H2S) may be a marker of 
inflammation and infection and hydrogen cyanide (HCN) may also act as a 
marker of infection, particularly caused by Pseudomonas aeruginosa.  
Firstly, the effects on measured VOC concentrations of the breath collection 
equipment and storage were assessed. Sample humidity declined faster than 
any analyte. Sample losses of 21%, 25% and 24% for acetone, H2S and HCN, 
respectively, were seen as a result of being passed through the sampling 
apparatus. Over 90% of initial breath VOC concentrations were detectable after 
90 min storage in Tedlar bags at 40°C. 
Secondly, a breath collection method for off-line analysis was validated in 20 
mechanically ventilated patients in the ICU. The effect on VOC concentrations 
of breath sampling from two locations after two breathing manoeuvres was 
explored, revealing significantly higher analyte concentrations in samples from 
the airways than from a T-piece in the breathing circuit, and after tidal 
breathing compared to a recruitment-style breath. Practical difficulties were 
encountered using direct airway sampling and delivering recruitment style 
breaths; end-tidal breath sampling from the T-piece was simplest to perform 
and results equally reproducible. 
Breath samples from 26 healthy anaesthetised controls were used to validate a 
breath collection method in the operating theatre. The effects of altering 
anaesthesia machine settings on inspiratory and exhaled acetone concentrations 
were explored. A difference in median inspiratory, but not exhaled, acetone 
concentrations was observed between the anaesthesia machines (ADU 
Carestation 276 ppb, Aysis Carestation 131 ppb, p=0.0005). Closing the 
adjustable pressure limiting (APL) valve resulted in a reduction in exhaled 
acetone concentration, as did breath sampling distal to the circuit filter, due to 
dilution by dead space air. Median (range) breath concentrations for samples 
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collected on the patient side of the circuit filter with the APL valve open 
(n=22): acetone 738 ppb (257±6594 ppb), H2S 1.00 ppb (0.71-2.49 ppb), HCN 
0.82 ppb (0.60-1.51 ppb). Breath acetone concentration was related to plasma 
acetone (rs=0.80, p<0.0001) and beta-hydroxybutyrate concentrations (rs=0.55, 
p=0.0075). 
Finally, breath and blood samples were collected daily from 32 mechanically 
ventilated patients in the ICU with stress hyperglycaemia (n=11) and/or new 
pulmonary infiltrates on chest radiograph (n=28). Samples were collected over 
a median 3 days (1-8 days). Median (range) breath VOC concentrations of all 
samples collected: acetone 853 ppb (162±11,375 ppb), H2S 0.96 ppb (0.22-5.12 
ppb), HCN 0.76 ppb (0.31-11.5 ppb). Median initial breath acetone 
concentration was higher than in anaesthetised controls (1451 ppb versus 812 
ppb; p=0.038). There was a trend towards a reduction in breath acetone 
concentration over time. Relationships were seen between breath acetone and 
arterial acetone (rs=0.64, p<0.0001) and beta-hydroxybutyrate (rs=0.52, 
p<0.0001) concentrations. Several patients remained ketotic despite insulin 
therapy and normal, or near normal, arterial glucose concentrations. Inspired 
and exhaled H2S and HCN concentrations were not significantly different. 
Breath H2S and HCN concentrations could not be used to differentiate between 
patients with pneumonia and those with pulmonary infiltrates due to other 
conditions. 
In conclusion, losses due to the sampling apparatus were determined and linear 
over the range of concentrations tested. End-tidal breath sampling via the T-
piece was the simplest technique, with reproducibility comparable to other 
methods. It was possible to replicate the breath sampling method in the 
operating theatre; pre-filter samples with inspiratory gas flow rate 6 L/min and 
APL valve open provided repeatable results avoiding rebreathing. There was 
no role for the use of breath H2S or HCN in the diagnosis or monitoring of 
pneumonia in critical illness. There was no relationship between breath acetone 
concentration and illness severity, however the utility of breath acetone in the 
modulation of insulin and feeding in critical illness merits further study. 
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««««««« 
Figure 2-9. The relationship between the concentrations of (a) acetone, (b) H2S 
and (c) HCN before and after the gas sample was passed through the tubing, 
filter and pump (linear regression lines with 95% confidence intervals marked). 
Individual data points for analyte concentrations, first post-apparatus samples 
QRWLQFOXGHG««««««««««««««««««««««««« 
Figure 2-10. The relationship between the concentrations of (a) acetone, (b) 
H2S and (c) HCN before and after the gas sample was passed through the pump 
alone (linear regression lines with 95% confidence intervals marked). 
Individual data points for analyte concentrations, first post-pump samples not 
LQFOXGHG««««««««««««««««««««««««««« 
Figure 2-11. The relationship between the concentration of acetone (a) and 
H2S (b) in humid air and that detected by SIFT-MS after passing through a 
small biological filter (linear regression lines with 95% confidence intervals 
PDUNHG««««««««««««««««««««««««««« 
Figure 3-1. Photographs display the location of the T-piece in the ventilator 
circuit (red circle) for inspired gas sampling, with (a) and without a humidifier 
in situ (b)««««««««««««««««««««««««««...91 
Figure 3-2. Schematic of the experimental set-up using the T-piece««« 
Figure 3-3. Photograph of the location of the T-piece within the breathing 
circuit«««««««««««««««««««««««««««« 
Figure 3-4. Breath sampling equipment attached to the T-piece (a) and inserted 
into the suction catheter mount (b)««««««««««««««««« 
Figure 3-5. Suction catheter situated inside the mount, sealed with two 
7HJDGHUPILOPGUHVVLQJV««««««««««««««««««« 
Figure 3-6. Individual mean patient tidal volumes delivered by the ventilator 
and group medians when using each breath collection method««««« 
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Figure 3-7. Individual mean patient breath volumes delivered by the ventilator 
and group medians when using each breath collection method««««« 
Figure 3-8. Individual mean patient end-exhaled acetone concentrations and 
group medians using each of the four breath sampling methods««««« 
Figure 3-9. Bland-Altman plots comparing mean exhaled acetone 
concentrations (ppb) seen using each method (dashed line = bias, dotted lines = 
95% limits of agreement): (a) T-piece after tidal breath minus T-piece after 
recruitment-style breath (bias 1056, -2812±4924), (b) airway after tidal breath 
minus T-piece after tidal breath (bias 1058, -2792±4908), (c) airway after tidal 
breath minus airway after recruitment-style breath (bias 221, -3366±3807), (d) 
airway after recruitment-style breath minus T-piece after recruitment-style 
breath (bias 1754, -2667±6175)««««««««««««««««« 
Figure 3-10. Individual mean patient end-exhaled H2S concentrations and 
group medians using each of the four breath sampling methods««««« 
Figure 3-11. Bland-Altman plots comparing mean exhaled H2S concentrations 
(ppb) seen using each method (dashed line = bias, dotted lines = 95% limits of 
agreement): (a) T-piece after tidal breath minus T-piece after recruitment-style 
breath (bias 0.46, -0.56±1.48), (b) airway after tidal breath minus T-piece after 
tidal breath (bias 0.19, -0.33±0.71), (c) airway after tidal breath minus airway 
after recruitment-style breath (bias 0.30, -0.26±0.86), (d) airway after 
recruitment-style breath minus T-piece after recruitment-style breath (bias 
0.38, -0.61±1.37)««««««««««««««««««««««« 
Figure 3-12. Individual mean patient end-exhaled HCN concentrations and 
group medians using each of the four breath sampling methods««««« 
Figure 3-13. Bland-Altman plots comparing mean exhaled HCN 
concentrations (ppb) seen using each method (dashed line = bias, dotted lines = 
95% limits of agreement): (a) T-piece after tidal breath minus T-piece after 
recruitment-style breath (bias 0.77, -0.96±2.49), (b) airway after tidal breath 
minus T-piece after tidal breath (bias 0.35, -2.20±2.90), (c) airway after tidal 
breath minus airway after recruitment-style breath (bias 0.27, -2.17±2.70), (d) 
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airway after recruitment-style breath minus T-piece after recruitment-style 
breath (bias 1.02, -1.71±3.76)«««««««««««««««««« 
Figure 3-14. Breath sampling equipment attached to a closed suction catheter 
unit«««««««««««««««««««««««««««« 
Figure 3-15. Individual data points show mean breath H2S (a) and HCN (b) 
concentrations at matched acetone concentrations using all four sampling 
methods«««««««««««««««««««««««««« 
Figure 3-16. Reduction and subsequent increase in precursor ion counts 
following salbutamol administration via the breathing circuit«««««« 
Figure 3-17. Mass spectrum of the empty glass sampling container analysed 
using the H3O+ precursor ion. The main peak at m/z 19 is the H3O+ precursor 
ion. The other two large peaks are the hydrated forms of the H3O+ precursor 
ion««««««««««««««««««««««««««««« 
Figure 3-18. Mass spectrum of salbutamol sprayed into a glass sampling 
container analysed using the H3O+ precursor ion. Main peak at m/z 93 is the 
product of the reaction between ethanol and H3O+«««««««««« 
Figure 4-1. Schematic of the experimental setup for pre-filter breath sampling. 
Arrows show direction of gas flow«««««««««««««««« 
Figure 4-2. Photographs show a T-piece (circled) within the inspiratory limb 
of the breathing circuit; (a) Aisys Carestation and (b) ADU Carestation 
anaesthesia machines««««««««««««««««««««« 
Figure 4-3. Photograph showing the T-piece and adaptor (circled) adjacent to 
the endotracheal tube (right) and circuit filter (left)«««««««««« 
Figure 4-4. Photographs display the location of the adjustable pressure limiting 
(APL) valve (red circle) in the Aysis Carestation (a) and ADU Carestation (b) 
anaesthesia machines««««««««««««««««««««« 
Figure 4-5. Photograph of the filter in-line between the dilution apparatus 
containing a permeation tube of acetone and the SIFT-MS instrument. The 
direction of gas flow is marked by an arrow«««««««««««« 
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Figure 4-6. Individual data points and column medians show the concentration 
of acetone in the inspired gas of the two main anaesthesia machines««« 
Figure 4-7. Acetone concentration of inspiratory gas at each flow rate«« 
Figure 4-8. Individual data points show the relationship between mean 
calculated exhaled breath acetone and plasma acetone concentrations«« 
Figure 4-9. Individual data points show the relationship between mean 
calculated exhaled breath acetone and plasma beta-hydroxybutyrate 
concentrations«««««««««««««««««««««««« 
Figure 5-1. Variation in breath acetone concentration for each patient over 
time (lines join each sampling event for an individual patient)««««« 
Figure 5-2. Individual data points of the relationship between breath and 
arterial acetone concentrations in the first two sets of samples collected from 
each patient««««««««««««««««««««««««« 
Figure 5-3. Modified Bland-Altman plot displaying the relationship between 
breath and arterial acetone concentrations as percentages of their maximal 
value. Average = average value of the normalised breath and arterial acetone 
concentrations; delta = difference between the normalised breath acetone 
concentration and the normalised arterial acetone concentration. Bias was -3.58 
(dashed line) with 95% limits of agreement of -24.9 and 17.8 (dotted 
lines)«««««««««««««««««««««««««««« 
Figure 5-4. Individual data points of the relationship between breath acetone 
and arterial glucose concentrations at enrolment (a) and the next sample 
collection (b). The red circle indicates patients with high breath acetone 
concentration with normal, or near normal, arterial glucose concentration« 
Figure 5-5. Individual data points show the change in mean breath acetone 
concentration after insulin administration in patients with hyperglycaemia, in 
whom pre-insulin and post-insulin samples were obtained (n=10)«««« 
Figure 5-6. Graphical comparison of (a) hourly (red) versus daily (blue) 
plasma glucose concentration, (b) breath acetone (blue) and plasma ketone 
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concentrations (acetone green, beta-hydroxybutyrate red), (c) modelled insulin 
sensitivity and (d) enteral dextrose (blue) and insulin (purple) administration 
over time in a patient with stress hyperglycaemia«««««««««« 
Figure 5-7. Box and whiskers plots compare mean breath acetone 
FRQFHQWUDWLRQV RI SDWLHQWV¶ ILUVW ,&8 VDPSOHV KHDOWK\ DQDHVWKHWLVHG SDWLHQWV
and patients returning to the ICU following surgery. Whiskers show the range 
of values, medians are indicated on boxes««««««««««««« 
Figure 5-8. Individual data points show mean breath acetone and arterial 
acetone concentrations collected daily on the ICU for a single patient. Surgery 
was performed on day 5, 4 hours prior to sample collection«««««« 
Figure 6-1. Individual data points of the relationship between inspired and 
mean exhaled H2S concentrations (all samples)««««««««««« 
Figure 6-2. Variation in breath acetone concentration for each patient over 
time (lines join each sampling event for an individual patient)««««« 
Figure 6-3. Modified Bland-Altman plot displaying the relationship between 
breath and arterial H2S concentrations as percentages of their maximal value. 
Average = average value of the normalised breath and arterial H2S 
concentrations; delta = difference between the normalised breath H2S 
concentration and the normalised arterial H2S concentration. Bias was 5.51 
(dashed line) with 95% limits of agreement of -39.4 and 50.4 (dotted 
OLQHV«««««««««««««««««««««««««««« 
Figure 6-4. Graph showing the relationship between arterial and central 
venous H2S concentrations. Individual data points are plotted. Solid line 
represents the linear regression line (equation shown), dotted lines show 95% 
confidence interval. R2 «««««««««««««««««« 
Figure 6-5. Individual data points of the relationship between inspired and 
PHDQH[KDOHG+&1FRQFHQWUDWLRQVDOOVDPSOHV«««««««««««180 
Figure 6-6. Variation in breath HCN concentration for each patient over time 
OLQHVMRLQHDFKVDPSOLQJHYHQWIRUDQLQGLYLGXDOSDWLHQW««««««« 
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Figure 6-7. Modified Bland-Altman plot displaying the relationship between 
breath and arterial HCN concentrations as percentages of their maximal value. 
Average = average value of the normalised breath and arterial HCN 
concentrations; delta = difference between the normalised breath HCN 
concentration and the normalised arterial HCN concentration. Bias was 22.45 
(dashed line) with 95% limits of agreement of -25.7 and 70.6 (dotted 
OLQHV«««««««««««««««««.........................................182 
Figure 6-8. Graph showing the relationship between arterial and central 
venous HCN concentrations. Individual data points are plotted. Solid line 
represents the linear regression line (equation shown), dotted lines show 95% 
confidence interval. R2 ««««««««««««««««««3 
Figure 6-9. Individual data points and medians to compare initial breath (a) 
and arterial (b) HCN concentrations between smokers and non-smokers ((a) 
Q EQ «««««««««««««««««««««««« 
Figure 6-10. Box and whiskers plots comparing exhaled volatile 
concentrations of initial breath samples from ICU patients, healthy 
anaesthetised patients (pre-op) and patients returning to the ICU following 
surgery (post-op); (a) exhaled H2S concentration and (b) exhaled HCN 
concentration. Whiskers show the range of values and boxes display the 
PHGLDQDQGLQWHUTXDUWLOHUDQJH«««««««««««««««««« 
Figure 6-11. Individual data points show mean breath and arterial (a) H2S and 
(b) HCN concentrations collected daily on the ICU for a single patient. Surgery 
ZDVSHUIRUPHGRQGD\KRXUVSULRUWRVDPSOHFROOHFWLRQ«««««« 
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1. Introduction 
Exhaled breath contains many trace compounds, some of which have been 
associated with illness states1-3. If those produced by metabolic processes or 
pathological organisms can be identified and investigated, using techniques 
such as mass spectrometry, the analysis of volatile organic compounds (VOCs) 
LQEUHDWKPD\SURYLGHXVHIXO LQIRUPDWLRQDERXWDSDWLHQW¶V FOLnical state. The 
non-invasive nature of breath analysis and its potential for providing rapid 
results in real time4 make it an attractive tool, however there are numerous 
confounding variables that must be controlled or taken into account when 
designing studies and interpreting results. 
Few investigations of breath analysis have been conducted in intubated patients 
in the Intensive Care Unit (ICU)5-9, possibly due technical difficulties 
surrounding sample collection. Making a diagnosis of pneumonia in intubated 
patients can be difficult, not least because there is no single diagnostic test 
available and many clinical features are not specific to pneumonia. If a breath 
test were developed that could differentiate between pulmonary infection and 
other causes of inflammation, it might improve diagnostic accuracy and, 
therefore, the timely administration of the correct targeted treatment. Two 
potential breath markers of pulmonary infection and inflammation are 
investigated in the experimental chapters of this thesis. 
Mechanically ventilated patients undergo continuous monitoring of their heart 
rate, blood pressure and oxygen saturation, but there are currently no 
techniques for monitoring metabolic status. This may be particularly important 
in patients with stress hyperglycaemia who have deranged glucose handling. 
Acetone is investigated as a marker of metabolic stress and monitored in 
patients with stress hyperglycaemia receiving treatment with insulin. 
1.1. Thesis outline 
In the introductory chapter, the features of critical illness, including associated 
hyperglycaemia, and the difficulty in diagnosing respiratory infection in 
intubated and ventilated patients are discussed. The potential applications of 
breath analysis for the detection of inflammation, infection and metabolic 
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disturbance are outlined, along with potential confounding variables, such as 
breathing pattern. Methodological issues concerning breath sampling, 
particularly in intubated and ventilated patients with critical illness, are 
considered. Selected ion flow tube mass spectrometry (SIFT-MS) is explained 
in detail, along with its utility in the analysis of VOCs in breath. Potential 
biomarkers of metabolic disease (acetone), inflammation and infection 
(hydrogen sulphide (H2S) and hydrogen cyanide (HCN)) are highlighted and 
described. Finally, the hypothesis and aims of the thesis are outlined. 
The first experimental part of this thesis involves the optimisation of the breath 
collection technique in intubated and mechanically ventilated patients in the 
ICU, with validation against previous study methods. Technical and patient 
factors which might affect breath measurement are discussed. 
Secondly, normal levels of exhaled acetone, H2S and HCN in intubated and 
mechanically ventilated patients undergoing elective surgical procedures in the 
operating theatre are studied. The effects of changing several of the anaesthesia 
machine settings during breath sampling were assessed to minimise any 
differences when compared to ICU ventilators. 
Finally, potential breath biomarkers of metabolic dysfunction, oxidative stress, 
inflammation and infection are investigated in patients in the ICU. Patients 
requiring insulin treatment for stress hyperglycaemia and those with new 
pulmonary infiltrates on chest radiograph (CXR) were studied over the course 
of their illness, with repeated breath analysis and blood, urine and sputum 
sampling. Any relationships between VOC concentrations in breath and blood 
are investigated. VOC concentrations are also compared to conventional 
markers of disease severity. Comparisons are made between measured breath 
analyte concentrations in the critical illness and control groups and the results 
discussed. 
The thesis concludes with a discussion of the studies performed, including their 
limitations, as well as the potential for further research in this area. 
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1.2. Critical Illness 
 Sepsis and multi-organ failure 1.2.1.
Septic shock is a major cause of death in patients in the ICU10,11, either as a 
result of early haemodynamic compromise or subsequently due to the 
development of multi-organ failure10,12,13. Despite many improvements in ICU 
care, including advances in diagnostic and therapeutic technologies and 
pharmacological therapies, the mortality rate from sepsis has remained above 
20% for patients requiring several dD\V¶DGPLVVLRQ10,12,14-16.  
Systemic Inflammatory Response Syndrome (SIRS) is the term used to 
describe the clinical features of multi-organ dysfunction associated with 
infection or other inflammatory processes, such as pancreatitis, burns, multi-
trauma or haemorrhagic shock. If two or more of the following criteria are 
satisfied, a diagnosis of SIRS can be made: (1) temperature >38°C or <36°C, 
(2) heart rate >90 beats per min, (3) respiratory rate >20 per min or PaCO2 <32 
mmHg, (4) white cell count (WCC) >12 x 109/L or <4 x 109/L or >10% 
immature neutrophils14. Sepsis is the term used to describe SIRS triggered by 
infection, severe sepsis is defined by sepsis associated with hypotension, 
hypoperfusion and end-organ dysfunction (for example lactic acidosis, oliguria 
and altered mental state), and septic shock is severe sepsis where hypotension 
persists despite adequate fluid resuscitation14.  
Around 27% of patients admitted to ICU departments across England, Wales 
and Northern Ireland between 1995 and 2000, met criteria for severe sepsis in 
the first 24 hours, an estimated 51 per 100,000 population per year. Patients 
remained in the ICU for, on average, 3.56 days and in the hospital for 18 days, 
representing a significant burden on health care resources16. In a European 
study of 3,147 ICU patients, sepsis, predominantly due to pulmonary infection, 
was associated with more severe organ dysfunction and increased length of 
ICU and hospital stay compared to alternative conditions10. In the United 
States, a study of the cost of ICU care in 2002 illustrated that not only was it 
more expensive to support a mechanically ventilated patient on a daily basis 
than a patient who did not require ventilation ($31,574 ± $42,570 versus 
$12,931 ± $20,569, respectively), but that mechanically ventilated patients 
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tended to require longer ICU admissions, further escalating the cost17. This led 
the authors to conclude that interventions to reduce the duration of mechanical 
ventilation and/or ICU length of stay could significantly reduce health care 
spending. 
Pathophysiology 
Microbial endotoxins are responsible for the initiation of a number of complex 
pro- and anti-inflammatory pathways that usually result in elimination of the 
pathogen. Imbalance between these pathways, however, can lead to excess 
systemic inflammation and host organ damage15. The exact mechanism by 
which sepsis-related multi-organ failure develops is unknown, however the 
combination of poor blood supply at the macro- and microvascular level 
causing hypoperfusion and impaired mitochondrial activity leading to inability 
to utilise oxygen have been implicated13,18. Distant organs may be affected by 
leakage of inflammatory mediators into the systemic circulation18. It is not 
clear why certain infective organisms cause damage to some organs and not 
others, and why the same infection in different individuals has different 
consequences18. 
Activation of macrophages, neutrophils, endo- and epithelial cells and the 
transcription factor nuclear factor-ț% 1)-ț% KHOS WR UHJXODWH the immune 
response to infection18. Cytokines, chemokines, platelet activating factor, 
interferon-Ȗ OHXNRWULHQHV DQG SURWHDVHV DUH UHOHDVHG VRPH RI ZKLFK FDXVH
further activation of NF-ț%15. Immune cell stimulation is important in order to 
clear the offending pathogen; macrophage activation caused by microbes, pro-
inflammatory mediators, and also hypoxia and acidaemia, intensifies the pro-
inflammatory cascade. Sepsis can cause delayed neutrophil apoptosis, resulting 
in increased inflammation and further tissue injury18. 
Reactive oxygen species (ROS) are released by activated neutrophils and are 
produced by oxidative phosphorylation in mitochondria. Under normal 
conditions, ROS produced in mitochondria act as signalling molecules and are 
scavenged by antioxidants such as vitamins C and E and glutathione. When 
overproduced during episodes of tissue hypoxia or in the presence of pro-
inflammatory cytokines, for example tumour necrosis factor-Į 71)-Į WKH
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anti-inflammatory pathway is overwhelmed and ROS cause systemic 
inflammation and organ damage13,15,18. The superoxide anion can react with 
increased levels of pro-inflammatory nitric oxide (NO), leading to the 
formation of peroxynitrite12,13. Like ROS, peroxynitrite causes damage to cells 
by reacting with components of the mitochondrial electron transport chain, 
reducing oxygen extraction and utilisation by tissues, and also induces DNA 
damage, both of which lead to cell death12,13. Reduced antioxidant levels have 
been seen in sepsis and Acute Respiratory Distress Syndrome (ARDS), but 
interestingly the administration of antioxidants as a treatment does not appear 
to have consistent effects in sepsis15. 
The vascular epithelium is involved in a number of processes occurring in 
association with sepsis, including leukocyte trafficking, the expression of 
adhesion molecules and involvement in clotting pathways18. Activation of the 
epithelium results in elevated levels of NO release due to its production from 
L-arginine, catalysed by nitric oxide synthase (NOS). Endothelial NOS (eNOS) 
produces small amounts of NO with anti-adhesive and protective properties, 
whereas inducible NOS (iNOS) causes the synthesis of large quantities of NO 
in sepsis, producing pro-inflammatory effects19. The resulting smooth muscle 
relaxation causes vasodilatation and hypotension, but the administration of NO 
blocking drugs causes significant adverse side effects18. This highlights the 
complexity of the inflammatory pathways; vasodilatation is also mediated by 
activation of potassium channels and changes in hormone levels, for example 
cortisol and vasopressin18.  
The lungs appear to be affected early in the course of severe sepsis20. ROS 
exhibit direct and indirect effects on the lung, with injury to the epithelium 
leading to leakage of fluid into the airways. Shear stresses generated by 
recruitment and derecruitment of alveoli during mechanical ventilation can 
augment pulmonary damage18. 
Features of illness severity and severity scoring systems in critical illness 
The severity of lung injury associated with hypoxaemia in ARDS is classified 
according to the ratio of the partial pressure of arterial oxygen divided by the 
fraction of inspired oxygen (PaO2/FiO2); mild 200 mmHg (26.7 kPa) < 
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PaO2/FiO2   PP+J  N3D PRGHUDWH  PP+J  N3D 
PaO2/FiO2 mmHg, severe PaO2/FiO2 PP+J7KHV\QGURPHDOVR
requires the following criteria to be fulfilled: (1) onset within one week of 
clinical insult or new or worsening respiratory symptoms, (2) bilateral 
infiltrates on CXR not fully explained by effusions, lung collapse or nodules, 
(3) respiratory failure not fully explained by pulmonary oedema or fluid 
overload, (4) use of positive end-expiratory pressure (PEEP) or continuous 
positive airway pressure (CPAP) >5 cmH2O21.  
Interestingly, the severity of pulmonary dysfunction related to sepsis does not 
appear to be associated with 30 day mortality, which is more closely linked to 
neurological and renal dysfunction as well as the degree of coagulopathy20. 
Increasing age10,11 and infection with Pseudomonas species are also risk factors 
for poorer outcomes10. Several, more specific independent variables appear to 
be associated with the progression from sepsis to severe sepsis and septic 
shock22; temperature >38°C, heart rate >120 beats per min, systolic blood 
pressure (BP) <100 mmHg, platelet count <150 x109/L, serum sodium >145 
PPRO/ELOLUXELQ!ȝPRO/PHFKDQLFDOYHQWLODWLRQDQGILYHRWKHU IHDWXUHV
characterising the infection (pneumonia, peritonitis, primary bacteraemia, 
infection with Gram positive cocci or aerobic Gram negative bacilli). Most of 
these form part of the critical illness severity scoring systems described below. 
Several validated scoring systems are used in the ICU to predict mortality 
based on a variety of clinical parameters and blood results in the first 24 hours 
of an admission. The most commonly used is the Acute Physiology and 
Chronic Health Evaluation (APACHE) II score23, which is slightly simpler to 
use than the APACHE III score24. Both of these scoring systems, along with 
four others (the Simplified Acute Physiology Score (SAPS) versions I and II, 
and the Mortality Probability Model (MPM) I and II)) were compared using a 
multicentre, multinational patient database, concluding that reliable results 
could be achieved by using any of the systems and that none was superior25. 
Another commonly used scoring system in the ICU is the Sequential Organ 
Failure Assessment (SOFA) score26, which can be calculated repeatedly 
WKURXJKRXWDSDWLHQW¶V,&8DGPLVVLRQWRJLYHDQLQGLFDWLRQRIH[WHQWRIRrgan 
failure, prognosis and mortality27. 
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Treatment of severe sepsis and septic shock 
Due to the high morbidity and mortality associated with severe sepsis and 
septic shock, and the evidence that early appropriate treatment can influence 
outcomes, guidelines for the management of these conditions were formulated 
in 200428 and updated in 200829. Key recommendations include early goal 
directed resuscitation in the first six hours, investigation of the causative 
organism prior to antibiotic therapy, but to administer the first dose of broad 
spectrum antibiotics within an hour of diagnosing the condition, and 
subsequent evaluation of microbiological results to narrow the antibiotic 
spectrum. Advice is given regarding the choice of fluid for resuscitation, the 
use of inotropic and vasopressor drugs, oxygen and steroid administration, 
ventilation in ARDS, treatment of severe renal impairment, patient positioning, 
correction of anaemia, coagulopathy and hyperglycaemia, protocols for 
sedation and weaning from the ventilator, and deep vein thrombosis (DVT) and 
stress ulcer prophylaxis. 
 Pneumonia in intubated and ventilated patients 1.2.2.
Ventilator-associated pneumonia 
Ventilator-associated pneumonia (VAP) affects 8-20% of ICU patients30-32 and 
up to 27% of mechanically ventilated patients32, and is associated with a high 
mortality rate of 20-50%30,32. This is increased further if VAP is caused by a 
multi-drug resistant pathogen32. 
Standardised criteria for the diagnosis of VAP are lacking33; most clinicians 
base their diagnosis on the presence of fever, elevated or low WCC, purulent 
secretions and new or persistent pulmonary infiltrates on CXR34, none of which 
are specific for VAP. Bacteriological data does not improve the accuracy of 
diagnosis32 and patients in whom there is a strong clinical suspicion of VAP 
have a high mortality rate irrespective of positive microbiological evidence of 
disease35. The difficulty surrounding diagnosis means that only half of patients 
with suspected VAP actually have it31,36 and in up to a third of patients who 
have VAP the diagnosis is missed. Alternative diagnoses revealed at autopsy 
include atelectasis, thromboembolic disease, pulmonary haemorrhage, 
pulmonary fibrosis, carcinoma and lymphoma32.  
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VAP is probably caused by microaspiration of secretions from above the 
endotracheal tube cuff32,33,36, which is why the incidence rises as the duration 
of mechanical ventilation increases33 and the common causative pathogens are 
different from those seen in community acquired pneumonia (CAP)37,38. It 
frequently complicates ARDS30,33,36 and lengthens the duration of ventilation 
and ICU stay30,33, increasing the cost of hospitalisation31. 
Rationale for accurate diagnosis of pulmonary infection 
The diagnosis of pneumonia is important so that empirical antibiotic treatment 
can be initiated early; delayed antibiotic treatment of community-acquired 
pneumonia (CAP)39,40 or VAP31,35, or using overly narrow spectrum antibiotics 
in severe infection41, are associated with increased mortality. Antibiotics are, 
therefore, often prescribed when infection is suspected, rather than proven, in 
RUGHU QRW WR IDLO WR WUHDW DQ LQIHFWLYH FDXVH RI D SDWLHQW¶V V\PSWRPV32,42. 
Conversely, if a patient is suspected of having infection but the diagnosis is 
non-infective, delays in identifying the true cause will prevent the delivery of 
appropriate treatment, which could lead to increased morbidity and mortality.  
There is no difference in outcome between empirically treated and pathogen 
directed treatment of CAP43, however broad spectrum antibiotic use in non-
severe CAP can increase the incidence of side effects41,43 and the likelihood of 
development of antibiotic resistance41. Respiratory infections account for over 
50% of antibiotic prescriptions, thus early increased certainty of the presence 
of infection, including identification of the organism responsible, could reduce 
the number of inappropriate antibiotic courses, enable narrowing of the 
antibiotic spectrum, allow appropriately shorter courses of antibiotics, improve 
compliance, and reduce costs, side-effects and antibiotic resistance40. 
Unfortunately, due to the difficulties obtaining a microbiological diagnosis, 
around 70% of patients with CAP never have a pathogen identified40,43-45.  
Problems with diagnosis 
The diagnosis of pneumonia in ventilated patients is challenging, not least 
because the patient cannot articulate symptoms, and physical examination is 
GLIILFXOWGXH WR WKHSDWLHQW¶VSRVLWLRQDQG WKHSUHVHQFHRIQXPHURXV OLQHVDQG
tubes for monitoring and delivering therapy. Many clinical features and 
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commonly used investigations are not helpful as they provide results that are 
not specific for the diagnosis of VAP33,36 or infectious, as opposed to non-
infectious, SIRS in critically ill patients46.  
Fever and elevated white blood cell count and C-reactive protein (CRP) are 
sensitive but not specific markers of sepsis and can be affected by other 
inflammatory conditions42. The sensitivity of these markers is lower for the 
diagnosis of VAP compared to other infections34. Temperature testing is easy, 
cheap, non-invasive and readily repeatable. The specificity for the diagnosis of 
infection increases when temperatures rise above 38°C42, however up to 40% 
of patients with CAP do not present with fever40. White cell count is a poor 
marker of sepsis42, does not correlate with response to therapy and can be 
affected by drugs commonly used in critical illness, for example 
corticosteroids, adrenaline and noradrenaline47. CRP, on the other hand, 
appears to increase with increasing severity of infection, including in VAP, and 
is higher in patients with SIRS due to infection than non-infective causes42. A 
CRP greater than 87 mg/L has been seen to exhibit a sensitivity of 93.4% and 
specificity of 86.1% for infection in critically ill patients, the specificity 
increasing when combined with a temperature over 38.2°C42.  
Yield for all culture-based tests is lower after antibiotic therapy48-50, and this 
can be more of a problem in patients with suspected VAP as they have 
commonly received prior antibiotics32. With increasing antibiotic resistance in 
organisms such as Streptococcus pneumoniae and Haemophilus influenzae45 it 
may become more important to culture the pathogenic organism to aid 
antibiotic choice. It should be noted, however, that in vitro antibiotic 
susceptibility testing requires more time than culture testing alone45 and does 
not always correlate with clinical efficacy in vivo51.  
Any test that could improve on current methods to diagnose infection or 
identify the organism responsible would be of great value in the ICU setting. 
Currently used diagnostic tools are outlined below. 
CXR  A study of radiological abnormalities and autopsy findings in ventilated 
patients who died in the ICU highlighted the difficulty of obtaining good 
quality imaging, particularly due to difficulties positioning ventilated patients, 
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and in interpretation of portable anteroposterior CXRs52, including the presence 
of tubes and lines causing the image to be less clear. The most useful 
radiological feature for the diagnosis of pneumonia was the air bronchogram, 
but this only predicted pneumonia in 64% of cases. There was a high 
probability that other conditions mimicked pneumonia, for example atelectasis, 
atypical pulmonary oedema, lung contusion and ARDS52. 
Blood culture  Blood stream infections carry a high mortality rate in patients 
with critical illness, which increases if inappropriate antibiotics are 
administered53. The positive yield of blood cultures in CAP, hospital-acquired 
pneumonia (HAP) and VAP is low47,51, with a higher chance of bacteraemia if 
bronchoalveolar lavage (BAL) is also positive54. Unfortunately, positive results 
do not always confirm the organism responsible for VAP, instead being 
associated with infection at another site47,54. In a prospective observational 
study of patients with CAP, bacteraemia was observed in only 5.7% of cases, 
however in over 60% of these cases the findings did not result in a narrowing 
of the antibiotic spectrum51. 
Other limitations of blood cultures are that results are not available 
immediately, some bacteria are difficult to culture from blood (including 
Chlamydophila, Mycoplasma and Legionella species), and it is not possible to 
culture viruses51.  
Sputum, tracheal aspirates and bronchoalveolar lavage  Purulent secretions 
alone cannot be used to aid the diagnosis of pulmonary infection in the ICU as 
they are almost always present in the context of prolonged mechanical 
ventilation36 and underlying lung diseases such as chronic obstructive 
pulmonary disease (COPD).  
Sputum culture takes at least 48 hours, however sputum Gram stain is 
inexpensive, can be performed rapidly and does not require sophisticated 
equipment55. The sensitivity of a sputum Gram stain for the diagnosis of 
pneumonia is modest but specificity is high44,49,55; the better the specimen the 
higher the sensitivity and specificity41. It is therefore a useful test for the 
diagnosis of pneumonia if a good sample is obtained49, which unfortunately 
can be significantly problematic43,44,49,55. Sputum culture from patients with 
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pneumonia is more likely to be positive in those with bacteraemia48 and will 
not be of use in pneumonia related to Chlamydophila pneumoniae, 
Mycoplasma pneumoniae and Legionella species, as they cannot be cultured 
from sputum55 and another diagnostic test must be performed.  
Intubated patients cannot provide spontaneous sputum samples, so tracheal 
aspirates or bronchoscopy with BAL must be performed. A study of patients 
with suspected VAP compared a group with quantitative BAL culture and a 
group with non-quantitative tracheal aspirate culture, revealing no difference in 
number of patients receiving targeted antibiotics, days alive off antibiotics, 
maximal organ dysfunction scores and length of ICU or hospital stay56. 
Positive BAL culture occurs in about 50% of clinically diagnosed VAP cases, 
however there does not appear to be a difference in mortality between those 
with positive BAL culture and those who are culture negative, or a benefit in 
mortality if antibiotics are changed based on the BAL result35. Considering that 
bronchoscopy is invasive, not a therapeutic technique in this setting, does not 
seem to give superior results to tracheal aspirate samples56 and positive BAL 
culture findings do not necessarily alter outcomes35, it is not used routinely and 
should probably only be considered if there is a failure of therapy or a 
causative pathogen has not been identified using other less invasive tests41.  
It is important to remember that there is still a chance of contamination of BAL 
samples with upper airways organisms41,57 and due to the heterogeneity of 
VAP, false positive and false negative results can be obtained if sampling from 
the non-affected area32. 
The interpretation of sputum, tracheal aspirate and BAL results can be difficult 
because hospitalised patients become colonised with bacteria within about 
three days of admission, more quickly if they are ventilated, therefore positive 
cultures may reflect the presence of colonising rather than infective organisms. 
The identification of a causative organism from tracheal aspirates of patients 
with VAP can be problematic as samples can grow two or more potential 
pathogenic bacteria47.  
Finally, the method of processing respiratory samples may affect the 
microbiological result; if there is a delay in sample preparation, causative 
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fastidious bacteria, for example S. pneumoniae, may fail to grow, while 
colonising bacteria, such as Enterobacteriacea47, or oral contaminants may 
proliferate57. Less fastidious microorganisms grow more readily on selective 
media, so contaminants such as Staphlococcus aureus and Gram negative 
bacteria, may be overrepresented57. 
Urinary antigen tests  8ULQDU\DQWLJHQWHVWLQJIRU/HJLRQQDLUH¶VGLVHDVHDQGS. 
pneumoniae is simple and rapid, but despite good specificity for the diagnosis 
of pneumonia relating to these organisms, the sensitivity of the tests is only 
modest41,50,58. False positives associated with the pneumococcal antigen test 
due to recent infection can be both a problem and a benefit of the test, as it will 
remain positive even if antibiotics have been administered41. The Legionella 
urinary antigen test appears to be highly specific for Legionella pneumophila 
subgroup 1 but not the other subgroups41,58 or subspecies. Legionella 
longbeachae is an important cause of pneumonia in New Zealand59, caused by 
its presence in potting compost60, and a polymerase chain reaction (PCR) test is 
required for diagnosis61. Obviously, urinary antigen tests cannot be performed 
if the patient is anuric, which makes the test less useful in the ICU where some 
patients with severe pneumonia also have severe renal dysfunction. 
PCR methods  PCR tests have been standardised for the testing of Legionella 
species and Mycobacterial species. They can be used to provide a probable 
diagnosis of M. pneumoniae and C. pneumoniae41 and there is likely to be an 
increase in the number of organisms that can be detected accurately in this way 
over time57. Advantages of PCR tests are that they provide rapid results41,57, 
remain positive after antibiotic therapy has been commenced41, and can be used 
to detect slow growing or difficult to culture bacteria62. Conversely, they are 
more expensive than conventional Gram stain and culture, occasionally lack 
sensitivity data and are not quantitative, so it may not be possible to determine 
whether a microorganism is colonising the patient or causing infection57. 
 Hyperglycaemia and its effects in critical illness 1.2.3.
Patients with critical illness commonly develop ³VWUHVV K\SHUJO\FDHPLD´
particularly in association with sepsis63,64. Hyperglycaemia, in the absence of 
previous evidence of diabetes mellitus, occurs with hyperinsulinaemia as a 
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consequence of peripheral and hepatic insulin resistance and subsequent 
increased gluconeogenesis and glycogenolysis63,65. Insulin resistance impairs 
glycogen synthesis and storage63,66, resulting in a failure to remove glucose 
from the circulation. Elevated insulin levels should suppress glucose 
production, however in critical illness the secretion of counter-regulatory 
hormones (for example cortisol, growth hormone and glucagon), 
catecholamines and pro-inflammatory cytokines promotes further hepatic 
insulin resistance and increased gluconeogenesis63,66; particularly implicated 
DUH71)Į LQWHUOHXNLQ ,/-1 and IL-663. Catecholamine infusions (adrenaline 
and noradrenaline) can cause further imbalance of glucose homeostasis through 
mechanisms that include the stimulation of gluconeogenesis63. Stress 
hyperglycaemia is associated with increased hospital mortality67 and the degree 
of hyperglycaemia appears to correlate with the severity of critical 
illness12,63,68.  
Excess glucose can be toxic to cells. Increased oxidative phosphorylation 
within mitochondria results in the generation of more ROS than can be 
scavenged by antioxidants, which are already reduced due to critical illness 
itself12. The production of peroxynitrite causes further cellular damage, as 
discussed previously (Chapter 1.2.1.)12,13. Endothelial dysfunction as a 
consequence of hyperglycaemia may exacerbate multi-organ failure, and may 
be why improved outcomes have been seen with insulin treatment66. Other 
potential complications of hyperglycaemia include lipid profile derangement12 
and the development of a catabolic state, platelet activation, acid/base 
disturbances and electrolyte and fluid shifts66. Neuronal cell uptake of glucose 
is independent of insulin; consequently critical illness polyneuropathy seems to 
correlate with glucose level12. Reduced neutrophil activity12, including 
impaired respiratory burst, may explain the increased risk of infection 
associated with hyperglycaemia63,66. 
 The effect of insulin treatment in critical illness 1.2.4.
Initial trials of aggressive insulin therapy to maintain normoglycaemia in the 
ICU setting revealed improvements in mortality, particularly in those with 
sepsis65,69. This was in agreement with earlier studies showing a reduction in 
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mortality in hyperglycaemic patients receiving insulin following myocardial 
infarction (MI)70-72. Administration of insulin to maintain normoglycaemia was 
associated with improved insulin sensitivity68. One detrimental effect of insulin 
administration was the development of hypoglycaemia, which was more 
common in patients with sepsis and conveyed an independent increase in 
mortality rate64,69. 
The inaugural study of insulin therapy in critical illness involved just over 
1,500 patients in a surgical ICU by Van den Berghe et al.65. Participants were 
randomised to receive intensive insulin therapy (IIT) aiming for blood glucose 
of 4.4-6.1 mmol/L or conventional treatment with insulin only if blood glucose 
rose to over 11.8 mmol/L, aiming for 9.9-11.0 mmol/L. Overall mortality was 
lower in the IIT group (4.6% versus 8.0%), with more marked improvements in 
mortality for ICU stays over four days. Reductions were seen in the incidence 
of bacteraemia, critical illness polyneuropathy, acute kidney injury (AKI) 
requiring renal replacement therapy (RRT) and liver dysfunction. Length of 
ICU stay was reduced, possibly as a result of a reduction in duration of 
mechanical ventilation.  
Further analysis of this study65 suggested an anti-inflammatory effect of IIT, 
indicated by an increased rate of reduction of CRP and attenuated increase in 
manose-binding lectin levels73. Significantly lower serum NO levels were seen 
in survivors than non-survivors, with elevated NO correlating with the risk of 
developing AKI. Suppression of iNOS in liver biopsy samples of those in the 
IIT group was believed to be partially due to a reduction in NF-ț%DFWLYLW\19. 
Structural and functional mitochondrial abnormalities seen in liver biopsies 
appeared to be prevented or reversed by IIT74.  
The follow-up study in a medical ICU69 involving 1,200 patients failed to 
report a significant reduction in mortality with IIT overall, in fact the mortality 
rate for those patients admitted to ICU for less than three days was elevated in 
the IIT arm. In contrast, for stays in ICU of three days or more mortality 
decreased from 52.5% to 43.0%. Similar morbidity benefits to those seen in the 
surgical ICU trial were described, with the exception of a reduction in 
bacteraemia rate. This discrepancy was argued to be as a result of medical 
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patients being admitted to the ICU due to sepsis, irrespective of their diagnosis 
at hospital admission. 
The difficulty of achieving normoglycaemia in patients with stress 
hyperglycaemia75,76, discrepancy in the results of subsequent trials with similar 
aims77,78 and anecdotal evidence from ICU clinicians that tight glycaemic 
control did not seem to result in the type of improvements seen in the trials by 
Van den Berghe et al.65,69, led to a large, international, parallel-group, 
randomised, controlled trial of 6,104 medical and surgical ICU patients76. 
Hyperglycaemic patients were randomised to receive IIT (glucose target range 
4.5-6 mmol/L) or conventional glucose control (8-10 mmol/L). There was a 
2.6% higher mortality rate in the ITT arm, with no difference between the two 
groups in terms of median duration of ventilation, RRT, ICU stay or hospital 
stay. Severe hypoglycaemia affected 6.8% of patients in the ITT group 
compared to only 0.5% in the conventional glucose control group. The authors 
concluded that the number needed to harm with tight glycaemic control was 
38, recommending maintenance of glucose concentration below 10 mmol/L to 
reduce mortality whilst avoiding hypoglycaemia. 
An Australian study of 168,337 blood glucose measurements in 7,049 critically 
ill patients79 demonstrated that intra-subject mean glucose concentration and 
fluctuations in glucose concentration (determined by the standard deviation and 
coefficient of variability of glucose concentrations), were independently 
predictive of ICU and hospital mortality. The authors hypothesised that 
controlling the variability, not just total concentration, of blood glucose may be 
beneficial.  
As a consequence of the NICE-SUGAR trial76 and two meta-analyses 
performed to assess the outcomes of IIT75,80, international guidelines now 
recommend the control of glucose to below 10 mmol/L in critical illness, the 
prevention of large fluctuations in glucose level, and the avoidance of tight 
glycaemic control due to potential detrimental effects. It is suggested that 
intravenous glucose infusions are limited to reduce the risk of 
hyperglycaemia81. 
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 The SPRINT protocol 1.2.5.
In Christchurch Hospital ICU, New Zealand, a unique system for glycaemic 
control was implemented as a change of practice in August 2005. The 
Specialised Relative Insulin Nutrition Tables (SPRINT) protocol is a simple 
wheel-based system that modulates not only insulin dose but also volume of 
feed (enteral or parenteral) administered hourly82,83. The system was developed 
from validated computer models that predict insulin sensitivity by looking at 
the handling of previous insulin and nutritional inputs83. Low carbohydrate 
feeding regimens aim to prevent further elevation of blood glucose level82,83. 
Unlike other protocols in the literature, insulin is administered as an 
intravenous bolus to avoid an inappropriate infusion dose running until the next 
blood glucose measurement. The protocol is commenced when a patient has 
two consecutive blood glucose measurements greater than 8 mmol/L during 
standard monitoring, or can be started by a specialist doctor if a patient with 
severe critical illness has a glucose level persistently over 7 mmol/L. If blood 
glucose levels remain high despite a maximum insulin dose of 6 units/hour, a 
background infusion of 0.5-2 units/hour can be initiated. This is most 
commonly required for patients with underlying diabetes mellitus. Unlike some 
insulin regimes where blood glucose is monitored every four hours, 
measurements are taken at one to two hourly intervals, with the aim of 
maintaining tight glucose control whilst preventing hypoglycaemia82. 
Hypoglycaemia is also avoided by withholding insulin when blood glucose 
drops by more than 1.5 units/hour if the glucose level is below 7 mmol/L83. 
The protocol is stopped when stable blood glucose measurements of 4-6 
mmol/L have been achieved over six hours or more, at an insulin dose of 2 
units/hour or less, with feed running at a minimum of 80% of the goal feed 
rate82. 
When compared to a retrospective cohort (413 patients), the SPRINT protocol 
(371 patients) led to a tightening of glucose control without an increase in 
hypoglycaemia seen in other studies65,69. A reduction in hospital mortality from 
34.1% to 25.4% was seen in patients with an ICU stay of three days or more, 
and 31.9% to 20.6% in patients staying over four days. There was no 
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significant difference in illness severity between the two groups, as determined 
by the APACHE II score82. 
A significant reduction in organ failure, as determined on a daily basis by the 
SOFA score, was seen when the SPRINT group was compared to the historical 
cohort. Organ failure also appeared to resolve more quickly in the SPRINT 
group83. 
 Feeding in the ICU 1.2.6.
7KHDVVHVVPHQWRIDSDWLHQW¶VQXWULWLRQDOVWDWXVLVSUREOHPDWLFLQWKH,&8DVLWLV
difficult to weigh the patient accurately, especially on a repeated basis, and 
even when it is possible the presence of oedema and fluid shifts make weight 
and body mass index (BMI) results unreliable. Energy expenditure is also not 
easy to calculate, but it is known to be a time of increased metabolism with 
subsequent development of a catabolic state84,85. Controversy surrounds the 
timing of initiation of feeding, the amount of feed administered and route of 
administration. 
European guidelines recommend early enteral feeding in critically ill patients 
who are not expected to be eating normally within three days, avoiding 
excessive caloric intake in the initial phase of critical illness86. Clear evidence 
for recommending early enteral feeding is lacking, however meta-analyses 
suggest a reduction in infection rate and length of stay86.  
Feeding via the enteral route is advised by both European and American 
guidelines84,86 to preserve gut integrity, and its barrier and immune functions84. 
Due to problems with gut motility associated with severe illness, adequate 
enteral intake is often not achieved85,87-89. In these cases supplementary 
parenteral feeding is recommended86, but not as the only route of feeding due 
to higher cost and increased rates of infection, particularly line sepsis, when 
compared to enteral feeding84,86. 
The appropriate amount of feeding required has also been of interest to ICU 
clinicians. Overfeeding, especially via the parenteral route, increases the 
likelihood of developing stress hyperglycaemia63 and can lead to increased 
carbon dioxide (CO2) production, which may be more concerning in patients 
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with respiratory compromise84. Some, mainly observational studies, have 
shown that significant underfeeding is related to increased mortality90, 
infection rate85,91, duration of mechanical ventilation85,90 and length of ICU 
stay85. In contrast, two studies showed that moderate underfeeding 
corresponded to improvements in mortality88,89 and return of spontaneous 
ventilation88 when compared to feeding at estimated maximum feed rate. The 
authors suggest that lower calorie intake might lead to improvements in 
outcome due to a reduction in metabolic rate and oxidative stress, thus a 
reduction in ROS generated in mitochondria, improvement in insulin 
sensitivity, and altered neuroendocrine and sympathetic nervous system 
function89.  
1.3. The analysis of volatile organic compounds in 
breath 
 The components of exhaled breath 1.3.1.
Exhaled breath is composed of a mixture of nitrogen, oxygen, CO2, water 
vapour, inert gases and numerous VOCs at the low parts per billion (ppb) 
level1,2. For centuries, physicians have recognised characteristic odours on a 
SDWLHQW¶V EUHDWK RU VNLQ FDXVHG E\ WKHVH WUDFH JDVHV DQG UHODWHG WKHP WR
disease states; the sweet smell of diabetic ketoacidosis (DKA), the fishy smell 
of liver failure and the urine smell of renal failure1-3. Initially about 250 
substances were separated from human breath, without specific identification92, 
however over 1,000 substances have now been identified of both endogenous 
and exogenous origin1,93. VOCs produced by both normal and pathological 
metabolic processes are transported in the blood stream and can be exhaled via 
the lungs.  
 The potential applications of breath analysis 1.3.2.
Breath analysis is an attractive method of obtaining information about a 
SDWLHQW¶V PHWDEROLF RU LQIODPPDWRU\ VWDWXV DV it is non-invasive and, using 
certain techniques such as SIFT-MS, can be performed rapidly and in real 
time4. Much research has been undertaken into the clinical applications of 
breath analysis, however there are currently very few examples of breath 
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testing in clinical practice; capnography is an important tool for monitoring 
CO2 OHYHOXVHGLQRSHUDWLQJWKHDWUHVDQGWKH,&8³EUHDWKDO\VHUV´DUHXVHGE\
the police to detect breath alcohol levels, the 13C-urea breath test is an 
important tool in the detection of Helicobacter pylori in the stomach, which 
can promote the development of ulcers, and eosinophilic inflammation in 
asthma can be monitored using the fraction of exhaled nitric oxide (FENO), for 
which a protocol for obtaining breath samples exists94. 
One of the important issues that needs to be addressed is the choice of VOC(s) 
for analysis, because to be used as a biomarker it needs to fulfil certain criteria. 
$ ELRPDUNHU LV GHILQHG DV ³D FKDUDFWHULVWLF WKDW LV REMHFWLYHO\ PHDVXUHG DQG
evaluated as an indicator of normal biological processes, pathologic processes, 
RU SKDUPDFRORJLFDO UHVSRQVHV WR D WKHUDSHXWLF LQWHUYHQWLRQ´95. Ideally a 
biomarker would be simple to measure, repeatable and reproducible, reflect 
changes associated with treatment and predict outcome or disease 
progression96. It is important that the relationships between the marker and 
underlying condition96, and for systemic processes between breath and blood 
concentrations, are clear8,97. The monitoring of FENO in asthma is a good 
example; FENO rises with increased eosinophilic inflammation and is reduced 
by steroid treatment98. FENO can be used to predict response to inhaled 
corticosteroids (ICS)99, to modify ICS dose without unwarranted side effects or 
loss of asthma control100, and elevated levels after the cessation of steroid 
treatment can predict relapse98. Elevated FENO can also discriminate between 
individuals with asthma (as determined by symptoms suggestive of the 
diagnosis and a positive bronchial provocation test or positive response to 
inhaled bronchodilator) and those without101,102, with a higher sensitivity than 
peak flow measurement and other spirometric parameters102. 
A number of potential breath biomarkers have been identified. Ethane and 
pentane appear to be linked to lipid peroxidation, acetone to glucose 
metabolism, isoprene to cholesterol biosynthesis and ammonia to protein 
metabolism1,2. Ethanol and hydrogen appear in human breath due to the action 
of gut bacteria2. Possible clinical applications have been investigated, including 
elevated ammonia as a biomarker in end-stage renal failure103 and the 
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assessment of dialysis efficacy104, the effects of surgery on metabolic stress105 
and the monitoring of intravenous anaesthetic drug levels106. 
Markers of infective pathogens have also been identified; 2-pentylfuran as a 
marker of Aspergillus fumigatus107, methyl nicotinate as a marker of 
Mycobacterium tuberculosis108,109, and hydrogen cyanide (HCN)110 and 2-
aminoacetophenone111 as markers of Pseudomonas aeruginosa in the cystic 
fibrosis (CF) lung. By using a combination of 22 VOCs, children with CF 
could be separated from those without CF with 100% reliability and using 14 
VOCs those with P. aeruginosa infection could be separated from those 
without112. 
 The potential of breath analysis for the detection of 1.3.3.
pneumonia and metabolic disturbance in critically ill patients 
For breath analysis to be clinically useful, results need to provide the clinician 
with information not readily available via conventional analysis of blood and 
urine samples97, and also be of diagnostic or prognostic benefit, or be useful in 
following response to treatment. Breath samples may be simpler to process as 
they might not need to undergo preparation as blood and urine samples do113 
and results may, therefore, be more rapidly available, particularly when 
compared to samples for microbiological culture. Blood and urine samples are 
generally used to measure levels of large molecular weight proteins and ions 
rather than very small quantities of volatile substances114. There is a suggestion 
that due to the variability of individual measurements of VOCs, such as 
acetone, in blood that breath analysis may be more reliable115. When evaluating 
airway inflammation, sputum analysis for inflammatory cells is not practical on 
a daily basis due to the difficulty of obtaining adequate samples, and 
identification and interpretation of inflammatory cells requires highly skilled 
laboratory staff116. Other methods of sample collection, such as bronchoscopy, 
can be more invasive and impractical on a regular basis. In addition, breath 
sampling can provide details that other investigations cannot, such as 
information about pulmonary function113 and may be able to provide 
information about several VOCs at the same time. 
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As described in Chapter 1.2.2., it is difficult to differentiate between 
inflammation due to infection and that due to other causes, especially in the 
lung and in patients with critical illness, on the basis of currently available 
diagnostic tests97. The differentiation between pneumonia, aspiration lung 
injury, pulmonary oedema and ARDS due to a cause other than pneumonia by 
a bedside test is currently not possible. Any test that could do this would be 
extremely useful in the ICU setting, where patients are unstable, their condition 
is rapidly changing, and management of the conditions above is different. 
Pneumonia requires antibiotic treatment and investigation of the organism 
responsible; aspiration lung injury usually requires supportive care without 
antibiotic therapy; pulmonary oedema requires pharmacological maintenance 
of cardiac function, and possibly mechanical support via a balloon pump; low 
volume ventilation or other ventilation strategies may be necessary in ARDS, 
as well as treatment of the underlying cause. It is important, therefore, to 
instigate appropriate management plans early and avoid unnecessary 
antibiotics, for example, with potential side effects of renal dysfunction or the 
promotion of bacterial resistance. 
The ventilatory and haemodynamic status of a ventilated patient is closely and 
continuously monitored in the ICU or operating theatre, however there are 
currently no tests available to quickly and accurately monitor rapidly changing 
levels of metabolic stress, inflammation and infection. Currently available 
tests, for example Swann-Ganz catheters, pulse contour continuous cardiac 
output (PiCCO) monitors and blood tests are often invasive and results are not 
always available immediately105.  
Two studies of exhaled NO in intubated and ventilated patients in the ICU have 
shown promise in the diagnosis of pneumonia, with higher concentrations in 
the breath of patients with pneumonia than those without117,118. Neither study 
found a difference in exhaled NO concentration between patients with sepsis 
and those without, or a correlation between breath NO and plasma nitrate 
concentration117,118. There was no relationship between exhaled NO 
concentration and degree of consolidation on CXR117 or markers of systemic 
inflammation, haemodynamic instability or disease severity118. Elevated NO 
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appeared to be associated with pulmonary infection and was not related to 
systemic production117,118. 
If the correct breath markers are identified, non-invasive breath sampling could 
be used to provide rapid, accurate, repeatable or continuous information to 
diagnose and monitor changes in breath marker concentrations as a 
consequence of infection, metabolic derangement or treatment in ventilated 
patients. 
 Breath analysis techniques 1.3.4.
There has been a great deal of progress in the identification and quantification 
of trace gases in breath since the first studies of Pauling et al.92 in the 1970s 
using gas-liquid partition chromatography. Several techniques are now in use, 
each with their own advantages and disadvantages, although only a few can 
accurately quantify VOCs at the low ppb level, on-line and in real time3. 
Gas Chromatography 
Gas chromatography (GC) is the most commonly used method of breath 
analysis, whereby different compounds in a mixture are separated by their 
reactions with the substance of the GC column119. It can be combined with 
various methods of ion detection and analysis, for example flame ionisation 
detection (FID), time-of-flight (TOF) and MS. Tandem mass spectrometry 
(MS-MS) can be used to increase the sensitivity and confidence in 
identification of compounds detected. Conventional ionisation, for example 
electron impact ionisation, is used. This results in many ion fragments to be 
analysed and enables substances to be confidently identified by their 
characteristic fragmentation pattern2. The instrument must be calibrated for 
each VOC with known gas standards.  
It is not possible to identify very low molecular weight compounds with 
accuracy using GC3,4,120, thus pre-concentration, requiring off-line sampling, is 
important. Breath is humid and condensation of water vapour interferes with 
this method of analysis, affecting results. Water vapour must, therefore, be 
removed from samples prior to analysis121, hampering the development of a 
method for directly breathing into a GC-MS instrument. Real-time breath 
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analysis is also precluded by the response time of the analyser to detect a 
change in concentration, which is too slow to accurately determine the 
concentration of a VOC over the duration of a single exhalation3,4. Pre-
processing of raw GC-MS data involves de-noising, alignment and 
normalisation, prior to analysis. Due to the preparation steps of the sample and 
raw results data, this technique is time-consuming and requires a skilled 
operator. Instrumental variation can be improved by analysing samples in 
batches119. 
Ion mobility mass spectrometry 
Ion mobility mass spectrometry (IMS) can be used to detect and quantify trace 
gases at the low ppb level. The device is smaller than other mass spectrometers 
as samples do not require heating prior to analysis122. A carrier gas of purified 
air or nitrogen, transports precursor ions, generated by a radioactive source, 
into a drift tube. A mass spectrum is produced when product ions with various 
molecular masses arrive at the detector at different times due to their different 
drift velocities. By changing the drift length, drift gas, electrical field strength, 
temperature or pressure, product ion separation can be improved119. This 
method is usually coupled with GC in order to separate complex gas 
mixtures3,4,122. Calibration of ion mobility for each ionic species at different 
humidity levels is necessary4, which can be time-consuming.  
Proton transfer reaction mass spectrometry and selected ion flow tube mass 
spectrometry 
Proton transfer reaction mass spectrometry (PTR-MS) and SIFT-MS are both 
able to identify and quantify multiple VOCs at the sub ppb level, 
simultaneously, from a mixed sample. Both techniques allow rapid, on-line, 
real time measurement of single breath samples without pre-
concentration3,4,120. The response time of PTR-MS instruments is around 100 
ms119 and 20 ms for SIFT-MS123. Instruments have reduced in size over the last 
10 years, but are still bulky and expensive. Analysis of breath samples, 
however, is cheap once a machine is available, as consumables are inexpensive 
and significant preparation of samples is unnecessary124. 
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 ³6RIW´ LRQLVDWLRQ LV XVHG SUHYHQWLQJ FRPSOLFDWHG DQDO\VLV RI PXOWLSOH
fragments125, with the H3O+ reagent ion being used in PTR-MS and either 
H3O+, NO+, or O2 in SIFT-MS. Reagent ions in the buffer gas react with trace 
gases to form product ions, which are detected downstream. Identification of 
product ions relies on their mass-to-charge ratios (m/z), the data for which is 
held in an inbuilt computer library, negating the need for calibration with 
known standards2-4,120. Isobaric product ions cannot be further separated by 
PTR-MS, thus a different method of analysis may be necessary. The choice of 
three precursor ions when using SIFT-MS resolves this problem and allows 
conclusive identification of compounds3. A detailed explanation of the SIFT-
MS technique can be found in Chapter 1.4. of this thesis. 
Secondary electrospray ionisation mass spectrometry 
Secondary electrospray ionisation mass spectrometry (SESI-MS) involves 
passing a gaseous sample in a stream of air or CO2 through a cloud of 
electrospray solution with which the volatile analytes react to become 
protonated. Product ions are driven by an electrical field and are sucked into 
the inlet of the triple quadrupole mass spectrometer for detection and 
analysis126,127. Analytes in the gaseous phase and those condensed in water 
droplets can be ionised by this technique128 with no need for sample 
preparation127. Excellent sensitivity, down to the low parts per trillion (ppt), is 
possible over a wide range of masses (over 600 Da)126, with results of a full 
mass scan available in less than 2 min127. Unlike PTR-MS and SIFT-MS, the 
fragmentation of compounds of interest by SESI enables exact compound 
identification by MS128.  
Optical spectroscopy 
Optical spectroscopy can be used to detect and quantify a single substance in 
breath, on-line and in real time. One example of this type of instrument is the 
chemiluminescent analyser for measuring FENO, which measures light produced 
by the reaction of NO in the airway with ozone98,116. A smaller, more portable 
tool has been developed that works on the electrochemical cell technique116. 
Standardised guidelines for on- and off-line breath collection have been 
produced by the American Thoracic and European Respiratory Societies94,129. 
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Electronic noses 
Sensor array devices, or electronic noses, utilise chemical vapour sensors to 
detect a pattern of trace gases in breath in order to diagnose a disease 
state130,1317KH³VPHOOSULQW´RU³EUHDWKSULQW´LVUHFRJQLVHGIURPVWRUHGSDWWHUQV
in a simple to use hand-held device130,131. Electronic noses derived their name 
from the comparison with the human nose, having the ability to recognise a 
unique smell without knowing the exact constituent compounds132. Results are 
generated immediately; however complex statistical methods are often required 
for data analysis133. The electronic nose has acceptable within day and between 
day repeatability; slightly lower than the repeatability of FENO and 
spirometry133. 
 Off-line breath collection and storage 1.3.5.
As discussed above, some techniques, such as GC, require off-line breath 
collection and others can be used off-line if it is not possible to move the 
instrument to the subject or vice versa. Off-line collection is used for sampling 
atmospheric gases134 and the headspace above blood samples and urine or cell 
cultures114. Sample loss and contamination are potential problems associated 
with off-line collection, pre-concentration, storage and subsequent desorption1. 
A comparative study of on-line versus off-line breath HCN quantification in 
polymer bags reported higher analyte concentrations in on-line samples; 
however, the difference may have been confounded by comparing mixed 
breath (off-line) and alveolar (on-line) samples135. 
Storage containers 
Gaseous samples can be collected into various containers, but the properties of 
stainless steel canisters134,136 and polymer bags120,134,135,137-140, importantly their 
inertness, have led to their common use. Despite being durable and long-
lasting, stainless steel canisters are complicated to use and expensive to 
purchase134. Polymer bags, on the other hand, are more popular as they are 
simple to use, cheap, inert and relatively durable134,140. Some bags can be 
cleaned and reused, whereas others are disposable, for example Nalophan® 
(polyethylene terephthalate)135,140. Damage from reuse can affect the inertness 
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of the bag and also lead to increased substance adsorption onto the inner 
wall140. 
Sample integrity within a polymer bag depends on the rate of diffusion out of 
the bag and adsorption of VOCs onto the inner wall, as well as contamination 
of the sample by diffusion of substances into the bag from the environment134. 
Bag thickness and surface area to volume ratio are important in these 
processes, with water vapour more likely to diffuse out of the bag than other 
gases134,138,139. Previously collected trace gases adsorbed onto the inner bag 
wall may also contaminate subsequent samples if the bag is not cleaned 
effectively134,141, thus it is advisable to clean bags as soon as possible and store 
them in a collapsed state if their re-use is intended141. Contamination from the 
bag material itself is a problem with Tedlar® (polyvinyl fluoride) bags; N,N-
dimethylacetamide at m/z 88, a solvent used in the bag production, and phenol 
at m/z 95 are released134,138, particularly if the bag is heated138. 
Different bags have different storage properties. Tedlar is the most commonly 
used polymer bag134 and, along with Mylar® bags, is recommended for the off-
line analysis of FENO94. It is suitable for the storage of sulphur compounds140 
and acetone134,135 for up to six hours with minimal loss and HCN for six hours 
with 35% loss135. Nalophan and FlexFoil® bags have been reported to show no 
significant loss of contents in the first six hours, unlike Teflon® 
(polytetrafluoroethylene) which demonstrated losses of between 10% and 20%. 
All bags showed significant losses at 24 hours134,135,137,140. The rate of reduction 
in volatile concentration is higher when bags are stored at room temperature 
compared to body temperature135, possibly as a result of sample condensation 
DQGDGVRUSWLRQRQWRWKHEDJ¶VLQQHUVXUIDFH 
Due to differences in storage properties of different bags for a variety VOCs, it 
is important to assess the storage capability of a chosen container for the 
particular VOCs of interest, so that any losses can be accounted for. It is 
desirable to store samples for the shortest time possible to minimise loss and 
contamination141. It has been recommend that the contents of all polymer bags 
are analysed within ten hours of collection, when recovery of alcohols, nitriles, 
aldehydes, ketones and aromatic compounds is over 80%134. 
27 
 
Sample pre-concentration techniques 
Discontinuous sampling techniques are attractive because the small size of 
some of the newer pre-concentration materials makes sample collection 
convenient142,143. As well as being a useful technique if the patient is remote 
from the device144, the ability to store samples for several days or more with 
little sample loss144,145 may allow a large number of samples collected at the 
same time to be processed over several days. This can improve the cost-
effectiveness of an analyser and aid collaboration of research work where only 
one site has direct access to an MS instrument145.  
As with any pre-concentration technique, despite improvements in sensitivity, 
some of the sample may be lost or contaminated in the collection and 
desorption processes3. Subsequent GC-MS analysis can be lengthy, so the 
results are not available in real time, which may limit the usefulness of this 
technique in clinical practice. Analytical techniques with instantaneous 
generation of results, such as SIFT-MS, may overcome this problem and allow 
easy and frequent measurement of breath volatiles, when combined with off-
line sampling146. 
A popular method of sample pre-concentration is solid phase microextraction 
(SPME), which is often used with GC-MS as substances can be automatically 
desorbed onto the GC column at the time of analysis. Other methods include 
direct cryogenic trapping136 and sorbent traps, for example activated 
carbon93,121, where desorption is achieved by heating or microwave energy. 
Thermal desorption (TD), onto a sorbent such as Tenax®, has been 
successfully used with SIFT-MS for the collection and storage of 
environmental gases146 and breath144. On-line breath sample and TD recovery 
rates were almost the same144. It was possible to collect samples from a single 
exhalation and store them for several days before rapid analysis144. The small 
cartridges loaded with analyte can be transported easily, including by air 
freight, without significant loss of sample over a period longer than two 
months, including time spent at altitude145. 
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 Technical and methodological considerations 1.3.6.
There is little standardisation for the analysis of trace gases in exhaled breath. 
In order to effectively compare results from different studies and use any data 
for clinical purposes the following factors must be taken into account and, if 
possible, controlled for2,147. 
Location of VOC production and gas exchange and the effect on breath 
concentrations 
VOCs in breath may originate in the blood and cross the alveolar membrane, or 
may be produced in the airways, sinuses, mouth, nose or gastrointestinal tract2. 
Sampling from the mouth or nose can result in differences in observed VOC 
concentration, for example volatiles produced by oral bacteria can contaminate 
orally exhaled breath samples148. H2S149, HCN150,151 and ammonia150 
concentrations are higher in oral than nasal breath samples, therefore 
uncontrolled oral exhalations of these trace gases are inappropriate, bringing 
into question the relevance of some previous study results110. In contrast, FENO 
is higher in nasal than oral exhalations, although lower concentrations have 
EHHQQRWHGLQFKLOGUHQDQGLQSDWLHQWVZLWK&)DQG.DUWDJHQHU¶VV\QGURPH152. 
The composition of expired gases changes with the phases of expiration. The 
concentration of exhaled CO2 and other endogenous low blood-soluble trace 
gases is very low on initiation of exhalation (Phase 1 or anatomical dead space 
air) and climbs during expiration to a plateau (Phase 3), which represents 
alveolar air reaching the mouth (Figure 1-1 parallel lines). The concentration of 
low blood-soluble gases in alveolar air is in equilibrium with the concentration 
in the pulmonary circulation. The rate of diffusion across the alveolar-capillary 
membrane is dependent upon the polarity of the molecule, its solubility, 
volatility and blood:gas partition coefficient124. Pathological conditions that 
affect pulmonary blood flow and capillary or alveolar surface area, membrane 
thickness and permeability will also have an effect on gas exchange of low 
blood-soluble gases153. 
In contrast, highly blood-soluble VOCs, such as ethanol and acetone, exchange 
wholly or predominantly in the airways154,155. There is very little or no dead 
space air as the trace gas is present in breath as soon as exhalation is 
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initiated156,157 7KHUH LV D ³ZDVK-in/wash-RXW´ HIIHFW ZKHUHE\ KLJK EORRG-
soluble gases present in airway tissue and the mucus layer transfer into luminal 
air during inspiration, saturating the air so that by the time it reaches the alveoli 
very little or no more gas exchange can occur. There is insufficient time for the 
tissues and mucus to be completely replenished with soluble gas from the 
bronchial circulation at the end of inspiration, so the saturated air deposits 
soluble gas down the concentration gradient back into the mucus during 
expiration154,155,157. As a consequence, the concentration of a highly soluble gas 
at end-exhalation is always lower than the alveolar concentration154,155,157 and, 
therefore, may not reflect its concentration in the pulmonary158 or systemic 
circulation156 or correlate with end-tidal CO2147 (Figure 1-1 solid line). A 
rebreathing technique may result in equilibrium between airway and mucus 
layer concentrations, therefore improving the accuracy of breath concentration 
measurements154,156,159,160, however subjects may not be able to rebreathe for 
long enough before hypoxia154,160 or hypercapnia become a problem160. 
The process of airways gas exchange is limited by airway tissue thickness, 
bronchial blood flow, airway temperature and blood:gas partition coefficient154-
156
. Variation in breath VOC concentrations has been seen in different 
temperature environments, some VOCs showing an increase and others a 
reduction in concentration161, although the changes may be related to 
differences in humidity rather than temperature alone. Airway gas exchange is 
also affected by changes in ventilation156,162,163, with increased bronchial 
exchange during exercise resulting from a combination of increased alveolar 
ventilation162, increased tidal volume163 and/or increased bronchial blood 
flow162.  
Bronchial blood flow can be affected by drugs157 and pathological respiratory 
states, for example increased bronchial blood flow is associated with airway 
inflammation in asthma; higher bronchial blood flow was seen in ICS naïve 
asthmatics than treated asthmatics, with the lowest flow in healthy controls164. 
As CF-related lung disease progresses the bronchial circulation becomes 
increasingly hypertrophied. This appears to augment gas exchange in the 
airways, with a greater percentage of cardiac output going to the lung165. 
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Airway remodelling in pulmonary disease may lead to thickened airway walls 
and impaired diffusion from the bronchial circulation to the airway lumen157.  
For gases with a blood:gas partition coefficient greater than 1,000 gas 
exchange occurs entirely in the airways and if the coefficient is less than 10 gas 
exchange occurs entirely in the alveoli. For gases with a blood:gas partition 
coefficient between those two values, gas exchange occurs in both the alveoli 
and airways, predominantly in the airways for coefficients greater than 
100155,157.  
 
 
 
Figure 1-1. Schematic showing the phases of an expirogram of a low blood-
soluble gas which exchanges in the alveoli (parallel lines) and a high blood-
soluble gas that exchanges in the airways (solid line). The partial pressure of 
exhaled gas (PE) is plotted against the exhaled volume. Red arrows show the 
SKDVHV RI EUHDWK FROOHFWHG LQ PL[HG H[SLUDWRU\ DQG µDOYHRODU¶ VDPSOLQJ
(Modified from the original157). 
Different breath sampling techniques and the effect on measured VOC 
concentrations 
Much importance has been given to the collection and/or analysis of alveolar 
gas samples because, as well as containing fewer exogenous contaminants166, 
they contain higher levels of some VOCs7,166, whereas whole breath or mixed 
Mixed expiratory sampling 
µ$OYHRODU¶VDPSOLQJ 
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expiratory samples are diluted by dead space gas147 (Figure 1-1). Multiple 
mixed breath samples generally contain lower VOC concentrations than a 
single large exhalation, probably as a result of a greater volume of dead space 
gas161.  
Alveolar samples can be identified using breath humidity167, via CO2-
conWUROOHGVDPSOLQJZKHUHE\WKHSRUWLRQRIH[KDOHGEUHDWKFRQWDLQLQJ
CO2 is collected for analysis7, or by using computer software to select only the 
last 20% of a breath by volume for analysis151,168. Discarding a fixed volume of 
breath at the beginning of an exhalation121 involves an incorrect assumption 
that all subjects have the same dead space volume169, and time-controlled 
sampling starting breath collection 1 sec after the initiation of expiration, for 
example, when compared to CO2-controlled sampling, leads to highly variable 
results166. 
Effect of breathing pattern on measured VOC concentrations 
The rate of alveolar ventilation is affected by aerobic cellular metabolism and 
acid-base balance, aiming to maintain CO2 at a steady state147. Spontaneously 
breathing subjects tend to hyperventilate when asked to perform breathing 
tests, reducing end-tidal CO2 concentration and possibly that of other low 
blood-soluble trace gases such as isoprene169,170, via a combination of increased 
tidal volume and minute ventilation169,171. Hyperventilation also causes a 
reduction in the end-tidal concentration of high blood-soluble gases like 
ethanol, where 20 sec hyperventilation can reduce the exhaled concentration by 
11% and only three deep breaths can result in a concentration reduction of 
4%154. This is due to an increased volume of air passing over the airway 
mucosa per unit time154. The control of respiratory rate and tidal volume, 
calculated according to body mass, reduces breath VOC concentration 
variability and improves inter-individual comparison, however paced breathing 
does not always result in improved correlation of VOC concentration with end-
tidal CO2169, presumably as a consequence of differences in blood:gas partition 
coefficient.  
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Breath holding before exhaled breath sampling causes an increase in almost all 
VOC161, including FENO152 and ethanol; a 30 sec breath hold can increase 
exhaled ethanol concentration by 16%154.  
Expiratory flow rate affects FENO; during a slower exhalation there is more time 
for NO to be released into the airway lumen causing an increase in measured 
breath concentration152,172. To allow comparison, FENO is reported as a 
concentration, however the exhaled flow rate must be kept constant and noted 
to allow the calculation of NO output per unit time94,152. Due to the wash-
in/wash-out effect, exhaled ethanol concentration increases over an exhalation 
at a constant flow rate154.  
Many investigations of exhaled flow rate, volume and duration do not control 
for the other variables, and have been performed in mixed and alveolar 
samples; therefore the behaviour of individual volatiles is not completely clear. 
The concentration of exhaled isoprene measured on-line increases over the 
duration of a single breath without reaching a plateau, with the concentration 
dependent on the duration of exhalation, making it impossible to accurately 
quantify during an uncontrolled on-line single breath exhalation159. In contrast, 
when whole breath samples are collected and analysed off-line, isoprene 
concentration does not increase when greater than 400 ml breath is exhaled144. 
Acetone concentration increases with greater breath volume in on-line 
exhalations159,168 and off-line mixed breath samples144, although the gradient of 
the Phase 3 slope for acetone is much shallower than that for isoprene159. This 
is, however, only the case if tidal breath samples are compared with each other 
or exhalations from vital capacity to residual volume are compared with each 
other, as a greater volume of air passing over the airway mucosa during a vital 
capacity breath has a diluting effect on breath acetone concentration163.  
For high blood-soluble gases like acetone, increasing the volume of an 
inspiratory breath, and the subsequent exhaled breath, moves the location of 
gas exchange deeper into the lungs; a larger volume of air will become less 
saturated with the same quantity of soluble gas, thus more gas exchange is 
possible in the alveoli than with shallower breaths157. Exhaled acetone has been 
reported to be dependent on expiratory flow rate156, however this was not the 
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case in subsequent studies159,168. Exhaled breaths were only analysed to the 
volume of the smallest breath, therefore it is possible for results to be explained 
by differing percentages of total lung volume analysed156.  
Due to possible effects of the breathing pattern on VOC concentration, if 
breath samples are not collected over a given time period but instead over a 
single exhalation, that breath must be representative of the whole breathing 
pattern otherwise averaged breath results are recommended1,97. 
Effect of VA/Q changes on breath VOC concentrations 
Changes in alveolar ventilation-perfusion ratio (VA/Q) affect the concentration 
gradient of VOCs and therefore their concentration in exhaled breath, which is 
also dependent on the blood:gas partition coefficient173,174. When the blood:gas 
partition coefficient equals VA/Q, 50% of the gas will remain in the pulmonary 
circulation and 50% will move into the alveolus. A greater proportion of the 
gas will be transferred to the alveolus as VA/Q increases and more will be 
retained in the circulation as VA/Q is reduced173. This means that highly 
soluble gases can still exchange in areas of high VA/Q, whereas in areas of low 
VA/Q even the smallest amount of perfusion allows exchange of low blood-
soluble gases173. This explanation does not, however, completely take into 
account airway gas exchange157.  
VA/Q is not homogeneous throughout the lung, with areas of VA/Q mismatch 
and shunt more marked in critical illness1,174. Physiological dead space is 
greater during anaesthesia than spontaneous breathing; alveolar dead space 
fraction (alveolar dead space/tidal volume) but not anatomical dead space can 
be reduced by increasing tidal volume and reducing respiratory rate175. Chronic 
lung diseases tend to increase VA/Q mismatch without significant shunt, 
however in acute lung diseases shunt is more common with less VA/Q 
mismatch (fluid in alveoli prevent gas exchange)176. Pronounced 
haemodynamic compromise can cause alterations in breath VOC 
concentrations, however small changes in cardiac output may not have any 
effect1,2,176. 
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VA/Q alters as a subject moves from a semi-supine to supine posture due to 
increased cardiac output, mainly as a consequence of increased stroke volume, 
causing increased pulmonary blood flow177, with less of an effect on 
ventilatory parameters. Breath isoprene concentration increases as a result of 
greater cardiac output in the supine position, whereas posture has no effect on 
acetone concentration171 or FENO152.  
Effect of exercise on breath VOC concentrations 
Exercise causes changes in cardiac output, thus pulmonary and bronchial 
perfusion, minute ventilation as a consequence of increases in tidal volume and 
respiratory rate, and alveolar ventilation, which all have an effect on measured 
breath VOC concentrations162,177,178. Breath isoprene increases at the onset of 
exercise then decreases back to baseline within 15 min171,177-179, due to an 
increase in cardiac output overwhelming the reduction in breath concentration 
that would be expected with an increase in respiratory rate171,178. An increase in 
airway gas exchange of acetone, as a consequence of increased cardiac output 
and subsequent bronchial blood flow162, is balanced by increased ventilation, 
however other metabolic factors influence breath acetone concentration. Breath 
acetone concentration climbs during exercise due to the production of acetone 
from carbohydrate and fat sources177,178 to anaerobic threshold, after which it is 
seen to fall as a consequence of increased lactate and decreased acetoacetate 
production during anaerobic metabolism178. The relationship between FENO and 
exercise is unclear116, however because one study found that NO output 
increased with exercise and FENO and nasal FENO fell, it is recommended that 
subjects refrain from exercise for one hour prior to breath testing (reviewed94). 
Effect of inspired VOCs on exhaled concentrations 
The rationale for investigating breath biomarkers involves a belief that 
endogenous breath VOCs in disease states will differ from healthy controls, 
however this does not take into account current or previously inspired VOCs. 
Most VOCs in breath are exogenous180 and are either inspired from the 
surrounding environment or absorbed through the skin, affecting exhaled VOC 
concentrations181. Rates of uptake, distribution in body tissues and excretion 
vary depending on the compound180, as can be seen in a recent study of 
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subjects breathing air polluted with seven VOCs of interest182. Breath volatile 
concentrations were examined as inspired air concentrations were reduced, 
showing some retention of all inspired VOCs under investigation and a close 
linear relationship between inspired and exhaled concentrations. The authors 
calculated VOC retention coefficients, concluding that it may be possible to 
ignore inspiratory concentrations of substances with low coefficients, such as 
acetone, methanol, formaldehyde and deuterated water182. Breath acetone 
concentrations have also been examined in workers exposed to industrial 
acetone, revealing higher concentrations than in non-exposed workers. 
Correlations existed between breath, blood and urine concentrations and 
environmental concentrations; a stronger relationship was seen between breath 
and blood concentrations in exposed workers than controls183. 
Even within the hospital, environmental levels of some common VOCs show 
significant variation in different locations at different times of the day184. 
Interestingly, there seemed to be less variability in VOC concentrations in the 
piped medical air supply than ambient room air when measured over three 
months185. Both indoor and outdoor pollutants could be responsible for the 
differences, including building and furnishing materials, disinfectants and air 
conditioning systems recycling air around the building180. This may have 
implications for the clinical application of breath testing in certain settings, 
particularly if environmental concentrations of VOCs of interest are high and 
endogenous concentrations are low.  
There is no standard way of dealing with different inspired trace gas 
concentrations. It is possible to calculate a VOC gradient by subtracting the 
atmospheric concentration from that found in breath samples93,121, although due 
to the physiology of some trace gases the relationship between inhaled and 
exhaled concentrations is not linear and the subtraction method may not give 
accurate results8,181$QRWKHUSRVVLEOHVROXWLRQLVWR³VFUXE´WKHLQspired air to 
remove trace gases, as is recommended for the determination of FENO94, but for 
some analytes this method can be difficult, time consuming, impractical for 
most clinical use and not always reliable93,147,182. The amount of time an 
individual must breathe scrubbed air before equilibrium is reached between the 
36 
 
inhaled gas and circulating blood is also unclear147; it may take days in the case 
of very lipid soluble gases such as isofluorane6. 
If inspired VOC concentrations are the same or higher than corresponding 
exhaled concentrations it can be difficult to interpret the results182. This has led 
some authors to recommend that results should be treated with caution if the 
inspired concentration is greater than 5%8, or more practically 25%2, of the 
expired concentration.  
Effect of cigarette smoking on breath VOC concentrations 
Cigarette smoke contains many VOCs123,186-189, some of which can be detected 
in human breath and could potentially confound breath analysis; pentane, 
isoprene190, HCN191 and methyl-nicotinate189 have all been investigated as 
potential biomarkers with higher concentrations in the breath of smokers than 
non-smokers. In one study, a combination of seven VOCs could be used to 
discriminate between smokers and non-smokers, the most important appearing 
to be HCN, acetonitrile and benzene192. FENO is lower in smokers than non-
smokers, increasing over time from the last cigarette smoked, but decreasing 
with increasing total number of cigarettes smoked over a lifetime193. The 
mechanism by which smoking causes a reduction in FENO is unclear. It is 
possible that NO in cigarette smoke causes a reduction in endogenous 
production in the airways due to a negative feedback loop, supported by lower 
eNOS and iNOS in smokers, however, due to its volatile nature, endogenous 
NO may simply be more readily oxidised in the lungs of smokers 
(reviewed193).  
Effect of food and drink on breath VOC concentrations 
Different foods and the timing of eating relative to breath sample collection can 
affect the results of breath testing. As a ketone body, acetone production is 
induced by fasting and reduced by eating167,194 (discussed in more detail in 
Chapter 1.5.). Breath acetone concentration is increased by eating a diet high in 
protein and fat and low in carbohydrate195,196. Following particular diets, for 
example a gluten-free diet197, can affect the concentration of a range of VOCs 
in breath. An initial reduction and then increase in breath ammonia 
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concentration has been seen after eating, the cause of which is unclear194, 
however it may be related to changes in salivary pH198.  
The consumption of alcohol will obviously affect the concentration of ethanol 
in the circulation, which will be reflected in breath concentrations154,199. Breath 
ethanol concentration also rises slightly after meals as a result of small 
quantities of alcohol in food and fermentation in the gut due to bacterial 
activity, especially in the presence of slow gastric emptying169,200,201.  
As with alcohol, it is possible that consumption of foods containing VOCs of 
interest will contaminate breath samples, particularly if oral exhalations are 
used. Examples include 2-aminoacetophenone for the detection of P. 
aeruginosa, which can be found in corn chips, canned tuna and some beer202, 
and three potential breath markers of M. tuberculosis; methyl p-anisate is found 
in some throat sweets, toothpaste and face cream, methyl nicotinate is found in 
cigarettes and chilli powder and methyl salicylate is the main component of 
³2LO RI :LQWHUJUHHQ´ ZKLFK HQKDQFHV WKH PLQW IODYRXU RI SURGXFWV OLNH
chewing gum and toothpaste189. Increased breath concentrations of 2-
aminoacetophenone were seen after ingestion of corn chips, falling back to 
baseline within two hours202. Controlling oral intake, breath sampling more 
than two hours after the last meal or snack, or enquiring about recent food and 
drink is therefore important in breath analysis. 
Effect of age and gender on breath VOC concentrations 
Ammonia in exhaled breath seems to rise with increasing age167,203, however 
this is not the case with acetone167,203, propanol167 or HCN203. Different VOC 
concentrations have been seen in children compared to adults203,204 and there is 
also a suggestion that breath acetone is affected by gender167,205.  
Effect of time of day on breath VOC concentrations 
Diurnal variation in breath isoprene concentration, being highest around 6 a.m. 
and lowest at about 6 p.m., has been linked in some way to the circadian 
rhythm1. Significant day-to-day variation167,168, as well as diurnal variation168, 
exists in the measurement of acetone, which is likely to be a consequence of 
eating or fasting.  
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Standardisation of results and normal values 
There are currently no agreed normal ranges available for exhaled trace gases 
and there is an ongoing need to standardised breath sampling methods and 
analysis161,166 and/or to normalise data1,2 so that results from different studies 
can be accurately compared.  
It has been suggested that the exhalation manoeuvre performed for FENO 
assessment94, an oral exhalation at a fixed flow against a fixed resistance, is 
used for all breath VOCs2. Cope et al.169 suggest normalising VOC 
concentrations in exhaled breath to CO2 concentration, therefore allowing 
comparison of mixed and alveolar samples, however this may be affected by 
breath pattern and sampling method7,169, or normalising results to body mass or 
surface area, however this may over-normalise results of obese patients169.  
It can be seen, however, from the discussion in this thesis so far that different 
trace gases have different properties and a single standardised manoeuvre may 
not be appropriate for all. The issue is so important to the breath research 
FRPPXQLW\WKDWD³7DVN)RUFH´ZDVUHFHQWO\VHWXSWRORRNLQWRDVWDQGDUGLVHG
approach, which may involve different standards for individual VOCs206. 
 Specific considerations when breath sampling from 1.3.7.
mechanically ventilated patients 
Technical difficulties exist in obtaining breath samples from critically ill 
patients as they are often intubated and mechanically ventilated. On-line 
sampling is challenging due to the nature of the ventilator circuit, the size and 
portability of the instrument used for breath analysis, health and safety and 
infection control issues. Off-line sampling is often required, with its associated 
benefits and drawbacks (see Chapter 1.3.5.). Breath sampling has been 
performed during anaesthesia, to assess breath concentrations of endogenous 
VOCs and the intravenous anaesthetic agent propofol. Real-time techniques 
such as SIFT-MS106, PTR-MS207,208 and ion-molecule reaction MS (IMR-
MS)209,210 have been used for continuous monitoring, and discontinuous 
techniques involving SPME8,143 and TD142 with GC-MS analysis have also 
been explored.  
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The physical dimensions of the devices used for continuous monitoring are still 
not suitable for positioning adjacent to a patient106,207,209. To overcome the 
physical limitation of the device, previous studies have used long sampling 
lines, which can affect sample integrity (compounds can be lost by adsorption 
onto the tubing) and have been found to change the humidity of the 
sample106,207. As with any technique these effects can be quantified and 
controlled for, however this method may be unsuitable for sampling some 
VOC.  
Mixed breath rather than alveolar sampling is sometimes performed in 
ventilated patients due to ease of collection97, however end-tidal breath has 
been determined by various methods; breath sample temperature208, breath CO2 
levels using valves in the respiratory circuit to identify and collect breath 
containing CO2 of at least 3.5% by volume7, and dual MS systems to trace CO2 
concentrations for software controlled collection210. An experimental circuit for 
use with SIFT-MS was developed to exclude the first 30% of each exhaled 
breath as dead space and collect the remaining 70% into Tedlar bags211,212. This 
method is likely to be less accurate than a CO2-controlled sampling technique, 
as a consistent expired breath volume is required for the mechanism to work 
and the alveolar portion of gas may not be the same percentage of the total 
volume when the breathing pattern changes.  
The downside of these techniques is the presence of additional equipment both 
in the operating theatre or ICU and in the ventilator circuit, which may 
introduFH GLIILFXOWLHV ZLWK WKH V\QFKURQLVDWLRQ RI WZR GHYLFHV¶ IORZ RU
sampling rates and data collection210, may not be appropriate or feasible in 
these environments, and would introduce additional factors that must be 
controlled for. 
Breath samples can be contaminated by inspired gases and compounds emitted 
by the ventilator and tubing, whilst dilution can occur due to the presence of 
dead space gas in the tubing7,97. Exhaled breath samples from anywhere along 
the expiratory limb of the ventilator tubing have been shown to contain similar 
trace gas levels, however it is advisable to collect inspiratory gas samples close 
to the ventilator to reduce contamination from expired gas6. Humidified 
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breathing circuits used in the ICU can result in higher water vapour 
concentration in exhaled samples, which may affect analysis by some 
techniques97.  
Ventilator settings vary from patient to patient and cannot be altered if a patient 
is breathing spontaneously. The differences in respiratory pattern can affect 
exhaled VOC concentrations169, potentially making interpretation and 
comparison of results difficult. Unlike awake volunteers, sedated patients will 
not be able to perform specific manoeuvres for breath collection. 
VOC concentrations in the breath of patients with critical illness may differ 
from healthy subjects due to gases not passing through the upper airways and 
greater shunt and dead space ventilation8, which is likely to affect the way 
VOCs are excreted in breath176 and the relationship between their 
concentrations in breath and blood8. 
1.4. SIFT-MS 
 The development of SIFT-MS 1.4.1.
The SIFT-MS technique was originally developed in 1976 as an alternative to 
GC. It was first used to study ionic reactions in the atmosphere213 and to 
quantitatively assess the production of molecules exiting interstellar clouds214. 
It is possible to analyse samples more quickly using this method than GC 
techniques, which usually require adsorption and concentration of samples onto 
traps, with subsequent release of samples to be analysed off-line. It can rapidly 
sense small changes in trace gas concentration allowing for analysis over a 
single exhalation. The SIFT-MS technique enables samples to be collected into 
storage containers and then analysed off-line or breath samples to be directly 
exhaled into the instrument for on-line analysis. Traditional MS produces a 
large number of mass fragments for any compound analysed, however SIFT-
MS has overcome this by using chemical ionisation via reagent ions (H3O+, 
NO+ and O2), resulting in a reduction in the degree of collision fragmentation. 
These reagent ions do not react with the major components of breath. Higher 
flow rates of air or breath through the chemical reactor than with other 
techniques have improved the sensitivity of this method4,114,123. 
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 The SIFT-MS technique 1.4.2.
A mixture of ions is produced when water vapour or air is passed through a 
microwave discharge ion source. A reagent ion species (H3O+, NO+ or O2) is 
selected by a quadrupole mass filter and injected into a fast-flowing stream of 
inert carrier gas, usually helium at a pressure of around 1 Torr, passing through 
a Venturi-type opening into a flow tube around 1 m long. The sample gas, for 
example breath, is injected into the analyser at a set flow rate via a heated, 
calibrated capillary. The trace gases in the sample react with the precursor ions 
to produce one or more product ions, their characteristic patterns allowing 
identification. The reagent and product ions then pass through another 
quadrupole mass spectrometer and ion-counting system for detection and 
analysis (Figure 1-2). The decay rate of the reagent ions and production rate of 
the product ions are analysed. The SIFT-MS technique has been described in 
more detail previously4,123.  
 
Figure 1-2. Schematic of the SIFT-MS instrument194. 
The device can be set up in two modes: Mass Scan mode (screening of a 
number of VOCs by their m/z ratios over a selected mass range) and Selected 
Ion Monitoring (SIM) mode, which targets only VOCs of interest, giving 
slightly more accurate quantitation4,114,123.  
An example of the reaction of trace gas, M, and the H3O+ reagent ion resulting 
in the product ion, MH+, is shown in equation (1): 
M + H3O+ ĺ0++ + H2O    (1) 
The relationship between count rates of reagent and product ions, detected 
downstream by the ion-counting system, are shown in equation (2): 
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   [MH+]t = [H3O+] k [M] t    (2) 
Quantification of product ions is possible because the integration time (t) and 
rate co-efficients (k) of reactions between analytes and reagent ions are known, 
and this information is stored within an on-board database4,114,123. Flow rate, 
temperature and pressure are important in the calculation of reaction rates215.  
The water vapour content of on-line breath samples can be used to determine 
the end-tidal portion of a breath119, however it can affect the analysis of gases 
by SIFT-MS216. The sample capillary tube and connecting tubing are heated to 
100°C to prevent condensation in the instrument215 as the error caused by water 
vapour is around 2%216. 
When using the H3O+ reagent ion to analyse a humid gas sample, hydronium 
ions are produced and form clusters: H3O+.(H2O)1,2,3. These ions subsequently 
react with the trace gas molecules to produce product ions, for example 
MH+.(H2O)1,2,3. Accurate quantitation of a trace gas requires the identification 
and addition of all product ions4. The results of these reactions are available for 
several trace gases216-218. 
Various product ions are produced by the reactions of the NO+ precursor ion 
with different trace gases: (M-H)+, M+ or NO+.M3. 
The O2 precursor ion is mainly used to detect small molecules that do not 
react with the other precursor ions and do not fragment during the reaction with 
O2. Such molecules include NO, NO2 and CS2. The molecules are protonated 
with concurrent formation of oxygen4. 
Accuracy and precision 
Initial studies of the accuracy of the SIFT-MS technique used dry gases 
including ethanol, benzene, toluene, xylene, acetone, 2-butanone, 1-methoxy-
2-propanol and trichloroethylene, at concentrations of 10 ppb to 20 parts per 
million (ppm) over a range of partial pressures, producing results to within 
10% of the true concentration using the syringe injection219 and permeation 
tube methods220. Further studies have examined the accuracy of analysis of 
humid samples216-218. Dummer et al.168 observed an 8% instrument 
measurement bias when using known concentrations of acetone at 100% 
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relative humidity. The inter-day and intra-day coefficients of variation (CVs) 
were 5.6% and 0.0%, respectively. 
The precision, or repeatability, of measurements depends upon the number of 
product ions counted; the standard error of an individual measurement is 
calculated as the square root of the total number of product ions. Typical 
standard errors for acetone and ammonia in single breath exhalations range 
from ±5% to ±20%4. The repeatability of SIFT-MS for breath analysis was 
investigated in an off-line study of breath samples collected from ten 
volunteers221. Samples were analysed for 60 sec and then immediately 
reanalysed for another 60 sec. Volatiles at higher concentrations, for example 
acetone and ammonia, had low instrument CVs (1-2%), whilst those at lower 
concentrations, such as HCN, had much higher CVs (19%). This can be 
explained by the differences in analyte concentration and count rate. 
Specificity 
The choice of precursor ion depends upon the trace gas to be analysed. Some 
compounds only react with a single precursor ion and others react with all 
three. The various product ions produced by the different reactions allow 
precise identification of the compound114. For example, the reactions between 
H3O+ precursor ions with acetone and propanal give isobaric product ions at 
m/z 59, however reactions of the NO+ reagent ion form product ions for 
acetone at m/z 88 and for propanal at m/z 57, so they can be accurately 
separated and identified3.  
Few compounds cannot be identified by SIFT-MS; hydrogen and smaller 
alkanes have high ionisation energies and low proton affinities, making 
identification impossible4. 
Dynamic response time 
The dynamic response time is the time taken for changes in analyte 
concentration to be detected by the instrument and differs depending on the 
VOC to be analysed. This has been reported for SIFT-MS as 20 ms4,123. 
Another study reported the 0-90% response time for the quantitation of acetone 
at physiological concentration as 500 ms222. The cause of the discrepancy is not 
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clear, although the instrument set-up may have differed up-stream of the 
sample inlet223. It has been suggested that for accurate measurement of an 
DQDO\WH WKH  UHVSRQVH WLPH VKRXOG EH  RI WKH WRWDO H[KDODWLRQ WLPH
therefore both dynamic response times mentioned above still allow the use of 
SIFT-MS for on-line measurement of single exhalations over 5 sec224. 
 The use of SIFT-MS for breath analysis 1.4.3.
Several studies have used the SIFT-MS technique for on-
line106,110,150,167,168,179,194,201,203,223,225,226 and off-line135,144,184,221 breath analysis. 
Most of these studies have taken healthy volunteers to determine normal trace 
gas values, before comments can be made on concentrations in disease states. 
The distributions of exhaled trace gases appear to be log-normal and an attempt 
to determine the normal ranges of some common VOCs has been made (Table 
1-1)200.  
Table 1-1. The concentrations of common volatile organic compounds in the 
breath of 30 healthy volunteers, as determined by SIFT-MS200.  
Analyte Mean (SD) (ppb) Range (ppb) 
Ammonia 833 (1.2)* 248 - 2935 
Acetone 477 (1.58)* 148 - 2744 
Methanol 450 (1.62)* 32 - 1684 
Ethanol 196 (244) 0 - 1663 
Propanol 18§ 0 - 135 
Acetaldehyde  24 (17) 0 - 104 
Isoprene 118 (68) 0 ± 474 
    *, geometric mean (multiplicative SD); §, median. 
1.5. Acetone 
 Acetone production and metabolism 1.5.1.
Acetone (2-SURSDQRQH GLPHWK\O NHWRQH ȕ-keto-propane, pyroacetic ether) is 
one of the most abundant VOCs found in breath. It is responsible for the 
GLVWLQFWLYH VPHOO RI ³SHDU GURSV´ RQ WKH EUHDWK RI SDWLHQWV ZLWK '.$ ,W LV
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produced as a result of ketosis, which is the consequence of increased lipolysis 
in adipose tissue and ketogenesis in the liver.  
When more acetyl-CoA is produced than can be utilised in the Krebs cycle, 
ketone bodies (acetoacetate and beta-hydroxybutarate) are formed and released 
into the circulation227,228 (Figure 1-3). To enter the Krebs cycle, acetyl-CoA 
must join with oxaloacetate, produced during glycolysis, but when glucose 
levels are low oxaloacetate is preferentially used in the process of 
gluconeogenesis, therefore driving ketogenesis229.  
Acetoacetate can be converted to acetone by enzymatic or non-enzymatic 
decarboxylation227,228,230, the acetone formed being excreted in breath. The 
enzymatic catalyst responsible for decarboxylation, acetoacetate 
decarboxylase, is induced by starvation and inhibited by acetone227,228. This 
process helps to regulate pH by removing excess acetoacetic acid227,229. During 
fasting in healthy individuals about 37% of acetoacetate is converted to acetone 
(up to 50% in those with diabetes), however acetone is by far the least 
abundant of the ketone bodies227. 
 
Figure 1-3. The pathway of ketone synthesis from excess acetyl-CoA. 
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The ratio beta-hydroxybutarate:acetoacetate depends on the redox state of the 
hepatic cells and is normally 1:1, rising to 6:1 after fasting and up to 10:1 in 
DKA229,231. Other pathological states that cause higher concentrations of NAD+ 
and, therefore, an increased ratio of beta-hydroxybutarate:acetoacetate include 
alcoholic ketoacidosis, salicylate poisoning, severe hypoxia, end-stage liver 
disease, hepatic ischaemia, metabolic disorders and multi-organ failure229.  
Ketone bodies perform a protective function as an energy source for vital 
organs in times when glucose is not readily available227,229. Ketones provide 2-
6% energy after an overnight fast and 30-40% after a three day fast. Unlike 
other tissues, the brain cannot use fatty acids as an energy source, so is reliant 
on ketones during starvation; nearly two thirds of its energy requirements are 
provided by ketones during prolonged fasting and starvation. Despite 
protective properties, ketones have also been implicated in the generation of 
ROS229. 
Acetone can be broken down via several pathways to pyruvate, lactate or 
acetate227,228. Very small amounts of glucose can be produced from acetone in 
an attempt to regulate glucose level227,228,232. Radiolabeled carbon within 
acetone molecules has subsequently been detected in glucagon, urea, 
cholesterol, amino acids, fatty acids and exhaled carbon dioxide in animal 
models228, and in lipids and proteins in humans232, showing that metabolised 
components of acetone play a role in anabolic processes.  
In the fasting state in the non-diabetic, ketone production increases in the 
presence of decreasing glucose and then insulin levels, with a concurrent 
increase in glucagon and stress hormone secretion (glucagon, corticosteroids, 
catecholamines and growth hormone). This sequence of events is not as evident 
in Type 1 diabetes, whereby insulin levels remain high despite hypoglycaemia, 
and there is a lack of glucagon and stress hormone release225,228. In DKA, 
elevated stress hormone levels promote ketogenesis, a concomitant abnormal 
increase in glycogenolysis and gluconeogenesis, and a reduction in the 
insulin:glucagon ratio. There is an associated reduction in peripheral uptake of 
glucose as a consequence of insulin resistance233,234. Glucagon stimulates 
further gluconeogenesis and ketogenesis and reduces the oxidation of fatty 
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acids to triglycerides234,235. Insulin is administered to switch off ketogenesis231, 
usually causing a reduction in beta-hydroxybutarate before acetoacetate229. 
Acetone levels appear to be elevated in hyperglycaemic diabetic patients 
without DKA230 and in diabetic patients without hyperglycaemia, in which case 
acetone may act as an early marker of loss of glycaemic control236. 
 Acetone in breath 1.5.2.
As with other highly soluble compounds, rather than exchanging in the alveoli, 
acetone appears to exchange in the airways155; its blood:gas partition 
coefficient has been quoted in the literature between 146 and 400154,174,183,237. 
As a consequence of the wash-in/wash-out phenomenon, the concentration of 
acetone in end-exhaled breath may not be in equilibrium with that in the 
systemic circulation156. This relationship may be improved by a rebreathing 
technique115, which allows at least partial equilibration of acetone in the 
airways and mucus lining, increasing the concentration of exhaled 
acetone156,160. Rebreathing concentrations of acetone, however, have been 
shown to be within measurement uncertainty of single-exhalation 
concentrations; therefore end-exhaled gas sampling and the rebreathing 
technique may be equivalent159. 
Due to its volatile nature, acetone is difficult to accurately analyse in breath 
and blood. Significant intra-individual variation in blood acetone was seen in a 
VWXG\ E\ 2¶+DUD HW DO115, whereas, despite significant inter-individual 
variation, breath acetone concentration appeared to be more consistent. Other 
studies have also shown low intra-individual within session CVs for breath 
acetone concentration (1.6% - 2.6%)168, but significant intra-day (36%) and 
inter-day (15%) variation167,168, as well as inter-individual variation 
(38%)105,167,168,196,238. Exhaled breath acetone concentration appears to correlate 
better with arterial than peripheral venous blood concentration115. 
As described in Chapter 1.3.6., exhaled acetone concentration appears to be 
dependent on breath volume but not expiratory flow rate159,168. A difference in 
breath acetone concentration between children and adults204 was not seen in an 
earlier study203, and some studies have reported higher breath concentration in 
men than women167,205, independent of height, weight and diet205. The observed 
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differences may be due to differences in energy consumption167 or may be 
attributed to discrepancies in exhaled lung volume168. No significant difference 
in acetone concentration was seen when nasal and oral exhalations were 
compared150,222,239 and cigarette smoking does not affect breath acetone 
concentration183,190. 
 Physiological and pathophysiological changes in exhaled 1.5.3.
acetone concentration 
For a long time it has been known that fasting causes a rise in acetone levels in 
blood, urine and breath230,232. Crofford et al.230 reported a linear relationship 
between the concentration of acetone in breath and blood during fasting. A 
more recent SIFT-MS study in healthy volunteers showed elevated breath 
acetone concentration after an overnight fast194, with a fall to nadir within five 
hours of ingestion of a protein-calorie meal. Acetone seems to be formed more 
slowly in obese compared to non-obese individuals during fasting230,232, yet 
there is no correlation between breath acetone concentration and BMI167,204. 
Exercise results in a small increase in breath acetone concentration, as has been 
described in Chapter 1.3.6., believed to be due to the breakdown of fat and 
carbohydrate as energy sources up to anaerobic threshold171,178. It should be 
noted, however, that the volunteers in the study by King et al.171 had high 
baseline acetone concentrations and had been starved for at least seven hours, 
so changes in breath acetone concentration may have been due to ongoing 
fasting.  
Breath acetone has been used to approximate blood glucose240 or plasma 
ketone level195,240 and has been proposed as a useful non-invasive method of 
monitoring response to treatment in diabetes mellitus, however a relationship 
between breath acetone and blood glucose concentrations has not always been 
seen205,226. Lee et al.241 found breath acetone concentration alone did not 
accurately predict blood glucose level, however when used in conjunction with 
other breath markers of glucose metabolism (ethanol, methyl nitrate and 
ethylbenzene) the accuracy of prediction was increased.  
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Differences exist between glucose metabolism in healthy subjects and those 
with diabetes mellitus. In various studies, patients with diabetes mellitus have 
been reported to have higher238,242,243 or similar breath acetone 
concentrations203,226 when compared to healthy individuals. Unfortunately, it 
was not always clear whether patients had Type 1 or Type 2 diabetes238, 
whether patients were fasted or not243, and the blood glucose level at the time 
of breath analysis was not always measured242, making the data difficult to 
evaluate. In any case, the difference in breath acetone concentration between 
patients with diabetes mellitus and healthy controls appeared to be smaller than 
the variation of breath acetone concentration seen in healthy subjects due to the 
time of day or change in diet196. Some individuals with Type 1 diabetes were 
mildly ketotic despite normal blood glucose concentrations243, which, as 
previously mentioned, may help to identify early loss of glucose control236. 
In patients with Type 1 diabetes, an insulin induced reduction in blood glucose 
has been associated with a reduction in breath acetone concentration, possibly 
because insulin has more of an effect on ketogenesis than glucose 
concentration226. In contrast, in healthy individuals a reduction in breath 
acetone concentration following ingestion of glucose as part of an oral glucose 
tolerance test (OGTT) has been associated with an initial increase followed by 
a reduction in blood glucose concentration225,240. Breath acetone concentration 
during OGTT could not distinguish between patients with diabetes, impaired 
glucose tolerance and healthy controls238. A correlation between breath acetone 
and grouped glucose and grouped haemoglobin A1C concentrations was not 
present when glucose and haemoglobin A1C were used as continuous 
variables243. These negative findings were confirmed in a later study in patients 
with Type 2 diabetes205.  
The detection of acetone in breath has been used to monitor the rate of dietary 
fat loss244, to check for ketosis when using ketogenic diets for the treatment of 
epilepsy associated with intractable seizures195, and to investigate metabolic 
stress during cardiac surgery105 and congestive cardiac failure245. During 
cardiac surgery, breath acetone increased slightly after sternotomy and 
significantly after cardiac bypass, mirroring plasma CRP and troponin 
levels105. In individuals with congestive cardiac failure, breath acetone levels 
50 
 
were elevated compared to controls, and much higher in the subgroup with 
marked signs of right heart failure. It was suggested that elevated breath 
acetone was due to a combination of elevated stress hormones, increased 
metabolic rate and malnutrition245.  
Breath acetone has been measured in ventilated patients in the ICU5,7,8 with no 
significant difference in acetone concentration seen in studies using whole 
breath compared to CO2-controlled breath sampling7. Exhaled acetone 
concentration appeared to be higher in patients with ARDS than those who did 
not meet the criteria, although there was no significant difference in 
concentration when patients with and without pneumonia were compared5. It is 
important to note that the inter-individual CVs in this study were high. Acetone 
concentration in blood was lower in patients with sepsis than post-operative 
patients, although exhaled acetone concentration was not significantly different 
between the two groups8. It was suggested that the discrepancy in blood levels 
was due to septic patients being fed and receiving insulin to control blood 
glucose, whereas surgical patients had been starved prior to their operation. 
This does not completely explain, however, why there was no significant 
difference in breath acetone concentration.  
The measurement of breath acetone concentration does not appear to be a 
surrogate for blood glucose monitoring, but has the potential to evaluate 
glucose metabolism and starvation, by way of ketosis, and the degree of 
metabolic stress in critical illness or due to surgery. Elevated levels may 
indicate reduced response to insulin treatment.  
1.6. Hydrogen Sulphide 
 The metabolism and biological role of hydrogen sulphide   1.6.1.
H2S is a colourless gas with a distinctive smell of rotten eggs. The human nose 
can detect H2S down to levels as low as 100 ppb246, however at higher 
concentrations of around 50 ppm it causes inflammation and irritation of 
mucous membranes246,247, and at 250-500 ppb causes severe irritation of the 
respiratory tract and the development of pulmonary oedema246. At atmospheric 
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concentrations over 700 ppm, inhalation of H2S is fatal within minutes, due to 
inhibition of cytochrome c oxidase and therefore cellular respiration246-249.  
The majority of H2S is metabolised via a series of oxidation steps, mainly 
occurring in mitochondria, to sulphate and thiosulphate, which are excreted via 
the kidney250,251. Activated neutrophils can also oxidise H2S252. It binds 
strongly to and can be scavenged by methaemoglobin (metHb)249; haemoglobin 
DFWV DVD FRPPRQ³VLQN´ IRU+2S, NO and carbon monoxide (CO)247,253. The 
administration of hyperbaric oxygen and nitrate in the treatment of H2S 
poisoning are intended to increase the rate of oxidation and the formation of 
metHb, respectively, preventing binding to cytochrome c oxidase254. 
H2S has been proposed as the third gaseous inflammatory mediator after CO 
and NO253. Its formation from amino acids L-cysteine, L-cystathionine, or L-
homocysteine, is catalysed by the pyridoxal-¶-phosphate-dependent enzymes 
cystathionine-Ȗ-lyase (CSE), cystathionine-ȕ-synthase (CBS) and, to a lesser 
H[WHQWȕ-mercaptopyruvate255 (Figure 1-4). The expression of these enzymes is 
tissue specific, for example CBS is mainly present in the brain253,256,257 and 
CSE predominant in vascular tissue253,258,259 and liver252,260,261. The rate of H2S 
production differs across organs, higher in the liver compared to the brain at all 
substrate concentrations, and under anaerobic compared to aerobic 
conditions262. At least partly via a direct effect on KATP channels, H2S can 
cause smooth muscle relaxation (resulting in vasodilatation, possibly 
bronchodilatation, and regulation of peristalsis) and a reduction in neuronal 
excitability, providing a neuromodulatory effect with involvement in learning 
and memory253,263.  
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Figure 1-4. Main pathways of H2S synthesis and removal255. 
There is conflicting evidence in the literature around whether H2S acts as a pro- 
or anti-inflammatory mediator. Its role in the inflammatory process is not clear; 
it seems to influence leucocyte function, it may modulate the activity of NO 
and appears to be involved in the release of cytokines and chemokines, such as 
substance P, calcitonin gene-related peptide and neurokinin A248, at least partly 
via the NF-ț% SDWKZD\264,265. A protective function has been suggested 
because by reacting with several cytotoxic species, such as perioxynitrite, 
hypochlorite, H2N2, O2- and NO, H2S can prevent oxidant-related cell death255.  
H2S is a weak acid and at physiological pH readily dissociates (reaction 
equation below), with around 18.5% remaining as H2S and 81.5% present as 
HS-255.  
H2S ' HS- + H+ ' S2- + 2H+ 
It is therefore unclear whether H2S, the hydrosulphide ion266 or sulphite is 
responsible for any effects seen252. In in vitro and live animal experiments, 
variable results have been produced by differences in the choice and dose of 
H2S donors and the concentration of CSE and CBS inhibitors266. The 
specificity of CSE and CBS inhibitors has been questioned, as well as the 
comparability of the effects of a bolus of H2S produced by the administration 
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of a common donor (NaHS or Na2S) and the endogenous release of H2S which 
is likely to be slower266. High experimental concentrations of H2S may inhibit 
cytochrome c oxidase, but at physiological concentrations could act as a 
substrate for the respiratory chain251. As a result of these problems, a newer 
H2S donor, GYY4137, has been developed, causing a slower and more 
sustained vasodilatory effect on rat aortic tissue than NaHS267 and may, 
therefore, produce a more physiological change in H2S concentration. 
Most interest has been focussed on the effects of H2S on the vasculature. 
Bacterial endotoxins appear to cause vasodilatation and hypotension by 
activation of KATP channels, and it has been proposed that H2S causes 
hypotensive shock via the same pathway266. H2S causes vasodilatation of rat 
aortic tissue in vitro, with and without an intact endothelium, implying a direct 
action on smooth muscle cells via KATP channel modulation258. Injection of an 
H2S donor causes vasodilatation and subsequent hypotension in rats in 
vivo258,267, with the administration of GYY4137 attenuating the development of 
chemically induced hypertension267.  
Elevated plasma H2S is seen in animal models of haemorrhagic shock259, 
endotoxic shock252,260,261 and pancreatitis268, and a small study of sepsis in 
humans261. By blocking CSE activity it is possible to cause a partial reduction 
in the degree of hypotension259 and reduce plasma H2S elevation and multi-
organ inflammation260,261,268. This suggests that organ damage associated with 
sepsis is not due to hypotension alone, and that the effects of H2S in septic 
shock are independent of its potential role in blood pressure regulation260. 
Injection of NaHS in mice produced similar effects to those of endotoxic 
shock, with increased myeloperoxidase (MPO) activity, neutrophil 
DFFXPXODWLRQLGHQWLILHGKLVWRORJLFDOO\DQGLQFUHDVHGOHYHOVRI71)Į261.  
In contrast, administration of GYY4137 to anaesthetised rats in a model of 
HQGRWR[LF VKRFN DWWHQXDWHG WKH GHYHORSLQJ K\SRWHQVLRQ LQKLELWHG 71)Į
production and reduced the rise in iNOS, NF-ț%DFWLYDWLRQDQGRWKHUPHDVXUHV
of inflammatory cascade activity269. In the same model but using conscious 
rats, GYY4137 administration reduced the rise in pro-inflammatory cytokines 
and CRP, reduced the rise in pulmonary MPO activity, increased the 
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production of anti-inflammatory IL-10 and reduced lung tissue damage. It is 
possible, therefore, that the role of H2S at physiological concentration is anti-
inflammatory. 
Oxygen concentration appears to modulate the effects of H2S on in vitro animal 
studies; the same H2S concentration that mediated aortic contraction at high 
oxygen concentration caused relaxation at lower oxygen levels, including 
physiological concentration270. Exogenous H2S caused the same vasoactive 
effects as hypoxia in isolated vascular tissue of rats270, cows and sea lions271. In 
renal tissue, improvements in medullary blood flow have been linked to 
hypoxia-induced H2S formation272. H2S metabolism, therefore, appears to be 
important in oxygen sensing pathways271,272. Progression of renal disease in 
rats corresponded with a reduction in plasma H2S concentration, due to a 
reduction in CBS and CSE expression in kidney and liver tissue272. 
At physiological concentration, H2S appears to exert anti-inflammatory effects 
in the brain and gut, hypothesised to be as a consequence of its influence on the 
regulation of gastric273 and cerebral256 microcirculation. Animal models of 
gastric mucosal damage demonstrated a reduction in plasma H2S and CSE 
expression, inflammatory changes improving on administration of NaHS, with 
DQDVVRFLDWHGDWWHQXDWLRQLQ71)ĮOHYHODQGOHXFocyte adherence in mesenteric 
venules273. An in vitro study by Whiteman et al.257 demonstrated the inhibitory 
effect of H2S on hypochlorous acid-induced oxidative stress in brain tissue. In 
$O]KHLPHU¶V GLVHDVH KXPDQ EUDLQ WLVVXH FRQWDLQV VLJQLILFDQWO\ OHVs H2S than 
expected and showed evidence of oxidative stress256. 
Several studies have examined the effect of H2S on insulin secretion. CBS is 
expressed in the whole of the mouse pancreas but CSE is mainly seen in 
exocrine pancreatic cells274,275. In in vitro animal models of insulin-secreting 
cell lines, increased H2S concentration, due to NaHS or L-cysteine 
administration or stimulation of CBS, caused a reduction in insulin 
secretion274,276, via opening of KATP channels274,277. These effects were reversed 
by CSE277 and CBS inhibition and the administration of glibenclamide274, a 
drug used to treat diabetes mellitus and known to block KATP channels, 
suggesting that H2S modulated the secretion of insulin via KATP channel 
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activity274. Hyperglycaemia was associated with a reduction in H2S production, 
increased insulin secretion277, but a slight increase in CSE expression275. 
Hyperglycaemia-related islet cell apoptosis was suppressed by the addition of 
NaHS, therefore it was suggested that H2S may be involved in the mechanism 
E\ZKLFKSDQFUHDWLFȕ-cells are protected from glucotoxicity in diabetes275. 
In diabetic rats, increased pancreatic and hepatic H2S production was 
associated with greater CBS expression in the pancreas and CSE and CBS 
expression in liver, when compared to non-diabetic animals278. Insulin 
administration restored these changes, but resulted in higher plasma H2S 
concentration compared to diabetic rats and controls, the cause of which is 
unclear278. H2S also appears to modulate glucose uptake in rat adipose tissue279. 
Endogenous formation of H2S due to CSE activity in rat adipose tissue caused 
a reduction in basal and insulin-mediated glucose uptake in adipocytes, which 
was reversed by CSE inhibition. As previously described in pancreatic 
tissue277, high glucose concentration was associated with lower H2S 
concentration in adipose tissue279. Inhibition of glucose uptake by H2S 
appeared to involve the PI3K rather than the KATP channel pathway279. 
In humans, plasma samples from male subjects with non-insulin dependent 
Type 2 diabetes mellitus (median concentration 10.5 µmol/L) were lower than 
those from BMI-matched overweight subjects (22.0 µmol/L) and lean men 
(38.9 µmol/L)280. There was a negative correlation between H2S concentration 
and blood pressure, microvascular function, glycaemic control and insulin 
sensitivity. Waist measurement and other measures of adiposity were 
independent predictors of H2S concentration, which may be confounded by 
peripheral insulin sensitivity280.  
 Hydrogen sulphide and airways disease 1.6.2.
H2S, via the addition of NaHS, has been demonstrated to cause tracheal smooth 
muscle cell relaxation, but had no effect on muscle tension when added to cells 
that had not been pre-contracted281. In isolated airway smooth muscle cells 
from resected or donor lungs, the administration of both NaHS and GYY4137 
resulted in inhibition of both cell proliferation and pro-inflammatory IL-8 
release282. By blocking CBS but not CSE activity, the effects of H2S were 
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reversed and further inflammation was seen, hence the effects of H2S seem to 
be anti-inflammatory and dependent on CBS activity282.   
Acute lung injury (ALI) in the oleic acid-induced rat was associated with 
reduced plasma and pulmonary H2S concentration283. Injection of NaHS 
reduced the degree of pulmonary injury and inflammatory cell infiltrate, and 
caused an elevation in the level of the anti-inflammatory cytokine IL-10283. 
Similar effects were also observed in a murine model of ALI associated with 
burns and smoke inhalation, where there was an associated reduction in 
mortality and improved survival rate284. These results differ from those of 
Bhatia et al.268, who saw elevated plasma H2S in a rat model of pancreatitis and 
ALI. In their experiment, the addition of a CSE-inhibitor reduced the degree of 
lung inflammation and MPO activity. 
The effects of administering NaHS and a CSE blocker were similar in animal 
models of asthma-related285 and cigarette-exposure-related lung 
inflammation281. Administration of NaHS led to a reduction in the previously 
induced lung inflammation, whereas injection of a CSE blocker further 
aggravated airway hyperresponsiveness. Injection of NaHS in ovalbumin 
(OVA)-treated rats caused a reduction in iNOS activity, indicating that H2S 
may modulate airway inflammation via interactions with the NO pathway285. 
The administration of NaHS in control rats had no effect on pulmonary 
function, lung pathology or cell counts in BAL fluid285. There were some 
important baseline differences between the two studies; lung tissue and serum 
from OVA-treated rats contained lower H2S concentration, in association with 
reduced CSE expression, when compared with controls285, however in 
cigarette-exposed rats lung CSE expression and plasma H2S were higher than 
controls281. In the asthma model, serum and lung tissue H2S concentrations 
negatively correlated with inflammatory cells (neutrophils and eosinophils) in 
BAL fluid285. The difference in CSE expression and production of H2S 
between the two models of lung inflammation may be in the chronicity of the 
exposure; OVA-treated rats may show an acute inflammatory response, 
whereas rats exposed to cigarette smoke daily for four months may display a 
pattern of chronic inflammation.  
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Stable patients with asthma have been observed to have lower serum H2S 
concentrations than controls, the lowest concentrations seen in patients with 
severe acute exacerbations (reviewed254,286). There was a positive correlation 
between H2S concentration and severity of airways obstruction, and a negative 
correlation with sputum cell count and neutrophilia. Serum H2S was lower in 
smokers than non-smokers in all groups. The authors hypothesised that airway 
H2S production in asthma causes inflammation and bronchoconstriction, 
however it is difficult to determine whether lower serum H2S in asthma 
patients is the cause or consequence of the condition. 
In contrast, studies of H2S in patients with COPD revealed higher serum 
concentrations when compared to controls, however worsening lung disease 
was associated with a reduction in H2S concentration, including during acute 
exacerbations. An inverse relationship was seen between H2S and sputum 
neutrophil count, but positive correlation between H2S and sputum lymphocyte 
and macrophage levels and lung function, as measured by forced expiratory 
volume in 1 sec (FEV1). The effect of smoking on serum H2S was not 
consistent in the two studies, with significantly lower H2S in smokers 
compared with non-smokers in the first study and no significant difference in 
the second287,288. Treatment with theophylline for one month did not affect 
serum H2S concentration, however it was associated with a reduction in sputum 
neutrophil count288. It was concluded that higher H2S levels were protective, 
with reduced inflammatory cells in sputum and increased smooth muscle-
related bronchodilation287,288.  
A further study of serum H2S and airways disease focussed on the relationship 
with pulmonary infection289. No significant difference in H2S concentration 
was seen between patients with acute exacerbations of COPD and controls. 
Acute infection was associated with significantly lower H2S concentration in 
those with pneumonia versus controls and those with infective exacerbations of 
COPD compared to non-infective exacerbations. There was a weak inverse 
relationship between serum H2S concentration and CRP. 
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 Hydrogen sulphide in breath 1.6.3.
The administration of intravenous Na2S resulted in a dose dependent increase 
in H2S concentration, measured by a sulphide gas detector, in the exhaled 
breath of mice290 and humans291. The concentration of exhaled H2S increased 
rapidly after commencement of the infusion with an equally rapid reduction 
when the infusion was stopped291. Although less than 1% of the total amount of 
sulphide injected was removed via the lungs291, it still seems possible that 
increased concentrations of H2S in exhaled breath could be used as a marker of 
elevated plasma H2S, as long as changes in breath could be measured at the 
ppb level. The quantification of H2S in humid air by SIFT-MS has enabled the 
use of this technique for the detection of H2S in human breath217. 
Oral bacteria produce H2S, along with other sulphur compounds, which is 
detectable in human breath292. Several methods have been employed in an 
effort to reduce the concentrations of these sulphur compounds that cause 
halitosis, the most effective being rinsing the mouth with hydrogen peroxide 
solution292. When measuring H2S in exhaled breath, levels were found to be up 
to ten times higher in oral than nasal samples, although this was a small study 
of only two subjects and it was unclear whether breath samples were taken 
following mouth or nose breathing149. By first rinsing the mouth with hydrogen 
peroxide solution and then performing a nasal exhalation, contamination by 
oral H2S can be avoided223. H2S is present in small quantities in cigarette 
smoke187 but there is no evidence that it is detectable in the breath of smokers.  
End-expiratory breath samples were collected orally from healthy volunteers, 
after a 15 sec breath hold with the mouth wide open, and analysed by a gas 
chromatograph equipped with a chemiluminescence sulphur detector. Results 
for exhaled H2S were only slightly higher than concentrations in ambient air262. 
These results are mirrored by those from nasal exhalations in experiments by 
Dummer223 using a SIFT-MS device. The concentration of H2S in exhaled 
breath correlated with the ambient air, thus the possibility of contamination by 
inspired air could not be ruled out. It was, therefore, not possible to identify 
whether exhaled flow or volume had any effect on H2S concentration223.  
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When examining H2S in breath as a potential marker of inflammation in 
airways disease, Dummer223 found no significant difference between mean-
exhaled or end-exhaled breath concentrations in subjects with COPD or asthma 
versus controls. There was a significant negative correlation between H2S and 
sputum neutrophil count in COPD patients and a positive correlation between 
H2S and markers of eosinophilic inflammation in asthmatic patients, although 
neither relationship reached statistical significance. 
Two studies of breath H2S have been performed in other inflammatory states, 
revealing higher breath concentrations in chronic pancreatitis compared to 
healthy controls293 and lower concentrations in lung transplant recipients with 
evidence of acute rejection compared to those with stable lung function, 
although the difference did not reach statistical significance294. Unfortunately, 
it was not possible to distinguish patients with disease from their respective 
controls using breath H2S results due to concentration overlap between the 
groups293,294. 
If H2S behaves in the same way as NO, it is possible that pulmonary infection 
will result in higher breath concentrations as a result of local production in the 
airways, as seen in two previous studies of exhaled NO in ventilated 
patients117,118. 
These findings suggest further studies are required to investigate whether H2S 
could act as a biomarker of airway inflammation. The relationship between 
breath and serum H2S requires further exploration as it is possible that breath 
H2S may act as a marker of systemic inflammation as well. 
1.7. Hydrogen Cyanide 
 Hydrogen cyanide exposure and its biological role 1.7.1.
At physiological pH and temperature, cyanide is largely found as volatile HCN 
gas295 which has a bitter almond smell. Its toxicity is well known, being lethal 
if inhaled at concentrations over 300 ppm296 and causing hypoxia and collapse 
at lower concentrations297. Its toxic effects are caused by the inhibition of 
aerobic respiration in mitochondria by the competitive inhibition of 
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cytochrome c oxidase249,295,298. Despite its toxicity, HCN has been found in 
small quantities in blood299 and breath of healthy individuals300. 
HCN is commonly detected at concentrations above 1,000 ppm in domestic 
fires, produced by the combustion of nitrogen-containing materials in solid and 
upholstered furniture and bedding297. Death probably results from rapid 
collapse (only requiring 2 min exposure at 200 ppm) preventing escape and 
allowing further exposure to poisonous levels of HCN and CO297. Blood 
cyanide levels in fire victims are usually low297, possibly because over 98% is 
bound to metHb298,299,301 and that remaining in the plasma disperses into 
tissues297 where it is detoxified by conversion to thiocyanate191,301. It is 
unbound HCN in plasma that causes toxic effects301. Antidotes for cyanide 
poisoning induce methaemoglobinaemia in the belief that the strong affinity of 
metHb for HCN249,298,299,301 will prevent it binding to cytochrome c 
oxidase249,297,298. 
HCN is found in cigarette smoke123,186-188 and in higher concentrations in the 
breath123,192,301, saliva191 and blood of smokers than non-smokers191,301. The 
detoxification of HCN to thiocyanate results in higher plasma191,301 and 
salivary thiocyanate191 concentrations in smokers than non-smokers, allowing 
distinction between the two groups191. Plasma thiocyanate concentrations 
decrease slowly, taking up to 14 days to return to normal after smoking 
cessation301, however a study of volunteers breathing HCN at 10 ppm for 1 min 
(equivalent to smoking one cigarette), showed that the half-life in exhaled 
breath was very short, only 10-22 sec302. This led the authors to conclude that 
even at fatal inspired concentrations the exhaled concentration of HCN should 
be low, therefore high breath concentration may indicate systemic intoxication.  
Oral exposure to HCN in food is not uncommon as many plants, particularly 
food crops, are cyanide producing, such as maize, rice, wheat, barley, rye, oats, 
apples, sugar cane and cassava. This property is believed to protect the plants 
against pests and ward off herbivores. Humans have overcome the problem by 
pre-processing food and detoxifying any HCN consumed by the activity of 
sulphurtransferases in the gut. These enzymes require sulphur-containing 
amino acids, which is why low protein diets in countries where large quantities 
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of high HCN-containing crops, particularly cassava, are eaten can lead to 
chronic HCN poisoning303.  
Leucocytes contain thiocyanate, MPO and hydrogen peroxidase, mixtures of 
which in other settings have been seen to contain HCN304, therefore the 
observed production of HCN within these cells is plausible. Under 
physiological conditions, thiocyanate has been found to be a major substrate 
for MPO305 and eosinophil peroxidase306, although the main product of these 
reactions was hypothyocyanite rather than HCN, which is believed to play an 
antimicrobial role in the oral cavity307. Further studies have confirmed the 
production of HCN by phagocytosing polymorphonuclear lymphocytes in the 
presence of Staphlococcus epidermidis and Escherichia coli308. Via the 
MPO/H2O2&OØ V\VWHP PRUH +&1 ZDV SURGXFHG E\ WKH FKORULQDWLRQ RI S. 
epidermidis than E. coli and this was explained by a larger amount of the 
substrate glycine in S. epidermidis cell walls. HCN production was augmented 
following damage to S. epidermidis cells by a sublethal dose of penicillin G308. 
In subsequent experiments, Stelmanszynska showed that, in the presence of S. 
epidermidis, leucocytes can produce cyanide from thiocyanate, again via the 
MPO/H2O2&OØV\VWHP2QO\PLQXWHTXDQWLWLHVRI+&1ZHUHIRUPHGKRwever, 
by leucocytes without bacterial stimulation309. The biological role of HCN 
LWVHOI LV VWLOO XQFOHDU DOWKRXJK LW DSSHDUV WR VWLPXODWH WKH ³UHVSLUDWRU\ EXUVW´
during phagocytosis310 and may therefore have a role in the inflammatory 
process. 
 Hydrogen cyanide production by Pseudomonas aeruginosa 1.7.2.
P. aeruginosa is a cyanogenic bacterium producing HCN from glycine, 
catalysed by the enzyme HCN synthase associated with its cell membrane. The 
function of this phenomenon is not fully understood295, however by excluding 
other microorganisms it may improve its chances of colonisation311. P. 
aeruginosa is not affected by high HCN concentrations itself, having 
developed a respiratory chain that is not inhibited by HCN and employing 
several mechanisms to detoxify its environment311. P. aeruginosa produces 
many other VOCs218,312 however the production of HCN311 and 2-
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aminoacetophenone111 appear to be almost unique to this organism, potentially 
allowing its identification. 
P. aeruginosa is an opportunistic pathogen, colonising and causing infection in 
patients with chronic lung diseases, particularly those with CF, and immune 
system compromise. It is one of the most common nosocomial pathogens and 
commonly causes VAP (reviewed313). The presence of P. aeruginosa in the CF 
lung is associated with poorer lung function and increased mortality314, 
therefore its detection is crucial in order to delay CF lung disease 
progression315 by modifying treatment and attempting eradication. 
Four different methods of detection of HCN or the cyanide ion in 
microbiological samples have been employed in previous studies; detection of 
HCN in the headspace above solid or liquid culture media by SIFT-MS218,312,316 
or GC-MS312, detection of the cyanide ion in sputum314 and BAL samples315 
using a cyanide ion selective electrode, and by liberating cyanide from sputum 
by acidification followed by cyanide assay test317. 
HCN is more consistently detected in the sputum of P. aeruginosa positive 
patients than in non-infected individuals314,315,317. It is not always detected in 
infected samples314, however, and can be detected in those that do not culture 
P. aeruginosa315,317; non-infected samples contained HCN at lower 
concentrations than infected samples315. Two studies show conflicting results 
in terms of correlation of cyanide concentration in sputum and lung 
function314,317. In the study by Ryall et al.314, the cyanide positive group 
showed significantly lower FEV1 and forced vital capacity (FVC) which could 
not be explained by age, sex or P. aeruginosa sputum load. Stutz et al.315 
proposed that HCN production was related to pulmonary inflammation rather 
than infection with P. aeruginosa because their study of 226 BAL samples 
from 96 children with CF reported an association between cyanide 
concentration and neutrophil count. The relationship between HCN and poorer 
lung function314 may also be explained by greater levels of neutrophil 
inflammation. In the CF lung, both neutrophils and Pseudomonas species may 
be producing HCN, therefore the relative effects of HCN from both of these 
sources is unknown307.  
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The use of antibiotics may affect the quantity of HCN produced by P. 
aeruginosa in the CF lung. In the study by Sanderson et al.317, the 
administration of intravenous antibiotics to treat P. aeruginosa chest infections 
was followed by a reduction the concentration of HCN to undetectable levels in 
the sputum of four of seven cases and the highest concentration was seen in a 
sputum sample from a patient with chronic P. aeruginosa infection who was 
not taking antibiotics. It was not clear whether decreased HCN production was 
related to a reduction in bacterial load, the level of pulmonary inflammation, or 
a direct effect of antibiotics on HCN production. 
A study by Gilchrist et al.311 revealed higher concentrations of HCN in sputum 
samples containing non-mucoid compared to mucoid strains, a study 
contradicted by Stutz et al.315 who found higher HCN concentrations in 
association with mucoid strains. Another study of several P. aeruginosa strains 
showed a difference of up to two orders of magnitude in the concentration of 
some VOCs produced, and that culturing P. aeruginosa on solid media 
produced higher concentrations of HCN than when the same sample was 
cultured in liquid media312. This suggests the difference in HCN concentration 
between mucoid and non- mucoid strains between the two studies could be the 
result of differences in culture media, or duration of incubation. It is, however, 
clear that the production of HCN by different strains of P. aeruginosa is 
variable, which probably explains why the production of HCN does not appear 
be related to the concentration of P. aeruginosa314. 
 Hydrogen cyanide in breath 1.7.3.
HCN is soluble with a blood:gas partition coefficient greater than 100, thus it is 
likely to behave like acetone and exchange predominantly in the airways302,318. 
HCN can be detected in breath after the administration of sodium nitroprusside 
as an anaesthetic agent. Breath concentrations follow changes in plasma 
concentration, with a linear relationship between log10 breath and plasma 
concentrations301. 
HCN can be identified in orally exhaled breath of healthy subjects203,319 at 
levels around 50 times higher than would be expected from plasma levels319. 
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Higher concentrations of HCN are found in orally compared to nasally exhaled 
air150,223,239,318, the highest concentrations being found in the oral cavity150. In 
order to investigate the source of HCN in the oral cavity, Lundquist et al.319 
performed in vitro experiments on saliva, demonstrating the formation of 
cyanide in aerated saliva at 37°C, enhanced by the presence of glucose. Further 
heating prevented cyanide production, implying enzymatic involvement, in 
agreement with previous experiments showing catalysation by salivary 
peroxidase304. A similar process is responsible for HCN production in the lung, 
catalysed by lactoperoxidase in the healthy lung and MPO in the presence of 
pulmonary inflammation307.  
HCN produced in the mouth can contaminate nasally exhaled breath, so for 
accurate HCN quantitation it has been suggested that nasal breathing followed 
by a nasal exhalation should be performed151. Oral, but not nasal, breath HCN 
concentration is increased after eating and drinking, implying HCN generation 
in the mouth318.  
Variation in HCN concentration at low levels in ambient air does not appear to 
affect exhaled concentrations151, however higher inspired concentrations result 
in higher exhaled concentrations302. Exhaled breath volume has no effect on 
HCN concentration151, however, due to low concentrations of HCN in the 
exhaled breath of healthy subjects and a correlation with ambient air, it was not 
possible for Dummer223 to fully examine the effects of exhaled flow rate on 
physiological concentrations of breath HCN. Due to differences in breath 
sample collection (oral versus nasal, mixed versus end-exhaled breath) and 
analysis, there is discrepancy in the literature around the effects of gender, age 
and oral intake on breath HCN concentration200,318,320,321. 
In studies by Dummer223, the concentration of exhaled HCN in patients with 
COPD and asthma was not statistically different when compared to healthy 
individuals. A negative correlation existed between HCN in breath and sputum 
neutrophil count in the COPD group and a positive correlation between HCN 
in breath and sputum eosinophil count in asthma, neither of which reached 
statistical significance. Larger studies are needed to further examine whether 
there is a true relationship between these markers. The role of HCN in the 
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inflammatory process is not fully understood, both in localised airway 
inflammation or systemic inflammation, and this requires further studies in the 
clinical field. 
Three SIFT-MS studies have been performed to assess the utility of breath 
HCN as a marker of P. aeruginosa colonisation or infection. Significantly 
higher breath HCN concentrations were seen in children with CF and known P. 
aeruginosa colonisation when compared to children with asthma110, but oral 
exhalations were performed in this study, which must be borne in mind when 
interpreting the results. In a recent study of 20 adults with CF, oral breath HCN 
concentrations were similar in P. aeruginosa colonised and non-colonised 
subjects, but higher median concentrations were observed in nasally exhaled 
breath of those with P. aeruginosa (11 ppb versus 0 ppb)239. The two groups 
could not be separated by breath HCN concentration, however, due to 
considerable overlap between the two groups; four subjects with chronic 
infection had nasal breath concentrations lower than 5 ppb and two without 
infection had nasal breath concentrations greater than 10 ppb239. In another 
recent study of 30 adults with bronchiectasis, including three with CF, there 
was a small but significant difference in nasal end-exhaled HCN concentration 
between those with bronchiectasis and healthy controls (median 3.7 ppb versus 
2.0 ppb), but no difference in breath concentration between patients colonised 
with P. aeruginosa and those who were not151. These results reveal that, at 
present, despite the known production of HCN by P. aeruginosa it cannot be 
used as a reliable breath marker for the presence of this bacterium in the lung. 
1.8. Hypotheses and aims 
There are two main hypotheses to be explored in this thesis. Firstly, that 
increased metabolic and oxidative stress in critical illness, as well as the 
development of stress hyperglycaemia, leads to increased breath acetone 
concentration. It is believed that elevated breath acetone concentration, despite 
adequate insulin therapy for hyperglycaemia, indicates an increased risk of 
developing further organ failure. Secondly, that exhaled H2S and HCN are 
elevated in the presence of infection and inflammation in this pro-inflammatory 
state. If these compounds are detectable in breath, there is uncertainty around 
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whether they originate in the airway or are due to systemic production. The 
utility of these VOCs for the diagnosis of pneumonia in intubated and 
ventilated patients is explored. 
The aims of the thesis are: 
x To evaluate the efficacy of the breath sampling apparatus and Tedlar 
bags for the collection and storage of acetone, H2S and HCN in breath. 
This is necessary to confirm the suitability of these materials for 
subsequent parts of the study, enabling causes of sample loss and 
contamination to be identified and quantified, if possible. 
x To develop an off-line end-exhaled breath sampling technique for use 
in intubated and ventilated patients in the ICU, ensuring that it is 
repeatable and will provide reproducible results. 
x To develop a breath sampling technique for use in anaesthetised 
intubated patients, comparable to that used in the ICU. The rationale for 
this aim was to develop a technique that allowed samples to be 
collected from a healthy control group and to explore how altering 
anaesthesia machine settings might alter the concentration of VOCs 
collected. 
x To explore changes in breath acetone concentration over time in two 
groups of patients in the ICU; patients with stress hyperglycaemia and 
those with new pulmonary infiltrates on CXR. Also, to assess the utility 
of breath acetone as a marker of illness severity and clinical outcomes. 
The rationale for this aim is that if acetone is a marker of oxidative and 
metabolic stress, seen as an alteration in glucose metabolism105,245, then 
it should correlate with conventional measures of illness severity. 
x To explore specifically the variation in breath acetone concentration 
with insulin administration and feeding, and to assess whether it could 
be used to guide insulin or feeding regimes.  
x To investigate any change in concentrations of H2S and HCN over time 
in ICU patients with new pulmonary infiltrates on CXR and to correlate 
these changes with clinical parameters, as well as assessing the utility 
of these VOCs for the diagnosis of pneumonia. 
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x To examine the effects of factors known to influence exhaled VOC 
concentration, for example breathing pattern152,157,163,168 and inspired 
VOC concentration181,182. 
x To investigate any relationship between breath and serum VOC 
concentrations. 
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2. The effect of breath collection apparatus and 
sample storage on breath analyte concentration 
2.1. Introduction and aims 
It is not always possible for an individual to travel to a SIFT-MS instrument 
and, due to its size, weight and infection control issues, the instrument cannot 
always be moved to an individual, therefore breath analysis may have to be 
performed off-line. Appropriate breath collection equipment and containers are 
thus required for the collection, storage and transport of breath samples in 
order to preserve their integrity. 
Volatile organic compounds (VOCs) behave differently in different containers, 
thus it is important to understand how the compounds of interest will behave in 
a chosen container. When stored in polymer bags, all breath samples are 
DIIHFWHG E\ D GHJUHH RI YRODWLOH DGVRUSWLRQ RQWR WKH EDJ¶V LQQHU VXUIDFH
diffusion out of the bag and contamination from pollutant diffusion into the bag 
and from compounds emitted by the bags themselves134,135,137-140. Effective bag 
cleaning is necessary to prevent analytes from one sample causing 
contamination of subsequent samples134,138,140.  
It is important to consider whether other components of the breath collection 
equipment might release or absorb volatile gases and, therefore, affect sample 
composition prior to analysis. In order to compare breath VOC concentrations 
across different studies, the effect of different equipment and sampling 
processes on sample concentration must be investigated. 
The aim of this part of the study was to evaluate any change in analyte 
concentration and humidity of breath samples due to the breath collection 
apparatus and storage in incubated Tedlar bags. It was important to use breath 
in the experiments wherever possible, rather than humid gas mixtures, to 
enable changes in physiological concentrations of VOCs and humidity to be 
explored. The process of bag cleaning will be described and evaluated. 
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2.2. Methods 
 Bag cleaning 2.2.1.
A standard cleaning procedure was established at the start of the study. 
Transparent 1 L Tedlar bags with single polypropylene hose/valve fittings (film 
WKLFNQHVVȝP6.&,QF86$ZHUHHPSOR\HGLQDOOVHFWLRQVRIWKLVWKHVLV
Bags were filled with medical air from the wall supply, left for over an hour 
then evacuated. This process was repeated three times, with the bags being left 
full of air overnight at least once. Bags were refilled a fourth time for analysis 
of the contents by SIFT-MS. Bags were not heated. Bags containing VOCs at 
concentrations less than 110% of medical air supply concentrations were 
DFFHSWHGDV FOHDQ µ'LUW\¶ EDJV FRQWDLQLQJ KLJKHU 92& FRQFHQWUDWLRQV ZHUH
flushed and analysed again until concentrations were no more than 110% of 
medical air concentrations. For all other parts of this thesis, clean Tedlar bags 
were used unless otherwise stated. 
 The effect of sample storage on analyte concentration and 2.2.2.
humidity 
Six Tedlar bags were filled with breath by healthy members of laboratory staff 
exhaling directly into them and each was analysed immediately by SIFT-MS. 
Bags were then incubated at 40°C (MIR-162, Sanyo Electric Co. Ltd, Japan) to 
prevent condensation of the humid samples. Higher temperatures were not used 
in order to avoid potential bag wall damage and impairment of storage 
integrity242. The contents of each bag were analysed by SIFT-MS at 30 min 
intervals for two hours, then hourly for another two hours. The concentrations 
of acetone, H2S and HCN were calculated along with a measure of the H3O+ 
precursor and hydrated ion counts. The concentration of Tedlar specific 
contaminant compounds was assessed. Each bag was removed from the 
incubator for the duration of analysis only, then immediately returned. Bags 
were stored in the incubator for a total of four hours, because breath samples 
were unlikely to need longer storage periods before analysis in subsequent 
parts of this thesis. 
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 The effect of the breath collection apparatus on sample 2.2.3.
concentration 
Firstly, the proposed breath sampling equipment was tested for the emission of 
volatile gases at the mass-to-charge ratios (m/z) of the three volatiles of 
interest. Air in a sealed inert container was analysed by SIFT-MS, then an item 
of proposed breath sampling equipment was placed inside. The container and 
its contents were incubated at 40°C for 30 min. The headspace above the piece 
of equipment was then analysed by SIFT-MS. This process was repeated with 
each piece of equipment that could be incubated. 
The breath collection apparatus was set up as if to collect a patient's breath 
sample. Two pieces of suction catheter tubing (4.7 mm x 53 cm, Ch14, Pennine 
Healthcare, UK) had their tips cut off up to the side holes and the tapered ends 
trimmed. The two suction catheters were connected by a sampling filter 
(DISMIC®-25, Advantec®, Toyo Roshi Kaisha Ltd, Japan) (total 8 ml dead 
VSDFHLQWXELQJDQGILOWHU2QHRIWKHVXFWLRQFDWKHWHUVZDVMRLQHGWRWKHµLQ¶
port of a handheld pump (Gilian® Personal Air Sampler, Sensidyne, USA) via 
the tapered end. The pump flow rate was set to 1.8 L/min (checked by a 
pneumotachometer (RSS 100, Hans Rudolph Inc, USA)). 
A Tedlar bag was filled with breath by a member of laboratory staff exhaling 
directly into it and was analysed immediately by SIFT-MS. It was then 
attached to the free end of the suction catheter. An empty Tedlar bag was 
attached to the pump output tube and the pump switched on for 4 sec (the 
duration over which a breath sample would be taken) (Figure 2-1). A breath 
sample of approximately 150 ml was transferred from the full to the empty bag. 
The pump was switched off and the new sample placed to one side whilst 
another empty Tedlar bag was attached to the pump and the process repeated to 
give a total of three new samples. Breath samples were analysed in turn by 
SIFT-MS. The remainder of the initial sample was re-analysed to look for any 
changes in volatile concentration and humidity. The process was performed 
with a total of seven original breath samples containing VOCs at different 
concentrations. The pump was turned on to suck room air through the 
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equipment for at least 2 min between different initial breath samples in order to 
flush out the previous sample and prevent contamination of further samples. 
 
Figure 2-1. Photograph displaying initial breath sample in Tedlar bag (right) 
and bag for collection of sample after it had passed through the suction 
catheters, biological filter and handheld pump (left). 
To eliminate any effect of dead space gas in the pump and tubing on the first 
sample drawn through the apparatus, the experiment was performed again, as 
above, with three further Tedlar bags of breath. This time, the first sample 
drawn through the pump was discarded. A fourth sample was drawn through 
the apparatus to give a total of three samples for analysis. The effect of 
discarding the first new sample on mean VOC concentrations and percentage 
CVs of VOC concentration for the three new samples from each initial sample 
bag were investigated. 
 The effect of the pump on sample concentration 2.2.4.
A Tedlar bag was filled with breath by a member of laboratory staff exhaling 
directly into it and was analysed immediately by SIFT-MS. It was then 
DWWDFKHGGLUHFWO\WRWKHµLQ¶SRUWRIWKHSXPSDQGDQHPSW\7HGODUEDJDWWDFKHG
to the output tube (Figure 2-2). The pump was switched on for 4 sec and 
approximately 150 ml of breath was transferred from the full to the empty bag. 
The pump was switched off, the new sample placed to one side and another 
empty Tedlar bag was attached to the pump. The process was repeated to give 
a total of three new samples. Samples were analysed in turn by SIFT-MS and 
Tedlar bag 
Biological filter 
Suction catheter 
tubing 
Hand-held pump 
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the rest of the initial sample was re-analysed. This process was repeated with 
five different breath samples containing VOCs at different concentrations. 
 
Figure 2-2. Photograph of the hand-held pump, original breath sample in a 
Tedlar bag (right) and the sample after it had passed through the pump (left). 
 The effect of the sampling filter on sample concentration 2.2.5.
A test gas of 100% relative humidity was produced using dilution apparatus 
(Syft Technologies Ltd, NZ), a permeation chamber (Dynacalibrator Model 
150, VICI Metronics, USA) and permeation tubes of acetone (Kin-tek, USA) 
and H2S (Metronics, USA). The permeation tubes had known emission rates of 
1269 and 489 ng/min at 40°C, respectively. Test gas flowed directly into the 
instrument and the concentration of acetone or H2S was analysed. The 
sampling filter was then attached to one end of the flow tube and to the SIFT-
MS instrument (Figure 2-3). The test gas was then analysed at least twice after 
passing through the filter. The concentration of each test gas was altered using 
the dilution apparatus to enable the experimental process to be repeated with 
six different acetone and six different H2S concentrations. 
Tedlar bags 
Hand-held pump 
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Figure 2-3. Photograph displaying the biological filter in-line with the test gas 
flow and SIFT-MS input port. Arrow shows direction of gas flow. 
 Selected ion flow tube mass spectrometry 2.2.6.
The concentration of volatiles in exhaled breath and humid gas samples was 
measured by SIFT-MS, Voice200® (Syft Technologies Ltd, NZ), described in 
detail in Chapter 1.4. of this thesis. Bag samples were attached to the sampling 
capillary end cap of the heated inlet extension of the SIFT-MS and analysed for 
30 sec (Figure 2-4). 
 
Figure 2-4. Photograph showing a Tedlar bag attached to the Breath Head and 
Heated Inlet Extension of the SIFT-MS instrument via a needle through the 
EDJ¶VYDOYH 
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Scans were performed in mass scan (MS) and selected ion monitoring (SIM) 
modes. Using the touch screen to control the instrument, results were displayed 
on a computer interface using LabSyft software. In SIM mode, the average 
concentration of an analyte over a desired time interval was calculated by 
dragging the cursor over the selected area of the trace, causing the 
concentration to appear in a pop-up box. 
Ion reactions 
The NO+ reagent ion was used to analyze breath acetone. The reaction is an 
ion-molecule collisional association with He atom stabilization322:  
NO+ + CH3COCH3 +Hĺ12+.CH3COCH3 (+ He) 
The NO+ reagent ion was monitored at m/z 30, and the NO+.H2O hydrated 
reagent ion at m/z 48 as this ion is formed in humid air mixtures. The 
NO+.CH3COCH3 product ion was monitored at m/z 88. 
The H3O+ reagent ion was used to analyse breath H2S and HCN. The reactions 
are proton transfer reactions217,218: 
H3O+ + H2S ' H3S+ + H2O 
H3O+ + HCN ' H2CN+ + H2O 
The H3S+ and H2CN+ product ions were monitored at m/z 35 and 28, 
respectively. The H3O+ reagent ion was monitored at m/z 19 and the hydrated 
ions H3O+.H2O, H3O+(H2O)2 and H3O+(H2O)3, formed in humid air mixtures, 
at m/z 37, 55 and 73, respectively.  
The H3O+ ion is the only reagent ion that can be used to measure H2S. It does 
not react with NO+ and the product of the reaction with O2+, H2S+, reacts 
quickly with H2O217. A proton donation reaction can only occur if the proton 
affinity of the acceptor is greater than that of the donor. The difference in 
proton affinities of H2S (705 kJ/mol) and H2O (691 kJ/mol) is 14 kJ/mol, 
which is less than the suggested 20 kJ/mol for proton donation to occur, 
therefore it is possible for the reverse reaction to occur if extra energy is 
generated by the protonated product ions323. The rate coefficient of the reaction 
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of H2S with H3O+ has been calculated in humid air217 allowing accurate 
calculation of concentration.  
The difference in proton affinity between HCN (713 kJ/mol) and H2O (691 
kJ/mol) is 22 kJ/mol, thus driving the reaction forward. Again, the rate 
coefficient of this reaction in humid air has been calculated218. 
Instrument accuracy and precision 
Before the start of the experiment the SIFT-MS instrument was calibrated with 
known concentrations of acetone, H2S and HCN in humid air from a 
commercial gas cylinder supply. The accuracy and precision of the instrument 
for the measurement of acetone, H2S and HCN in humid air has previously 
been investigated151,168,223 and found to be appropriate for the quantification of 
these compounds at physiological concentrations in breath. 
Indicators of sample humidity 
Sample humidity was investigated by analysing changes in relative 
concentrations of the H3O+ precursor ion and its hydrated ions. 
 Statistical analysis 2.2.7.
The percentage change in analyte concentration over storage time was 
calculated. Means, standard deviations and CVs of analyte concentrations in 
bag samples after being drawn through the sampling apparatus were calculated. 
Linear regression was performed to look at the difference between initial 
breath sample analyte concentrations and concentrations after breath was 
passed through the apparatus. Statistical analyses were performed using 
GraphPad Prism version 5.01 for Windows (GraphPad Software, USA). 
2.3. Results 
 The effect of sample storage on analyte concentration and 2.3.1.
humidity 
Acetone, H2S and HCN concentrations all decreased over time, as did the 
humidity of the breath samples. Figure 2-5 shows the absolute change in 
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analyte concentrations during storage and Figure 2-6 shows the percentage 
change in analyte concentration when compared to baseline concentration. 
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Figure 2-5. Change in analyte concentration over time in each of the six Tedlar 
bags; (a) acetone, (b) H2S, (c) HCN. 
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Figure 2-6. Mean change in analyte concentration over time as a percentage of 
the starting concentration. 
Acetone 
There was a greater reduction in acetone concentration in the two bags 
containing the highest starting concentration (Figure 2-5). Losses from the 
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other bags were minimal over four hours. Over 92% of the initial sample 
concentration was detected in each bag after 90 min of storage, and the 
concentration had dropped by more than 10% in only one bag after three hours. 
A small increase in acetone concentration was seen in most of the samples in 
the first 30 min of incubation. 
Hydrogen sulphide 
The concentration of H2S was stable for 2 hours in five out of six of the bags 
and then tended to slowly decline (Figure 2-5). When looking at the mean data 
of all of the bags, the concentration of H2S appears to be stable for 90 min and 
satisfactory for two hours (Figure 2-6). A small initial increase in H2S 
concentration was noted in 4 of the bag samples (Figure 2-5). 
Hydrogen cyanide 
The concentration of HCN was stable over the full four hours of sample 
storage (Figures 2-5 and 2-6), with 93% of the initial concentration detected at 
that time. There was a fluctuation in HCN concentration over time, with a 
tendency for initial reduction and subsequent increase in concentration. 
Humidity 
The reduction in humidity was assessed by looking at changes in the 
percentage of H3O+ precursor ion counts (Hz) compared to hydrated ion 
counts. The reduction in hydrated ions as a percentage of the total counts can 
be seen in Figure 2-7. The percentage of H3O+ hydrated ions fell from 64% to 
32% of the total H3O+ ion count with a corresponding increase in H3O+ 19 ions. 
NO+ does not form hydrated ions as readily as H3O+, however there was still a 
reduction in the percentage of hydrated ions over the experimental time. There 
was a slight increase in the percentage of hydrated precursor ions in all six bags 
when analysed at 30 min, however humidity fell more rapidly over the four-
hour storage period than any of the analyte concentrations. 
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Figure 2-7. Change in H3O+ m/z 19 precursor and hydrated precursor ion 
counts (m/z 37, 55 and 73) as a percentage of the total H3O+ counts. 
Tedlar contaminants 
There was an increase in the mean concentration of contaminants specific to 
Tedlar bags during incubation at 40°C (Figure 2-8). The concentration of 
phenol (m/z 95) appeared to plateau after a peak in concentration at 120 min, 
whereas the concentration of N,N-dimethylacetamide (m/z 88) continued to rise 
throughout the incubation period. 
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Figure 2-8. Change in mean contaminant counts over storage time; (a) phenol 
(H3O+ m/z 95), (b) N,N-dimethylacetamide (H3O+ m/z 88). 
 The effect of the breath collection apparatus on sample 2.3.2.
concentration 
There was no change in acetone, H2S or HCN concentrations of headspace air 
in the storage container before and after incubation of the breath sampling 
equipment. The apparatus tested was as follows: suction catheter tubing 
(Pennine Healthcare, UK), sampling filter (DISMIC®-25, Toyo Roshi Kaisha 
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Ltd, Japan), oxygen enrichment attachment (Respironics Inc, USA), tubing 
adaptor (Care Medical Ltd, NZ), cut-off tip of a 1 ml syringe (Becton, 
Dickinson and Company, Singapore). 
There was a reduction in the concentrations of acetone, H2S and HCN after the 
breath sample was passed through the two suction catheters, sampling filter and 
hand-held pump. Data for acetone can be seen in Table 2-1. When the first 
post-apparatus breath sample was discarded, the CV of the three post-apparatus 
samples improved. This did not alter the mean percentage reduction in acetone 
concentration (Table 2-2). Similar improvements in the CVs of H2S and HCN 
samples were seen (median CV H2S 12.9 improved to 4.2, HCN 11.8 improved 
to 5.3). 
Table 2-1. Initial and post-apparatus breath acetone concentration and the 
percentage change in acetone concentration. The percentage coefficient of 
variation (CV) of the three post-apparatus samples is shown. 
Initial acetone 
concentration 
(ppb) 
Post-apparatus acetone concentration (ppb) CV 
(%) 
% 
change Sample 
1 
Sample 
2 
Sample 
3 
Mean 
1360 786 1030 1070 962 16.0 29.3 
1020 593 682 670 648 7.4 36.4 
992 566  805 532 54.9 46.4 
803 571 643 669 628 8.1 21.8 
719 491 545 638 558 13.3 22.4 
644 273 328 333 311 10.7 51.7 
439 280 325 410 338 19.5 22.9 
    median 13.3 29.3 
CV, coefficient of variation; % change, percentage change between initial 
sample and mean acetone concentrations after sample was passed through the 
apparatus. Missing value was due to sample leakage via a hole in the Tedlar 
bag. 
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Table 2-2. Initial and post-apparatus breath sample acetone concentration and 
the percentage change in acetone concentration after the first post-apparatus 
sample is discarded. The percentage coefficient of variation (CV) of the three 
post-apparatus samples is shown. 
Initial acetone 
concentration 
(ppb) 
Post-apparatus acetone concentration (ppb) CV 
(%) 
% 
change Sample 
2 
Sample 
3 
Sample 
4 
Mean 
843 578 619 647 615 5.6 27.1 
665 468 470 506 481 4.4 27.6 
484 301 330 315 315 4.6 34.8 
    median 4.6 27.6 
CV, coefficient of variation; % change, percentage change between initial 
sample and mean acetone concentrations after sample was passed through the 
apparatus.  
 
According to the linear regression equation comparing initial and subsequent 
acetone concentrations (y = 0.79x ± 46.14), there was a fixed loss of 46 ppb 
and a variable loss of 21%. The equation of the linear regression line for H2S 
concentration (y = 0.75x ± 1.43) explains a fixed reduction of 1.4 ppb followed 
by a loss of 25% from the rest of the sample. The linear regression equation for 
the reduction in HCN concentration (y = 0.76x + 0.68) reveals a decrease of 
24% associated with the sampling equipment. Losses were reproducible across 
the analyte concentrations measured (Figure 2-9).  
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Figure 2-9. The relationship between the concentrations of (a) acetone, (b) H2S 
and (c) HCN before and after the gas sample was passed through the tubing, 
filter and pump (linear regression lines with 95% confidence intervals marked). 
Individual data points for analyte concentrations, first post-apparatus samples 
not included. 
 The effect of the pump on sample concentration 2.3.3.
There was a reduction in the concentrations of acetone, H2S and HCN in the 
breath samples caused by being passed through the pump alone (Table 2-3). In 
a similar way to the results presented in section 2.3.2., there appeared to be an 
effect of dead space dilution on the first sample passed through the pump, 
therefore the first post-pump samples were excluded from linear regression 
analysis (Figure 2-10). There was a higher degree of variability in H2S 
concentration in post-pump samples than was seen for acetone and HCN 
concentrations within the same breath samples. 
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Table 2-3. Initial and post-pump breath sample analyte concentration and the 
percentage change in analyte concentration. The percentage coefficient of 
variation (CV) of the three post-apparatus samples is shown. 
Analyte Initial analyte 
concentration 
(ppb) 
Post-pump analyte concentration 
(ppb) 
CV 
(%) 
% 
change 
Sample 1 Sample 2 Sample 3 
Acetone 1160 862 907 890 2.5 23.6 
Acetone 684 544 536 542 0.8 20.1 
Acetone 502 338 398 393 8.8 25.0 
Acetone 378 260 281 304 7.8 25.5 
Acetone 361 299 301 303 0.7 16.6 
H2S 1.10 0.69 0.70 0.73 3.0 35.9 
H2S 1.01 0.99 0.95 1.06 5.6 1.0 
H2S 0.94 0.80 0.91 0.83 7.2 9.8 
H2S 0.83 0.76 0.70 0.73 4.2 12.9 
H2S 0.66 0.56 0.55 0.54 1.7 17.2 
HCN 7.24 4.62 5.92 6.31 15.8 22.4 
HCN 6.68 4.35 5.22 5.61 12.7 24.3 
HCN 5.69 3.64 4.65 4.96 15.6 22.4 
HCN 4.61 3.27 3.47 3.79 7.5 23.9 
HCN 4.47 3.69 3.87 3.70 2.7 16.0 
CV, coefficient of variation; % change, percentage change between initial 
sample and mean analyte concentrations after sample was passed through the 
pump.  
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Figure 2-10. The relationship between the concentrations of (a) acetone, (b) 
H2S and (c) HCN before and after the gas sample was passed through the pump 
alone (linear regression lines with 95% confidence intervals marked). 
Individual data points for analyte concentrations, first post-pump samples not 
included. 
Linear regression equations suggest a 24% reduction in acetone concentration, 
a 33% reduction in H2S concentration and a 14% drop in HCN concentration as 
a result of breath samples being passed through the pump. 
 The effect of the sampling filter on sample concentration 2.3.4.
A small fixed reduction in acetone and H2S concentration was seen due to the 
sampling filter alone (Figure 2-11). When the filter was placed in the line of 
gas flow from the dilution apparatus to the SIFT-MS instrument, it was noted 
that no analyte could be detected if the filter was turned through 180°. This 
highlights that the filter must be positioned in the correct orientation or no 
analyte will be detected downstream. 
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Figure 2-11. The relationship between the concentration of acetone (a) and 
H2S (b) in humid air and that detected by SIFT-MS after passing through a 
small biological filter (linear regression lines with 95% confidence intervals 
marked).  
2.4. Discussion 
 Storage of breath samples 2.4.1.
This study confirms the appropriateness of Tedlar bags for the collection and 
short-term storage of acetone, H2S and HCN at physiological concentrations in 
breath. The concentration of each of these analytes decreased over the four 
hours of incubation, however on average over 90% of the initial sample 
concentration was detected at 90 min and over 80% at 120 min. The results 
described here are more applicable to the rest of the thesis than previous 
studies using dry gases instead of breath, which is humid, with VOCs at 
concentrations far exceeding physiological concentrations, where the 
concentration gradients across the bags were steeper and would be expected to 
result in greater losses of analyte due to diffusion out of the bags134,139,140. Few 
studies have explored the storage of HCN135 and sulphur compounds140 in 
Tedlar bags, therefore it was important to evaluate the utility of the bags for the 
storage of these compounds in particular. 
The concentration of acetone in Tedlar bags at physiological concentration was 
stable over four hours of incubation at 40°C, confirming findings of previous 
studies134,135,242. The two bags with the highest initial starting concentrations 
showed the greatest percentage losses over time. This may have been due to a 
higher acetone concentration gradient between the inside of the bag and the 
atmosphere (room air acetone concentration 25±50 ppb), leading to increased 
85 
 
diffusion out of the bag. It is also possible that these two bags were older and 
had more microdamages causing greater losses140. 
The concentration of H2S dropped most rapidly, a finding similar to that seen 
in a previous study of sulphur compounds stored in transparent Tedlar bags140. 
In that study, H2S recovery was at least 90% at six hours compared to 77% at 
four hours in this study. The difference in percentage H2S recovery between 
the two studies may be due to the difference in initial H2S concentration; less 
than 2.5 ppb in this study, 61.8 ppb in the study of Mochalski et al.140. Humid 
breath was analysed in this study, whereas the previous study used a dry test 
gas. H2S dissolves readily in water droplets present in humid breath, which 
may have reduced the concentration of H2S in the gaseous phase available for 
detection by SIFT-MS in this study. 
A recent study of breath samples stored in Tedlar and Nalophan bags for off-
line analysis of HCN showed that, when incubated at 37°C, HCN concentration 
was stable for up to six hours135, in agreement with this study. They did not, 
however, measure volatile concentrations immediately, but at 1, 6, 24 and 48 
hours, so any loss over the first hour was not quantified.  
As seen in other studies, humidity declined faster than analyte 
concentrations134,135. There was an initial increase in humidity after 30 min 
incubation. It is possible that this increase was due to larger water droplets in 
the breath samples turning to water vapour as the sample was heated above 
body or room temperature. This may lead to an increase the concentration of 
hydrated ions in the mixture. This process may explain the initial increases in 
analyte concentration in some bags. Analyte dissolved in water droplets is 
unable to be analysed by SIFT-MS, however heating may have moved the 
substances into the gas phase, therefore enabling their detection. In contrast to 
this idea, Steeghs et al.138 did not find any difference in analyte concentration 
when the relative humidity of bag samples was increased.  
Other possible causes of an increase in analyte concentration are contamination 
IURP92&VSUHYLRXVO\DGVRUEHGRQWRWKHEDJ¶VLQQHUZDOOEHLQJPRELOLVHGLQWR
the sample gas on heating, and substances diffusing into the bag from the 
environment.   
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Increases in the concentrations of known Tedlar contaminants, N,N-
dimethylacetamide and phenol, were seen during incubation, confirming the 
findings of previous studies134,138. These compounds, found in clean Tedlar 
bags, can affect the analysis of other compounds with peaks at m/z 88 and m/z 
95, however they do not affect the detection or calculation of acetone, H2S and 
HCN necessary for the rest of this thesis. The product of the reaction of NO+ 
with acetone has a peak at m/z 88, but it can be separated from the peak at m/z 
88 due to the reaction of N,N-dimethylacetamide with H3O+. 
 The effect of breath sampling apparatus on analyte 2.4.2.
concentration 
None of the separate pieces of breath sampling equipment caused a change in 
the m/z peaks of acetone, H2S and HCN after incubation. It was concluded, 
therefore, that the sampling equipment would not contaminate breath samples. 
It was also necessary to explore whether the sampling apparatus would lead to 
a reduction in analyte concentration. 
Reductions in acetone, H2S and HCN concentrations due to the breath 
sampling apparatus were seen. However, because the losses were linear over 
the range of concentrations tested it is possible to use the apparatus, since 
actual analyte concentrations can be calculated from observed concentrations. 
Loss of analyte was due to the pump, tubing and filter. Adsorption of analyte 
onto the surface of the filter and tubing, and reduction in humidity as a sample 
travelled through the pump are the most likely causes of a reduction in 
observed concentrations. Unfortunately, when the filter was tested separately, 
breath could not be used and the concentration range of H2S in humid gas was 
not within the physiological range. The concentration range of acetone used 
was also at the upper end of physiological concentration. It is therefore 
possible that the filter has a different affect at the lower concentrations that will 
be seen in the rest of this thesis. It was also not possible to repeat the 
experiment with HCN in humid gas as HCN permeation tubes were not 
available.  
By assessing analyte loss using all of the equipment together, then removing 
the pump and filter and testing them separately, the identification of the 
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sources of analyte loss was attempted. The reduction in acetone concentration 
was similar using the pump alone or all of the apparatus, with narrower 95% 
confidence intervals when breath was passed through the pump alone. The 
increased variability in concentration using all of the equipment might have 
been due to a variable concentration of acetone sticking to the inner surface of 
the suction catheter tubing. HCN concentration reduction by the full set of 
breath sampling apparatus was greater than with the pump alone. As with 
acetone, it is likely that HCN in the samples was adsorbed onto the inner 
surface of the suction catheter tubing.  
The concentration of H2S was significantly lower and more variable when 
using the pump alone compared to using all of the sampling apparatus together. 
It is difficult to explain this increased loss; it may be related to differences in 
laboratory temperature or humidity on the days of testing. The concentration of 
H2S in both sets of initial samples was very low, lower in the pump only 
experiment, close to the limit of detection of H2S by the SIFT-MS instrument. 
All H2S concentrations were determined by physiological concentrations in 
breath of the volunteers who provided samples. Any small changes in absolute 
concentration resulted in large percentage changes in concentration; therefore, 
it would be useful to repeat the experiments with breath or humid gas 
containing higher H2S concentrations to improve accuracy.  
Although it was not possible to accurately identify the relative loss of analyte 
due to individual parts of the apparatus, the most important of the equipment 
testing experiments was that using all of the equipment together with test bags 
of breath, as this is the proposed apparatus for the rest of the thesis and 
investigates changes in concentration of VOCs in a humid mixture at 
physiological concentrations. 
Dead space gas in the tubing and pump led to dilution of the first sample 
collected after being passed through the pump or pump, filter and tubing. 
Deposition of analyte from the first sample onto the surface of the filter and 
tubing, possibly saturating the filter, may also have contributed to lower 
analyte concentrations measured in the first sample compared to subsequent 
samples. Discarding the first sample improved the CV of the three samples run 
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through the apparatus without greatly affecting the percentage reduction in 
analyte concentration. The first breath sample collected from each subject in 
other parts of this thesis will be discarded to minimise analyte concentration 
variability due to the sampling method. Running the pump for at least two 
minutes after collecting breath from each subject should flush the pump and 
prevent, or at least reduce, contamination from a previous sample. 
 Summary 2.4.3.
It is recommended that breath samples are incubated to prevent sample cooling 
and condensation prior to analysis, and that samples are analysed as soon as 
possible after collection, preferably within 90 min. According to the results of 
this investigation, the recovery of, on average, greater than 90% of the initial 
sample concentration is possible if samples are stored in transparent Tedlar 
bags at 40°C.  
The breath sampling apparatus did not emit analytes at the m/z peaks of 
acetone, H2S or HCN and its use resulted in losses of up to 25% of analyte 
concentration. Losses were linear over the range of concentrations studied; 
therefore, it should be possible to calculate the absolute concentrations of 
VOCs in breath from measured concentrations. The apparatus studied is 
therefore suitable for the collection of breath in the following parts of this 
thesis. 
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3. Are breath volatile concentrations affected by 
sampling location and breathing manoeuvre? 
3.1. Introduction and aims 
In order to accurately quantify volatile compounds in the breath of intubated 
and ventilated patients, a robust and reproducible method of breath collection is 
necessary. End-exhaled breath is often analysed because the composition of 
VOCs better reflects that of alveolar breath, thus reducing the chance of sample 
contamination or dilution with dead space gas7,147,166. In spontaneously 
breathing ambulatory subjects, end-exhaled breath has been identified by the 
elimination of the first few seconds of an exhaled breath240, use of 
humidity150,167, and analysis of the last 15-20% of a breath sample by 
volume168. These studies used forced vital capacity manoeuvres, with or 
without expiratory flow rate restriction. 
Several breath collection and analysis techniques have been used in intubated 
patients in the operating theatre and in the ICU; off-line breath collection with 
pre-concentration prior to analysis5,7,105, mixed breath continuous on-line 
sampling106,207, or on-line sampling using computer software to pinpoint the 
alveolar portion of breath143,209,210. A CO2 switch has also been used to 
determine alveolar breath for collection7.  
The aims of this study were to compare end-exhaled single breath 
concentrations of acetone, H2S and HCN collected from two different locations 
in the breathing circuit following tidal breathing and a larger volume breath, 
replicating a vital capacity breath. Attempts were made to collect samples as 
similar to alveolar composition as possible by sampling directly from the 
airways. The reproducibility of each sampling method and the ease of 
performing each technique were assessed. 
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3.2. Methods 
 Subjects 3.2.1.
Study procedures were approved by the Upper South A Regional Ethics 
Committee, New Zealand. Non-diabetic adult patients admitted to the ICU, 
Christchurch Hospital, requiring intubation and ventilation on a controlled 
mode due to lack of spontaneous breathing were recruited between September 
and October 2011. Patients or their next of kin provided written consent prior 
to sample collection. In addition, if the patient had not given their own consent 
prior to inclusion, and regained adequate cognitive functioning, they confirmed 
their consent to participate in retrospect. Each patient was ventilated using a 
1HOOFRU 3XULWDQ %HQQHWW YHQWLODWRU V\VWHP 86$ RQ 6\QFKURQLVHG
Intermittent Mandatory Ventilation (SIMV) mode with volume control or Bi-
Level mode with pressure control. Some ventilator circuits included a 
humidifier (Fisher & Paykel MR 730 Respiratory Humidifier, NZ). Initial 
ventilator modes and settings, including fraction of inspired oxygen (FiO2), 
were determined by ICU staff. Drug infusion rates were kept constant 
throughout breath sampling. The following data was collected for each patient: 
diagnosis and reason for admission, age, gender, ethnicity, smoking status, 
ventilator settings and end-tidal CO2. 
 Inspiratory air sampling  3.2.2.
All methods utilised a T-piece (oxygen enrichment attachment, Respironics 
Inc, USA) inserted into the breathing circuit at the ventilator gas outlet, or 
humidifier outlet, for inspiratory gas sampling (Figures 3-1(a) and (b)).  
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  (a) 
  (b)  
Figure 3-1. Photographs display the location of the T-piece in the ventilator 
circuit (red circle) for inspired gas sampling, with (a) and without a humidifier 
in situ (b). 
 Exhaled breath collection 3.2.3.
Four different methods of breath collection were explored in each patient, 
using two different sampling locations within the breathing circuit and two 
different exhalation techniques (Table 3-1). Full experimental set-up can be 
seen in Figure 3-2 and a photograph of the location of the T-piece for breath 
sampling in Figure 3-3 (Written patient consent obtained). 
Table 3-1. Exhaled breath collection methods. 
Method Sample location Exhalation manoeuvre 
A T-piece Tidal breath 
B T-piece Recruitment-style breath 
C Airway Tidal breath 
D Airway Recruitment-style breath 
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Figure 3-2. Schematic of the experimental set-up using the T-piece. 
 
 
Figure 3-3. Photograph of the location of the T-piece within the breathing 
circuit. 
Three breath samples were collected using each sampling method into separate 
1L transparent Tedlar® bags (SKC Inc, USA). During breath sampling, the 
pressure sensitivity setting on the ventilator was temporarily altered so the 
collection of exhaled breath did not trigger the ventilator to deliver another 
inspiratory breath. All inspiratory and exhaled breath samples were incubated 
at 40°C and analysed within 40 min of collection by SIFT-MS. The pump was 
flushed by running through room air for at least 2 min between patients. 
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Sampling location  
The first sampling location utilised a T-piece inserted into the respiratory 
circuit on the ventilator side of the suction catheter mount (Fisher & Paykel, 
NZ). Suction catheter tubing (4.7 mm x 53 cm, Ch14, Pennine Healthcare, UK) 
was connected to the side port of the T-piece using the cut-off tip of a 1 ml 
syringe (Becton, Dickinson and Company, Singapore). The other end of the 
tubing was connected via a sampling filter (DISMIC®-25, Advantec®, Toyo 
Roshi Kaisha Ltd, Japan) and another length of suction catheter tubing to a 
handheld pump (Gilian® Personal Air Sampler, Sensidyne, USA) (Figure 3-
4(a)).  
The second sampling location allowed collection of breath samples directly 
from the airways. Two lengths of suction catheter tubing, with a sampling filter 
between them, were connected to the hand-held pump. The free end of the 
suction catheter was inserted into the suction catheter mount and down the 
endotracheal tube (ETT) (Portex® Tracheal Tube, Smiths Medical Australasia 
Pty Ltd, Australia) until it was 1 cm from the end (Figure 3-4(b)). With the 
suction catheter in situ, the opening of the suction catheter mount was sealed 
ZLWK WZR 7HJDGHUP ILOP Gressings (6 cm x 7 cm, 3M HealthCare, USA) 
(Figure 3-5). 
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       (a) 
       (b) 
Figure 3-4. Breath sampling equipment attached to the T-piece (a) and inserted 
into the suction catheter mount (b). 
 
Figure 3-5. Suction catheter situated inside the mount, sealed with two 
7HJDGHUPILOPGUHVVLQJV 
Breathing manoeuvre 
Breath samples were collected after a tidal breath and after a larger volume 
lung recruitment-style breath. Sampling location order was randomised by 
flipping a coin, however breath samples were always collected following tidal 
breathing first to minimise the number of times ventilator settings were altered 
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and ensure that delivery of a large volume breath that might recruit previously 
collapsed airways did not alter subsequent tidal volumes. 
After a tidal breath, the expiratory pause button was held down for 4 sec to 
allow the collection of approximately 150 ml of end-expiratory breath into a 
Tedlar bag via the pump. The volume of the tidal breath was noted. The 
ventilator delivered several standard breaths before this process was repeated 
using another Tedlar bag.  
Pressure-controlled lung recruitment-style breaths were delivered using Bi-
Level mode. If necessary, the mode was changed and the inspiratory positive 
airway pressure (IPAP) and expiratory positive airway pressure (EPAP) 
adjusted to maintain the previous tidal volume. The IPAP was then set to 35 
cmH2O, the respiratory rate reduced to three breaths per minute, and at end-
expiration after the recruitment-style breath, approximately 150 ml breath was 
collected over 4 sec during the natural pause before the next inspiratory breath. 
Recruitment-style breath volume was noted. Pressure and respiratory rate 
settings were returned to starting levels before the ventilator delivered the next 
breath. The ventilator delivered several standard tidal breaths before this 
process was repeated.  
Direction of air flow during breath sample collection 
A pneumotachometer (RSS 100, Hans Rudolph Inc, USA) was inserted into the 
respiratory circuit on the ventilator side of the T-piece to check the direction of 
flow during sample collection.  
 Infection control 3.2.4.
The suction catheters and sampling filter were disposable and used for only one 
patient. The T-piece was decontaminated for re-use. Disinfectant wipes were 
used on the surfaces of the hand-held pump and Tedlar bags (Azo wipes, W. 
M. Bamford & Co Ltd, NZ). None of the cleaning procedures changed the 
VOC composition of samples. 
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 Selected ion flow tube mass spectrometry 3.2.5.
Volatile gas concentrations were measured by SIFT-MS, Voice200® (Syft 
Technologies Ltd, NZ), using SIM mode. The technique and ion reactions have 
been described in detail in Chapter 2. Each Tedlar bag was attached to the 
sampling capillary end cap of the heated inlet extension of the SIFT-MS and 
analysed for 30 sec. 
 Statistical analysis 3.2.6.
Previous studies of breath testing in non-intubated and ventilated subjects have 
demonstrated CVs of 0-5.6%168, however it is recognised that CVs in patients 
with disease are often higher than normal subjects324. As this the first study to 
explore the effects of breath sampling location, including directly from the 
airway, and of breathing manoeuvre on breath volatile concentrations in 
intubated and ventilated patients, the variability due to breath volume or 
sampling location were unknown.  Sample size was therefore estimated from 
previous experience to allow the determination of clinically meaningful change 
for the purpose of more focussed future study design. 
Means and percentage CVs of three end-exhaled breath samples were 
calculated for the four different breath sampling methods for each patient. 
Comparisons were made using Wilcoxon signed rank tests. Correlations were 
GHWHUPLQHGE\6SHDUPDQ¶VUDQNFRUUHODWLRQUs). Bland-Altman plots were used 
to compare breath VOC concentrations using each method. Statistical analyses 
were performed using GraphPad Prism version 5.01 for Windows (GraphPad 
Software, USA). A value of p<0.05 was considered to be statistically 
significant. 
3.3. Results 
 Subjects 3.3.1.
Twenty non-diabetic patients (12 male, 8 female), median age 67.5 years 
(range 48-84 years), were recruited. Patient demographics, diagnosis and 
reason for admission to ICU can be seen in Table 3-2. Ethnicity data reflects 
that of the wider Christchurch population325. Medical concerns prevented large 
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volume breaths being delivered to two patients (patients 2 and 9). In two 
further patients (patients 8 and 14) it was not possible to collect direct airway 
breath samples due to significant air leak around the suction catheter with 
subsequent reduction in tidal volume. The pneumotachometer confirmed the 
direction of flow during breath sampling was from the patient and not the distal 
ventilator tubing.         
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Table 3-2. Patient demographics and ventilation data. 
Subject Age 
(years) 
Gender Ethnicity Smoking 
status 
Reason for admission to ICU RR 
(breaths/min) 
FiO2 PEEP or 
IPAP/EPAP 
(cmH2O) 
PetCO2 
(mmHg) 
1 61 M NZ European N Cardiac surgery 16 0.4 10 41 
2 72 F NZ European N Cardiac surgery 14 0.4 7.5 33 
3 63 M NZ European - Sepsis and ARDS 18 0.4 25/15 48 
4 70 F Caucasian Ex Pneumonia 18 0.3 27/10 29 
5 69 F NZ European N Cardiac surgery 16 0.4 5 31 
6 66 M NZ European N Cardiac surgery 16 0.4 5 35 
7 78 M NZ European N Cardiac surgery 12 0.4 5 42 
8 75 F NZ European N Cardiac surgery 16 0.3 5 22 
9 61 M NZ European Ex Pneumonia 20 0.95 25/12.5 36 
10 64 F NZ Maori Y Cardiac surgery 16 0.4 5 31 
11 69 M NZ European N Intracranial bleed 18 0.3 5 30 
12 73 M NZ Maori Y Vascular surgery 16 0.35 10 33 
13 74 F NZ European N Cardiac surgery 12 0.4 5 36 
14 52 M NZ European Ex Out of hospital cardiac arrest 16 0.3 5 38 
15 74 F NZ European N Cardiac surgery 16 0.4 5 34 
16 63 M NZ European Ex Cardiac surgery 12 0.6 10 39 
17 48 M NZ European Y Asthma 15 0.35 21/10 42 
18 64 M NZ European Ex Cardiac surgery 14 0.35 5 36 
19 84 F NZ European Ex Vascular surgery 16 0.6 5 25 
20 65 M NZ European N Cardiac surgery 16 0.45 5 42 
M, male; F, female; N, Non-smoker; Y, smoker; Ex, ex-smoker; ARDS, acute respiratory distress syndrome; RR, respiratory rate; FiO2, fraction of inspired       
oxygen; PEEP, positive end-expiratory pressure; IPAP, inspiratory positive airways pressure; EPAP, expiratory positive airways pressure; PetCO2, partial 
pressure of end tidal CO2.
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Table 3-3. Ventilation method, tidal volume and recruitment-style breath volume for the four breath collection methods. 
Subject Ventilation 
mode for 
tidal 
breathing 
Breath from T-
piece after tidal 
breath (method A) 
Breath from 
airways after tidal 
breath (method C) 
Breath from T-piece after recruitment-
style breath (method B) 
Breath from airways after recruitment-
style breath (method D) 
Tidal volume (ml) Tidal volume (ml) Tidal volume 
(ml)  
Mean recruitment-style 
breath volume (ml) 
Tidal volume 
(ml) 
Mean recruitment-style 
breath volume (ml) 
1 SIMV 500 500 
450 
300 
230 
330 
365 
480 
- 
350 
480 
480 
465 
434 
- 
450 
600 
440 
430 
450 
480 
 
450 
475 1388 
- 
730 
539 
1174 
1435 
1404 
778 
- 
1326 
1534 
853 
1078 
1603 
1204 
988 
1100 
1410 
1086 
1870 
 
1189 
475 1033 
- 
500 
300 
660 
1136 
1227 
- 
- 
700 
985 
678 
707 
- 
662 
883 
763 
999 
661 
1375 
 
735 
2 SIMV 450 - - 
3 Bilevel 470 470 300 
4 Bilevel 475 460 230 
5 SIMV 480 480 330 
6 SIMV 500 500 500 
7 SIMV 480 480 480 
8 SIMV 420 405 - 
9 Bilevel 460 - - 
10 SIMV 463 460 460 
11 SIMV 490 500 480 
12 SIMV 500 470 470 
13 SIMV 435 425 425 
14 SIMV 430 520 - 
15 SIMV 473 420 375 
16 SIMV 570 550 550 
17 Bilevel 540 580 420 
18 SIMV 440 470 480 
19 SIMV 450 445 430 
20 SIMV 480 510 480 
     
 Median 474 473 465 
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 Breath volume 3.3.2.
Individual patient breath volumes for each of the four sampling methods can be 
seen in Table 3-3. Tidal volume was significantly larger when samples were 
taken from the T-piece than directly from the airways (tidal breath p=0.01, 
recruitment-style breath p=0.008) (Figure 3-6). The reduction in tidal volume 
with direct airway sampling was due to air leaking around the suction catheter 
in the mount, despite sealing the area with Tegaderm film dressings, and 
resulted in a greater degree of inter-subject variation in mean breath volume 
when sampling at this location. Air leaks were more pronounced at higher 
positive end-expiratory pressure (PEEP) settings. 
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Figure 3-6. Individual mean patient tidal volumes delivered by the ventilator 
and group medians when using each breath collection method. 
There was a significant difference between mean tidal breath volume and 
recruitment-style breath volume at each sampling location (T-piece p=0.0002, 
airway p=0.0005). When the IPAP required to maintain adequate tidal volume 
(during routine ventilation) was close to 35 cmH2O, the recruitment-style 
breath volume was similar to the tidal breath volume. Unfortunately, increasing 
the ventilation pressure led to greater air leak around the suction catheter 
during direct airway sampling, attenuating the increase in breath volume and 
causing a significant difference between mean recruitment-style breath volume 
at the different sampling locations (p=0.0005). There was also greater inter-
subject variation in mean recruitment-style breath volume compared to tidal 
volume at each sampling location (Figure 3-7). 
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Figure 3-7. Individual mean patient breath volumes delivered by the ventilator 
and group medians when using each breath collection method. 
 Breath acetone concentration 3.3.3.
Individual patient breath acetone concentration for each of the four sampling 
methods can be found in Appendix C. Group median exhaled acetone 
concentrations using each of the breath sampling methods, as well as 
reproducibility data, can be seen in Table 3-4. 
Table 3-4. Median breath acetone concentration and intra-subject CV for 
breath acetone concentration using each breath sampling technique. 
Breath sampling method 
Median acetone 
concentration (range) 
(ppb) 
Median intra-
method CV 
(IQR) (%) 
A T-piece after tidal breath 4060 (261±27800) 8.4 (3.9±11.4) 
B T-piece after recruitment-style breath 4005 (322±20500) 8.3 (5.7±13.1) 
C Airway after tidal breath 5500 (449±35367) 8.0 (4.1± 6.6) 
D Airway after recruitment-style breath 5250 (465±28800) 6.0 (4.7±10.8) 
CV, coefficient of variation; IQR, interquartile range. 
 
7KHUH ZDV D VWURQJ FRUUHODWLRQ EHWZHHQ DQ LQGLYLGXDO¶V EUHDWK DFHWRQH
concentrations using each of the four breath sampling techniques (rs>0.98 and 
p<0.0001 for each of the four analyses). Individual mean acetone concentration 
in breath samples directly from the airway was significantly higher than in 
samples from the T-piece (tidal breath p=0.004, recruitment-style breath 
p=0.0005). End-tidal breath samples collected from the T-piece had 
significantly higher mean acetone concentration than those collected following 
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a recruitment-style breath (p=0.03), however the difference in group median 
acetone concentrations was small (Figure 3-8). No relationship was seen 
between breath acetone concentration and breath volume when data from each 
sampling location was analysed (T-piece rs= -0.01, p=0.95; airway rs=0.26, 
p=0.13). 
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Figure 3-8. Individual mean patient end-exhaled acetone concentrations and 
group medians using each of the four breath sampling methods. 
Bland-Altman plots show increased variability between sampling methods at 
higher breath acetone concentrations. In general, at acetone concentrations 
under 10000 ppb, there was only a small difference between methods (Figure 
3-9). 
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Figure 3-9. Bland-Altman plots comparing mean exhaled acetone 
concentrations (ppb) seen using each method (dashed line = bias, dotted lines = 
95% limits of agreement): (a) T-piece after tidal breath minus T-piece after 
recruitment-style breath (bias 1056, -2812±4924), (b) airway after tidal breath 
minus T-piece after tidal breath (bias 1058, -2792±4908), (c) airway after tidal 
breath minus airway after recruitment-style breath (bias 221, -3366±3807), (d) 
airway after recruitment-style breath minus T-piece after recruitment-style 
breath (bias 1754, -2667±6175). 
Breath acetone concentration following surgery 
Twelve of the 20 subjects who provided breath sampled were admitted to the 
ICU following cardiac surgery (Table 3-5). Median end-tidal acetone 
concentration from T-piece samples in post-operative patients was higher than 
in patients who had not undergone surgery (6750 ppb, range 689±27800 ppb 
versus 867 ppb, range 261±8940 ppb) (p=0.01). There was no relationship 
between the duration of fasting and breath acetone concentration and no 
difference in breath acetone concentration between cardiac surgical patients 
who required cardiac bypass and those who did not.  
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Table 3-5. Cardiac surgical procedure and duration of fasting of post-operative 
patients enrolled. 
Subject Cardiac surgical procedure Cardiac bypass? 
Duration of 
fasting (hours) 
1 AVR, CABG Y 16 
2 AVR, MVR Y 16 
5 CABG N 13 
6 CABG N 11.5 
7 AVR, CABG Y 15.5 
8 MV repair Y 16 
10 CABG Y 14 
13 Repair Type A dissecting aortic 
aneurysm Y 20 
15 CABG N 17.75 
16 CABG N 10 
18 AVR, Bentall procedure, CABG Y 14.75 
20 CABG N 10.25 
AVR, aortic valve replacement; Bentall procedure, composite graft 
replacement of aortic valve, aortic root and ascending aorta, with re-
implantation of the coronary arteries into the graft; CABG, coronary artery 
bypass graft; MV, mitral valve; MVR, mitral valve replacement; N, no; Y, yes. 
Corrected acetone concentrations 
Median inspiratory acetone concentration corrected for losses due to the 
sampling apparatus was 149 ppb (range 87.0-427 ppb). Median corrected 
breath acetone concentrations can be seen in Table 3-6 below. The linear 
regression equation used for this correction is described in Chapter 2 of this 
thesis. 
Table 3-6. Median corrected breath acetone concentration and intra-subject CV 
for breath acetone concentration using each breath sampling technique. 
Breath sampling method 
Median acetone 
concentration (range) 
(ppb) 
Median intra-
method CV (IQR) 
(%) 
A T-piece after tidal breath 5198 (389-35248) 7.9 (3.9-13.1) 
B T-piece after recruitment-style 
breath 5128 (466-26008) 7.9 (5.6-12.8) 
C Airway after tidal breath 7020 (627-44826) 7.8 (4.1-16.5) 
D Airway after recruitment-style 
breath 6704 (647-36514) 5.9 (4.6-10.3) 
CV, coefficient of variation; IQR, interquartile range. 
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 Breath H2S concentration 3.3.4.
Individual patient breath H2S concentration for each of the four sampling 
methods can be found in Appendix C. Group median exhaled H2S 
concentrations using each of the breath sampling methods, as well as 
reproducibility data, can be seen in Table 3-7. 
Table 3-7. Median breath H2S concentration and intra-subject CV for breath 
H2S concentration using each breath sampling technique. 
Breath sampling method 
Median H2S 
concentration 
(range) (ppb) 
Median intra-
method CV (IQR) 
(%) 
A T-piece after tidal breath 1.7 (0.7 - 4.2) 9.7 (7.3 ± 12.7) 
B T-piece after recruitment-style breath 1.5 (0.7 - 3.9) 12.0 (8.3 ± 16.4) 
C Airway after tidal breath 2.1 (0.7 - 4.7) 9.3 (6.7 ± 15.5) 
D Airway after recruitment-style breath 2.0 (0.7 ± 4.5) 9.8 (8.5 ± 16.0) 
CV, coefficient of variation; IQR, interquartile range. 
 
7KHUH ZDV D VWURQJ FRUUHODWLRQ EHWZHHQ DQ LQGLYLGXDO¶V EUHDWK +2S 
concentrations using each of the four breath sampling techniques (rs>0.95 and 
p<0.0001 for each of the four analyses). There were small but significant 
differences in breath H2S concentration between all four breath collection 
techniques. The concentration of H2S in samples taken from the airways was 
higher than from the T-piece (after tidal breath p=0.009, after recruitment-style 
breath p=0.02), and in end-tidal samples compared to those collected after a 
recruitment-style breath (T-piece p=0.0006, airways p=0.0009) (Figure 3-10). 
No relationship was seen between breath H2S concentration and breath volume 
when data from each sampling location was analysed (T-piece rs= -0.08, 
p=0.62; airway rs=0.07, p=0.71). 
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Figure 3-10. Individual mean patient end-exhaled H2S concentrations and 
group medians using each of the four breath sampling methods. 
Bland-Altman plots show a bias towards higher exhaled H2S concentrations 
when sampling from the airways and using the end-tidal method; this did not 
change when the H2S concentration measured increased (Figure 3-11). 
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Figure 3-11. Bland-Altman plots comparing mean exhaled H2S concentrations 
(ppb) seen using each method (dashed line = bias, dotted lines = 95% limits of 
agreement): (a) T-piece after tidal breath minus T-piece after recruitment-style 
breath (bias 0.46, -0.56±1.48), (b) airway after tidal breath minus T-piece after 
tidal breath (bias 0.19, -0.33±0.71), (c) airway after tidal breath minus airway 
after recruitment-style breath (bias 0.30, -0.26±0.86), (d) airway after 
recruitment-style breath minus T-piece after recruitment-style breath (bias 
0.38, -0.61±1.37). 
 Breath HCN concentration 3.3.5.
Individual patient breath HCN concentration for each of the four sampling 
methods can be found in Appendix C. Group median exhaled HCN 
concentrations using each of the breath sampling methods, as well as 
reproducibility data, can be seen in Table 3-8. 
 
 
 
108 
 
Table 3-8. Median breath HCN concentration and intra-subject CV for breath 
HCN concentration using each breath sampling technique. 
Breath sampling method 
Median HCN 
concentration (range) 
(ppb) 
Median intra-
method CV (IQR) 
(%) 
A T-piece after tidal breath 1.7 (0.7±13.2) 11.8 (8.0±29.5) 
B T-piece after recruitment-style breath 1.2 (0.7±9.8) 14.5 (6.4±18.2) 
C Airway after tidal breath 2.1 (0.7±18.2) 12.8 (10.6±18.9) 
D Airway after recruitment-style breath 1.9 (0.7±14.1) 11.4 (3.6±21.8) 
CV, coefficient of variation; IQR, interquartile range. 
 
7KHUH ZDV D VWURQJ FRUUHODWLRQ EHWZHHQ DQ LQGLYLGXDO¶V EUHDWK +&1
concentrations using each of the four breath sampling techniques (rs>0.91 and 
p<0.0001 for each of the four analyses). Median breath HCN concentration 
was significantly higher in end-tidal samples compared to those after a 
recruitment-style breath at the T-piece (p=0.001). When samples were 
collected after a recruitment-style breath, the concentration of HCN was higher 
from the airways than the T-piece (p=0.0001). There was no significant 
difference in median HCN concentrations when comparing end-tidal breath 
samples at each location or the two breath manoeuvres when sampling directly 
from the airways (Figure 3-12). No relationship was seen between breath HCN 
concentration and breath volume when data from each sampling location was 
analysed (T-piece rs= -0.07, p=0.67; airway rs=0.19, p=0.30). 
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Figure 3-12. Individual mean patient end-exhaled HCN concentrations and 
group medians using each of the four breath sampling methods. 
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Bland-Altman plots show an increased variability between sampling methods 
at higher HCN concentrations. At lower HCN concentrations the sampling 
methods appear to provide similar results (Figure 3-13). 
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Figure 3-13. Bland-Altman plots comparing mean exhaled HCN 
concentrations (ppb) seen using each method (dashed line = bias, dotted lines = 
95% limits of agreement): (a) T-piece after tidal breath minus T-piece after 
recruitment-style breath (bias 0.77, -0.96±2.49), (b) airway after tidal breath 
minus T-piece after tidal breath (bias 0.35, -2.20±2.90), (c) airway after tidal 
breath minus airway after recruitment-style breath (bias 0.27, -2.17±2.70), (d) 
airway after recruitment-style breath minus T-piece after recruitment-style 
breath (bias 1.02, -1.71±3.76). 
 Inspiratory volatile concentrations 3.3.6.
Individual patient inspired VOC concentrations can be seen in Appendix C of 
this thesis. Group median concentrations and concentration ranges can be seen 
in Table 3-9 below. Relationships between inspiratory and exhaled breath 
concentrations were affected by the location and type of breath prior to sample 
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collection, therefore calculations for each of the breath sampling methods were 
required. 
Table 3-9. Group median inspiratory volatile concentrations and ranges. 
Volatile organic compound Median inspiratory concentration (range) (ppb) 
Acetone 71.7 (22.6-291) 
H2S 0.87 (0.42-1.62) 
HCN 0.87 (0.66-1.30) 
Acetone 
Higher inspiratory acetone concentrations were seen when exhaled 
concentrations were higher, with a relationship seen between the two 
concentrations (rs=0.50, p<0.0001). As the exhaled acetone concentration in 18 
out of the 20 cases was at least one order of magnitude greater than the 
corresponding inspired acetone concentration, it is unlikely that inspired 
acetone concentrations had an effect on exhaled concentrations. It is more 
likely that higher breath acetone concentration led to greater contamination of 
the ventilator tubing due to adsorption.  
Inspiratory samples were always obtained prior to collection of exhaled breath 
samples so that the collection apparatus did not become contaminated by 
higher breath compared to inspiratory concentrations. 
Hydrogen sulphide 
There was no relationship between inspired and exhaled H2S concentrations 
when the results were analysed together or separately (T-piece after tidal breath 
rs=0.15, p=0.54). Exhaled H2S concentrations were significantly higher than 
inspired concentrations (T-piece after tidal breath: median exhaled 
concentration 1.7 ppb, median inspired concentration 0.87 ppb, p=0.0002). 
Hydrogen cyanide 
There was no relationship between inspired and exhaled HCN concentrations 
using breath collected from the T-piece after a tidal breath rs=0.40, p=0.09. 
Exhaled HCN concentrations were significantly higher than inspired 
concentrations (T-piece after tidal breath: median exhaled concentration 1.7 
ppb, median inspired concentration 0.87 ppb, p=0.0029). 
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Effect of the humidified circuit on inspired volatile concentrations 
Humidification units were used in five of the 20 breathing circuits. This is 
fewer than would be expected in the ICU population; the majority of patients 
underwent elective surgery and were expected to be ready for extubation 
within several hours, therefore they were not felt to require humidified 
inspiratory air or oxygen by the ICU team.  
The numbers in the humidified circuit group were low, however there did not 
appear to be any difference in inspiratory volatile concentration between 
breathing circuits containing a humidification unit or not (acetone p=0.16, H2S 
p=0.10, HCN p=1.00). 
 External factors affecting measured breath volatile 3.3.7.
concentration 
Closed suction catheter unit 
When an intubated patient in the ICU has a communicable respiratory 
infection, it is necessary to replace the standard suction catheter mount with a 
closed suction catheter unit (KimVent: Turbo-Cleaning Closed Suction System 
for Adults, Kimberly-Clark, USA), to prevent droplet spread into the 
surrounding atmosphere. It was possible to replace one of the standard suction 
catheters with the closed suction catheter unit for breath sampling, as long as 
the valve was open (depressed) at the time of sampling (Figure 3-14). It was 
noticed, however, that breath acetone and HCN concentrations obtained via the 
closed suction catheter were much higher than expected, and decreased with 
each sample collected.  
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Figure 3-14. Breath sampling equipment attached to a closed suction catheter 
unit. 
In an in vitro experiment, the headspace over a closed suction catheter unit was 
sampled after 30 min incubation at 40°C. Concentrations of acetone, H2S and 
HCN were higher than background air levels (Table 3-10). Breath samples 
collected via the closed suction catheter unit were therefore discarded due to 
contamination by compounds emitted by the tubing itself. All other breath 
sampling equipment had been tested for the presence of volatiles at greater than 
atmospheric concentration prior to commencing the study (described in 
Chapter 2). 
Table 3-10. Comparison of volatile concentrations in the headspace of the box 
(room air) before and after incubation of a closed suction catheter unit. 
Volatile of interest Headspace concentration (ppb) 
Empty box Box containing closed suction catheter 
Acetone 19.7 3500 
H2S 0.7 5.2 
HCN 1.1 38.6 
Precursor ion stripping 
At higher breath acetone concentrations, corresponding concentrations of 
breath H2S and HCN also appeared to be higher (Figures 3-15 (a) and (b)). The 
increase in H2S and HCN concentrations appeared to rise more steeply at 
concentrations of breath acetone over 10,000 ppb. 
H3O+ precursor ion counts were examined in samples with very high acetone 
concentrations. In inspiratory samples, where acetone concentrations were 
Valve 
Regular 
suction 
catheter 
Sampling 
filter 
Closed 
suction 
catheter 
Closed suction 
catheter mount 
Endotracheal 
tube 
113 
 
much lower, H3O+ counts were greater than 3,000,000 Hz. At acetone 
concentrations of 20,000 ppb, H3O+ counts were between 13,000 and 50,000 
counts. 
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Figure 3-15. Individual data points show mean breath H2S (a) and HCN (b) 
concentrations at matched acetone concentrations using all four sampling 
methods.  
Salbutamol administration 
Whilst collecting breath samples from a patient with asthma, salbutamol 
5HVSLJHQ0\ODQ 1HZ =HDODQG /WG ZDVDGPLQLVWHUHGYLD D metered dose 
inhaler (MDI) through an adapter in the ventilator circuit adjacent to the T-
piece. Acetone concentration in the samples after salbutamol administration 
was much higher than in previous samples, the concentration decreasing over 
subsequent samples. Both NO+ and H3O+ precursor ions were depleted. Figure 
3-16 shows the change in precursor ion counts in breath samples prior to and 
following salbutamol administration to the breathing circuit.  
 
(a) (b) 
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Figure 3-16. Reduction and subsequent increase in precursor ion counts 
following salbutamol administration via the breathing circuit. 
To explore this phenomenon further, an in vitro experiment was performed, 
whereby salbutamol was sprayed into a glass jar and the headspace analysed. 
Initially it was not possible to analyse the sample at all due to a complete lack 
of precursor ions; the ion count gradually increased over time. At low 
precursor ion counts, the concentrations of compounds analysed were falsely 
elevated. In full mass scan mode using the H3O+ precursor ion, a large ion peak 
was seen at m/z 93 corresponding to the product of the reaction between 
ethanol and H3O+ ((C2H6O+)2.H+), which is known to be a co-solvent in 
salbutalmol MDIs326 (Figures 3-17 and 3-18). 
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Figure 3-17. Mass spectrum of the empty glass sampling container analysed 
using the H3O+ precursor ion. The main peak at m/z 19 is the H3O+ precursor 
ion. The other two large peaks are the hydrated forms of the H3O+ precursor 
ion.  
 
 
Figure 3-18. Mass spectrum of salbutamol sprayed into a glass sampling 
container analysed using the H3O+ precursor ion. Main peak at m/z 93 is the 
product of the reaction between ethanol and H3O+.  
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3.4. Discussion 
This is the first study to explore the differences in VOC concentrations of 
breath samples obtained from two sampling sites following two breathing 
manoeuvres in intubated and ventilated patients in the ICU. End-tidal breath 
sampling from the T-piece produced less variability in breath volume, lower or 
comparable variability in volatile concentrations, similar mean breath volatile 
concentrations, and was technically the easiest to perform, therefore it was the 
favoured method. Equipment routinely available in the hospital setting was 
used in each of the breath sampling methods, enabling replication of this 
technique in clinical practice.  
 Breath sampling location 3.4.1.
It is preferable to collect samples from as close to the airways as feasible to 
minimise dilution or contamination by components of the breathing 
circuit7,147,166. Analyte concentrations of breath samples collected directly from 
the airways were generally higher than those collected from the T-piece in the 
breathing circuit. This is likely to be predominantly due to increased dilution 
by dead space gas in samples from the T-piece. Unfortunately, despite sealing 
around the suction catheter in the mount when sampling from the airway, small 
air leaks required adjustments in PEEP to maintain airway pressure and tidal 
volume. Additionally, in a few patients, significant air leak around the suction 
catheter was observed and direct airway sampling was abandoned because tidal 
volumes could not be maintained adequately. In extreme cases this could have 
had detrimental consequences in certain patients on the ICU, for example those 
with severe pneumonia, when periods of reduced PEEP and tidal volume may 
lead to de-recruitment of airways and hypoxia. When sampling from the T-
piece there was little reduction in PEEP, therefore no need to alter ventilator 
settings, making sampling from this location quicker, simpler and safer. 
The suction catheter mount used in this study is widely available and designed 
to hold a suction catheter when removing secretions from the airway. A small 
amount of air leak is tolerated during this procedure, however the suction 
catheter must remain in the mount for longer when obtaining breath samples. It 
would be possible to design an attachment for the ventilator circuit that would 
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have a tighter seal to prevent air leaks, but this may well be expensive and not 
as freely available, thus the collection method could not be performed in 
routine clinical practice. If there was an alternative attachment readily 
available, sampling from the airway would be more attractive. 
 Breathing manoeuvre 3.4.2.
Pressure-controlled breaths were used to deliver a recruitment-style breath to 
each patient, replicating a vital capacity breath. A similar technique is used 
routinely in the ICU to recruit collapsed airways and improve oxygenation and 
was favoured over volume-controlled large volume breaths due to lower risk of 
barotrauma327. In most cases, a recruitment-style breath of larger volume could 
be delivered when sampling from the T-piece than from the airway in the same 
person, as increased air leak around the suction catheter attenuated the increase 
in breath volume. Unfortunately, in one case, the recruitment-style breath 
volume delivered when sampling via the airway was smaller than the 
corresponding tidal breath volume when sampling via the T-piece. There was 
no added benefit in terms of repeatability of breath acetone concentration after 
the delivery of a recruitment-style breath rather than a tidal breath at the T-
piece, and a modest improvement during airways sampling, however there 
were difficulties in sampling via this technique. Firstly, it was sometimes 
necessary to change the ventilation mode, which required knowledge of the 
ventilator set-up. Secondly, a wide range of recruitment-style breath volumes 
was produced, thus the change in breath acetone concentration due to change in 
breath volume was difficult to evaluate. Only small breath volume increases 
from tidal volume were possible when the IPAP required for on-going 
ventilation was close to 35 cmH2O. Despite a significant difference in breath 
volume using each of the breathing manoeuvres the difference in breath VOC 
concentrations was small. 
Variability in breath acetone concentration due to breath volume was less than 
that caused by other factors, notably surgical stress; therefore it was difficult to 
quantify the effect of breath volume on breath acetone concentration. As with 
other VOCs that are highly soluble, for example ethanol, larger breath volumes 
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in, wash-RXW´SKHQRPHQRQ154. 
 Breath volume and flow rate 3.4.3.
Unlike on-line studies, the use of an off-line method did not allow real-time 
evaluation of breath concentrations106,207,209,210 or the ability to select a 
particular phase of the respiratory cycle of interest209,210. The timing of each 
breath sample at the very end of expiration did, however, enable the first 
portion of an exhalation to be delivered to the ventilator tubing as dead space 
gas. In comparison to off-line collection methods that require sample pre-
concentration, analysis of breath samples by SIFT-MS is rapid and avoids 
potential sample loss or contamination during adsorption and desorption 
processes328. Results obtained using the end-tidal breath collection technique 
via a T-piece, with analysis as described, should also be comparable to on-line 
analysis techniques reporting end-exhaled breath concentrations. Sample losses 
due to the collection apparatus can be quantified and are discussed in Chapter 2 
of this thesis. No other authors have published quantified losses due to the 
sampling method, either in on-line or off-line sampling. 
In contrast to previous studies159,168, there was no relationship between breath 
acetone concentration and breath volume. This could be a result of our 
sampling technique because, when collecting breath samples as described in 
this study, we could not predict residual volume and therefore 150 ml breath 
samples represent a different percentage of that volume in different patients. 
There was no relationship between breath H2S or HCN concentrations and 
breath volume, which is consistent with previous studies151,223.  
Exhalation in intubated patients ventilated on controlled modes is passive and 
therefore it is not possible to control the exhalation flow rate. The flow rate of 
the hand-held pump during breath collection was constant at 1.8 L/min and 
sample collection was timed, thus ensuring a constant adequate volume of 
breath for analysis by SIFT-MS. The pump used could not run faster than this 
rate, however the flow rate of the suction units attached to the wall in the ICU 
was around 4.8 L/min. This suggests that higher pump flow rates would be 
suitable for breath sample collection as they would not cause lung trauma, as 
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long as they did not induce coughing, which would affect sample collection. 
Unlike breath concentrations of nitric oxide172, the concentrations of breath 
acetone, H2S and HCN do not appear to be flow rate dependent151,168,223. 
Ventilatory pattern169 and cardiac output1,2,97,176, as well as degree of 
pulmonary shunt174,176, have been shown to affect breath volatile 
concentrations, and may have played a part in determining the measured breath 
VOC concentrations in this study. The effect of these variables, other than 
EUHDWK YROXPH RQ DQ LQGLYLGXDO¶V EUHDWK DQDO\WH FRQFHQWUDWLRQV ZDV QRW
assessed, as these variables did not change significantly over the duration of 
EUHDWK VDPSOLQJDQG LWZDV LPSRUWDQW WKDW WKHSDWLHQW¶VFDUHZDVGLVUXSWHGDV
little as possible by the breath sampling technique. Patients acted as their own 
controls, thus inter-subject changes due to the different breath sampling 
techniques were more important than inter-subject breath volatile 
concentrations.  
 Breath acetone concentration 3.4.4.
Previous studies have shown a high degree of inter-person variation in breath 
acetone concentration5,167,168, which is confirmed in this study. In this patient 
group other factors, for example degree of metabolic stress associated with 
sepsis and surgery, are likely to account for the higher degree of inter-person 
variability in breath acetone concentrations compared to intra-person 
variability as a consequence of the breath collection method. As mentioned 
previously, inter-person variation in breath acetone concentration was less 
important in this study as each patient acted as their own control when 
comparing each of the four breath collection methods.  
The mode of ventilation (SIMV versus Bi-Level) was determined by ICU staff. 
In general, patients who had just returned from the operating theatre were 
ventilated on SIMV and those with respiratory compromise were ventilated on 
Bi-Level. Medical patients were fed via a nasogastric tube, not fasted, and had 
lower breath acetone concentrations. Post-operative patients underwent breath 
sampling within four hours of arriving in the ICU from the operating theatre 
and their high breath acetone concentrations are likely to be a combination of 
fasting194,196,225 and metabolic stress caused by surgery105. 
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 Breath H2S and HCN concentrations 3.4.5.
Breath concentrations of H2S and HCN in this study were very small; all 
observed H2S concentrations were less than 5 ppb and less than 20 ppb for 
HCN. Differences due to sampling technique were, therefore, also very small 
and although statistically significant were probably not clinically significant. 
Only one patient was a current smoker, and although breath HCN 
concentrations are known to be raised due to cigarette smoking191, it was not 
possible to assess the effect of smoking on breath HCN concentrations in this 
study. 
High concentrations of endogenous compounds in breath, in this case acetone, 
can affect the calculated concentration of volatiles by increasing the number of 
reactions with precursor ions and depleting the precursor ion count rates. 
Product ion count rates of the lower concentration volatiles should not be 
affected, but the ratio of product ions to precursor ions is affected, leading to 
the generation of a higher than would be expected calculated concentration. It 
may, therefore, be necessary to look at product ion count rates and not 
calculated concentrations if a compound at a very high concentration is also 
present in the breath sample. It is possible that high H2S and HCN 
concentrations seen in the breath of subjects with high acetone concentrations 
were due to precursor ion stripping, although it is also possible that those with 
higher breath acetone concentrations had greater levels of metabolic stress and 
inflammation and this was reflected in true increases in breath H2S and HCN. 
Again, the absolute concentrations of H2S and HCN were less important than 
changes in their concentrations due to different sampling methods, as each 
subject acted as their own control. 
 Effect of inspiratory on exhaled volatile concentrations 3.4.6.
There was no relationship between inspired and exhaled volatile 
concentrations, and in all cases the median exhaled concentration was greater 
than the median inspired concentration. The inspired concentrations of H2S and 
HCN were almost always greater than 25% of exhaled concentrations, 
however, and should therefore be treated with caution2,8. Scrubbing inspired air 
to remove VOCs of interest can be difficult, time consuming and not always 
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reliable93,147, especially if it is being delivered via a ventilator. It was therefore 
not attempted in this study where it was not felt to be particularly important, as 
inspired VOC concentrations did not appear to interfere with breath 
concentrations. There did not appear to be any difference in inspired volatile 
concentrations when a humidification device was added to the breathing 
circuit. 
 Sample loss and contamination 3.4.7.
It is possible that condensation of water vapour occurred in the Tedlar bags or 
other parts of the equipment at the time of breath collection due to using cold 
equipment. This may have altered observed sample concentrations, however 
samples were immediately incubated and analysed as soon as possible to 
minimise any such losses. The pump was flushed after use and other equipment 
disposable or cleaned to prevent contamination of future samples. The effect of 
the sampling apparatus on breath VOC concentrations is important so that it 
can be taken into account when comparing results from different studies using 
different sampling techniques, as previously described in Chapter 2 of this 
thesis.  
In a previous study, chlorofluorocarbons (CFCs) present in inhalers used to 
deliver bronchodilator drugs produced characteristic peaks when measured by 
SIFT-MS in vitro and in vivo107, which interfered with the quantification of 
substances with product ions at the same mass/charge ratios. Salbutamol MDIs, 
however, no longer contain CFCs as propellants and instead use 
hydrofluoroalkanes (HFAs) but can still cause problems when analysing breath 
samples. In order for the active compound to remain dispersed, ethanol must 
also be present as a co-solvent. The concentration of ethanol present in 
different preparations of salbutamol (Salamol® and Airomir®) has led to 
positive roadside alcohol breath tests329 and two investigations show that after 
two puffs of salbutamol it is necessary to wait 3 min in order to pass the 
alcohol breath test330,331. It is likely that the high concentration of ethanol 
SUHVHQW LQ WKH5HVSLJHQIRUPXODWLRQRIVDOEXWDPROLQ WKLVFDVHGHSOHWHG WKH
precursor ions by reacting with them, affecting the concentration of analytes 
measured. It would therefore be prudent to wait at least 10 min after a subject 
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has used inhaled medication before performing breath tests, which includes 
collecting breath samples from a ventilator circuit. 
 Sample size 3.4.8.
One final limitation of the study was the sample size. There was a higher 
degree of inter-subject variability in breath volatile concentration, particularly 
acetone, than expected; some patients having much higher acetone 
concentrations than reported in previous studies. This meant that intra-subject 
changes in volatile concentration due to breathing manoeuvre and location 
were smaller than inter-subject differences caused by patient factors. 
Importantly, patients acted as their own controls, which enabled differences for 
each of the four sampling methods to be seen. A larger sample size may have 
helped to separate further the differences in volatile concentrations due to 
sampling techniques. 
 Summary 3.4.9.
Although measured analyte concentrations were slightly lower than with direct 
airway sampling, there was comparable intra-subject reproducibility when 
sampling from the T-piece. End-tidal breath sampling via the T-piece was the 
simplest technique and was able to be successfully carried out in all patients, so 
this method of sampling is recommended. In subsequent parts of this thesis, the 
method of end-tidal breath collection via a T-piece will be employed. It is 
important to be aware that high concentrations of analytes, even if they are not 
of interest in terms of quantification, can affect the way in which VOC 
concentrations are calculated by SIFT-MS, and these should be minimised as 
much as possible. 
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4. Off-line end-exhaled breath testing in healthy 
anaesthetised patients 
4.1. Introduction and aims 
Ideally, when choosing a group of subjects to act as controls, consideration 
should be paid to the ability to collect and analyse all breath samples using the 
same technique to minimise the number of variables. There is no suitable 
control group of intubated and ventilated patients in the ICU with which to 
compare patients with critical illness, as respiratory, cardiac or neurological 
failure, including that induced by drugs, may all affect breath volatile 
concentrations. Intubated and ventilated patients undergoing surgical 
procedures constitute a group of healthy individuals from whom baseline 
concentrations of exhaled volatiles could be collected. By sampling following 
intubation, but prior to the start of a surgical procedure, breath VOC 
concentrations will not be affected by surgery itself.  
Anaesthesia machines are designed for rebreathing of exhaled gases, including 
volatile anaesthetic agents, unlike ventilators in the ICU that vent exhaled 
gases to the atmosphere and deliver fresh medical air/oxygen directly into the 
breathing circuit on every inspiratory breath. The recycling of exhaled breath 
into the inspiratory limb of the anaesthesia ventilator allows the concentration 
of anaesthetic volatiles to be controlled, so that equilibrium can be reached 
between breath and plasma concentrations. The oxygen content of the gas mix 
is altered by adding as much medical oxygen as necessary and CO2 is removed 
from the breathing circuit by soda lime granules. When breath sampling in the 
operating theatre, it is necessary to use higher inspired gas flow rates than 
sometimes used during anaesthesia to prevent rebreathing of endogenous 
volatiles, which may affect measured breath concentrations. The use of total 
intravenous anaesthesia (TIVA) not only prevents potential contamination with 
anaesthetic volatiles, but also allows the gas flow rate to be increased without 
using large quantities of anaesthetic gases, which are not only expensive but 
have been argued to be damaging to the environment332,333.  
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It was the intention in this study to develop an off-line sampling technique for 
use in anaesthetised intubated patients, comparable to the end-tidal breath 
collection technique via a T-piece described in Chapter 3 of this thesis, using 
equipment readily available in the hospital environment. As with the method 
developed in the ICU, the physical location of the SIFT-MS device 
necessitated an off-line discontinuous technique. Acetone was selected as a 
model compound to validate the breath collection technique as it is present in 
human breath in large quantities and can be easily and accurately measured 
using SIFT-MS168. Whilst altering the anaesthesia machines so that they 
behaved like ICU ventilators, it was necessary to investigate the effects of 
breath sampling from either side of the filter in the breathing circuit, altering 
the inspiratory gas flow rate, and the position of the adjustable pressure 
limiting (APL) valve on inspiratory and exhaled acetone concentrations, as 
well as the reproducibility of these measurements. The final aim was to provide 
control concentrations of acetone, H2S and HCN for comparison with breath 
samples obtained from intubated and ventilated patients in the ICU. 
4.2. Methods 
 Subjects and anaesthesia 4.2.1.
The study procedures were approved by the Upper South A Regional Ethics 
Committee, New Zealand. Twenty-six elective and semi-elective, non-diabetic, 
adult patients awaiting various surgical procedures at Christchurch Hospital, 
for which endotracheal intubation was indicated, consented to take part. 
Patients were recruited during October and November 2011. Immediately prior 
to the surgical procedure, subjects performed spirometry and peripheral venous 
blood was obtained and sent to Canterbury Health Laboratory for analysis of 
fasting glucose, ketones (acetone, beta-hydroxybutyrate), renal function (urea, 
creatinine) and inflammatory marker status (WCC and CRP). The sample for 
acetone testing was immediately put on ice with subsequent laboratory analysis 
of the headspace by gas chromatography. The analysis of H2S concentration in 
blood samples was carried out at Canterbury University, Christchurch, New 
Zealand, using a protocol described by Zhang et al.334 as there is no 
commercially available assay. Blood samples had to be prepared for storage at 
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Christchurch Hospital before transfer to Canterbury University in batches; 
whole blood samples were centrifuged and the plasma immediately frozen at -
25°C, with subsequent freezing at -80°C. Past medical history, drug history, 
duration of fasting prior to surgery and planned surgical procedure were noted 
for each subject. 
The breath sampling technique required little change to standard anaesthetic 
practices; patients were pre-oxygenated before induction of anaesthesia with 
propofol and an opiate chosen by the anaesthetist. A paralysing agent was 
given before intubation. Two different anaesthesia machines were used in the 
operating theatres; Aisys Carestation (GE Healthcare/Maddison, Helsinki) and 
ADU Carestation (Datex-Ohmeda/GE Healthcare, Helsinki). Each patient was 
ventilated using a circle breathing system. Ventilator settings were determined 
by the anaesthetist, commonly a tidal volume of 500 ml and respiratory rate of 
10 breaths per minute. Unless otherwise stated, the inspiratory gas flow rate 
was set at 6 L/min and the APL valve was in the fully open position. End-tidal 
CO2 was monitored continuously along with all other routine monitors. Data 
was collected on ventilatory parameters (FiO2, respiratory rate and tidal 
volume). 
 Exhaled breath collection apparatus 4.2.2.
A schematic of the apparatus is shown in Figure 4-1. A T-piece (oxygen 
enrichment attachment, Respironics Inc, USA) was inserted into the breathing 
circuit at the ventilator gas outlet to facilitate inspiratory gas sampling (Figures 
4-2(a) and (b)). Another T-piece, connected to an adaptor (Care Medical Ltd, 
NZ), was inserted between the endotracheal tube and breathing circuit filter 
(Inmed Manufacturing Sdn Bhd, Malaysia) (Figure 4-3)). As described in 
Chapter 3, two suction catheters with a sampling filter between them were 
connected at one end to the side port of the T-piece using the cut-off tip of a 1 
ml syringe and at the other end to a hand-held pump.  
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Figure 4-1. Schematic of the experimental setup for pre-filter breath sampling. 
Arrows show direction of gas flow. 
 
      (a)    (b) 
Figure 4-2. Photographs show a T-piece (circled) within the inspiratory limb 
of the breathing circuit; (a) Aisys Carestation and (b) ADU Carestation 
anaesthesia machines. 
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Figure 4-3. Photograph showing the T-piece and adaptor (circled) adjacent to 
the endotracheal tube (right) and circuit filter (left). 
 Exhaled breath collection 4.2.3.
The apparatus was assembled as above. The ventilator was switched off at the 
end of expiration, timed by observing the position of the bellows, for 4 sec 
whilst a sample of approximately 150 ml of breath was collected into a 1 L 
transparent Tedlar® bag (SKC Inc, USA) via the pump. The ventilator was 
switched back on and several standard breaths were delivered. The process was 
then repeated until three samples had been collected into separate Tedlar bags.  
All breath samples were obtained prior to the start of the surgical procedure 
and incubated at 40°C prior to analysis. All but one set of samples were 
analysed within 30 min of collection by SIFT-MS. A pneumotachometer (RSS 
100, Hans Rudolph Inc, USA) was inserted into the respiratory circuit to 
confirm the direction of flow during sample collection was from the patient and 
not the distal breathing circuit. The pump was flushed by running through 
room air for at least 2 min between patients. 
 The effect of the breathing circuit filter 4.2.4.
To investigate whether the filter located in the breathing circuit had any effect 
on the concentration of acetone detected in breath samples, triplicate end-
expiratory breath samples were collected, as described above, from T-pieces 
located on each side of the circuit filter. Pre-filter sample collection was carried 
out in 22 patients and post-filter sample collection in seven patients, including 
three patients for whom samples were collected from both sides of the filter. 
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 The effect of altering the inspiratory gas flow rate 4.2.5.
In all patients the flow rate was set at 6 L/min during the sampling process, 
however, to explore whether varying the inspiratory gas flow rate would affect 
inspiratory and/or exhaled acetone concentrations the effects of four different 
flow rates were investigated. In two patients, different flow rates were 
investigated by collecting an inspiratory gas sample and triplicate end-
expiratory breath samples. For patient A, the flow rates tested were 2 L/min, 6 
L/min, 10 L/min, and 15 L/min. For patient B, the same flow rates, but in 
descending order, were tested. A 2 min equilibration period was used between 
each different flow rate.  
 The effect of the adjustable pressure limiting (APL) valve 4.2.6.
The APL valve is adjusted during manual ventilation; closing the valve allows 
the build-up of pressure and inflation of the manual ventilation bag, as well as 
delivery of the contents of the bag to the patient. When fully open, no gas is 
allowed to build up in the circuit and any excess gas is vented to ventilator 
scavenging system. The valve can be positioned partially or fully open, or 
closed (Figure 4-4). During mechanical ventilation it is not important whether 
the APL valve is open or closed as it is no longer part of the ventilation circuit, 
however it is routinely fully opened. In order to obtain end-expiratory breath 
samples as described above, the ventilator had to be switched off, diverting the 
breathing circuit to the manual ventilation bag. Because of this, the position of 
the APL valve during sampling becomes relevant, and closing the value might 
be expected to cause unquantifiable dilution of the sample. To confirm that 
closing the valve would lower the concentration in the sample, breath was 
collected with the valve fully open (usual position during mechanical 
ventilation) and partially closed (a position chosen by the anaesthetist). 
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 (a)     (b) 
Figure 4-4. Photographs display the location of the adjustable pressure limiting 
(APL) valve (red circle) in the Aysis Carestation (a) and ADU Carestation (b) 
anaesthesia machines. 
 Infection control 4.2.7.
The suction catheters and sampling filter were disposable and used for only one 
set of samples. The T-piece and adapter were decontaminated for re-use. 
Disinfectant wipes were used on the surfaces of the hand-held pump and Tedlar 
bags (Azo wipes, W. M. Bamford & Co Ltd, NZ). None of the cleaning 
procedures changed the VOC composition of samples. 
 Selected ion flow tube mass spectrometry 4.2.8.
Breath volatile concentrations were measured by SIFT-MS, Voice200® (Syft 
Technologies Ltd, NZ) as described in Chapter 2.2.6. of this thesis. Bag 
samples were attached to the heated inlet extension of the SIFT-MS and 
analysed for 30 sec. 
 Statistical analysis and calculations 4.2.9.
There was limited previous work on which to base a calculation of sample size 
in order to determine differences in breath volatile concentrations between 
controls (patients in this investigation) and patients in the ICU (subsequent 
investigations in this thesis). No other breath studies in the operating theatre 
examine the volatiles of interest here along with off-line analysis without pre-
concentration of samples. Intra-subject, inter-day and intra-day CVs for 
exhaled acetone in a previous study of non-intubated and ventilated healthy 
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volunteers were between 0% and 5.6%168. The sample size chosen was 
equivalent to that of the first investigation in this thesis, looking for clinically 
significant change to plan future studies. 
Means and percentage CVs of three end-exhaled breath samples for each 
patient were calculated. Comparisons were made using Mann-Whitney U tests 
for unpaired and Wilcoxon signed rank tests for paired data. Correlations were 
GHWHUPLQHGE\6SHDUPDQ¶VUDQNFRUUHODWLRQFRHIILFLHQWUs). Statistical analyses 
were performed using GraphPad Prism version 5.01 for Windows (GraphPad 
Software, USA). A value of p<0.05 was considered to be statistically 
significant. 
Inspired and exhaled acetone concentrations were adjusted for losses caused by 
the sampling apparatus using the linear regression equation formulated in 
Chapter 2.3.2. Due to very low concentrations observed, H2S and HCN 
concentrations were not adjusted and measured concentrations are displayed. 
4.3. Results 
 Patients 4.3.1.
Nine male and 17 female patients were recruited in total, median age 60 years 
(range 22-91 years). Patient demographics and ventilator settings are shown in 
Table 4-1. Interpretable spirometry results were available for 17 patients. Of 
these, 15 were normal and two showed an obstructive pattern (one mild, one 
moderately severe335). Two patients were current smokers and five confirmed 
ex-smokers. Ethnicity data reflects that of the wider Christchurch 
population325. All patients had normal fasting glucose, renal function and 
inflammatory marker status. Median duration of fasting prior to breath 
sampling was 12 hours (range 6.5-17.8 hours). Following breath collection, 
patients underwent a variety of surgical procedures; twelve laparoscopic 
procedures, six open abdominal or pelvic procedures and seven others. Breath 
samples were collected prior to commencement of the operation, so no 
influence on breath biomarkers as a result of operation type could be 
determined.  
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Table 4-1. Subject characteristics and ventilation data. 
Subject Gender Age 
(years) 
Ethnicity Smoking 
status 
Surgical procedure FEV1 (L) (% 
predicted) 
FVC (L) (% 
predicted) 
FEV1/FVC 
(%) 
Tidal volume 
(ml) 
RR (breaths 
per min) 
PetCO2 
(mmHg) 
1 m 44 NZ European N Abdominal wall 4.86 (116) 5.94 (115) 82 500 10 42 
2 m 64 NZ European N Open abdominal 3.52 (111) 3.86 (95) 91 500 12 43 
3 m 79 NZ European Ex Open abdominal 2.92 (112) 3.61 (103) 81 500 10 39 
4 m 54 NZ European N Hand surgery 3.64 (99) 4.61 (100) 79 500 10 34 
5 m 29 NZ European N Open abdominal    550 10 38 
6 m 66 NZ European N Laparoscopy 3.88 (124) 5.49 (136) 71 450 10 37 
7 m 69 NZ European N Laparoscopy 2.58 (80) 3.29 (78) 79 500 10 40 
8 m 64 NZ European Ex Open abdominal 3.50 (103) 4.63 (106) 76 500 12 36 
9 m 29 NZ European Ex ENT 3.62 (86) 4.74 (95) 76 500 10 38 
10 f 40 NZ European N Laparoscopy 2.66 (92) 3.29 (99) 81 500 10 35 
11 f 40 NZ European N Laparoscopy    400 10 36 
12 f 34 Maori Smoker Laparoscopy    550 10 40 
13 f 57 Polynesian N Open pelvic 1.65 (79) 2.28 (92) 72 450 10 43 
14 f 41 Maori N Laparoscopy    500 10 40 
15 f 69 NZ European Ex Hand surgery    425 8 38 
16 f 48 African N Laparoscopy    500 12 34 
17 f 43 Maori Smoker Laparoscopy 2.99 (98) 3.73 (106) 80 550 10 39 
18 f 91 NZ European N Breast surgery 0.85 (52) 1.39 (63) 61 450 10 40 
19 f 62 NZ European N Breast surgery 1.17 (54) 2.34 (90) 50 500 10 38 
20 f 88 NZ European N Breast surgery    400 10 42 
21 f 46 NZ European N Laparoscopy 3.00 (108) 4.07 (126) 74 500 10 33 
22 f 73 NZ European N Open abdominal    500 10 32 
23 f 65 NZ European Ex ENT 1.42 (84) 2.66 (129) 53 450 10 39 
24 f 22 NZ European N Laparoscopy    450 10 45 
25 f 26 Asian N Laparoscopy 2.88 (87) 3.80 (100) 76 500 10 35 
26 f 37 Caucasian Ex Laparoscopy 3.23 (101) 3.83 (104) 84 500 12 33 
            Ex, ex-smoker; N, non-smoker; ENT, Ear, Nose and Throat surgery; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; Tidal volume delivered by the ventilator; RR, 
respiratory rate; PetCO2, partial pressure of end-tidal CO2.
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 The effect of the breathing circuit filter 4.3.2.
Median CV for breath acetone concentration in samples collected from the 
patient side of the filter was lower than in samples taken from the distal side 
(pre-filter CV 8.3% (IQR 6.9±14.5%) n=22, post-filter 10.1% (IQR 6.8±
14.1%) n=7).  
Data was available for three patients who had samples collected from both 
sides of the biological filter, making it possible to compare the absolute change 
in concentration. Acetone concentrations were higher when measured on the 
patient side of the filter (Table 4-2).  
Table 4-2.  Difference in mean exhaled breath acetone concentration between 
samples taken from either side of the biological filter in the respiratory circuit. 
Patient Mean acetone concentration (ppb) Change in acetone 
concentration 
 
Patient side of 
filter 
Anaesthesia 
machine side of 
filter 
ppb % 
2 303 205 98 32 
3 386 366 20 5 
13 157 65 92 59 
 
The reason for the change in acetone concentration caused by the breathing 
circuit filter was explored in greater detail in the laboratory. Test gases of 
100% relative humidity were produced using dilution apparatus (Syft 
Technologies Ltd, NZ), a permeation chamber (Dynacalibrator Model 150, 
VICI Metronics, USA) and permeation tubes of acetone (Kin-tek, USA). Gas 
mixtures containing different concentrations of acetone were individually 
passed into the SIFT-MS instrument for quantification of acetone, then passed 
through an identical filter to those used in the operating theatre breathing 
circuits and the acetone concentration again analysed directly via SIFT-MS 
(Figure 4-5). The concentration of acetone once it had been passed through the 
filter was initially lower than the pre-filter acetone concentration, but increased 
over 15 sec to a plateau equivalent to the pre-filter concentration. The filter had 
a dead-space volume of 50 ml. We therefore surmise that the reduction in 
acetone concentration across the filter observed in patients was due to a 
dilutional/dead space effect rather than absorption across the filter. 
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Figure 4-5. Photograph of the filter in-line between the dilution apparatus 
containing a permeation tube of acetone and the SIFT-MS instrument. The 
direction of gas flow is marked by an arrow. 
 The effect of different anaesthesia machines on inspired and 4.3.3.
exhaled volatile concentrations 
Ventilator settings were chosen by the anaesthetist, delivering tidal volumes of 
400-550 ml at respiratory rates of 8-12 breaths per minute. There was no 
relationship between the anaesthesia machine used and tidal volume or 
respiratory rate. 
Of the two different types of anaesthesia machine present in the operating 
theatres, the Aysis Carestation was used in 61.5% (n=16) of cases and the 
ADU Carestation in 38.5% (n=10).  
Acetone 
Median inspired acetone concentration for all 26 patients was 151 ppb (range 
90-577 ppb). Acetone concentration of the inspired gas from the ADU 
Carestation was higher than from the Aysis Carestation (medians 284 ppb and 
134 ppb, respectively; p=0.0002) (Figure 4-6). Despite the differences in 
inspired acetone concentration associated with the different anaesthesia 
machines, there was no significant difference in exhaled acetone concentration 
Dilution apparatus 
Biological filter 
SIFT-MS inlet 
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in subjects ventilated by the different devices (medians: ADU 630 ppb, Aysis 
513 ppb; p=0.95). In addition, there was no relationship between acetone 
concentrations of inspired gas and exhaled breath in the 22 patients in whom 
pre-filter samples were collected (rs=0.33, p=0.14). 
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Figure 4-6. Individual data points and column medians show the concentration 
of acetone in the inspired gas of the two main anaesthesia machines. 
Hydrogen sulphide and hydrogen cyanide 
Median inspired H2S concentration for all 26 patients was 1.26 ppb (range 
0.53±6.83 ppb). H2S concentration of the inspired gas from the ADU 
Carestation was higher than that from the Aysis Carestation (medians 1.95 ppb 
and 0.92 ppb, respectively; p=0.0078). There was no difference in exhaled H2S 
in subjects ventilated by the different anaesthesia machines. 
Median inspired HCN concentration for all 26 patients was 0.77 ppb (range 
0.44±6.41 ppb). There was no significant difference between inspired HCN 
concentrations collected from each model of anaesthesia machine (medians: 
ADU 0.72 ppb, Aysis 0.81 ppb; p=0.51). There was no difference in exhaled 
HCN in subjects ventilated by the different anaesthesia machines. 
 The effect of altering the inspiratory gas flow rate 4.3.4.
Despite a large variation in inspired concentration (Figure 4-7), the exhaled 
acetone concentration was not affected by altering the flow rate (Table 4-3). 
For the two patients tested the median (inter-flow) CV for expired acetone 
concentration across the four different flow rates (5.6%) was comparable to the 
median CV for the triplicate samples collected at a single flow rate (6.6%).  
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Figure 4-7. Acetone concentration of inspiratory gas at each flow rate. 
Table 4-3.  Mean inspired and exhaled acetone concentrations at different 
inspiratory gas flow rates. 
Inspiratory gas flow 
rate (L/min) 
Mean exhaled acetone concentration (ppb) 
Subject 9 Subject 10 
2 998 364 
6 946 341 
10 967 365 
15 923 322 
 
 The effect of the APL valve 4.3.5.
In the three patients tested (subjects 23, 25 and 26), exhaled acetone 
concentration was higher when the APL valve was fully open compared to 
partially closed. With the valve open, the mean concentration was 1389 ppb, 
compared to 783 ppb with the valve closed. There was a median 37% reduction 
in acetone concentrations between the two valve positions. 
 Analyte concentrations in exhaled breath 4.3.6.
The pneumotachometer was used to visually confirm that samples were 
collected from the patient and there was no significant back flow from the 
ventilator circuit. Median breath volatile concentrations and reproducibility 
data are presented in Table 4-4. 
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Table 4-4. Median inspired and exhaled breath concentrations and median 
intra-subject CVs of VOC concentrations in healthy anaesthetised patients 
(n=22). 
Analyte  Median exhaled breath 
concentration (range) (ppb) 
Median intra-subject CV 
(IQR) (%) 
Acetone Measured 537 (157-5163) 9.2 (7.6-16.0) 
 Calculated 738 (257-6594) 8.3 (6.9-14.5) 
H2S Measured 1.00 (0.71-2.49) 10.0 (8.2-14.8) 
HCN Measured 0.82 (0.60-1.51) 6.8 (3.8-10.5) 
  CV, coefficient of variation; IQR, interquartile range. 
Acetone 
There was a relationship between exhaled breath acetone concentration and 
both plasma acetone (rs=0.80, p<0.0001) (Figure 4-8) and plasma beta-
hydroxybutyrate concentrations (rs=0.55, p=0.0075) (Figure 4-9). There was no 
relationship between breath acetone and blood glucose concentrations (rs= -
0.31, p=0.17). Duration of fasting did not correlate with breath acetone, plasma 
acetone, plasma beta-hydroxybutyrate or blood glucose concentrations.  
The patient with the highest breath and plasma ketone levels was male, with no 
significant past medical history or regular medications. He was not diabetic, as 
confirmed by his normal fasting glucose concentration, and did not fast 
significantly longer than other subjects (15 hours compared to a median of 12 
hours), however he showed a more marked ketotic response to fasting. If his 
data is excluded, the relationships between breath acetone and plasma acetone 
(rs=0.77, p<0.0001) and plasma beta-hydroxybutyrate concentrations are not 
affected (rs=0.49, p=0.025).  
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Figure 4-8. Individual data points show the relationship between mean 
calculated exhaled breath acetone and plasma acetone concentrations. 
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Figure 4-9. Individual data points show the relationship between mean 
calculated exhaled breath acetone and plasma beta-hydroxybutyrate 
concentrations. 
There was no significant correlation between the concentrations of acetone in 
inspired gas and exhaled breath (n=22, rs=0.14, p=0.54). Breath acetone 
concentration did not correlate with tidal volume delivered by the ventilator 
(n=22, rs= -0.23, p=0.29), FVC (n=15, rs=0.32, p=0.24) or FEV1 (n=15, 
rs=0.15, p=0.60). There was no relationship between breath acetone 
concentration and height (rs=0.21, p=0.34), weight (rs=0.075, p=0.74) or body 
mass index (BMI) (rs= -0.14, p=0.54). There was no relationship between 
breath acetone concentration and age (rs=0.04, p=0.87).  
Exhaled breath acetone concentrations measured in men were higher than those 
in women, however this difference was not statistically significant (medians 
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1046 ppb and 738 ppb, respectively; p=0.36). There was no significant 
difference in tidal volumes delivered by the ventilator to men and women 
(median 500 ml in both groups, p=0.31), however there was a difference 
between the FVC values in the two groups (median 4.61 L male and 3.59 L 
female, p=0.05).  
Hydrogen sulphide and hydrogen cyanide 
It was not possible to calculate corrected HCN concentrations at the low 
measured concentrations seen, and although intra-subject CVs for H2S 
concentrations were improved by correcting for losses due to the apparatus, the 
results are likely to be unreliable at such low concentrations, where any minor 
error in analysis is exaggerated.  
There was no significant difference between breath concentrations and inspired 
gas concentrations of either analyte (H2S p=0.12, HCN p=0.24), and for this 
reason there was a relationship between the concentrations of both volatiles in 
inspired gas and exhaled breath (H2S rs=0.59, p=0.004; HCN rs=0.52, 
p=0.014). 
Due to the very low concentrations of these volatiles, it was not possible to 
accurately determine the effects of the breathing circuit filter, inspired gas flow 
rate and ALP valve position on breath concentrations. No interpretation could 
be made about the effect of age or gender on breath H2S and HCN 
concentrations as a result of the very low analyte concentrations and 
relationship between inspired and exhaled concentrations. 
Median venous H26FRQFHQWUDWLRQIRUDOOSDWLHQWVZDVȝPRO/UDQJH
6.1±ȝPRO/7KHUHZDVQRUHODWLRQVKLSEHWZHHQEUHDWKDQGSODVPD+2S 
concentrations (n=22, rs= -0.056, p=0.80), and no relationship between breath 
H2S or HCN concentrations and WCC or CRP blood results. 
4.4. Discussion 
This is the first description of a single end-exhalation breath sampling method 
analysed by SIFT-MS in anaesthetised, intubated and ventilated patients. While 
this method was designed for use with SIFT-MS, it is applicable to other 
139 
 
techniques, including PTR-MS, where off-line sampling of these breath 
volumes is possible, or in combination with SPME for GC-MS analysis. The 
importance of exploring the influences of flow rate, sampling site and other 
aspects of ventilator mechanics, on volatile concentration, has been 
demonstrated. By doing this and establishing a defined protocol, analyte 
concentrations in breath can be repeatedly and reproducibly measured in 
samples from anaesthetised patients and compared with samples obtained from 
patients ventilated in the ICU. Few authors have reported CVs for sample 
collection in the intubated patient, however the CVs for this technique and 
subsequent analysis are of comparable magnitude to others reported for the 
repeat on-line analysis of acetone168,221. 
It was important in this study that the method of breath sample collection did 
not interfere with standard anaesthetic procedures. This was deliberate, to 
ensure smooth sample collection, and high compliance from operating theatre 
staff. Additionally, it was important that the apparatus used to collect the 
samples was the same as that used in other parts of this thesis and readily 
available in the hospital environment. For these reasons, items common to the 
operating theatre and ICU were used (suction catheters, oxygen enrichment 
attachment T-pieces), which could be disposed of or decontaminated after use, 
protecting biological safety of the patient and all staff.  
 Inspiratory gas flow rate and APL valve 4.4.1.
During the method development phase, to avoid possible contamination of 
breath samples with anaesthetic volatile gases and allow higher gas flows 
through the circuit to prevent rebreathing of organic volatiles, TIVA (i.e. 
propofol and an opiate) was used. This enabled a method of breath collection 
comparable to that used in the ICU to be performed, but did limit the study to a 
specific group of operative procedures and therefore a particular group of 
patients for which TIVA was appropriate; generally laparoscopic and 
gynaecological surgery. There is no reason why this method of breath 
collection and analysis could not be applied when inhaled anaesthetic gases are 
used if the effects of the anaesthetic volatiles were properly quantified and did 
not interfere with the quantification method336. However, this should be 
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approached with caution as anaesthetic flow rates are frequently delivered at 
less than 1 L/min, therefore the effects of this on all VOCs of interest would 
need prior investigation. 
Analyte concentrations could be reliably and reproducibly measured in samples 
obtained using the default 6 L/min inspiratory gas flow rate on these 
anaesthesia machines, with the APL valve open as is routine during mechanical 
ventilation. An inspiratory gas flow rate of 6 L/min was greater than each 
SDWLHQW¶V PLQXWH YROXPH VR VKRXOG KDYH SUHYHQWHG UHEUHDWKLQJ LQ WKH
anaesthesia machine. When the soda lime granules, used to absorb CO2 from 
the breathing circuit, were removed from the anaesthesia machine at this flow 
rate, no increase in the partial pressure of end-tidal CO2 was seen, thus 
indicating no significant rebreathing of CO2. APL position can be variable, 
especially if the same anaesthetist is not used for a whole study, i.e. one 
SHUVRQ¶V SDUWLDOO\ RSHQHG PD\ be different from the next. In this regard, 
VWLSXODWLQJ WKDW WKH$3/ YDOYHPXVWEH³IXOO\RSHQ´ VLPSOLILHV WKHSURFHGXUH
and minimises potential variation.  
As has been shown, altering the flow rate or the position of the APL valve has 
the potential to affect both the inspired gas and measured breath 
concentrations. To achieve reproducible results a consistent well described 
method should be used for all patients in a study population.  
 Composition of breath samples and timing of sample 4.4.2.
collection 
The composition of breath at end-exhalation is presumed to represent that of 
alveolar gas147,166. By switching the ventilator off at the end of a tidal 
exhalation, VOCs contained within the subsequent breath sample collected 
should be equivalent to end-exhaled concentrations, thus the introduction of 
additional devices into the respiratory circuit (i.e. fractionating devices212) can 
be avoided. End-exhaled acetone concentrations reported here are comparable 
to results of non-diabetic subjects in other studies167,168,204 and those of 
anaesthetised patients via a continuous breath sampling technique in the 
operating theatre106. That the concentrations measured are comparable to other 
techniques where end-exhaled breath is known to be collected suggest that the 
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technique described here does target alveolar breath. However this method is 
not without limitations; it is not possible to identify other parts of the breath if 
analysis of a different expiratory phase is desired. 
Other discontinuous sampling techniques have used CO2 monitoring or 
temperature to judge the end-expiratory phase, since these devices are 
generally already in the breathing circuit. Continuous end-tidal CO2 monitoring 
was used in the operating theatre, the trace being displayed on the anaesthesia 
mDFKLQH PRQLWRU &DSQRJUDSKV KDYH DQ LQKHUHQW GHOD\ EHWZHHQ WKH SDWLHQW¶V
alveoli and the analyser interface, and also due to the computation method, thus 
it could not reliably be used for the timing of breath collection. 
Some discontinuous techniques require an additional intermediate step such as 
the use of a gas tight syringe to remove sample and then application of the 
sample onto SPME or TD tube. This can introduce additional absorption or 
condensation problems. The technique described here involves collecting the 
sample into the bag that is analysed, so sample loss is limited to the method of 
breath collection, particularly as samples were analysed almost immediately 
after collection. Additionally, rapid analysis can be achieved by SIFT-MS 
despite using this discontinuous technique. Results are readily available as 
analysis takes only a few minutes when lengthy sample preparation with SPME 
or TD is not required. 
The presence of an endotracheal tube may reduce anatomical dead space by 
bypassing the upper airways, however the observed concentration of highly 
soluble VOCs in breath may also be reduced by avoiding an area of gas 
exchange. One benefit of the presence of an endotracheal tube is the 
elimination of breath sample contamination by mouth reservoirs of 
H2S149,262,292 and HCN150,151. Breath H2S and HCN concentrations in the 
current study are similar to previous studies involving nasally exhaled 
breath150,151,262, where nasally exhaled breath concentrations were only slightly 
higher than ambient air.  
As sampling took place prior to the start of the surgical procedure, any possible 
changes in VOC concentration associated with the stress of surgery105,106 were 
avoided.  
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 Location of breath sample collection 4.4.3.
It is advisable to take samples from the patient side of the filter within the 
respiratory circuit to avoid any unquantified analyte loss. The dead-space of the 
filter is one third the volume of each breath sample collected and because it is 
purged with fresh gas on every inspiratory breath, sample dilution may occur. 
In a study of the differences in exhaled isoflurane (an anaesthetic gas) 
concentration at different positions within the respiratory circuit of 
mechanically ventilated patients, the authors concluded there was no 
significant difference between the concentrations of exhaled isoflurane 
measured at various sites in the expiratory limb of the breathing circuit, 
however there was no filter present in the breathing circuit6. The best place to 
monitor inspired gas concentrations was as close to the ventilator as possible6, 
however a subsequent study in the operating theatre has shown that rebreathing 
of VOCs can occur around the biological filter in the breathing circuit337 
(discussed below). 
 Inspired volatile concentrations 4.4.4.
It is evident from the results of this and other studies that different anaesthesia 
machines, machine settings, and hospital environments184 alter inspired volatile 
concentrations. We observed a large discrepancy between inspiratory acetone 
and H2S concentrations in the different anaesthesia machines, the cause of 
which is unclear. It may be the result of volatiles being absorbed or released by 
components of the breathing system within the anaesthesia machines, differing 
gas concentrations in the oxygen supply of different areas of the hospital, or 
another difference in the operating theatre set-up.  
In a recent study of exhaled isoprene in anaesthetised patients337, high 
concentrations of inspiratory isoprene collected on the patient side of the 
breathing circuit filter were felt to be due to the rebreathing nature of the 
anaesthesia machine and contamination from exhaled VOC liberated from the 
breathing circuit filter on each inspiratory breath. Inspiratory samples were 
collected from the gas outlet of the anaesthesia machine in this study, before it 
had passed through the circuit filter, eliminating any effect of rebreathing 
around the filter. Inspiratory samples were not collected from the patient side 
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of the filter. The correlation between inspired and exhaled concentrations of 
H2S and HCN may be due to the previously described influence of inspired 
concentrations of some VOCs147,180,337, but no relationship was seen between 
inspired and exhaled acetone concentrations at the relatively high inspiratory 
flow rate used in this study. It is difficult to know whether a relationship 
between inspiratory and exhaled acetone concentrations would have been 
present if the inspiratory flow rate was lower and/or both types of sample had 
been collected from the same location, as in the study by Hornuss et al.337. 
Inspired concentrations from this location may more accurately reflect true 
inspired VOC concentrations. 
As a result of the lack of correlation between inspiratory and exhaled acetone 
concentrations, standardising the air supply or limiting this study to a single 
operating theatre and type of anaesthesia machine, which would have made it 
unnecessarily difficult to recruit participants, was not attempted. Correcting for 
inspired gas concentrations by simply subtracting them from exhaled 
concentrations does not take into consideration the complexity of the 
relationship, which has led some authors to recommend that care should be 
taken when interpreting breath volatiles if the inspired concentration is greater 
than 5%8 or 25% of the exhaled concentration2, which would apply to both H2S 
and HCN in this study. As has been discussed in Chapters 1.3.6. and 3.4.6. of 
this thesis, inspired air can be scrubbed to remove VOCs, but this can be 
problematic and unreliable93,147 so was not attempted. 
 Breath acetone concentration 4.4.5.
As has been noted in other studies167,168,205, there was a difference in breath 
acetone concentration between men and women, though in this study it did not 
reach statistical significance. The cause for the observed difference is 
unknown; differences in metabolic demand have been proposed by some 
authors167, and others have suggested gender differences in lung volume, which 
are important in the forced exhalation methods used to obtain breath 
samples168. In this study, the median tidal volume delivered by the ventilator 
was the same for both male and female subjects, removing any gender 
variation in exhaled breath volume. There was no correlation between breath 
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acetone and either FEV1, FVC, height, weight or BMI. Despite this, our study 
shows a small gender difference in exhaled breath acetone concentration, 
which may be the result of a larger airway surface area for exchange of acetone 
in men or imply that breath acetone concentration is related to metabolic 
factors rather than exhaled breath volume. 
In mechanically ventilated patients, it is even more important than in awake, 
spontaneously breathing patients to understand the relationship between breath 
and blood VOC concentrations as there is a greater chance of contamination of 
the inspired gas8. Several studies have reported a relationship between exhaled 
acetone concentration and blood acetone, beta-hydroxybutyrate or glucose 
concentrations in serial measurements in both diabetic and non-diabetic 
populations195,226,240,243. A relationship between breath acetone and plasma 
acetone concentrations was observed, comparable to results seen in studies of 
fasted healthy subjects230,232, and a positive correlation between breath acetone 
and plasma beta-hydroxybutyrate concentrations, previously seen during 
glucose tolerance tests240 and the ingestion of ketogenic meals195. No 
significant relationship was seen between exhaled acetone and blood glucose 
concentrations in this study, similar to a previous study of individuals with 
Type 2 diabetes205. In contrast, two studies looking at breath acetone and blood 
glucose concentrations in healthy volunteers during a glucose tolerance 
test225,240 and a study of subjects with Type 1 diabetes243 revealed positive 
relationships between breath acetone and blood glucose concentrations.  
When drawing comparisons with other studies it is important to note that our 
study involved fasting healthy individuals; patients with diabetes were 
excluded due to known effects of diabetes mellitus on breath acetone 
concentration226,242. No significant difference in breath acetone concentration 
has been found between individuals with Type 1 diabetes and healthy 
controls226, however those with Type 2 diabetes appear to have significantly 
higher breath acetone concentration242. It is possible that relationships of breath 
acetone concentration with plasma measurements may be affected by the 
abnormal glucose metabolism of individuals with diabetes, and the absence of 
significant change in glucose concentration in healthy fasted individuals 
despite marked changes in breath acetone concentration. We did not control for 
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dietary factors because all patients were fasted for more than six hours, 
however fasting itself has been shown to cause an increase in breath acetone 
concentrations in non-diabetic subjects167,194,196. 
Patients in this study were starved for a considerable amount of time prior to 
surgery, up to 17.8 hours, which is greater than the six hours required 
according to North American338 and UK339 guidelines. This is often because 
elective surgical patients are fasted from midnight before surgery, with 
possible delays building up over the day in the operating theatre. Clear fluids 
are permitted up to two hours before surgery. Interest in the utility of pre-
operative carbohydrate-rich drinks has led to studies reporting attenuation in 
pre-operative thirst, hunger, anxiety and general discomfort340, post-operative 
nausea and vomiting341, and earlier return of gut function following colorectal 
surgery342. Pre-operative oral carbohydrate treatment also reduces the 
development of immediate post-operative insulin resistance343. The evidence 
has led to a British Consensus Guideline recommending the consideration of 
pre-operative carbohydrate-rich drinks 2-3 hours before induction of 
anaesthesia for elective surgical procedures in adult non-diabetic patients with 
normal gastric emptying344.  Patients in this study showed signs of pre-
operative ketosis due to fasting, which may have been improved by the 
administration of carbohydrate-rich fluid. 
 Breath H2S and HCN concentrations 4.4.6.
Breath concentrations of H2S and HCN were not significantly different from 
inspired gas concentrations in this study, however it was anticipated that breath 
volatile concentrations, other than acetone, would not be elevated because 
subjects were healthy and did not have significant systemic or pulmonary 
inflammation or infection. Due to very low H2S and HCN concentrations 
measured, it was not possible to correct concentrations for losses due to the 
sampling apparatus using the linear regression equations in Chapter 2.3.2. At 
such low concentrations, corrected results for these two volatiles were likely to 
be unreliable; any minor error in analysis is exaggerated and the linear 
regression line is not as reliable when volatile concentrations are around their 
limit of detection in humid gas by SIFT-MS. The concentrations of exhaled 
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H2S and HCN appeared to be influenced by inspired concentrations. In 
contrast, a recent investigation of six healthy volunteers found no relationship 
between inspired gas (room air and medical air supply) and nasally exhaled 
breath HCN concentrations151. The higher breath HCN concentrations in that 
study may reflect the upper airways contribution to breath HCN concentration 
eliminated here by the presence of an endotracheal tube.  
There was no relationship between breath and blood H2S concentrations, 
however it is still unclear whether H2S detected in breath is a result of systemic 
or airway production223, or mouth contamination149,292. Blood H2S 
concentrations have been reported for two patients with sepsis261, and in small 
numbers of patients with COPD287-289 and asthma (reviewed254), as well as 
healthy controls, however there is no agreed normal range for this compound 
or commercial assay available. 
The concentrations of these VOCs in illness will be explored in subsequent 
chapters of this thesis, when breath concentrations are predicted to be higher 
than inspired gas concentrations if, like NO, they are produced in the airways94. 
 Limitations and appropriateness of baseline volatile 4.4.7.
concentrations 
It is recommended that spirometry is performed after measurements of NO 
concentration in breath94, as the exhalation manoeuvres appear to temporarily 
reduce NO concentrations345-347. Repeated spirometric manoeuvres caused a 
reduction in NO that lasted for less than one hour in a group of asthmatics and 
healthy subjects346 and up to eight hours in a group of allergic asthmatics345. By 
performing spirometry 30-60 min prior to breath sample collection in this 
study, it is possible that VOC concentrations were altered, however there is no 
data available for the effects of spirometry on VOCs other than NO. 
Breath samples were taken at any time of the day, which may have had an 
impact on breath volatile concentrations, however it is unclear whether diurnal 
variation in breath acetone concentration, for example, is related to timing of 
meals or another cause. It is known that inter-subject variability is greater than 
inter-day variability of breath acetone concentration167,168. In most other studies 
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of breath acetone there has been no attempt to link breath and blood levels, 
whereas in this study we could see that breath acetone concentrations 
correlated with blood concentrations. 
For this group of anaesthetised patients to provide baseline breath volatile 
concentrations they needed to be healthy, without conditions known to affect 
breath volatile concentrations, but also be representative of the population they 
would be compared to. As previously mentioned, patients with diabetes were 
excluded due to known difficulties in interpreting breath acetone 
concentrations226,242. The exclusion of patients with significant lung disease 
and smoking was attempted, however in reality it was not fully possible due to 
the greater need to identify patients in whom TIVA would be appropriate and 
where theatre staff were happy to be involved in the study. Cigarette smoke 
contains numerous volatile organic compounds188, although of the three VOCs 
of interest in this study only HCN from cigarette smoke can be detected in 
human breath190. For this reason non-smokers were recruited if possible to 
reduce any possible contamination of breath samples, however they would not 
have smoked for several hours prior to breath sample collection, reducing the 
level of potential contamination. Including two smokers and two patients with 
obstructive spirometry improved the relevance of any results to the whole 
population, as patients admitted to the ICU will not all be non-smokers with 
normal lung function. Although children were excluded from the study, 
subjects were recruited over a wide age range which makes them more 
representative as a control group. 
 Summary 4.4.8.
This off-line method for single end-exhalation breath collection with SIFT-MS 
analysis in intubated, ventilated patients is repeatable and reproducible. The 
study highlights the importance of exploring variation in volatile 
concentrations associated with local theatre and ICU environments and 
equipment. Patient numbers in some parts of the study are small, making exact 
assessment of the impact of components of the breathing circuit or changes in 
anaesthesia machine set-up difficult. However, it is still possible to conclude 
that it is important to keep all settings the same in order to make accurate 
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comparisons between different patient samples. A suitable method can be 
established with set parameters to minimise variation introduced by the 
sampling methods and therefore reproducibly measure VOC concentrations.  
The sampling method presented here is comparable to that described for breath 
sampling in intubated patients in the ICU. The ease of this sampling method 
lends itself to serial measurements of breath volatiles to monitor changes 
during an operation or to test treatment algorithms in the operating theatre or 
ICU. Breath VOC concentrations obtained via this method are comparable to 
previous studies and can, therefore, be used as a reference point in any 
intubated patient in whom it is not possible to collect a baseline breath sample. 
This breath collection and analysis technique is suitable for further 
investigation of these and other breath volatiles in the operating theatre, for 
example to assess the effects of surgical procedures. 
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5. Breath acetone analysis in critical illness  
5.1. Introduction and aims 
Non-invasive breath acetone monitoring in the ICU could provide rapid, 
frequent or continuous assessment of physiological changes occurring as a 
consequence of critical illness. Breath acetone has been investigated as a 
marker of ketosis195,244, and metabolic stress in patients with heart failure245 
and during surgery105,106. It is produced by decarboxylation of acetoacetate 
mainly during lipolysis and is excreted in breath227,228. Beta-hydroxybutyrate is 
also produced from acetoacetate; the direction of this reaction is dependent 
upon the redox state of the cells, therefore the relationship between the relative 
quantities of acetoacetate, acetone and beta-hydroxybutyrate is not constant348. 
For VOCs like acetone that are produced by metabolic pathways, it is 
important to understand the relationship between their concentrations in 
exhaled breath and the systemic circulation in order for them to be useful8. The 
high variability seen in repeated measurements of acetone concentration in 
plasma compared to breath means the monitoring of breath acetone 
concentration may be more reliable than plasma measurements115.  
Sepsis is a major cause of mortality in the ICU, due to haemodynamic 
compromise and multi-organ failure10-13. Activation of the inflammatory 
FDVFDGH LV NQRZQ WR FDXVH ³VWUHVV K\SHUJO\FDHPLD´ ZKLFK LV FRPPRQ LQ
patients with critical illness in the absence of pre-existing diabetes mellitus12. 
Glucose control appears to be important in the prevention of unnecessary 
morbidity and mortality in this situation65,69,76,81.  
The aims of this part of the study were to explore any changes in breath 
acetone concentration over time in two groups of intubated and ventilated 
patients in the ICU; patients with stress hyperglycaemia and those with new 
pulmonary infiltrates on chest radiograph. Variation of breath acetone 
concentration with insulin administration and feeding was examined, with the 
ultimate aim of assessing whether it could be used to guide insulin or feeding 
regimes. Breath acetone was investigated as a marker of pulmonary infection 
versus other causes of pulmonary infiltrates on chest radiograph. The utility of 
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breath acetone as a marker of metabolic stress and therefore illness severity and 
clinical outcomes was explored, comparing it to other validated tests and tools. 
The relationships between breath acetone and arterial acetone, beta-
hydroxybutyrate and glucose concentrations were examined, along with the 
effects of factors known to influence breath acetone concentration, including 
breathing pattern (described in Chapter 1).  
5.2. Methods 
 Subjects 5.2.1.
Study procedures were approved by the Upper South A Regional Ethics 
Committee, New Zealand. Between October 2011 and April 2012, consecutive 
critically ill non-diabetic adult patients requiring mechanical ventilation on a 
controlled mode in the ICU, Christchurch Hospital, were enrolled if they had 
either or both of the following: stress hyperglycaemia requiring insulin therapy 
as per local protocol82 and/or new pulmonary infiltrates on chest radiograph. 
Baseline sampling was performed prior to insulin administration and/or within 
24 hours of intubation or development of infiltrates if already intubated. 
Patients, or their next of kin, provided written consent prior to sample 
collection. In addition, if the patient had not given their own consent prior to 
inclusion, and regained adequate cognitive functioning, they confirmed their 
consent to participate in retrospect.  
Each patient was ventilated using D 1HOOFRU 3XULWDQ %HQQHWW YHQWLODWRU
system (USA). Some ventilator circuits included a humidifier (Fisher & Paykel 
MR 730 Respiratory Humidifier, NZ). Ventilator modes and settings were 
determined by ICU staff and not altered for the purpose of breath collection.  
Breath and contemporaneous arterial blood samples were taken at enrolment 
(between 07:00 and 17:00) and daily thereafter. Subsequent samples were 
taken between 07:00 and 13:30 unless the patient was spontaneously breathing 
or not present on the ICU, for example in the operating theatre or radiology 
department. Arterial, rather than venous, blood samples were collected as this 
is routine practice in the ICU and was non-invasive due to the presence of an 
arterial line for continuous BP monitoring. Arterial blood gas samples were 
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processed using a blood gas analyser in the ICU. Other blood samples were 
sent to Canterbury Health Laboratory immediately for processing; the sample 
for acetone testing was sent on ice and the headspace analysed by GC. In 
several patients, contemporaneous arterial and central venous blood samples 
were drawn to look for differences in acetone concentration as a consequence 
of its excretion in breath. Sampling was discontinued if the patient no longer 
required controlled ventilation, was extubated, underwent tracheostomy or 
died.  
The following data was collected for each patient: diagnosis and reason for 
admission, number of days on the ICU, age, gender, ethnicity and smoking 
status. Note was made of physiological parameters at the time of breath 
collection, as well as feeding, current medication and disease severity scores. 
The requirement for continuous veno-venous haemodiafiltration (CVVHDF) 
and microbiological and radiological results were recorded. All information 
was updated on a daily basis at the time of breath sample collection. 
 Inspiratory air sampling  5.2.2.
All methods utilised a T-piece (oxygen enrichment attachment, Respironics 
Inc, USA) inserted into the breathing circuit at the ventilator gas outlet, or 
humidifier outlet, for inspiratory gas sampling.  
 Exhaled breath collection 5.2.3.
End-tidal breath collection was performed via a T-piece as described in 
Chapter 3.2.3. of this thesis. The volume of the tidal breath was noted. The 
ventilator delivered several standard breaths before this process was repeated in 
triplicate using separate Tedlar bags. All inspiratory and exhaled breath 
samples were incubated at 40°C and analysed within 40 min of collection by 
SIFT-MS. The pump was flushed by running through room air for at least 2 
min between patients. 
 Infection control 5.2.4.
The suction catheters and sampling filter were disposable and used for only one 
set of samples. The T-piece was decontaminated for re-use. Disinfectant wipes 
were used on the surfaces of the hand-held pump and Tedlar bags (Azo wipes, 
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W. M. Bamford & Co Ltd, NZ). None of the cleaning procedures changed the 
VOC composition of samples.  
 Selected ion flow tube mass spectrometry 5.2.5.
Breath acetone concentration was measured by SIFT-MS, Voice200® (Syft 
Technologies Ltd, NZ), using SIM mode with the NO+ reagent ion (described 
in Chapter 2). Each Tedlar bag was attached to the sampling capillary end cap 
of the heated inlet extension of the SIFT-MS and samples were analysed for 30 
sec.  
 Calculations and statistical analysis 5.2.6.
No previous studies examine the change in breath volatile concentrations over 
time in patients in the ICU. A previous study by Schubert et al.8 explored the 
relationships between inspiratory and venous acetone concentrations, 
ventilatory and cardiac parameters on breath acetone concentration in 46 
patients in the ICU using an off-line sampling technique with sample pre-
concentration. Breath H2S and HCN concentrations have not been studied in 
this patient group. The sample size chosen should allow assessment of the 
relationship between breath volatile concentrations and their inspiratory and 
blood concentrations, as well as the influence of ventilatory and cardiac 
variables. 
Inspired and exhaled acetone concentrations quoted have been corrected for 
losses due to the sampling apparatus (linear regression equations are presented 
in Chapter 2). 
Means and percentage CVs of each set of three end-tidal breath samples were 
calculated. Comparisons between groups were made using Mann Whitney U 
tests for unpaired and Wilcoxon signed rank tests for paired data. Correlations 
ZHUHGHWHUPLQHGE\6SHDUPDQ¶VUDQNFRUUHODWLRQUs). In some cases, only data 
from days 1 and 2 were compared so that data from patients enrolled for many 
more days did not skew the results. As the units of measurement were 
different, a modified Bland-Altman plot was used to compare breath acetone 
and arterial acetone measurements as percentages of their maximum 
concentration208. Statistical analyses were performed using GraphPad Prism 
153 
 
version 5.01 for Windows (GraphPad Software, USA). A value of p<0.05 was 
considered to be statistically significant. 
The ratio of inspiratory acetone as a percentage of exhaled acetone 
concentration ((Cinsp/Cexp)*100) was calculated with a mean and standard error 
of the mean (SEM). Acetone elimination rate was calculated using the 
following equation: Cexp*(VT*RR). 
Alveolar dead space ratio (ValvD/VT) was estimated using the modified Bohr 
equation: (ValvD/VT) = (PaCO2 ± PetCO2) / PaCO2. Alveolar-arterial oxygen 
gradient (A-a gradient) was calculated by using the formula (FiO2 * 
(atmospheric pressure ± water pressure) ± (PaCO2/0.8)) ± PaO2, when 
atmospheric pressure and water pressure at sea level are 760 mmHg and 47 
mmHg, respectively (Christchurch Hospital Heliport is at 17 m elevation349). 
SIRS criteria were met when two or more of the following were present: (1) 
temperature >38°C or <36°C, (2) heart rate >90 beats per minute, (3) 
respiratory rate >20 breaths per minute or PaCO2 <32 mmHg, (4) white blood 
FHOOFRXQW!RUȝORU!LPPDWXUHIRUPV14. 
5.3. Results 
 Patient demographics and health status 5.3.1.
Thirty-four consecutive patients admitted to the ICU, Christchurch Hospital, 
who fulfilled the inclusion criteria were enrolled, however data from two 
patients was subsequently excluded from analysis as consent from their next of 
kin was revoked. Results from 32 patients were analysed; 20 male and 12 
female, median age 61.5 years (range 26±85 years). Demographic data can be 
seen in Table 5-1. Thirty patients were NZ European (93.75%), one patient was 
Asian and one patient was of Maori descent. Ethnicity data reflects that of the 
wider Christchurch population325. Thirteen patients were current smokers, eight 
were ex-smokers an eleven were non-smokers. 
Twenty-eight patients had new pulmonary infiltrates on chest radiograph and 
19 patients were hyperglycaemic requiring insulin therapy. It was not possible 
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to obtain breath and blood samples prior to administration of insulin in eight of 
the 19 patients with hyperglycaemia.  
At enrolment, 22 patients fulfilled the criteria for SIRS14, 17 of whom had 
clinical or microbiological evidence of infection and therefore fulfilled criteria 
for sepsis14. Twelve patients had pneumonia; two of these patients did not have 
sepsis. Positive microbiological results were obtained from eight of the twelve 
patients with pneumonia; five patients had positive legionella DNA PCR tests 
(Legionella longbeachae was cultured from one of these patients), two patients 
had tracheal aspirates with moderate to heavy growth of Haemophilus 
influenzae and Streptococcus pneumoniae, and one patient grew Group B 
Streptococcus on blood culture. Of the other patients with sepsis, one had 
Staphlococcus aureus line sepsis, five had intra-abdominal infection (including 
one with alpha haemolytic streptococcus cultured from blood and intra-
abdominal fluid), one had urosepsis and one patient grew Klebsiella 
pneumoniae in their blood, urine and tracheal aspirate.  
At enrolment, 22 patients fulfilled PO2/FiO2 ratio criteria for ARDS21 (nine 
mild, eleven moderate, two severe) and six patients had pulmonary oedema.  
Samples were collected for a median of three days (range 1±8 days). Sampling 
was most frequently discontinued due to development of spontaneous 
breathing (65.6%), which prevented breath sampling by the method described. 
The next most common reasons for discontinuation of sampling were death 
(18.8%), extubation (12.5%) and tracheostomy (3.1%). 
A variety of medications were administered on a daily basis, all of which were 
FKRVHQE\ WKH ,&8 WHDPGHSHQGLQJXSRQ WKHSDWLHQW¶VPHGLFDO FRQGLWLRQDQG
could not, therefore, be controlled for. All patients were sedated using a 
combination of intravenous propofol and fentanyl according to local protocol. 
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Table 5-1. Patient demographics, inflammatory status, physiology and ventilation mode at enrolment. 
Subject Gender Age 
(years) 
SIRS Sepsis Infiltrates Insulin Sampling days Ventilator mode Breath acetone 
(ppb) 
PO2/FiO2 PetCO2 
(mmHg) 
Alveolar dead space 
1 m 61 3 y y* # 3 Bi-Level 11375 54.7 35 0.54 
2 m 66 3 y y* # 5 Bi-Level 1130 101.4 - - 
3 m 81 3 y  y 2 Bi-Level 1785 150.0 22 0.19 
4 f 71 3 y y*  2 SIMV 3054 167.5 31 0.30 
5 f 60 4 y y  1 SIMV 763 220.0 41 0.11 
6 m 51 1 n y  1 SIMV 1793 225.7 40 0.15 
7 m 85 3 y y*  3 Bi-Level 701 222.5 43 0.22 
8 m 74 0 n y # 3 SIMV 2565 226.7 29 0.42 
9 m 62 4 y y*  2 Bi-Level 722 165.8 52 0.31 
10 f 77 3 n y  2 SIMV 853 363.3 33 0.27 
11 f 78 0 y y* # 2 Bi-Level 2265 284.4 27 0.36 
12 f 42 3 n y  1 SIMV 839 168.3 53 0.17 
13 f 40 2 y y*  6 SIMV 1598 101.3 43 0.26 
14 m 67 2 y y y 3 SIMV 515 72.0 40 0.07 
15 m 46 1 n y* y 3 Bi-Level 1750 323.3 38 0.19 
16 m 54 2 y y* # 8 SIMV 1332 118.3 33 0.38 
17 m 60 2 n y y 2 Bi-Level 2379 168.3 34 0.29 
18 m 81 2 y y* y 5 SIMV 1191 141.8 43 0.15 
19 f 55 3 y y* # 5 Bi-Level 6696 245.7 32 0.24 
20 f 53 1 n  y 2 SIMV 1201 260.0 27 0.27 
21 f 59 3 y y y 3 SIMV 2590 217.5 31 0.52 
22 m 46 2 y y y 8 Bi-Level 1266 146.0 43 0.17 
23 m 38 2 n y  3 SIMV 1569 336.7 26 0.41 
24 m 37 1 n y*  6 SIMV 259 116.0 57 0.23 
25 m 74 0 n  y 4 SIMV 2227 240.0 37 0.14 
26 m 64 3 n y # 6 Bi-Level 753 152.0 32 0.16 
27 m 83 3 n y # 5 SIMV 260 202.0 42 0.29 
28 f 83 2 y y  2 SIMV 4236 385.7 37 0.14 
29 f 26 3 y y  2 Bi-Level 333 426.7 46 0.04 
30 m 39 1 n  y 1 Bi-Level 1147 348.0 40 -0.14 
31 m 67 2 n y  2 Bi-Level 4366 108.3 50 0.43 
32 f 85 1 n y y 2 SIMV 2354 358.3 43 0.19 
SIRS (systemic inflammatory response syndrome): 0-1, no SIRS; 2-4, SIRS. Sepsis: n, criteria for sepsis not fulfilled; y, criteria for sepsis fulfilled. Infiltrates, new pulmonary infiltrates on chest 
radiograph; y, yes; n, no; *, pneumonia present; #, requiring insulin but no pre-insulin samples obtained. SIMV, synchronised intermittent mandatory ventilation. Breath acetone, mean breath 
acetone concentration. PO2/FiO2, arterial partial pressure of oxygen divided by the fraction of inspired oxygen; PetCO2, partial pressure of end-tidal CO2; alveolar dead space ratio calculated by 
(PaCO2-PetCO2)/PaCO2.
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 Inspired and exhaled acetone concentrations 5.3.2.
A pneumotachometer was used to visually confirm that samples were collected 
from the patient and there was no significant back flow from the ventilator 
circuit.  
Median inspired acetone concentration was 110 ppb (range 73-412 ppb) for all 
samples obtained. Median breath acetone concentration of all samples collected 
was 853 ppb (range 162-11375 ppb). There was a high degree of inter-subject 
variation in breath acetone concentration. There was a relationship between 
inspired and exhaled acetone concentrations (rs=0.39, p<0.0001), however 
exhaled acetone concentrations were between 1.4 and 100 times greater than 
their corresponding inspired concentrations. Mean (Cinsp/Cexp)*100 was 11.8% 
(SEM ± 1.4). 
Median intra-subject CV for breath acetone concentration of all breath samples 
collected was 8.51% (IQR 5.8-12.4%). There was no relationship between 
intra-subject CV for breath acetone concentration and alveolar dead space or 
lower PO2/FiO2, indicating that the degree of ventilation-perfusion mismatch 
and impairment in gas transfer did not increase the variability of breath acetone 
concentration in the three consecutive breath samples collected for each patient 
daily. There were changes in alveolar dead space fraction and PO2/FiO2 over 
time, however there was no relationship between changes in these 
measurements and changes in mean breath acetone concentration.  
In general, there was a reduction in breath acetone concentration over time 
(Figure 5-1). Increases in breath acetone concentration were associated with 
surgery, reduction or discontinuation of feeding, increase in gastric aspirate 
volume (indicating a reduction in gut motility and/or malabsorption of enteral 
feed), general deterioration in condition (which may be an indicator of a 
reduction in gut motility and/or malabsorption of enteral feed) and imminent 
death. Changes in breath acetone concentration over time mirrored changes in 
arterial acetone concentration, although the relationship between breath and 
arterial concentrations was not constant.  
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Figure 5-1. Variation in breath acetone concentration for each patient over 
time (lines join each sampling event for an individual patient). 
 Pulmonary dead space and shunt 5.3.3.
Physiological dead space and pulmonary shunt could not be calculated as it 
was not possible to measure the partial pressure of mixed exhaled CO2 or 
mixed venous CO2 (patients did not require pulmonary artery catheters for 
routine management). A-a gradient was used as an estimate of combined shunt 
and dead space ventilation. 
As expected, there was a reciprocal relationship between alveolar dead space 
and PO2/FiO2 ratio (rs= -0.32, p=0.015). There was a positive relationship 
between exhaled acetone concentration and alveolar dead space (rs=0.42, 
p=0.017), but not with PO2/FiO2 ratio or A-a gradient. Calculated alveolar 
dead space was greater in patients with ARDS than those who did not meet 
criteria for ARDS (patients with pulmonary oedema excluded) (medians: 
ARDS 0.25, no ARDS 0.04; p=0.039), as would be expected in this 
condition153.  
There was a significant difference in PO2/FiO2 ratio between men and women 
(medians: men 159, women 253; p=0.022), men had poorer lung function, but 
this did not result in a difference in breath acetone concentration (medians: 
men 1299 ppb, women 1932 ppb; p=0.32). 
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 Relationship between central venous and arterial acetone and 5.3.4.
glucose concentrations 
A total of ten matched central venous and arterial blood samples were taken 
from two patients, revealing identical acetone concentrations irrespective of 
blood sampling location. 
Central venous blood glucose samples were paired with arterial glucose 
samples in four patients, a total of 20 matched samples; mean difference 0.1 
mmol/L (arterial greater than central venous concentration), range arterial 
glucose 1.7 mmol/L less than to 2.2 mmol/L greater than central venous 
concentration. 
 Relationship between breath acetone and arterial ketones 5.3.5.
There was a strong relationship between breath and arterial acetone 
concentrations in the first two sets of samples collected from each patient 
(rs=0.64, p<0.0001) (Figures 5-2 and 5-3). The modified Bland-Altman plot 
shows that as the normalised average concentration of acetone increases the 
difference between the two measurements (breath and arterial) increases. There 
was a stronger correlation between breath and arterial acetone concentrations in 
patients with pneumonia than in all patients (rs=0.78, p<0.0001). The 
relationship between breath acetone and arterial beta-hydroxybutyrate 
concentrations (rs=0.52, p<0.0001), was similar to the relationship between 
arterial acetone and arterial beta-hydroxybutyrate concentrations (rs=0.56, 
p<0.0001). Neither relationship was changed by subtracting inspired from 
exhaled acetone concentration. 
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Figure 5-2. Individual data points of the relationship between breath and 
arterial acetone concentrations in the first two sets of samples collected from 
each patient. 
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Figure 5-3. Modified Bland-Altman plot displaying the relationship between 
breath and arterial acetone concentrations as percentages of their maximal 
value. Average = average value of the normalised breath and arterial acetone 
concentrations; delta = difference between the normalised breath acetone 
concentration and the normalised arterial acetone concentration. Bias was -3.58 
(dashed line) with 95% limits of agreement of -24.9 and 17.8 (dotted lines). 
Removing the results from the patient with the highest breath and arterial 
ketone concentrations did not alter the relationships between breath acetone 
and arterial ketone concentrations. The Bland-Altman plot, however, showed a 
reduction in bias and an increase in the 95% limits of agreement (-37.4±42.2), 
i.e. the variability between the two measurements of acetone concentration 
appeared to increase.  
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 Relationship between breath acetone and arterial glucose 5.3.6.
There was no significant difference in breath acetone concentration between 
hyperglycaemic and euglycaemic patients. There was no relationship between 
breath acetone and arterial glucose concentrations in the first two sets of 
samples collected from each patient, either in all patients or in the group of 
hyperglycaemic patients. Figure 5-4 shows the relationship between exhaled 
acetone and arterial glucose concentrations at enrolment (a) and in the next set 
of samples taken (b). The graphs highlight that some patients remained ketotic, 
signified by high breath acetone concentration, despite normal, or near normal, 
arterial glucose concentration.  
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Figure 5-4. Individual data points of the relationship between breath acetone 
and arterial glucose concentrations at enrolment (a) and the next sample 
collection (b). The red circle indicates patients with high breath acetone 
concentration with normal, or near normal, arterial glucose concentration. 
 The effects of insulin and feeding on breath acetone 5.3.7.
concentration 
There was a significant reduction in breath acetone concentration between pre-
insulin and post-insulin samples in patients with hyperglycaemia (medians: 
pre-insulin 1767 ppb, post-insulin 980 ppb; p=0.002) (Figure 5-5). There was 
no clear relationship between breath acetone concentration and modelled 
insulin sensitivity in the group of patients receiving exogenous insulin (Figure 
5-6). 
(a) (b) 
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Figure 5-5. Individual data points show the change in mean breath acetone 
concentration after insulin administration in patients with hyperglycaemia, in 
whom pre-insulin and post-insulin samples were obtained (n=10). 
There was a reciprocal relationship between breath acetone concentration and 
the percentage of estimated feed requirement administered hourly in all 
patients (rs= -0.39, p<0.0001) and when subjects requiring insulin were 
analysed separately (n=19, rs= -0.36, p=0.0018). This may be explained by 
fasting causing ketosis and elevated breath acetone concentration167,194,196. 
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Figure 5-6. Graphical comparison of (a) hourly (red) versus daily (blue) plasma glucose concentration, (b) breath acetone (blue) and plasma ketone 
concentrations (acetone green, beta-hydroxybutyrate red), (c) modelled insulin sensitivity and (d) enteral dextrose (blue) and insulin (purple) administration 
over time in a patient with stress hyperglycaemia.  
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 Relationship between breath acetone and clinical parameters 5.3.8.
When looking at patients with pulmonary infiltrates only (n=28), there was no 
significant difference in breath acetone concentration or acetone elimination 
rate between patients with pneumonia, SIRS, sepsis or ARDS and those 
without these diagnoses. Therefore, breath acetone concentration could not be 
used to distinguish between these conditions.  
Initial breath acetone concentration as a marker of metabolic stress did not 
correlate with mortality in the ICU or during hospital stay, validated scores of 
illness severity (APACHE II score23 and SOFA score26), or the requirement for 
renal replacement therapy. Initial breath acetone concentration was not 
predictive of number of ventilator days, length of ICU or hospital stay.  
There was no relationship between breath acetone concentration and tidal 
breath volume, respiratory rate, minute ventilation, heart rate or systolic blood 
pressure (SBP) on a daily basis. There was no significant difference in SBP 
between patients receiving ionotropic or vasopressor drugs and those who were 
not; no difference in breath acetone concentration was seen between patients in 
these two groups indicating that these drugs had no effect on exhaled acetone 
concentration.  
 Breath acetone in the ICU, pre-operative and post-operative 5.3.9.
settings 
Day 1 breath acetone samples in the ICU cohort were significantly higher than 
breath acetone concentrations in healthy fasted anaesthetised patients prior to 
surgery (medians: ICU 1451 ppb, pre-operative patients 812 ppb; p=0.038) 
(patient cohort described in Chapter 4; comparison of patient demographics see 
Appendix D). There was also a significant difference in breath acetone 
concentration between pre- and post-operative patients (median post-operative 
patients 8603 ppb; p<0.0001) (n=13, post-operative patients described in 
Chapter 3) and patients in ICU compared to post-operative patients (p<0.0001) 
(Figure 5-7).  
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Figure 5-7. Box and whiskers plots compare mean breath acetone 
FRQFHQWUDWLRQV RI SDWLHQWV¶ ILUVW ,&8 samples, healthy anaesthetised patients 
and patients returning to the ICU following surgery. Whiskers show the range 
of values, medians are indicated on boxes. 
Only one patient in the ICU had breath and blood samples taken pre- and post-
operatively, showing an increase in both breath and arterial acetone 
concentrations (Figure 5-8). Post-operative breath and blood samples were 
collected 4 hours after the surgical procedure (rotator cuff surgery). The patient 
had been admitted due to pneumonia following a road traffic accident and had 
been fed via a nasogastric tube since admission to ICU; feeding was stopped 
for five hours due to surgery. 
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Figure 5-8. Individual data points show mean breath acetone and arterial 
acetone concentrations collected daily on the ICU for a single patient. Surgery 
was performed on day 5, 4 hours prior to sample collection. 
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5.4. Discussion 
Using a single breath end-tidal breath collection method, a reliable and 
repeatable method of breath collection for analysis of acetone concentration by 
SIFT-MS has been presented. The technique is simple to perform and uses 
equipment readily available in the ICU environment, thus making it attractive 
IRUXVHLQURXWLQHFOLQLFDOSUDFWLFH'LVUXSWLRQWRDSDWLHQW¶VYHQWLODWLRQSDWWHUQ
was minimised as much as possible and arterial blood samples were collected 
from an arterial cannula in situ for continuous BP monitoring and routine blood 
sampling. 
 Measuring ketone concentrations 5.4.1.
The concentration of acetone in arterial samples at room temperature is not 
stable as it rapidly moves into the gas phase230. Spontaneous decarboxylation 
of acetoacetate also occurs230,348, therefore blood samples must be kept cold 
until analysis, which can be a problem. It has been suggested that the 
variability of repeated measurements of blood acetone concentration in single 
blood samples is higher than that of breath samples, indicating that breath 
acetone concentration may be a more reliable measurement115. Due to the 
problems with blood acetone measurement and with a reasonable correlation 
between breath and arterial acetone concentrations in this study, it can be 
concluded that breath acetone may be used as a surrogate for systemic acetone 
concentrations. 
The detection of ketone bodies other than acetone in breath is not possible as 
they are not excreted in this way227,228, but it is possible to detect acetoacetate 
and beta-hydroxybutyrate in blood. Dipstick tests (described below) are 
occasionally used to detect the presence of acetoacetate, however an exact 
measurement of the concentration is not possible with this method, and due to 
its volatile nature, laboratory testing involves the same problems as acetone 
analysis. Beta-hydroxybutyrate can be measured in the laboratory, but results 
are not available as rapidly as breath results via SIFT-MS, and on point of care 
instruments229, however these are often not available in the ICU and are not 
truly non-invasive. 
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Urinary ketone measurement 
An alternative non-invasive method of ketone detection involves using a urine 
dipstick. Relying on the reaction of acetoacetate with nitroprusside, a semi-
quantitative measurement of ketosis is possible, however the tests cannot 
identify beta-hydroxybutyrate in the sample, and can only detect acetone if 
glycine is added to the test strip229. Beta-hydroxybutyrate is the most abundant 
ketone body and its formation from acetoacetate is increased in many 
conditions present in the ICU, for example severe hypoxia, hepatic ischaemia 
and multi-RUJDQ IDLOXUH WKXV UHGXFLQJ WKH XULQH GLSVWLFN¶V DELOLW\ to detect 
severe ketosis229. Urinary ketone concentrations may not reflect blood levels 
due to hydration levels, urinary volume, and renal haemodynamics348. Urinary 
testing in patients with critical illness is impossible if the patient is anuric; in 
this study that would have applied to seven patients and 19 daily 
measurements. 
Arterial versus central venous acetone and glucose concentrations 
No difference was seen between central venous and arterial acetone 
concentrations in the small number of patients sampled. Blood acetone levels 
were reported to whole numbers and all but 8 values were single integers. This 
did not provide enough sensitivity to enable conclusions to be drawn about the 
effect on blood concentration of the excretion of acetone in breath. A small 
difference was noted between contemporaneous arterial and central venous 
glucose concentrations; in some cases arterial acetone concentration was higher 
and in other patients central venous concentration was higher. Discrepancies 
were generally very small and may have been true differences or might have 
been caused by sampling or analysing errors. 
 Relationship between breath acetone and arterial ketone 5.4.2.
concentrations 
The relationship between breath and arterial acetone concentrations seen in this 
and other studies8,115,232 may enable breath acetone to be used as a non-invasive 
marker of ketosis in intubated and ventilated patients in the ICU. The modified 
Bland-Altman plot, however, seems to indicate that the relationship changes as 
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acetone concentration increases. In the study by Reichard et al.232 the ratio of 
plasma to breath acetone in fasted subjects was smaller when the plasma 
concentration was above 1 mg/L when compared to lower plasma 
concentrations, which applies to almost every sample in this study.  
The relationship was not changed by using breath concentration after 
subtracting inspired acetone concentration. The correlation between inspired 
and exhaled acetone concentrations seen is unlikely to have affected exhaled 
concentrations as, on average, the inspiratory concentration was only 11.8% of 
the exhaled concentration. Inspired gas samples were collected as close to the 
ventilator outlet as possible to minimise contamination, however, as described 
in Chapter 4.4.4., it is possible that rebreathing occurred around the filter in the 
breathing circuit, thus inspiratory gas sampling from the same location as 
exhaled breath sampling may more accurately quantify true inspired VOC 
concentrations. In all cases the ventilator, breathing circuit and breath 
collection apparatus were the same, so limiting the differences in acetone 
released from these components in different individuals. 
The relationship between breath acetone and arterial beta-hydroxybutyrate 
concentrations was not as strong but still significant. Our results were very 
similar to the relationship seen in subjects fed a ketogenic diet195. The 
relationship between the different ketone bodies is dependent on the redox state 
of the cells, therefore the relationship between breath and arterial acetone 
concentrations can be expected to be stronger than that between breath acetone 
and other arterial ketone concentrations348. 
 Causes of changes in breath acetone concentration 5.4.3.
This is the first study to collect daily breath and blood samples for up to eight 
days from patients in the ICU. Changes in breath acetone concentration were 
seen over time, with a general trend towards reduction in acetone concentration 
with treatment and feeding. The reduction in breath acetone concentration over 
time was not constant, with a more rapid decrease in the first 48 hours, which 
may have reflected the fact that patients who had rapid clinical improvement 
started to breathe spontaneously earlier and therefore did not provide many 
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breath samples. Patients who were enrolled for a greater length of time were 
likely to be more unwell and may have shown less rapid improvement in breath 
acetone concentration over time.  
Unfortunately, because many factors appear to affect breath acetone 
concentration, including degree of lipolysis, breathing pattern169, dead space 
ventilation and pulmonary shunt176, cardiac output97 and airway perfusion, 
some of which cannot be controlled for, interpretation of results remains 
difficult.  
Each patient was ventilated using a mode, tidal volume and respiratory rate set 
E\ WKH ,&8VWDII VR LWZDVSRVVLEOH WKDWGLIIHUHQWSDWLHQWV¶EUHDWKLQJSDWWHUQV
may have led to differences in breath acetone concentration169. Relationships 
between respiratory rate, tidal breath volume, or minute ventilation and breath 
acetone concentration was not observed, however, so these variables were not 
felt to have a strong influence on breath acetone concentration in this study.  
It was not possible to measure cardiac output or pulmonary shunt in this study 
as patients did not have a pulmonary artery catheter in situ. Alveolar dead 
space ventilation was calculated instead of total dead space ventilation as 
mixed expiratory CO2 could not be measured. There was no relationship 
between the change in alveolar dead space and breath acetone concentration 
over time, which indicates that factors other than alveolar dead space fraction 
were more important in determining breath acetone concentration.  
In a study by Schubert et al.8, the degree of pulmonary shunt was greater in 
patients with sepsis but dead space ventilation was not different between 
groups. A difference in the degree of alveolar dead space but not A-a gradient 
was observed in patients with ARDS versus no ARDS in this thesis, however 
the study population was different to that of Schubert et al.8. Here, patients 
with pulmonary infiltrates and/or insulin requirement were enrolled, and 
samples could only be collected from patients requiring mandatory ventilation, 
so spontaneously breathing ventilated patients who had less severe illness were 
H[FOXGHG 7KH EHQHILW ZDV WKDW VDPSOHV ZHUH WDNHQ YHU\ HDUO\ LQ D SDWLHQW¶V
ICU stay, before aggressive treatment had been instigated, therefore patients 
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should have had the severest metabolic derangement making any changes in 
breath concentration more obvious. It is possible that if a less unwell group of 
patients were included as a control, then differences between patients with and 
without sepsis, SIRS and ARDS would have been greater. ARDS guidelines 
have recently been updated21 so, in comparison to previous studies, the group 
of ARDS patients described in this study included those with less severe lung 
injury, previously termed acute lung injury350. Moving this sub-group of 
patients to the non-ARDS group did not, however, change the results of the 
analysis. 
 Breath acetone and pneumonia 5.4.4.
It was not possible, in this study, to use breath acetone concentration or acetone 
elimination rate to distinguish between pneumonia and other causes of 
pulmonary infiltrates, or ARDS and those with less severe lung injury. This is 
in agreement with a study by Schubert et al.8, who found no difference in 
breath acetone concentration between septic and non-septic patients. They did, 
however, find a significant difference in mixed venous and arterial blood 
acetone concentrations between septic and non-septic patients, which was not 
observed here. 
In the sub-group of patients with pneumonia, there appeared to be a stronger 
relationship between breath and arterial acetone concentrations. The 
explanation for this is unclear. Eight of the 12 patients had positive 
microbiological findings for Legionella species, H. influenzae and S. 
pneumoniae. Unlike P. aeruginosa ,which produces characteristic compounds, 
including hydrogen cyanide314,316,351 and 2-aminoacetophenone111, there is no 
data on VOCs produced by Legionella species and little data for H. influenzae 
and S. pneumoniae. Studies of VOCs produced by bacteria in various culture 
media128,351-353 show individual patterns related to different species, and that 
most produce small quantities of acetone, although only one these studies 
included samples containing the bacteria detected in our study353. Acetone was 
frequently detected in the headspace above various bacterial cultures on agar 
plates, although seldom at significantly higher concentrations than background 
levels produced by heated culture media354. It is possible that acetone was 
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produced in the lungs by pathogenic bacteria in this study, however it is 
unlikely to have reached high enough concentrations to be detected in single 
breath samples without pre-concentration355. 
 Breath acetone and surgery 5.4.5.
Metabolic stress during surgery105,106 and in patients with heart failure245 has 
previously been described. Comparison between patients in the ICU and 
anaesthetised patients before the start of a surgical procedure with post-
operative patients in the ICU shows that something other than duration of 
fasting causes elevation of breath acetone concentrations. The single patient in 
the ICU who underwent a surgical procedure had significantly higher breath 
and arterial acetone concentrations post-operatively compared to relatively 
stable concentrations pre-RSHUDWLYHO\ 7KLV SDWLHQW¶V SRVW-operative breath 
acetone concentration was not as high as that of some post-cardiac surgical 
patients, however the surgical procedure was shorter in duration and less 
complicated, therefore likely to generate less of a metabolic response. No 
different medications were used during the operation and there was no 
appreciable change in ventilator or cardiovascular parameters to explain the 
difference. In order to further investigate the rise in acetone concentration due 
to surgery, it would be necessary to monitor a group of patients undergoing a 
range of surgical procedures pre-, peri- and post-operatively. 
 Breath acetone and arterial glucose concentrations, feeding 5.4.6.
and insulin 
There was no relationship between breath acetone and blood glucose 
concentrations in these non-diabetic subjects. Starvation and ketogenic meals 
increase breath acetone concentration194-196, with a rise in breath acetone 
concentration seen in our patients when feed volume was reduced, feeding was 
stopped, or the patient was not absorbing their feed adequately. There is no 
data to suggest that enteral feed itself contains or produces acetone (or another 
compound with an identical m/z ratio that would interfere with its analysis by 
SIFT-MS), or that feed sitting in the stomach of patients with high gastric 
aspirates alters measured breath acetone concentration. In fact, the presence of 
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a cuffed endotracheal tube is likely to reduce contamination of breath samples 
by gastric contents, for example ethanol, which may be released by food itself 
or by the activity of gut bacteria201. Increased feed volume appeared to reduce 
breath acetone concentration, which is in agreement with studies in healthy 
subjects who were fasted and then fed194,225. Feeding in the ICU is 
administered continuously, therefore any changes in breath acetone 
concentration are likely to occur gradually, without diurnal variation seen in 
normal subjects eating meals167,168.  
There was a significant reduction in breath acetone concentration between pre- 
and post-insulin samples in hyperglycaemic patients, which is likely to be due 
to a combination of treatment with insulin and feeding. There is no formal 
agreement around several areas of feeding in the ICU, mainly when feeding 
should be started and the carbohydrate content and composition of the feed. 
Overfeeding can be detrimental, not only due to the increased risk of aspiration 
if gastric emptying is delayed, but it may also contribute to hyperglycaemia if it 
is present. Despite high glucose requirements due to accelerated protein 
catabolism84, lower calorie feeding may improve ICU and hospital 
outcomes88,89.  
The results of this study highlight that some patients remained ketotic despite 
normal, or near normal, glucose concentrations, which may be because 
insufficient time had elapsed following insulin treatment to see a reduction in 
breath acetone concentration, or may reflect a group of patients with a high 
degree of inflammation and catecholamine release driving the ketogenic 
pathway and promoting insulin resistance12,245. These patients may also be 
ketotic due to relative starvation and require more carbohydrate feeding. In 
patients receiving insulin treatment in this study, reductions in breath acetone 
concentration were not associated with improvements in insulin sensitivity, 
implying not only that the relationship between glucose, ketones and insulin in 
critical illness is complex, but also that many factors may affect breath acetone 
concentration. 
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To explore further whether breath acetone concentration could track the degree 
of ketosis and aid the modulation of feeding and insulin regimes in this group 
of patients, the frequency of breath acetone sampling must be increased or a 
continuous sampling method should be employed. 
 Limitations of the breath sampling technique 5.4.7.
In this study, representative breath samples were collected using a single breath 
collection technique as each patient was ventilated on a controlled mode 
without spontaneous breathing, so an almost identical tidal volume was 
delivered with each breath. A problem with this method compared to other 
breath collection methods was that breath sampling had to be discontinued 
ZKHQ WKH SDWLHQW¶V FRQGLWLRQ LPSURYHG HQRXJK IRU VSRQWDQHRXV DVVLVWHG
ventilation. If the pump ran faster, it may have been possible to collect a 
sufficiently large end-tidal breath sample for analysis, though if the respiratory 
rate was too fast there would not have been adequate time to collect enough 
breath from a single exhalation before the initiation of inspiration and either 
mixed breath or multiple breath samples would have been necessary. 
 Summary 5.4.8.
In this study, it was possible to accurately and reliably measure breath acetone 
concentrations in intubated and ventilated patients in the ICU using SIFT-MS. 
A relationship was observed between breath acetone and arterial acetone and 
beta-hydroxybutyrate concentrations that may enable breath acetone to be used 
as a surrogate for blood concentrations. The administration of insulin and 
feeding caused a significant reduction in breath acetone concentration in 
patients with stress hyperglycaemia, and the reduction in feed volume and 
difficulty absorbing feed resulted in increased breath acetone concentration. 
The relationship between breath acetone, feed volume and insulin 
administration needs further investigation before breath acetone can be used to 
aid the modulation of feeding regimes and insulin therapy. 
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6. Exhaled hydrogen sulphide and hydrogen 
cyanide in the Intensive Care Unit 
6.1. Introduction and aims 
Hydrogen sulphide (H2S) and hydrogen cyanide (HCN) may be breath markers 
of inflammation and/or infection, but their biological roles are still uncertain. It 
is not yet known whether these VOCs may be useful in the ICU setting, where 
early accurate detection of pulmonary infection and subsequent administration 
of appropriate treatment may alter outcomes28,39.  
H2S has been proposed as the third gaseous inflammatory mediator after 
carbon monoxide and NO253. The role of H2S in the inflammatory cascade is 
not completely clear; it appears to influence leucocyte function and the release 
of cytokines and chemokines248,264,265,334. It may also modulate the activity of 
NO (reviewed248). HCN is produced by neutrophils308,309 and appears to be 
associated with the respiratory burst of phagocytosis310.  It is also produced by 
some bacteria in vitro, notably Pseudomonas species311,316, and appeared to be 
seen in the breath of P. aeruginosa infected children with CF110. 
If these VOCs are produced by metabolic pathways, an understanding of the 
relationship between their concentrations in exhaled breath and the systemic 
circulation is important8, however, if like NO they are produced in the airways, 
breath concentrations will not reflect plasma concentrations (reviewed152). 
The aims were to investigate the measurement of H2S and HCN in ICU 
patients with new pulmonary infiltrates on CXR and to correlate any changes 
in concentration over time with clinical parameters. The effects of factors 
known to cause variation in breath volatile concentrations, for example 
breathing pattern, were examined, as well as any relationship between breath 
and arterial concentrations. The possibility of distinguishing between 
pneumonia and other causes of pulmonary infiltrates on CXR using breath H2S 
and HCN concentrations was explored. 
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6.2. Methods 
 Subjects 6.2.1.
Patient selection, ventilator set-up, sampling and data collection are described 
in Chapter 5.2.1. Only patients with new pulmonary infiltrates were included. 
 Blood samples 6.2.2.
Arterial blood gas samples were processed using a blood gas analyser in the 
ICU. Routine blood samples were sent to Canterbury Health Laboratory for 
processing straight away; samples for HCN testing were immediately put on 
ice and the headspace analysed by gas chromatography. The analysis of H2S 
concentration in blood samples was carried out as described in Chapter 4.2.1. 
In several patients, arterial and central venous blood samples were drawn to 
look for differences in volatile concentrations. 
 Inspiratory air sampling 6.2.3.
The process is described in Chapter 5.2.2. 
 Exhaled breath collection 6.2.4.
End-tidal breath collection was performed via a T-piece as described in 
Chapter 3.2.3. of this thesis. The volume of the tidal breath prior to breath 
sample collection was noted. Several standard breaths were delivered by the 
ventilator before this process was repeated in triplicate using separate Tedlar 
bags. All inspiratory and exhaled breath samples were incubated at 40°C and 
analysed within 40 min of collection by SIFT-MS.  
 Infection control 6.2.5.
The suction catheters and sampling filter were disposable and used for only one 
set of samples. The T-piece was decontaminated for re-use. Disinfectant wipes 
were used on the surfaces of the hand-held pump and Tedlar bags (Azo wipes, 
W. M. Bamford & Co Ltd, NZ). None of the cleaning procedures changed the 
VOC composition of samples.  
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 Selected ion flow tube mass spectrometry 6.2.6.
Breath H2S and HCN concentrations were measured by SIFT-MS, Voice200® 
(Syft Technologies Ltd, NZ), using SIM mode with the H3O+ reagent ion 
(described in Chapter 2). Each Tedlar bag was attached to the sampling 
capillary end cap of the heated inlet extension of the SIFT-MS and samples 
were analysed for 30 sec.  
 Calculations and statistical analysis 6.2.7.
Measured H2S and HCN concentrations are quoted in this chapter, as volatile 
concentrations were too low to accurately correct for losses due to the sampling 
apparatus (linear regression equations developed in Chapter 2.3.2.). 
Statistical analyses were performed using GraphPad Prism version 5.01 for 
Windows (GraphPad Software, USA) as discussed in Chapter 5.2.6. A value of 
p<0.05 was considered to be statistically significant. Calculations were also 
performed as described in Chapter 5.2.6., including A-a gradient, SIRS scores 
and ratios of inspiratory H2S and HCN as percentages of exhaled 
concentrations. 
6.3. Results 
 Patient demographics and health status 6.3.1.
The patients enrolled in the study are described in detail in Chapter 5.3.1. In 
this part of the study, results from 28 patients with pulmonary infiltrates on 
CXR were included; 17 male (60.7%), 11 female (39.3%), median age 61.5 
years (range 26-85 years). Twelve patients were current smokers and 16 were 
non-smokers (six ex-smokers). 
The pneumotachometer was used to visually confirm that samples were 
collected from the patient and there was no significant back flow from the 
ventilator circuit. 
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 Breath hydrogen sulphide 6.3.2.
Inspiratory and exhaled H2S concentrations 
Median exhaled H2S concentration was 0.96 ppb (range 0.22-5.12 ppb) for all 
samples obtained. The degree of respiratory failure did not appear to affect 
breath H2S concentration; there was a weak relationship between exhaled H2S 
concentration and alveolar dead space ratio (rs=0.04, p=0.04), but not with 
PO2/FiO2 (rs= -0.01, p=0.98) or A-a gradient (rs= -0.11, p=0.57). Median intra-
subject CV for exhaled breath H2S concentration for all samples collected was 
9.97% (IQR 6.8-14.6%), which was not affected by the alveolar dead space 
ratio (rs=0.05, p=0.65) or lower PO2/FiO2 (rs= -0.15, p=0.15).  
Median inspiratory H2S concentration for all samples collected was 0.91 ppb 
(range 0.18-4.70 ppb). There was a relationship between inspiratory and 
exhaled H2S concentrations (rs=0.83, p<0.0001) (Figure 6-1) with no 
significant difference between inspiratory and exhaled concentrations (p=0.47). 
Mean (Cinsp/Cexp)*100 was 99.7% (SEM ± 4.9).  
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Figure 6-1. Individual data points of the relationship between inspired and 
mean exhaled H2S concentrations (all samples). 
Changes in breath H2S concentration over time 
There was generally very little change in breath H2S concentration over time 
(Figure 6-2). One of the two patients who had breath H2S concentrations 
greater than 5 ppb underwent a surgical procedure and will be discussed in 
Section 6.3.4. The other was a patient admitted to the ICU following an out of 
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hospital cardiac arrest with evidence of pulmonary oedema. There was no 
evidence of infection and no change in clinical condition over the three days of 
sampling to account for changes in breath H2S concentration. At the time of 
elevation of breath H2S concentration, corresponding breath acetone 
concentration was not significantly elevated (less than 2000 ppb except for one 
patient following surgery when breath acetone concentration was 3767 ppb). 
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Figure 6-2. Variation in breath acetone concentration for each patient over 
time (lines join each sampling event for an individual patient). 
Relationship between breath and blood H2S concentrations 
Median arterial H26FRQFHQWUDWLRQRIDOOVDPSOHVZDVȝPRO/UDQJH-
 ȝPRO/ 7KHUH ZDV QR UHODWLRQVKLS EHWZHHQ EUHDWK DQG DUWHULDO +2S 
concentrations in the first two samples taken from each patient (rs=0.22, 
p=0.12) (one missing blood sample due to processing errors, total 52 samples). 
This was not altered by analysing patients with two or more SIRS criteria, 
sepsis and pneumonia separately. The modified Bland-Altman plot (Figure 6-3) 
shows a high degree of variability between normalised breath and arterial H2S 
concentrations irrespective of the absolute concentration, confirming there is 
no relationship between the two types of sample concentration. 
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Figure 6-3. Modified Bland-Altman plot displaying the relationship between 
breath and arterial H2S concentrations as percentages of their maximal value. 
Average = average value of the normalised breath and arterial H2S 
concentrations; delta = difference between the normalised breath H2S 
concentration and the normalised arterial H2S concentration. Bias was 5.51 
(dashed line) with 95% limits of agreement of -39.4 and 50.4 (dotted lines). 
Relationship between arterial and central venous H2S concentrations 
A total of ten matched arterial and central venous blood samples were taken 
from two patients. MHDQGLIIHUHQFHEHWZHHQPDWFKHGVDPSOHVZDVȝPRO/
(arterial concentration higher than central venous concentration), range 2.3 
ȝPRO/ ZKHQ FHQWUDO YHQRXV FRQFHQWUDWLRQ LV KLJKHU DQG  ȝPRO/ ZKHQ
arterial concentration is higher. The relationship between arterial and central 
venous concentrations can be seen in Figure 6-4. 
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Figure 6-4. Graph showing the relationship between arterial and central 
venous H2S concentrations. Individual data points are plotted. Solid line 
represents the linear regression line (equation shown), dotted lines show 95% 
confidence interval. R2=0.62. 
Relationship between H2S concentration and clinical factors 
There was no correlation between breath or arterial H2S concentration and age 
(breath rs= -0.12, p=0.56; arterial rs=0.25, p=0.20). There was no difference in 
initial breath or plasma H2S concentration between men and women (breath 
p=0.56, arterial p=0.78) and there were no relationships seen between breath 
H2S concentration and tidal volume (rs= -0.02, p=0.88), respiratory rate (rs= -
0.13, p=0.21), minute ventilation (rs= -0.07, p=0.47), mean arterial pressure 
(rs=0.07, p=0.51) or heart rate (rs=0.06, p=0.57) on a daily basis. 
There was no significant difference in breath or arterial H2S concentrations in 
patients with SIRS compared to those without SIRS (breath p=0.43, arterial 
p=0.79), sepsis compared to those without sepsis (breath p=0.73, arterial 
p=0.63), and patients with pneumonia compared to those with another cause 
for pulmonary infiltrates on CXR (breath p=0.32, arterial p=0.66). Neither 
breath nor arterial H2S concentrations displayed relationships with commonly 
used blood markers of infection and inflammation: WCC (breath rs= -0.08, 
p=0.58; arterial rs=0.00, p=0.99), CRP (breath rs= -0.18, p=0.19; arterial 
rs=0.00, p=1.00). 
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 Breath hydrogen cyanide 6.3.3.
Inspiratory and exhaled HCN concentrations 
Median breath HCN concentration was 0.76 ppb (range 0.31-11.53 ppb) for all 
samples obtained. The degree of respiratory failure did not appear to affect 
breath HCN concentration; a weakly positive relationship was observed 
between exhaled HCN concentration and alveolar dead space ratio (rs=0.39, 
p=0.047), but not with PO2/FiO2 (rs= -0.13, p=0.51) or A-a gradient (rs=0.00, 
p=1.00). Median intra-subject CV for exhaled HCN concentration was 8.53% 
(IQR 4.9-11.2%) for all samples collected; variability was not increased by 
increased alveolar dead space ratio (rs=0.11, p=0.33) or lower PO2/FiO2 
(rs=0.03, p=0.78).  
Median inspiratory HCN concentration for all samples collected was 0.67 ppb 
(range 0.28-2.45 ppb). There was a relationship between inspiratory and 
exhaled HCN concentrations (rs=0.66, p<0.0001) (Figure 6-5), with no 
significant difference between inspiratory and exhaled concentrations (p=0.07). 
Mean (Cinsp/Cexp)*100 was 88.0% (SEM ± 2.7).  
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Figure 6-5. Individual data points of the relationship between inspired and 
mean exhaled HCN concentrations (all samples). 
Changes in breath HCN concentration over time 
There was little change in breath HCN concentration over time for each 
individual patient (Figure 6-6). The highest breath HCN concentration at 
enrolment (10.1 ppb) was taken from a smoker. The concentration remained 
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high the next day before falling. The patient with the next highest initial HCN 
concentration (3.9 ppb) was admitted following an out of hospital cardiac arrest 
associated with pulmonary oedema. There was no evidence of infection and 
despite a reduction in breath HCN concentration there was a general 
deterioration in clinical condition resulting in death. The other two patients 
who displayed increases in breath HCN concentration that can be seen on the 
graph, were admitted following motor vehicle accidents and the development 
of pneumonia (Haemophilus influenzae and Streptococcus pneumoniae isolated 
from tracheal aspirates of both patients). Both patients showed gradual clinical 
improvement over time and breath HCN concentration did not reflect changes 
in other markers of inflammation and infection (WCC and CRP). 
No patients had positive microbiological samples for Pseudomonas species or 
other bacteria known to produce HCN311,316. 
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Figure 6-6. Variation in breath HCN concentration for each patient over time 
(lines join each sampling event for an individual patient). 
Relationship between breath and blood HCN concentrations 
0HGLDQDUWHULDO+&1FRQFHQWUDWLRQDFURVV DOOEORRG VDPSOHVZDVȝPRO/
(range 0- ȝPRO/ %ORRG VDPSOHV IURP WKH ILUVW  SDWLHQWV ZHUH QRW
analysed for HCN concentration, therefore results were available for 17 
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patients. Only eight of the 58 blood samples (13.8%) contained an HCN 
FRQFHQWUDWLRQJUHDWHUWKDQWKHQRUPDOUDQJHȝPRO/7KHUHZDVDFKDQJH
in the laboratory reporting of blood HCN concentrations during the study, 
therefore 37 samples were reported to whole numbers and 21 samples were 
reported to two significant figures. 
There was a weakly positive relationship between breath and arterial HCN 
concentrations in the first two samples taken from each patient (rs=0.39, 
p=0.041), which appeared to be stronger in patients with sepsis compared to all 
patients (n=7, rs=0.93, p=0.0067). The modified Bland-Altman plot (Figure 6-
7) shows that as the average of the normalised concentrations increases, the 
difference between breath and arterial concentrations increases. 
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Figure 6-7. Modified Bland-Altman plot displaying the relationship between 
breath and arterial HCN concentrations as percentages of their maximal value. 
Average = average value of the normalised breath and arterial HCN 
concentrations; delta = difference between the normalised breath HCN 
concentration and the normalised arterial HCN concentration. Bias was 22.45 
(dashed line) with 95% limits of agreement of -25.7 and 70.6 (dotted lines). 
Relationship between arterial and central venous HCN concentrations 
A total of ten matched arterial and central venous blood samples were taken 
IURPWZRSDWLHQWV0HDQGLIIHUHQFHEHWZHHQPDWFKHGVDPSOHVZDVȝPRO/
(arterial concentration higher than central venous concentration), range 1 
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ȝPRO/ ZLWKHLWKHUFRQFHQWUDWLRQKLJKHU WKDQ WKHRWKHU )LJXUH-8 shows the 
relationship between arterial and central venous concentrations. 
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Figure 6-8. Graph showing the relationship between arterial and central 
venous HCN concentrations. Individual data points are plotted. Solid line 
represents the linear regression line (equation shown), dotted lines show 95% 
confidence interval. R2=0.88. 
Relationship between HCN concentration and clinical factors 
There was no difference in initial breath or plasma HCN concentration between 
men and women (breath p=0.67, arterial p=0.35) and no relationship between 
initial breath or plasma HCN concentration and age (breath rs= -0.24, p=0.21; 
arterial rs= -0.51, p=0.60), tidal volume (rs= -0.16, p=0.88), respiratory rate (rs= 
-0.15, p=0.14), mean arterial pressure (rs=0.039, p=0.71) or heart rate (rs= -
0.010, p=0.92) on a daily basis. There was a weak relationship between breath 
HCN concentration and minute volume (rs= -0.22, p=0.028). 
There was a difference between breath HCN concentration in patients with 
SIRS compared to those without SIRS (p=0.0068), however the difference in 
group median concentrations was small (SIRS group 0.82 ppb and no SIRS 
group 1.57 ppb, respectively). There was no difference in breath HCN 
concentration between patients with sepsis and those without sepsis (p=0.53), 
and patients with pneumonia and those with another cause for pulmonary 
infiltrates on CXR (p=0.59). No significant difference in arterial HCN 
concentrations was seen between patients with SIRS and those without SIRS 
(p=1.00), patients with sepsis compared to those without sepsis (p=0.48), and 
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patients with pneumonia compared to those with another cause for pulmonary 
infiltrates on CXR (p=0.89). Neither breath nor arterial HCN concentrations 
displayed strong relationships with widely used and validated blood markers of 
infection and inflammation: WCC (breath rs= -0.20, p=0.15; arterial rs=0.35, 
p=0.011), CRP (breath rs= -0.20, p=0.16; arterial rs= -0.092, p=0.51). 
 The effect of smoking on H2S and HCN concentrations 6.3.4.
There were 13 smokers (40.6%) and 19 non-smokers (59.4%) in the ICU 
cohort; 12 smokers (42.9%) and 16 non-smokers (57.1%) with pulmonary 
infiltrates on CXR. There were no significant differences in reason for 
admission to ICU between smokers and non-smokers; five of 12 smokers 
(41.7%) and seven of 16 non-smokers (43.8%) had pneumonia, two of 12 
smokers (16.7%) and three of 16 non-smokers (18.8%) were treated for 
infection from another source. 
There was no significant difference in initial breath or arterial H2S 
concentrations between smokers and non-smokers (breath: smokers 1.18 ppb, 
non-VPRNHUV  SSE S  DUWHULDO VPRNHUV  ȝPRO/ QRQ-smokers 
ȝPRO/S  
There was no difference in exhaled HCN concentration of initial samples 
between smokers and non-smokers (smokers 1.11 ppb, non-smokers 0.93 ppb, 
p=0.63), but initial arterial HCN concentration was significantly higher in 
smokers than non-VPRNHUV VPRNHUV  ȝPRO/ QRQ-VPRNHUV  ȝPRO/
p=0.047) (Figure 6-9). 
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Figure 6-9. Individual data points and medians to compare initial breath (a) 
and arterial (b) HCN concentrations between smokers and non-smokers ((a) 
n=28, (b) n=14). 
 Breath H2S and HCN in the ICU, pre-operative and post-6.3.5.
operative settings 
There was an overlap in the range of exhaled H2S concentrations in each cohort 
of patients, with concentrations in the pre-operative (from Chapter 4) and ICU 
groups being lower than that of the post-operative group (from Chapter 3) 
(medians: ICU 1.12 ppb, pre-op 1.00 ppb, post-op 2.6 ppb). Median post-
operative exhaled HCN concentration was greater than in the other two cohorts 
(medians: ICU 0.99 ppb, pre-op 0.82 ppb, post-op 2.28 ppb), and the variation 
in breath HCN concentrations was greater in both ICU groups compared to the 
pre-operative group. A significant difference between exhaled H2S and HCN 
concentrations in post-operative patients compared to both pre-operative 
patients (H2S p<0.0001, HCN p<0.0001) and those with critical illness in the 
ICU (H2S p=0.0004, HCN p=0.0011) was observed. There was no difference 
between exhaled H2S and HCN concentrations in pre-operative controls and 
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ICU patients (H2S p=0.57, HCN p=0.39) (Figure 6-10). A comparison of 
patient demographics between ICU patients and healthy anaesthetised controls 
can be seen in Appendix D. 
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Figure 6-10. Box and whiskers plots comparing exhaled volatile 
concentrations of initial breath samples from ICU patients, healthy 
anaesthetised patients (pre-op) and patients returning to the ICU following 
surgery (post-op); (a) exhaled H2S concentration and (b) exhaled HCN 
concentration. Whiskers show the range of values and boxes display the 
median and interquartile range. 
One patient in the ICU cohort had breath and blood samples taken before and 4 
hours after rotator cuff surgery. The patient was admitted to the ICU with 
pneumonia requiring invasive ventilation following a road traffic accident, his 
clinical condition improving throughout his ICU stay. An increase in breath, 
but not arterial, H2S and HCN concentrations was observed following surgery 
(Figure 6-11); the rise in H2S concentration was more marked than that for 
HCN. Of note, a concurrent increase in arterial and exhaled acetone 
concentrations was also seen. Acetone results are presented in Chapter 5.3.9. 
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and discussed in Chapter 5.4.5. The potential effects of high breath acetone 
concentration on the calculation of breath H2S concentration is discussed in 
Chapter 3.4.5. 
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Figure 6-11. Individual data points show mean breath and arterial (a) H2S and 
(b) HCN concentrations collected daily on the ICU for a single patient. Surgery 
was performed on day 5, 4 hours prior to sample collection. 
 Plasma H2S in the ICU and pre-operative settings 6.3.6.
There was no significant difference between blood H2S concentrations in 
healthy pre-operative patients and the first sample collected for all patients in 
the ICU (p=0.11). In fact, median blood H2S concentration was higher in pre-
operative patients than ICU SDWLHQWV  XPRO/ YHUVXV  ȝPRO/
respectively). 
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6.4. Discussion 
This study appears to be the first to collect breath and blood samples from 
intubated and ventilated patients in the ICU for analysis of H2S and HCN 
concentrations. There was no significant difference in breath volatile 
concentrations between patients with pulmonary infection and other causes of 
pulmonary infiltrates on CXR. Using the breath collection and analysis method 
described, it is, therefore, not possible to use breath H2S or HCN for the 
diagnosis or monitoring of pneumonia in critical illness. 
 The relationship between inspiratory and exhaled breath 6.4.1.
concentrations 
Inspiratory and exhaled H2S and HCN concentrations were similar, with 
relationships observed between the two sets of values. This makes further 
interpretation of any results difficult. As illustrated by other authors, care 
should be exercised when interpreting breath volatile concentrations in cases 
where the inspired volatile concentration is greater than 5%8 or 25% of the 
exhaled concentration2. There are several factors that may have led to a 
relationship between inspired and exhaled volatile concentrations, however, it 
is important to remember that due to the lack of previous research into these 
volatiles in breath it was not known whether they would be produced in the 
lungs due to local inflammation, emitted by bacteria in the lungs, excreted via 
the lungs due to their presence in the systemic or bronchial circulation, or not 
detected at all.  
Firstly, inspired concentrations of some VOC have previously been shown to 
influence expired concentrations147,180,337, thus it is possible that exhaled breath 
concentrations here merely reflect inspired volatile concentrations. Inspired 
concentrations in this study are very low, far lower than those commented on in 
the articles mentioned above, and a recent study has shown that in healthy, 
spontaneously breathing adults, low atmospheric inspired HCN concentrations 
did not affect exhaled concentrations151, arguing against this level of inspired 
HCN affecting exhaled concentrations. It has already been shown that the 
apparatus used for breath sampling did not emit compounds at m/z peaks 
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relating to H2S or HCN (Chapter 2.3.2.), but it is possible that re-breathing of 
volatiles occurred around the breathing circuit filter. This phenomenon was 
described in a study in the operating theatre, where fresh gas passing through 
the filter on inspiration released volatiles from the breathing circuit filter that 
had accumulated during expiration337. It could not have occurred in all patients 
in this study, however, because a breathing circuit filter was not always 
present. 
Secondly, inspired and exhaled volatile concentrations may have been in 
equilibrium because very little or no H2S or HCN is present in human breath in 
the setting of critical illness. This is backed up by the lack of difference 
between healthy subjects in the operating theatre setting (Chapter 4) and in the 
ICU. Furne et al.262 demonstrated an atmospheric H2S concentration of 1.6 ppb 
and exhaled breath concentrations around 0.33 ppb above atmospheric 
concentrations. Despite analysing oral breath samples, after a breath hold with 
the mouth open to prevent contamination, H2S concentrations are comparable 
with this study. Inspired and nasally exhaled H2S concentrations were also 
similar to those of a study of healthy subjects by Dummer223 (median inspired 
concentration 0.5 ppb, exhaled 1.1 ppb) and inspired HCN concentrations were 
comparable to those seen in previous work150,151. Group median exhaled HCN 
concentrations in this study seem to be lower than in studies of nasally exhaled 
breath in spontaneously breathing healthy volunteers (0.76 ppb versus around 2 
ppb)150,151 but similar to nasally exhaled breath of subjects with CF who were 
not colonised by P. aeruginosa239. The higher concentrations in spontaneously 
breathing subjects may be a result of oral contamination of nasal breath 
samples, for example if an oral inspired breath was taken before a nasal 
exhalation151 or if swallowing occurred before sample collection.  
Lower concentrations of exhaled H2S and HCN were seen in this study than in 
orally exhaled breath in other studies149-151,223,318 because the ETT bypassed the 
upper airways, therefore preventing contamination of breath samples with H2S 
and HCN produced in this area. Both compounds are highly soluble and it is 
likely that at least some gas exchange occurs in the airways rather than just the 
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alveoli157, therefore the presence of the ETT may also have resulted in a 
reduction in gas exchange in the upper airways. 
 Bacterial production of H2S and HCN in breath 6.4.2.
As briefly mentioned above, H2S and HCN may not be produced in the lungs at 
all, or not in high enough quantities to be detected by this breath collection and 
analysis method. No patients had evidence of colonisation or infection with 
Pseudomonas species, either in the chest, urine or skin, so it is not possible to 
draw any conclusions about whether HCN may be elevated in breath or blood 
due to the presence of bacteria known to produce HCN in vitro311,316. The lack 
of P. aeruginosa detected may be due to several factors; none of the patients 
enrolled had hospital acquired or ventilator associated pneumonia, where 
infection with P. aeruginosa is more common than in community acquired 
pneumonia37,38, or COPD or bronchiectasis, specifically no patients with CF, 
with known P. aeruginosa colonisation, as none were present on the ICU 
during the data collection period.  
H2S is produced by several bacterial species in vitro, including Escherichia 
coli, Streptococcus pneumoniae, Staphlococcus aureus, Neisseria meningitidis 
and Proteus species352,354. The production of H2S by Legionella species and 
Haemophilus influenzae has not been investigated. These species were 
predominant in the pneumonia patients investigated, thus it is unclear whether 
breath H2S concentration would be expected to be elevated. It is possible that 
H2S was produced in the lungs by pathogenic bacteria, but did not reach high 
enough quantities to be detected in single breath samples without pre-
concentration355. 
 Systemic and airways production of H2S and HCN   6.4.3.
Hydrogen sulphide 
Endogenous H2S is produced from cysteine, cystathionine and/or homocysteine 
by the action of the enyzymes CSE and CBS253, both expressed in human 
airway smooth muscle282 where H2S appears to inhibit airway smooth muscle 
proliferation and production of the pro-inflammatory cytokine IL-8282. Despite 
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studies showing lower serum H2S levels in patients with acute exacerbations of 
COPD compared to stable COPD287,289, and in pneumonia compared to healthy 
controls289, no studies have been performed to examine breath H2S levels in 
humans during episodes of pulmonary infection. In a small study of patients 
with septic shock, plasma H2S concentration was significantly higher than in 
healthy controls261, but breath concentrations were not measured, and 
unfortunately the authors give little clinical information about these patients. It 
is therefore not possible to determine whether breath concentrations reflect 
airway or lung tissue H2S production or systemic production due to systemic 
inflammation or cardiovascular instability. 
In contrast to the studies above, there was no significant difference in breath or 
plasma H2S concentration between patients with pneumonia and those with 
pulmonary infiltrates caused by other conditions. There was also no significant 
difference in breath or serum H2S concentration when patients with SIRS and 
sepsis were compared to those without SIRS or sepsis, respectively. This may 
be due to the low numbers in the study, or because breath levels were too low 
to be quantified in single breath samples without pre-concentration. Some of 
the less unwell patients in the cohort still had higher levels of inflammation 
than healthy subjects so there may not have been enough difference in disease 
states to see a difference in H2S concentration. Many patients with pulmonary 
infection, where plasma H2S may have been expected to be lower285,287,289, also 
had septic shock, which has been seen to increase plasma H2S concentrations 
in humans261 and animal models261,264, thereby cancelling out the effects. It is 
also unclear whether the use of inotropic and vasopressor support administered 
to some patients may have affected the concentration of plasma H2S due to 
modulation of the cardiovascular system.  
Due to the high levels of inflammation in the patients from whom samples 
were collected in the ICU, it would be expected that there would be a 
difference between these patients and healthy pre-operative controls. There was 
no difference in breath H2S concentrations between these two groups; serum 
H2S concentrations were lower in ICU patients than healthy patients, but this 
difference did not reach statistical significance. Again, this could have been 
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due to small numbers in the study, or as a result of issues surrounding H2S 
analysis in blood, which will be discussed later. Despite low serum 
concentrations in anaesthetised controls, blood samples were taken prior to 
anaesthetic delivery so any drugs given or changes in cardiovascular 
parameters would not have affected blood results. 
In contrast to the study by Chen et al.289, where a weak inverse correlation was 
seen between plasma H2S and CRP in patients with pneumonia and COPD, 
there was no relationship between CRP and plasma H2S in this study.  
There was no correlation between breath and arterial H2S concentrations in this 
study. This may be because plasma concentrations were low and any systemic 
H2S produced was rapidly scavenged and bound to methaemoglobin 
(metHb)282, therefore it could not be excreted in breath. Another possible 
explanation is that, like NO, any H2S in breath is produced in the airways 
themselves, in which case a relationship between breath and plasma 
concentrations would not be expected. There were a few exhaled breath 
samples containing an H2S concentration above the inspiratory concentration 
and without a corresponding high plasma H2S concentration. These were likely 
to have been true high readings, rather than being influenced by high 
corresponding breath acetone concentrations; all but one breath sample 
contained an acetone concentration of less than 2000 ppb, which is unlikely to 
have been high enough to significantly reduce the number of precursor ions 
available and affect the concentration calculations of the SIFT-MS instrument 
(precursor ion stripping is discussed in Chapter 3.4.5.). 
Hydrogen cyanide 
A significant difference in breath HCN concentration was observed when 
patients who fulfilled the criteria for a diagnosis of SIRS were compared to 
those who did not; the absolute difference in median breath concentrations was, 
however, very small and there was overlap between the two groups. The 
difference may not have been clinically significant and it was also noted that 
fluctuations in breath HCN concentration over time did not appear to be related 
WRFKDQJHVLQDQLQGLYLGXDOSDWLHQW¶VFOLQLFDO condition. 
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There was no difference between breath concentrations in ICU patients and 
healthy anaesthetised subjects; however the range of concentrations was higher 
in the ICU cohort. This may be a consequence of a greater number of smokers 
in the group of ICU patients compared to healthy volunteers, although smokers 
were not excluded. Patients with high breath HCN concentrations, or serum 
HCN concentrations exceeding physiological levels, were all smokers, which is 
almost certainly the cause and will be discussed in Chapter 6.4.4. 
The production of HCN by neutrophils has been demonstrated in vitro308,309, 
but not in vivo. In studies of sodium nitroprusside administration during 
general anaesthesia, HCN could be detected in breath when the plasma 
concentration was high and there was a relationship between the two. Only a 
small proportion of HCN remains unbound in plasma, allowing it to cause 
toxic effects, with 98% being strongly bound to metHb299,301. That remaining in 
the plasma is detoxified when it travels into the tissues and is converted to 
thiocyanate191,301. This means that, if much lower levels of HCN are produced 
than seen in poisoning, for example in this study, it is possible that very little 
HCN will be present in plasma due to a combination of binding to metHb and 
conversion to thyocyanate, thus no HCN will be excreted in breath. A weakly 
positive correlation was seen between breath and arterial HCN concentrations 
in this study, however this may be due to the low concentrations in each type of 
sample. 
The quantification of HCN in blood was only available during the latter half of 
the study so a limited number of patients had samples analysed. This may have 
affected the ability of this study to draw any conclusions regarding the analysis 
of blood HCN concentrations. Unfortunately, HCN concentrations were not 
analysed in the blood of the healthy anaesthetised volunteers, so comparison 
with patients in the ICU was not possible. 
 Effect of smoking on H2S and HCN concentrations 6.4.4.
Hydrogen sulphide 
No significant difference was seen between breath or arterial H2S 
concentrations in smokers versus non-smokers. This is in contrast to two 
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studies of subjects with COPD287 and asthma (reviewed254), in which smokers 
in the disease group or healthy controls displayed lower serum H2S 
concentrations. In both of these studies, there was a negative correlation 
between serum H2S concentration and the percentage of sputum neutrophils, 
although no breath samples were taken. There is evidence of neutrophilic 
inflammation in exhaled breath condensate of smokers356, which may explain 
why they have lower plasma H2S concentrations than non-smokers. 
Another study by Chen et al.281 showed conflicting results, with higher serum 
H2S concentration and CSE expression in lung tissue of rats exposed to 
cigarette smoke compared to controls. In this and another study in rats, the 
administration of H2S appeared to improve inflammation caused by cigarette 
smoke281,284. It is possible that the response to cigarette smoke in rats is not 
identical to that in humans, or that the type of exposure caused an acute 
response that is different to that of chronic cigarette smoking. 
H2S might be expected to be detected in the breath of smokers as it is present in 
small quantities in cigarette smoke187, though the concentration may be too low 
to enable quantification in breath by SIFT-MS if the last cigarette was smoked 
several hours or more ago. 
Hydrogen cyanide 
There was no significant difference in day 1 breath HCN concentration 
between smokers and non-smokers, however one smoker had a breath HCN 
concentration over ten times higher than the group median concentration for 
two days. Unfortunately, no information was available about the time interval 
between the last cigarette smoked and the time of breath sampling. Day 1 
samples should give highest chance of detecting differences associated with 
cigarettes and would be expected to reduce as time from last cigarette 
increases. Four smokers were responsible for the eight arterial HCN 
concentrations above physiological levels, gradually decreasing over time. 
There were no other important differences between these patients and the rest 
of the cohort, therefore it is likely that smoking was the cause of the elevated 
concentrations. 
  
 
195 
 
 
Not only is there evidence for the presence of HCN in cigarette smoke 
itself123,186,188, but higher exhaled HCN concentrations have also been see in 
oral breath samples123,192,301 and blood samples of smokers compared to non-
smokers301, supporting the results of this study. Higher plasma thiocyanate 
concentrations have been seen in smokers than non-smokers191,301, presumably 
due to detoxification of HCN inhaled from cigarette smoke191. Plasma 
thiocyanate concentrations have been seen to decrease slowly, taking up to 14 
days to return to normal after smoking cessation, though the duration of 
reduction in breath HCN concentrations is unknown301. 
 Possible errors in breath sampling and analysis 6.4.5.
Minor variation in H2S and HCN concentrations seen in this study may be due 
to errors in the sampling and analysis process, thus not clinically significant. 
The concentrations of H2S and HCN were very low, nearing the lower limit of 
detection of the SIFT-MS instrument, so any small errors in absolute 
concentration would have resulted in large percentage changes. Significant 
differences and relationships produced by the analysis of both volatiles 
sometimes reflected very small differences in median concentrations. The 
results may, therefore, not be clinically significant and may reflect the fact that 
numerous analyses were conducted. 
Another possible explanation for the low concentrations of exhaled volatile 
detected is loss due to the sampling apparatus or breathing circuit. Owing to the 
high solubility of H2S and HCN, if water droplets form due to condensation of 
humid breath the volatiles will be dissolved in the droplets and cannot be 
measured in the gas phase, falsely lowering the concentration observed. 
Condensation could have occurred in the breathing circuit itself (not all circuits 
contained a humidifier) or in the collection apparatus, which was not heated 
prior to sample collection. Tedlar bags containing breath samples were 
immediately incubated to try and prevent condensation of samples and 
analysed as soon as possible to reduce the chance of volatile loss (see Chapter 
2 for further details). Some sample was probably lost due to sticking to the 
inside of the ETT and ventilator circuit tubing, breath collection tubing, pump, 
and Tedlar bags, as well as being removed by adhering to the biological filter 
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in the collection process. Unfortunately it is not easy to quantify all of this loss 
and it is not routinely reported on in studies of breath volatiles. Any reduction 
in volatile concentration would have occurred in inspiratory as well as exhaled 
samples, therefore the relationship between the two sets of samples is not likely 
to have been significantly affected. 
 Exhaled H2S and HCN concentrations following surgery 6.4.6.
A significant difference was identified between breath H2S and HCN 
concentrations in ICU patients with pulmonary infiltrates compared to patients 
admitted to the ICU following cardiac surgery. Post-operative breath volatile 
concentrations were higher, but overlap in concentration range between the two 
groups prevented their separation on the basis of breath volatile levels. There 
was also a patient with pneumonia who had an orthopaedic procedure whilst in 
the study, where the exhaled H2S and HCN concentrations were elevated post-
operatively. 
There seems to be an increase in inflammation caused by undergoing a surgical 
procedure, which may be reflected in an elevation in breath H2S and HCN 
concentrations. Any changes seen in this study were, however, confounded by 
changes in breath acetone concentration, thus interpretation of the difference 
between ICU patients and post-operative patients is difficult. As has been 
discussed in Chapter 3, corresponding breath acetone concentrations were very 
high in the post-operative group and were likely to have caused problems in the 
calculation of volatiles at much lower concentrations by the SIFT-MS 
instrument. Precursor ion stripping is unlikely to have occurred in patients with 
pulmonary infiltrates as breath acetone concentrations were sometimes 100 
times lower than in the post-operative group. 
 Analysis of H2S in blood samples 6.4.7.
Samples for H2S sampling were partially processed in Christchurch Hospital, 
then frozen and sent in batches to Canterbury University on the other side of 
the city for further processing using the protocol most widely used in the 
literature334 7KLV PHWKRG PD\ PHDVXUH µIUHH¶ +2S and also H2S-derived 
species at physiological pH (HS- and S2-). It is comparable to other techniques 
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used to measure H2S concentration; the main one used in human studies 
involves a sulphide-selective electrode287,357(reviewed255). 
Plasma H2S concentrations were low in all parts of this thesis, lower than in 
other studies285,287,289,357. Healthy control subjects in these studies had plasma 
H26 FRQFHQWUDWLRQV JUHDWHU WKDQ  ȝPRO/ FRPSDUHG WR  ȝPRO/ in 
KHDOWK\ DQDHVWKHWLVHG SDWLHQWV &KDSWHU  DQG  ȝPRO/ LQ ,&8 SDWLHQWV
with pulmonary infiltrates in this study. Due to a lack of data, the normal range 
for plasma H2S concentrations in humans is unknown. Five patients with sepsis 
in a study by Li et al.261 had a mean plasma H26FRQFHQWUDWLRQRIȝPRO/
FKLOGUHQ ZLWK SRVWXUDO RUWKRVWDWLF WDFK\FDUGLD V\QGURPH  ȝPRO/357, but 
patients in two studies by Whiteman et al. involving patients with knee 
effusions358 and lean healthy men280 had plasma concentrations 36-ȝPRO/
The cause for the discrepancy in plasma H2S concentrations is unclear. Low 
plasma H2S concentrations in patients with all causes of pulmonary infiltrates 
may be due to high levels of pulmonary inflammation, however concentrations 
did not seem to change over time with clinical condition or treatment, and this 
does not explain the low concentrations seen in anaesthetised controls. The 
measurement of plasma H2S concentration in ICU patients does not seem to be 
useful in the diagnosis of pneumonia, sepsis or degree of pulmonary or 
systemic inflammation, and cannot be used to track changes in clinical 
condition. 
There may have been errors in blood sample processing. Firstly, samples were 
centrifuged as soon after collection as possible, within a few minutes, although 
due to the volatile nature of H2S this delay may have allowed time for 
reduction in H2S concentration due to volatilisation or aerial oxidation255. 
Secondly, samples were spun down for 15 min, during which time the 
centrifuge was not cooled, therefore H2S contained in the sample may have 
degraded, with a possible further delay of around 10 min between centrifuging 
and plasma pipetting. Plasma samples were initially frozen at -25°C for several 
days, before being transferred and frozen at -80°C. Samples were then 
transported across the city in an insulated box with ice, which may have 
permitted a degree of thawing in transit; again, this may have led to sample 
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degradation. Interestingly, when a group of samples were processed as above 
and identical samples had the first processing step (the addition of zinc acetate 
to enable the formation of stable zinc sulphide) performed at Christchurch 
Hospital prior to freezing, there was no significant difference in H2S 
concentration between the matched samples (data not presented). This implies 
that sample concentration was not significantly affected by being transported to 
Canterbury University on ice.  
 Central venous and arterial blood samples 6.4.8.
Arterial blood sampling was used in this study because it was the usual method 
for blood sampling in Christchurch Hospital ICU. It was non-invasive as every 
patient had an arterial line inserted on admission to the ICU for continuous 
EORRGSUHVVXUHPRQLWRULQJ%\WDNLQJDOORIWKHSDWLHQW¶VGaily blood samples at 
the time of breath sampling as well as study specific samples, the volume of 
blood aspirated was minimised. 
Most patients also had a central line inserted for the administration of 
medication. It is possible to take blood samples from this line, however it is 
necessary to stop infusions first so that blood results are not diluted, which 
DIIHFWVDSDWLHQW¶VWUHDWPHQW:KHQWDNLQJVDPSOHVIURPHLWKHUOLQHWKHILUVW-
10 ml blood aspirated must be discarded due to possible contamination, 
therefore the collection of blood from both the central venous and arterial lines 
involved the removal of up to 40 ml blood per day.  
For the reasons above, central venous blood samples were not routinely drawn 
and comparisons between matched central venous and arterial samples were 
made in only a small number of patients. Despite this, there did not appear to 
be a significant difference between the concentrations of H2S and HCN from 
each site. There was no particular pattern of one site having higher measured 
volatile concentrations than the other, thus arterial blood sampling was used in 
preference as it was more convenient than central venous sampling. The lack of 
difference between central venous and arterial concentrations means there is 
unlikely to have been a significant difference between peripheral venous and 
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arterial concentrations, thus blood samples taken from healthy anaesthetised 
controls and ICU patients should be comparable. 
 Summary 6.4.9.
Exhaled H2S and HCN were detected at very low concentrations in the group 
of intubated and ventilated patients in the ICU with new pulmonary infiltrates 
on CXR. The relationship between inspired and exhaled concentrations makes 
any further analyses difficult to interpret. There was no relationship between 
breath and arterial H2S concentrations, and only a weak relationship between 
breath and arterial HCN concentrations, therefore the concentrations of these 
volatiles in exhaled breath do not reflect concentrations in the systemic 
circulation. 
Higher blood HCN, but not breath, concentrations were seen in smokers than 
non-smokers, however concentrations could not be used to distinguish between 
the two groups. H2S and HCN concentrations in breath could not be used to 
distinguish between patients with pneumonia and other causes for pulmonary 
infiltrates on CXR, between patients with differing levels of systemic 
inflammation or organ failure, or between patients in the ICU or healthy 
anaesthetised controls. 
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7. Discussion 
7.1. Summary of findings 
The analysis of breath biomarkers to detect or monitor pulmonary 
inflammation or infection and metabolic dysfunction is attractive due to its 
non-invasive nature and the ability to provide results rapidly, repeatably, 
accurately and in some cases in real time4. The challenge rests in identifying 
useful compounds to act as biomarkers.  
Many factors confound the results of breath testing, including those involved in 
the collection and analysis of samples, patient and environmental factors, 
particularly the effects of inspired VOCs. Apart from the analysis of exhaled 
NO in asthma94, no agreed method of breath sampling or standardisation of 
results exists2,147,169,206. Unfortunately, it is not possible to control all of the 
elements above, which affect different VOCs in different ways, therefore it 
may be necessary to develop several standard techniques for individual, or 
JURXSVRIWUDFHJDVHV$³7DVN)RUFH´KDVUHFHQWO\EHHQVHWXSWRH[SORUHWKHVH
areas and hopefully, with the support of the breath research community, will 
find some solutions206. 
In this thesis, a technique was developed to allow the collection of end-exhaled 
breath samples repeatedly, reliably and safely from mechanically ventilated 
patients in the ICU and from anaesthetised patients in the operating theatre. As 
with other breath studies involving patients in the ICU, due to the size of the 
SIFT-MS instrument it was necessary to perform analysis off-line5-8. In the first 
part of the study, two different breathing manoeuvres at two breath sampling 
locations were investigated, and the most appropriate technique chosen for use 
throughout the rest of the thesis.  
Breath sampling directly from the airways is appealing, as it should reduce 
contamination and dilution due to dead space in the endotracheal tube (ETT) 
and ventilator tubing. However in practice, with the equipment available in the 
Christchurch Hospital setting, there were significant difficulties with this 
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method due to air leakage and loss of tidal volume, preventing its use in some 
patients. Sampling from a T-piece was, therefore, preferred.  
Delivering a recruitment-style breath to a patient, mimicking a vital capacity 
breath, was possible in most cases, but required knowledge and skill when 
adjusting ventilator settings. Pressure-controlled rather than volume-controlled 
breaths were delivered to reduce the risk of barotrauma327, however that 
resulted in higher inter-individual variability in breath volume when compared 
to tidal breath volume. The increased variability makes the method less suitable 
for use in further studies. Due to its high solubility154, end-tidal acetone 
concentration was slightly higher than end-exhaled concentration after a 
recruitment-style breath. No significant benefit was observed in the 
repeatability of breath acetone measurement with the delivery of recruitment-
style breaths, so end-tidal T-piece sampling was chosen.  
As in other studies of breath acetone, including in healthy 
individuals5,105,115,167,168,196, there was high inter-subject variation in breath 
acetone concentration, greater than intra-subject variation due to changing the 
location of breath sampling or breathing manoeuvre. This was not felt to be 
important in this part of the study as patients acted as their own controls.  
Very high breath acetone concentrations appeared to affect concentration 
calculations of H2S and HCN by reacting with most of the precursor ions. This 
problem may not apply to analytical methods other than SIFT-MS and PTR-
MS and may have affected analytes present at higher concentrations to a lesser 
extent; if the absolute error was the same it would have represented a smaller 
relative error. Salbutamol administration during breath collection caused 
similar effects. It is therefore advisable not to collect breath samples for 10 min 
following inhaled medication330,331.  
Due to the potential effects of recent surgery, other causes of inflammation or 
drugs on breath VOC concentrations, there was no suitable control group of 
patients in the ICU. A group of healthy volunteers awaiting surgery was 
selected so that breath samples could still be collected from intubated 
individuals. It was therefore necessary to validate an off-line breath collection 
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method in the operating theatre, comparable to that used in the ICU. By using 
total intravenous anaesthesia (TIVA) and a relatively high inspiratory gas flow 
rate, fixing the anaesthesia machine settings and not altering them between 
patients, and breath sampling as close to the patient as possible, reproducible 
and reliable results were obtained. The same drugs, or classes of drugs, were 
used for intubation and TIVA as for sedation and paralysis in the ICU cohort, 
therefore reducing the number of confounding factors. The control group 
contained a larger proportion of women than the ICU group, due to the types of 
surgery for which TIVA is appropriate, and a slightly lower proportion of 
smokers. A few control patients had obstructive spirometry, which is likely to 
have been similar in the ICU group, although it was not possible to confirm 
this by performing spirometry in patients with critical illness. 
This is believed to be the first study to investigate the changes in breath VOCs 
over time in patients with critical illness. Breath acetone concentration tended 
to decrease over time, being significantly higher in ICU patients on the first 
day of sampling than in fasted controls, however there was significant overlap 
in acetone concentrations between the groups. The concentration appeared to 
rise in association with surgery105,106, deteriorating clinical condition and low 
feed intake, as a consequence of reduced input or poor absorption as 
determined by high volume gastric aspirates. This would be expected due to 
the known relationship between acetone concentration and 
fasting194,227,228,230,232. Initial breath acetone concentration was not related to 
outcome measures, such as mortality and length of stay, or other markers of 
inflammation and organ dysfunction. As in previous studies, there was no 
difference in breath acetone concentration between patients with, compared to 
without, pneumonia5 and in those with sepsis compared to those without8. In 
the study by Schubert et al.8 a lower blood acetone concentration was reported 
in patients with sepsis, which was not seen in this study. A slightly higher 
acetone elimination rate was previously observed in patients with ARDS 
compared to those without the diagnosis5, although the difference did not reach 
statistical significance and was not replicated here.  
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Irrespective of the type of blood sample, there was a relationship between 
breath acetone and blood acetone and beta-hydroxybutyrate concentrations in 
both ICU patients and anaesthetised controls8,115,195,230,232. The relationship was 
not lost in patients in the ICU who would have had higher degrees of 
pulmonary dead space and shunt1,174  8QOLNH WKH VWXG\ RI 2¶+DUD HW DO115, 
there was no difference in the correlations of breath acetone with peripheral 
venous versus arterial blood concentrations. Identical acetone concentrations 
were observed when a small number of matched peripheral venous and arterial 
blood samples were compared. These results confirm those of other studies 
suggesting breath acetone could be useful as a non-invasive marker of 
ketosis8,115,195. 
Breath H2S and HCN were detected at very low ppb concentrations in ICU 
patients and controls, comparable to previous studies reporting nasally exhaled 
breath concentrations in patients with bronchiectasis and healthy 
controls150,151,223,262. Breath concentrations of these two volatiles were related 
to inspired concentrations; in fact exhaled and inspiratory concentrations were 
similar, which makes interpretation of breath results difficult2,8. Breath 
concentrations could have been truly low, or reduced due to adsorption onto 
the inner surface of the pump and tubing during sampling. No patients had 
confirmed infection with P. aeruginosa, so HCN concentrations would not be 
predicted to be elevated for that reason311,316. Systemic H2S and HCN may 
have been at low enough concentrations to be completely scavenged by 
metHb249,298, thus not easily detectable in breath. As the first study to look at 
breath H2S and HCN concentrations in mechanically ventilated patients, the 
hypothesis was that breath concentrations would be higher in patients with 
pulmonary infection if they behaved in the same way as NO117,118. 
Unfortunately, this was not observed and neither of the trace gases could be 
used to distinguish patients with pneumonia, or sepsis, from those without the 
conditions.  
There was no strong correlation between breath and blood H2S and HCN 
concentrations or relationships with conventional markers of infection and 
inflammation. Unlike studies of plasma H2S concentration in individuals with 
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COPD and pulmonary infection, in which infection was associated with lower 
plasma concentration287,289, there was no difference in plasma H2S 
concentration in patients with pneumonia compared to those with an alternative 
pathology. There was also no difference in plasma H2S concentration in 
patients with sepsis compared to other diagnoses, in contrast to a small study of 
patients with septic shock in which plasma concentrations were high261. Little 
information is reported on the nature of the infections or the respiratory and 
cardiovascular status of the patients in that study, therefore concentrations may 
have been high due to vascular dysfunction, which was not the case in patients 
in this thesis. Of note, plasma H2S concentrations in ICU patients and controls 
in this thesis were low compared to previously reported concentrations in other 
human studies280,285,287,289,357,358. The cause of this discrepancy is unknown and 
may relate to patient factors, or the way in which samples were processed 
(discussed in more detail in Chapter 6.4.7). 
As in other studies, smokers appeared to have higher plasma HCN 
concentrations than non-smokers. Higher initial breath HCN concentrations 
were also seen in smokers, although this difference did not reach statistical 
significance123,192,301. Unfortunately, HCN concentration was not measured in 
blood samples from healthy controls, so the relationship may have been due to 
other illness factors. Previous human studies have shown lower plasma H2S 
concentrations in smokers than non-smokers254,287, however the relationship 
was not seen in this study. The differences may relate to the timing of sample 
collection after the last cigarette. 
7.2. Limitations of the study 
 Study population size 7.2.1.
One of the limitations of this study was low patient numbers, particularly in the 
first ICU investigation and in the subsections of the control group study. Inter-
subject variation in acetone concentration was greater than expected and higher 
than intra-subject variation due to changing the location of breath sampling or 
breathing manoeuvre. Patients acted as their own controls, enabling 
conclusions to be drawn about the effects of altering the sampling location or 
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breathing manoeuvre, however a larger study population may have permitted 
more specific results of the absolute or percentage change in acetone 
concentration with different sampling techniques.  
Only small numbers of patients were recruited to each of the subsections when 
validating the breath collection method in the operating theatre. This was 
because each of the tests was time consuming and needed to be completed 
before the start of the surgical procedure, thus it was not possible to perform all 
of them in every patient. It was necessary for the anaesthetist and surgeon to be 
happy for these tests to be carried out without delaying the flow of patients 
through the operating theatre. It was not possible to quantify the effects of 
altering the APL valve, changing the inspiratory gas flow rate and sampling 
from each side of the biological filter, nevertheless it was possible to conclude 
that making alterations did affect inspired or exhaled acetone concentrations, 
highlighting the need to keep settings the same in order to compare results. 
 Inability to collect breath samples from spontaneously 7.2.2.
breathing patients 
A problem with the method of breath collection developed was that samples 
could not be obtained from spontaneously breathing patients. It did allow the 
delivery of recruitment-style breaths, which would not have been possible if 
WKH SDWLHQWV¶ EUHDWKLQJ KDG QRW EHHQ FRQWUROOHG KRZHYHU LW UHVXOWHG LQ WKH
curtailment of breath sampling in the ICU cohort during the final study. This 
was partly a consequence of the flow rate of the hand-held pump, which was 
measured at 1.8 L/min. In order to collect a large enough breath sample for 
analysis using this pump flow rate, it had to run for 4 sec, longer than the 
duration of an exhalation. It should be possible to use a pump with a faster flow 
rate, as long as it did not induce coughing, to obtain samples from patients with 
faster respiratory rates (discussed in more detail below).  
 Timing of breath sample collection 7.2.3.
End-expiratory breath samples were collected by turning off the anaesthesia 
machine or pressing the respiratory pause button on the ICU ventilator and then 
FROOHFWLQJ VDPSOHV $ SDWLHQW¶V UHVLGXDO YROXPH FRXOG QRW EH FDOFXODWHG DQG
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may have differed between patients, possibly affecting breath VOC 
concentrations. It should be noted, however, that in mechanically ventilated 
patients breath acetone concentration was not significantly different when 
mixed breath and CO2-controlled alveolar breath samples were compared7. The 
timing of breath sample collection using the capnography trace would not have 
been possible as it did not change quickly enough to allow sampling at CO2 
plateau and there would not have been sufficient time between breaths for 
adequate breath volumes to be collected via the pump. A CO2-controlled 
sampling device was not available, so the technique was developed to collect 
end-expiratory breath using readily available equipment. 
 Off-line breath collection 7.2.4.
Due to the physical limitations of the SIFT-MS instrument, it was not possible 
to perform on-line analysis of breath samples, therefore there were inherent 
problems with collecting and analysing samples off-line1. The method 
developed allowed rapid but not real time breath analysis and did not permit 
the selection of different parts of the respiratory cycle, which is possible if 
breath is sampled continuously on-line106,207,208,210,337. Losses of around 25% 
were seen with all analytes due to breath collection and storage in this study. 
These losses are comparable to other studies using Tedlar bags134,135,140. All 
breath collection methods, on-line and off-line, involve some loss or 
contamination of samples7,97, but this is not always investigated or mentioned 
in research articles. Long sampling lines for on-line analysis will also show a 
degree of loss of sample due to adsorption onto the inner surface of the tubing 
and due to reduction in humidity of the sample106,207, condensation preventing 
volatile in water droplets being measured. By quantifying the loss in this study 
it was possible to correct inspiratory and exhaled acetone concentrations, 
allowing better comparison with other studies. 
 Arterial versus venous blood analysis  7.2.5.
Peripheral venous blood was drawn in control patients and arterial blood in 
ICU patients, which may have had an impact on the relationship between 
volatiles in breath and blood and the ability to compare the two groups. The 
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difference was due to the presence of an arterial line for continuous blood 
pressure monitoring in ICU patients, which made arterial sampling non-
invasive, and was the source of blood for routine tests, therefore little extra 
blood needed to be drawn for the study itself.  Peripheral blood sampling was 
preferred in control patients due to increased levels of safety and convenience. 
In the small number of patients where contemporaneous central venous and 
arterial blood samples were drawn, there was little or no difference in VOC 
concentrations. This is in contrast to a previous study115 where a stronger 
correlation was seen between breath acetone and arterial versus peripheral 
venous concentrations. It is not clear whether differences in spontaneously 
breathing compared to mechanically ventilated patients would affect this 
relationship. 
7.3. Future work 
There are several ways in which this work could be developed and these are 
discussed below. Firstly, further study is required to confirm the results of this 
pilot and secondly, to investigate these trace gases in similar settings to explore 
their usefulness as biomarkers in clinical practice. 
 Increased numbers of study participants 7.3.1.
It would be important to repeat the breath collection and analysis technique in 
another ICU to explore its reproducibility by other researchers or clinicians in a 
similar group of patients. Due to high inter-individual variability, particularly 
in breath acetone concentration5,105,115,167,168,196,238, it would also be interesting 
to study the effects of respiratory pattern and cardiovascular 
parameters1,97,169,171 on breath VOCs in a larger group of patients. 
 Rebreathing around the biological filter 7.3.2.
The study by Hornuss et al.337 was published after the collection of breath 
samples in this study and reported high isoprene concentrations in inspiratory 
breath on the patient side of the biological filter in the breathing circuit of an 
anaesthesia machine. The authors felt that inspiratory gas sampling from that 
site, rather than from next to the ventilator outlet, more closely reflected the 
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actual inspired concentration due to rebreathing of VOCs around the filter. 
Rebreathing of isoprene was not seen in a similar study of ventilated patients in 
the ICU, however a filter was not used in the circuit210. The inspiratory gas 
flow rate of the anaesthesia machine was not reported, thus this phenomenon 
may not have occurred in the studies of this thesis due to the use of relatively 
high gas flow rates in the operating theatre and the use of ICU ventilators that 
do not use a rebreathing technique.  
It would be useful to explore the possibility of rebreathing of acetone, H2S and 
HCN around the biological filter, by comparing inspiratory breath from the 
ventilator outlet and from the same location as the collection of exhaled breath 
samples in both ICU ventilators and operating theatre anaesthesia machines 
using the high flow rates used in this thesis. 
 Breath acetone in stress hyperglycaemia 7.3.3.
Stress hyperglycaemia is common in patients in the ICU, particularly those 
with sepsis63, and is treated with exogenous insulin. The optimum feed rate for 
patients in the ICU setting is unclear, although both overfeeding63,84 and 
significant underfeeding85,90,91 appear to be detrimental. The SPRINT method 
of treating stress hyperglycaemia is unique to the ICU in Christchurch 
Hospital, New Zealand, and involves the modulation of feeding as well as 
insulin administration82,83. The system was developed by using computer-based 
modelling of previous insulin handling, including calculations of insulin 
sensitivity83. It has been shown in this and other studies that breath acetone can 
be used as a surrogate for blood concentrations, which could be an easily 
repeatable and more reliable measure of ketosis115.  
If breath acetone could be monitored much more frequently than once daily in 
patients with stress hyperglycaemia, then further investigation into the possible 
usefulness of acetone in the modulation of feed and insulin would be possible. 
This may be particularly important in the group of patients reported in this 
study who remained ketotic despite normal, or near normal, blood glucose 
concentration. These patients may require increased carbohydrate feeding and 
insulin to reduce fatty acid metabolism. 
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 The metabolic stress of surgery 7.3.4.
Further studies of acetone in post-operative patients, especially comparing 
blood and breath concentrations to explore the relationship at higher breath 
concentrations, would be beneficial. It would be useful to enrol larger numbers 
of patients to compare breath acetone concentrations with disease severity 
scores and outcome measures to investigate the relationship between metabolic 
stress and organ dysfunction or length of hospital stay. Further investigation of 
acetone concentrations may help to explain the metabolic stress of surgery and 
identify patients who require more intensive monitoring or changes to 
treatment, including particular types of surgery where patients may benefit 
from pre-operative carbohydrate rich drinks342-344. 
 Breath sampling in spontaneously breathing subjects 7.3.5.
Using the method of breath collection described in this study, it was not 
possible to obtain breath samples from spontaneously breathing subjects, as 
discussed above. In order to increase the number of days a patient could 
provide breath samples for, and to allow the inclusion of patients who do not 
require controlled ventilation at all, a method for sampling in these patients 
could be developed. 
As previously mentioned, it may be possible to use a hand-held pump with a 
faster flow rate so that the same volume of breath could be collected over a 
shorter time. Suction units used in the ICU to remove airway secretions by 
passing a catheter into the ETT had a flow rate of 4.8 L/min when measured by 
a pneumotachometer (pressure 60 kPa), therefore suction pumps up to this flow 
rate should be safe to use. It may permit breath sampling in patients with faster 
respiratory rates than observed in controlled ventilation, as long as the 
LQYHVWLJDWRU¶VUHDFWLRQWLPHIRURSHUDWLQJWKHSXPSZDVTXLFNHQRXJKDQGWKH
delay before suction was initiated was short. It still may not allow sample 
collection over a single breath in patients with very rapid respiratory rates, 
therefore it may be necessary to collect several breath samples into the same 
bag so that enough gas is available for analysis. This brings up further issues 
that would have to be investigated, for example how many breaths should be 
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collected or over what time period1,97. Multiple breaths into the same bag may 
increase dilution by any dead space in the circuit161, however this should be 
less of a problem due to the collection of end-expiratory rather than mixed 
breath samples, needing comparison with single breath concentrations if 
possible.  
If a discontinuous sampling technique was not used, an on-line monitoring 
system may reduce VOC losses and enable the selection of the phase of breath 
of interest for analysis106,207,208,210,337. Another benefit of an on-line method 
would be the ability to apply it to the analysis of both spontaneous and 
controlled breathing patterns, though this would require further specialist 
equipment and validation, and at present would not be feasible due to the size 
of instruments. If the size of on-line MS instruments was reduced, this type of 
analysis would be attractive for monitoring changes in breath VOCs in real 
time, like the current practice of continuous BP and CO2 measurement. 
 Other markers of inflammation and infection 7.3.6.
It would be interesting to look at other trace gases or groups of VOCs in 
patients with pulmonary infiltrates to try to find better markers of pulmonary 
infection.  
Two interesting studies of FENO in ventilated patients showed promise in the 
detection of pulmonary infection117,118. Unfortunately, NO is not routinely 
measured by SIFT-MS as it only reacts with the O2+ precursor ion4 and is more 
commonly measured using a chemiluminescent analyser116. There is currently 
no standardised method for the analysis of FENO in mechanically ventilated 
patients94, as even using an off-line method the breath flow rate cannot be 
controlled. Further studies that investigate breath NO concentration in this 
patient group would be useful. 
Differences of opinion exist within the breath research community regarding 
the importance of compound identification in exhaled breath and knowledge of 
the pathophysiology behind changes in concentration with disease states, 
versus the appropriateness of simply looking for changes in single or groups of 
compounds as a fingerprint of disease without actually identifying them206. 
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Data trawling by comparing whole mass spectra is quicker than VOC 
identification but may miss important changes in very low concentration 
compounds. Identifying individual volatiles for analysis by first looking at their 
biological plausibility is more time consuming, but understanding their origin 
in breath may make them more useful. 
Due to multiple confounding variables in the analysis of single VOCs, 
particularly those produced by metabolic processes, it is likely to be better to 
concentrate on patterns of multiple VOCs and/or explore VOCs produced by 
microorganisms to identify infection, possibly using qualitative rather than 
quantitative tests. 
7.4. Final remarks 
In this study, breath acetone concentration was seen to correlate with blood 
concentration and, using the technique described, it was possible to sample and 
analyse breath accurately, allowing the assessment of systemic acetone 
concentration using breath. The utility of breath acetone to help modify insulin 
and feed administration in patients with stress hyperglycaemia in the ICU is 
worthy of further investigation if more frequent sampling is possible. Breath 
H2S and HCN in the setting of new pulmonary infiltrates on CXR in 
mechanically ventilated patients were not useful in the diagnosis of infection 
and did not allow monitoring of disease progression.  
Given the marked number of sources of variability when analysing exhaled 
volatile gases, particularly in mechanically ventilated patients, it appears to be 
more important to monitor changes in concentration over time in an individual 
rather than comparing WR D ³QRUPDO´ OHYHO 5DSLG sequential analysis is also 
important, where repeated off-line or on-line real time analytical techniques 
like SIFT-MS will be more useful. 
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Appendix A: Patient Information Sheets and 
Consent Forms 
 
 
I wrote the application forms as well as the information sheets and consent 
forms (examples on following pages) for submission to the Upper South 
Regional Ethics Committee, South Island, New Zealand. 
Canterbury Respiratory Research Group 
Canterbury Respiratory Services 
Christchurch Hospital 
Private Bag 4710 
Christchurch 
 
Telephone:  (64) (3) 364-1157 
Facsimile:  (64) (3) 378-6299 
Exhaled Breath in Critical Illness - Information Sheet Version 2, 26 July 2011 
 
Information Sheet for Elective Surgical 
Patients 
(Version 2, 26 July 2011) 
 
Exhaled Breath in Critical Illness 
 
Principal Investigator 
 
Name: Dr Sharon Sturney, Research Fellow,  
 Canterbury Respiratory Research Group 
 
Address: Canterbury Respiratory Services 
 Christchurch Hospital 
 Private Bag 4710 
 Christchurch 
 
Phone: (03) 364-1157 
 
Introduction 
 
You are invited to take part in a study designed to develop new techniques for breath 
testing in sedated, intubated and ventilated patients, looking into markers of 
inflammation, infection, metabolic and kidney dysfunction and anaesthetic drug 
levels, by testing breath and blood samples.  This study will be written up as part of Dr 
6WXUQH\¶VDFDGHPLFWKHVLVSURMHFW7KLVOHDIOHWH[SODLQVWKHUHDVRQVIRUWKHVWXG\DQG
what is going to happen if you agree to take part.  Please read it carefully.  You will be 
given an opportunity to discuss this study with the investigators and ask any questions 
you may have.  You may have a friend, family or whanau support to help you 
understand the risks and/or benefits of this study and any other explanation you may 
require.  If you decide to take part, you will be asked to sign a consent form. 
 
General 
 
If you need an interpreter, one can be provided. 
 
Participation 
 
Your participation is entirely voluntary (your choice).  You do not have to take part in 
this study, and if you choose not to take part this will not affect any future care or 
treatment.   
 
If you do agree to take part you are free to withdraw from the study at any time, 
without having to give a reason and this will in no way affect your health care. 
Participation in this study will be stopped should any harmful effects appear or if the 
doctor feels it is not in your best interests to continue. 
 
About The Study 
 
What are the aims of the study? 
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We are working to identify ways to quickly and easily diagnose inflammation, 
infection, metabolic and kidney dysfunction in critically ill patients.  There are 
currently blood and sputum tests available to diagnose some of these conditions, 
however they are not always as accurate as we would like and it can take some time to 
UHFHLYHUHVXOWV7KHDUHDRIFULWLFDOLOOQHVVLVG\QDPLFZLWKUDSLGFKDQJHVLQDSDWLHQW¶V
condition, therefore it is important to find rapid methods to detect problems in order to 
allow earlier treatment which might be more effective.  For this reason we are trying 
to develop breath tests and blood tests which might be quicker and more accurate than 
our current tests. 
 
You have been asked to take part because you will be undergoing an elective surgical 
procedure requiring sedation, intubation and mechanical ventilation.  We are looking 
at this group of patients to provide us with normal levels of markers in breath and 
blood.  The results will then be compared to those obtained from patients in the 
Intensive Care Unit, enabling us to look at changes in levels due to critical illness. 
 
We will be measuring several substances in your breath, including acetone, hydrogen 
sulphide, hydrogen cyanide, 2-Aminoacetophenone, trimethylamine, dimethylamine 
and ammonia.  We believe these substances are higher in the breath of people with 
critical illness because they have increased metabolic demands due to infection and 
inflammation and a degree of kidney dysfunction.  In addition we are measuring 
sedative and painkilling drug levels in the breath to look into the properties of the 
drugs used in general anaesthesia and whether breath samples may help to determine 
the level of sedation.  A blood sample will be taken for substances including glucose, 
ketones, hydrogen sulphide, renal function, white cell count and C-reactive protein (a 
marker of inflammation).  No samples that are taken will be stored and all samples 
will be disposed of as per New Zealand standards. 
 
How were participants selected for this study, and who selected them? 
We are studying subjects who are undergoing elective surgical procedures, with no 
evidence of lung disease, infection, inflammation, kidney dysfunction, or diabetes.   
 
We are contacting people via pre-operative assessment clinics. The anaesthetic and 
surgical teams will be helping to identify people who may wish to take part. 
 
Where will the study be held? 
In the pre-operative clinic rooms and operating theatres, Christchurch Hospital. 
 
What is the time span for the study? 
Each volunteer will spend 15 minutes participating in the study at the pre-operative 
assessment clinic.  Breath and blood collection will occur whilst you are in the 
operating theatre.  The breath tests will be taken under general anaesthetic. 
 
What will happen during the study? 
Firstly, at your pre-operative assessment clinic we will ask some questions about your 
health.  We will then ask you to perform a breath test (spirometry), whereby you will 
breathe hard and fast into a hand-held machine.   
 
When you come to the hospital for your surgery you will be given a general 
anaesthetic by the anaesthetist as normal.  When you have an intravenous cannula (a 
little tube) inserted into your vein, as is routine before an operation, we will take some 
blood samples.  Once you are asleep we will take a number of breath samples from 
your airways via a syringe connected to the breathing circuit.  This will not have any 
impact on your breathing or your surgery.   
 
 Exhaled Breath in Critical Illness - Information Sheet Version 2, 26 July 2011 
Benefits Risks And Safety 
 
What are the benefits of the study? 
There are no immediate benefits to participating in the study.   
 
What are the risks and/or inconveniences of the study? 
The performance of spirometry (breath test) is a simple and safe procedure with no 
significant risks or side effects.  The session will last 15 minutes and will be linked to 
your preoperative assessment so that you do not need to come up to the hospital for a 
second appointment. 
 
Collection of exhaled breath when you are intubated is a similar process to suctioning 
sputum from the airways.  There are no identified significant risks or side effects.  
 
Blood tests may cause minor discomfort, which quickly passes.  Blood testing may 
cause minor bruising. 
 
There will be no payment made for participation in this study. 
Compensation 
 
The Upper South A Regional Ethics Committee has certified that this clinical trial is 
being conducted principally for the benefit of the manufacturer or distributor of the 
medicine or item in respect of which this trial is being carried out.  This means that if 
you suffer injury as a result of your participation, you will not be eligible for cover by 
ACC.  Compensation however, will be provided by Syft Technologies Limited in 
DFFRUGDQFHZLWKWKH³1HZ=HDODQG5HVHDUched Medicines Industry (RMI) Guidelines 
on Clinical Trials ± Compensation for injury resulting from participation in Industry 
6SRQVRUHG&OLQLFDO7ULDOV´ 
 
These RMI Guidelines are only guidelines and until your claim is assessed by the 
insurers of Syft Technologies Limited it cannot be said with any certainty exactly 
what type or amount of compensation you will receive if you suffer injury as a result 
of your participation, or exactly what sort of injury will be covered.  However the 
guidelines require that compensation must be provided by Syft Technologies Limited 
where the injury you suffer is serious and not just temporary and is one caused by the 
trial medicine or item or where you would not have suffered injury but for your 
inclusion in this trial. The guidelines also require that the compensation you receive 
must be appropriate to the nature, severity and persistence of your injury.  This means 
that you will be likely to receive some compensation from Syft Technologies Limited 
unless your injury is minor or temporary.  However, you might not receive 
compensation from Syft Technologies Limited if your injury was caused solely by you 
or by the negligence of the research staff of institution. 
 
In the event of a dispute over the cause of the injury or level of compensation, Syft 
7HFKQRORJLHV/LPLWHGZLOODFFHSWWKHGHFLVLRQRID1HZ=HDODQGPHGLFDO³UHIHUHH´DV
agreed to by yourself and Syft Technologies Limited. 
 
Advocacy 
 
If you have any queries or concerns regarding your rights as a participant in this study 
you may wish to contact a Health and Disability Advocate.  This is a free service 
provided under the Health and Disability Commissioner Act. 
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Telephone (NZ Wide): 0800 555-050 
Free Fax (NZ Wide): 0800 2787-7678 
E-mail: advocacy@hdc.org.nz 
 
For Maori Health support:  Nga Ratonga Hauora Maori Health Service based at 
Christchurch Hospital campus when available will endeavour to provide awhi/support 
to turoro/patient and whanau/family while they are involved in study participation.  
Please contact Tahu Potiki Stirling, Pouarahi Roopu / Team Leader of Nga Ratonga 
Hauora Maori and Chairperson of Te Komiti Whakarite. Telephone: (03) 364-0640, 
ext 88797. 
 
Confidentiality 
 
No material which could personally identify you will be used in any reports on this 
study.   
 
Records and information about the study and the results will be kept at the Canterbury 
Respiratory Research Group offices, in locked rooms, for 15 years. 
 
Results 
 
7KLVVWXG\ZLOOEHZULWWHQXSDVSDUWRI'U6WXUQH\¶VDFDGHPLFWKHVLVRYHUVHHQE\WKH
University of Nottingham, UK.  We plan to publish the results of this research in 
international medical journals.  No data which might identify you will be published. 
 
Statement Of Approval 
 
This study has received ethical approval from the Upper South A Ethics Committee.  
The General Manager of Christchurch Hospital has given permission for this study to 
be carried out. 
 
Who To Contact 
 
Please feel free to ask questions about the study ± further information can be obtained 
at any time from the following researchers: 
 
Dr Sharon Sturney, Principal Investigator        
Ph: (03) 364-1157 
Dr Michael Epton, Director, Canterbury Respiratory Research Group     
Ph: (03) 364-1157 
Julie Cook, Research Nurse           
Ph: (03) 364-1157 
 
Who to contact in an emergency (24 hours) 
Business Hours: Canterbury Respiratory Research Group
 Ph: (03) 364-1157 
After Hours: Dr Sharon Sturney
 Ph: 021 023 20985 
 
Thank you for taking the times to read this information 
 
Canterbury Respiratory Research Group 
Canterbury Respiratory Services 
Christchurch Hospital 
Private Bag 4710 
Christchurch 
 
Telephone:  (64) (3) 364-1157 
Facsimile:  (64) (3) 378-6299 
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Participant Study Number: ________________ 
 
Consent Form for Elective Surgical Patients 
Statement by patient 
(Version 2, 26 July 2011) 
 
Exhaled Breath in Critical Illness 
 
Principal Investigator 
 
Name: Dr Sharon Sturney, Research Fellow,  
 Canterbury Respiratory Research Group 
 
Address: Canterbury Respiratory Services 
 Christchurch Hospital 
 Private Bag 4710 
 Christchurch 
 
Phone: (03) 364-1157 
 
Request for an Interpreter 
 
English I wish to have an interpreter Yes No 
Deaf I wish to have a NZ sign language interpreter Yes No 
Maori E hiahia ana ahau ki tetahi kaiwhakamaori / kaiwhaka 
pakeha korero 
Ae Kao 
Samoan 2XWHPDQD¶RLDLDLVHID¶DPDWDODXSX Ioe Leai 
Tongan 2NXRXILHPD¶XKDIDNDWRQXOHD Io Ikai 
Cook Island Ka inangaro au i tetai tangata uri reo Ae Kare 
Fijian Au gadreva me dua e vakadewa vosa vei au Io Sega 
Niuean Fia manako au ke fakaaoga e taha tagata fakahokohoko 
kupu 
E Nakai 
 
¾ I have read and I understand the Information Sheet dated 26 July 2011 
for participants taking part in a study designed to develop new techniques 
for breath testing in sedated, intubated and ventilated patients, looking 
into markers of inflammation, infection, metabolic and renal dysfunction 
and anaesthetic drug levels, by testing breath and blood samples. I have 
had the opportunity to discuss this study.  I am satisfied with the answers 
I have been given. 
 
¾ I have had the opportunity to use whanau support or a friend to help me 
ask questions and understand the study. 
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¾ I understand that taking part in this study is voluntary (my choice) and 
that I may withdraw from the study at any time and this will in no way 
affect my future health care, academic progress or employment. 
 
¾ I understand that my participation in this study is confidential and that no 
material that could identify me will be used in any reports on this study. 
¾ I understand that the investigation will be stopped if it should appear 
harmful to me. 
 
¾ I understand the compensation provisions for this study. 
 
¾ I know whom to contact if I have questions about the study. 
 
¾ I consent to the researches collecting samples of my breath and blood and 
testing it as part of this study.  I understand that any blood samples taken 
during this study cannot be returned to me. 
 
¾ I consent to the researches doing a breath analysis as part of this research. 
 
¾ I have had time to consider whether to take part. 
 
¾ This study has been given ethical approval by the Upper South A 
Regional Ethics Committee.  This means that the Committee may check 
at any time that the study is following appropriate ethical procedures. 
 
¾ I wish to receive a copy of the results of this study.                YES / NO 
 
¾ I consent to my GP being informed of the results of this study.  YES / NO 
 
 
 
,«««««««««««««««««««««KHUHE\ consent to take 
part in this study. 
 (Full Name) 
 
 
___________________________ ___________________________ 
Printed Name of Study Participant Signature of Study Participant  
 
_________________ 
Date 
 
Using language that is understandable and appropriate, I have discussed this 
study with the participant.  I have offered to answer any questions and have 
fully answered such questions.  I believe that the participant understands my 
explanations and has freely given informed consent. 
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______________________________ ___________________________  
Printed Name of Individual Conducting Signature of Individual Conducting  
Informed Consent Discussion Informed Consent Discussion 
 
___________ 
Date 
 
Dr Sharon Sturney, Principal Investigator             Ph:  (03) 364-1157 
Dr Michael Epton, Director, Canterbury Respiratory Research Group 
Ph:  (03) 364-1157 
Julie Cook, Research Nurse         Ph:  (03) 364-1157 
 
Thank you for taking the time to read this Consent Form 
Thank you in advance for your help with this study 
Canterbury Respiratory Research Group 
Canterbury Respiratory Services 
Christchurch Hospital 
Private Bag 4710 
Christchurch 
 
Telephone:  (64) (3) 364-1157 
Facsimile:  (64) (3) 378-6299 
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Information Sheet for Intensive Care 
Patients 
 (Version 2, 26 July 2011) 
 
Exhaled Breath in Critical Illness 
 
Principal Investigator 
 
Name: Dr Sharon Sturney, Research Fellow,  
 Canterbury Respiratory Research Group 
 
Address: Canterbury Respiratory Services 
 Christchurch Hospital 
 Private Bag 4710 
 Christchurch 
 
Phone: (03) 364-1157 
 
Introduction 
 
You are invited to take part in a study designed to develop new techniques for breath 
testing in sedated, intubated and ventilated patients, looking into markers of 
inflammation, infection, metabolic and kidney dysfunction and sedative drug levels, 
by testing breath and blood samples.  This study will be written up as part of Dr 
6WXUQH\¶VDFDGHPLFWKHVLVSURMHFW7KLVOHDIOHWH[SODLQVWKHUHDVRQVIRUWKHVWXG\DQG
what is going to happen if you agree to take part.  Please read it carefully.  You will be 
given an opportunity to discuss this study with the investigators and ask any questions 
you may have.  You may have a friend, family or whanau support to help you 
understand the risks and/or benefits of this study and any other explanation you may 
require.  If you decide that you would like to take part, you will be asked to sign a 
consent form. 
 
General 
 
If you need an interpreter, one can be provided. 
 
Participation 
 
Participation is entirely voluntary (your choice).  You do not have to take part in this 
study, and if you choose not to take part this will not affect any future care or 
treatment that you receive.   
 
If you do agree to take part you are free to withdraw from the study at any time, 
without having to give a reason and this will in no way affect your health care. 
Participation in this study will be stopped should any harmful effects appear or if the 
doctor feels it is not in the your best interests to continue. 
 
About The Study 
 
What are the aims of the study? 
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We are working to identify ways to quickly and easily diagnose inflammation, 
infection, metabolic and kidney dysfunction in critically ill patients.  There are 
currently blood and sputum tests available to diagnose some of these conditions, 
however they are not always as accurate as we would like and it can take some time to 
UHFHLYHUHVXOWV7KHDUHDRIFULWLFDOLOOQHVVLVG\QDPLFZLWKUDSLGFKDQJHVLQDSDWLHQW¶V
condition, therefore it is important to find rapid methods to detect problems in order to 
allow earlier treatment which might be more effective.  For this reason we are trying 
to develop breath tests and blood tests which might be quicker and more accurate than 
our current tests. 
 
You have been selected to take part because you have a condition requiring sedation, 
intubation and mechanical ventilation in the Intensive Care Unit.  We are comparing 
people undergoing elective surgery with patients in the Intensive Care Unit to look at 
differences in levels of breath and blood markers of inflammation, infection, kidney 
and metabolic dysfunction, and levels of sedative drugs. 
 
We will be measuring several substances in breath, including acetone, hydrogen 
sulphide, hydrogen cyanide, 2-Aminoacetophenone, trimethyamine, dimethylamine 
and ammonia.  We believe these substances are higher in the breath of people with 
critical illness because they have increased metabolic demands due to infection and 
inflammation and a degree of kidney dysfunction.  In addition we are measuring levels 
of sedative and painkilling drugs in the breath to look into the properties of these 
drugs and whether breath samples may help to determine the level of sedation.  A 
blood sample will be taken for substances including glucose, ketones, hydrogen 
sulphide, renal function, white cell count and C-reactive protein (a marker of 
inflammation).  Blood samples will be taken to look accurately at the oxygen level, as 
is routine on the Intensive Care Unit. No samples that are taken will be stored and all 
samples will be disposed of as per New Zealand standards. 
 
How were participants selected for this study, and who selected them? 
We are studying patients in the Intensive Care Unit who are sedated, intubated and 
ventilated, most with high blood sugar levels and some with evidence of lung changes 
on chest x-ray or kidney dysfunction.   
 
We are contacting people in the Intensive Care Unit.  The Intensive Care specialists 
and nurses at Christchurch Hospital are helping identify people who may wish to take 
part. 
 
Where will the study be held? 
In the Intensive Care Unit, Christchurch Hospital. 
 
What is the time span for the study? 
To help us develop our method of collecting breath samples, some participants will 
have 4 sets of breath samples taken on a single day.  Other participants will have 
breath and blood samples taken once a day whilst on insulin therapy, or until treatment 
for lung disease has been stopped, in order to compare these results with the results 
collected from surgical patients.   
 
What will happen during the study? 
Breath samples will be taken from the airways either via a syringe connected to a T-
piece within the respiratory circuit, or by passing a suction catheter into the airways 
and sucking a sample into a syringe.  It may be necessary to take samples on a daily 
basis until your treatment is finished. Arterial blood samples will be taken from an 
arterial catheter (a small tube that has been inserted into the artery in the wrist) daily in 
those subjects who also have breath samples taken on a daily basis.  The arterial 
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catheter will already be present for ongoing management by the Intensive Care Unit 
team. Urine samples will be taken and analysed as per ICU protocol, including for 
urinary creatinine level. 
 
Benefits Risks And Safety 
 
What are the benefits of the study? 
There are no benefits to participating in the study.   
 
What are the risks and/or inconveniences of the study? 
Collection of exhaled breath when a patient is intubated is a similar process to 
suctioning sputum from the airways.  There are no identified significant risks or side 
effects.  
 
Blood tests taken from the arterial line will not cause any extra risk or discomfort. 
 
There will be no payment made for participation in this study. 
 
Compensation 
 
The Upper South A Regional Ethics Committee has certified that this clinical trial is 
being conducted principally for the benefit of the manufacturer or distributor of the 
medicine or item in respect of which this trial is being carried out.  This means that if 
you suffer injury as a result of your participation, you will not be eligible for cover by 
ACC.  Compensation however, will be provided by Syft Technologies Limited in 
DFFRUGDQFHZLWKWKH³1HZ=HDODQG5HVHDUFKHG0HGLFLQHV,QGXVWU\50,*XLGHOLQHV
on Clinical Trials ± Compensation for injury resulting from participation in Industry 
6SRQVRUHG&OLQLFDO7ULDOV´ 
 
These RMI Guidelines are only guidelines and until your claim is assessed by the 
insurers of Syft Technologies Limited it cannot be said with any certainty exactly 
what type or amount of compensation you will receive if you suffer injury as a result 
of your participation, or exactly what sort of injury will be covered.  However the 
guidelines require that compensation must be provided by Syft Technologies Limited 
where the injury you suffer is serious and not just temporary and is one caused by the 
trial medicine or item or where you would not have suffered injury but for your 
inclusion in this trial. The guidelines also require that the compensation you receive 
must be appropriate to the nature, severity and persistence of your injury.  This means 
that you will be likely to receive some compensation from Syft Technologies Limited 
unless your injury is minor or temporary.  However, you might not receive 
compensation from Syft Technologies Limited if your injury was caused solely by you 
or by the negligence of the research staff of institution. 
 
In the event of a dispute over the cause of the injury or level of compensation, Syft 
7HFKQRORJLHV/LPLWHGZLOODFFHSWWKHGHFLVLRQRID1HZ=HDODQGPHGLFDO³UHIHUHH´DV
agreed to by yourself and Syft Technologies Limited. 
 
Advocacy 
 
If you have any queries or concerns regarding your rights as a participant in this study, 
you may wish to contact a Health and Disability Advocate.  This is a free service 
provided under the Health and Disability Commissioner Act. 
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Telephone (NZ Wide): 0800 555-050 
Free Fax (NZ Wide): 0800 2787-7678 
E-mail: advocacy@hdc.org.nz 
 
For Maori Health support:  Nga Ratonga Hauora Maori Health Service based at 
Christchurch Hospital campus when available will endeavour to provide awhi/support 
to turoro/patient and whanau/family while they are involved in study participation.  
Please contact Tahu Potiki Stirling, Pouarahi Roopu / Team Leader of Nga Ratonga 
Hauora Maori and Chairperson of Te Komiti Whakarite. Telephone: (03) 364-0640, 
ext 88797. 
 
Confidentiality 
 
No material which could personally identify you will be used in any reports on this 
study.   
 
Records and information about the study and the results will be kept at the Canterbury 
Respiratory Research Group offices, in locked rooms, for 15 years. 
 
Results 
 
7KLVVWXG\ZLOOEHZULWWHQXSDVSDUWRI'U6WXUQH\¶VDFDGHPLFWKHVLVRYHUVHHQE\WKH
University of Nottingham, UK. We plan to publish the results of this research in 
international medical journals.  No data which might identify your relative/friend will 
be published. 
 
Statement Of Approval 
 
This study has received ethical approval from the Upper South A Ethics Committee.  
The General Manager of Christchurch Hospital has given permission for this study to 
be carried out. 
 
Who To Contact 
 
Please feel free to ask questions about the study ± further information can be obtained 
at any time from the following researchers: 
 
Dr Sharon Sturney, Principal Investigator        
Ph: (03) 364-1157 
Dr Michael Epton, Director, Canterbury Respiratory Research Group     
Ph: (03) 364-1157 
Dr Geoff Shaw, Intensive Care Specialist        
Ph: (03) 364-0640 
Julie Cook, Research Nurse           
Ph: (03) 364-1157 
 
Who to contact in an emergency (24 hours) 
Business Hours: Canterbury Respiratory Research Group
 Ph: (03) 364-1157 
After Hours: Dr Sharon Sturney
 Ph: 021 023 20985 
 
Thank you for taking the times to read this information 
 
Canterbury Respiratory Research Group 
Canterbury Respiratory Services 
Christchurch Hospital 
Private Bag 4710 
Christchurch 
 
Telephone:  (64) (3) 364-1157 
Facsimile:  (64) (3) 378-6299 
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Participant Study Number: ________________ 
 
Consent Form for Intensive Care Patients 
Statement by patient 
(Version 2, 26 July 2011) 
 
Exhaled Breath in Critical Illness 
 
¾ Principal Investigator 
 
Name: Dr Sharon Sturney, Research Fellow,  
 Canterbury Respiratory Research Group 
 
Address: Canterbury Respiratory Services 
 Christchurch Hospital 
 Private Bag 4710 
 Christchurch 
 
Phone: (03) 364-1157 
 
Request for an Interpreter 
 
English I wish to have an interpreter Yes No 
Deaf I wish to have a NZ sign language interpreter Yes No 
Maori E hiahia ana ahau ki tetahi kaiwhakamaori / kaiwhaka 
pakeha korero 
Ae Kao 
Samoan 2XWHPDQD¶RLDLDLVHID¶DPDWDODXSX Ioe Leai 
Tongan 2NXRXILHPD¶XKDIDNDWRQXOHD Io Ikai 
Cook Island Ka inangaro au i tetai tangata uri reo Ae Kare 
Fijian Au gadreva me dua e vakadewa vosa vei au Io Sega 
Niuean Fia manako au ke fakaaoga e taha tagata fakahokohoko 
kupu 
E Nakai 
 
¾ I have read and I understand the Information Sheet dated 26 July 2011 
for participants taking part in a study designed to develop new techniques 
for breath testing in sedated, intubated and ventilated patients, looking 
into markers of inflammation, infection, metabolic and renal dysfunction 
and anaesthetic drug levels, by testing breath and blood samples. I have 
had the opportunity to discuss this study.  I am satisfied with the answers 
I have been given. 
 
¾ I have had the opportunity to use whanau support or a friend to help me 
ask questions and understand the study. 
 
¾ I understand that taking part in this study is voluntary (my choice) and 
that I may withdraw from the study at any time and this will in no way 
affect my future health care, academic progress or employment. 
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¾ I understand that my participation in this study is confidential and that no 
material that could identify me will be used in any reports on this study. 
 
¾ I understand that the investigation will be stopped if it should appear 
harmful to me. 
 
¾ I understand the compensation provisions for this study. 
 
¾ I know whom to contact if I have questions about the study. 
 
¾ I consent to the researches collecting samples of my breath and blood and 
testing it as part of this study.  I understand that any blood samples taken 
during this study cannot be returned to me. 
 
¾ I consent to the researches doing a breath analysis as part of this research. 
 
¾ I have had time to consider whether to take part. 
 
¾ This study has been given ethical approval by the Upper South A 
Regional Ethics Committee.  This means that the Committee may check 
at any time that the study is following appropriate ethical procedures. 
 
¾ I wish to receive a copy of the results of this study.                  YES / NO 
 
¾ I consent to my GP being informed of the results of this study.  YES / NO 
 
 
 
, «««««««««««««««««««««Kereby consent to take 
part in this study. 
 (Full Name) 
 
 
______________________________ __________________________  
 
Printed Name of Study Participant Signature of Study Participant  
 
 
___________ 
Date 
 
Using language that is understandable and appropriate, I have discussed this 
study with the participant.  I have offered to answer any questions and have 
fully answered such questions.  I believe that the participant understands my 
explanations and has freely given informed consent. 
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_____________________________ __________________________  
Printed Name of Individual Conducting Signature of Individual Conducting 
Informed Consent Discussion Informed Consent Discussion 
 
 
___________ 
Date 
 
Dr Sharon Sturney, Principal Investigator  
Ph:  (03) 364-1157 
Dr Michael Epton, Director, Canterbury Respiratory Research Group 
Ph:  (03) 364-1157 
Dr Geoff Shaw, Intensive Care Specialist            
Ph: (03) 364-0640 
Julie Cook, Research Nurse               
Ph:  (03) 364-1157 
 
Thank you for taking the time to read this Consent Form 
Thank you in advance for your help with this study 
Canterbury Respiratory Research Group 
Canterbury Respiratory Services 
Christchurch Hospital 
Private Bag 4710 
Christchurch 
 
Telephone:  (64) (3) 364-1157 
Facsimile:  (64) (3) 378-6299 
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Information Sheet for Intensive Care 
Patients 
For use after urgent enrolment 
For relatives/friends/family/whanau 
(Version 3, 7 October 2011) 
 
Exhaled Breath in Critical Illness 
 
Principal Investigator 
 
Name: Dr Sharon Sturney, Research Fellow,  
 Canterbury Respiratory Research Group 
 
Address: Canterbury Respiratory Services 
 Christchurch Hospital 
 Private Bag 4710 
 Christchurch 
 
Phone: (03) 364-1157 
 
Introduction 
 
Your relative/friend is invited to continue to take part in a study designed to develop 
new techniques for breath testing in sedated, intubated and ventilated patients, looking 
into markers of inflammation, infection, metabolic and kidney dysfunction and 
sedative drug levels, by testing breath and blood samples.  It was important that your 
relative/friend received treatment for his/her illness swiftly, therefore he/she has 
already been enrolled in the study and breath and blood samples have been taken.  The 
Upper South A Regional Ethics Committee has approved this process including your 
relative/friend in the study without prior consent at the time, but with your 
relative/friend/whanau or yourself being approached about the study as soon as 
possible afterwards. 
 
7KLV VWXG\ZLOOEHZULWWHQXS DVSDUWRI'U 6WXUQH\¶V DFDGHPLF WKHVLVSURMHFW 7KLV
leaflet explains the reasons for the study, what has already happened and what is going 
to happen if you agree for them to continue to take part.  Please read it carefully.  You 
will be given an opportunity to discuss this study with the investigators and ask any 
questions you may have.  You may have a friend, family or whanau support to help 
you understand the risks and/or benefits of this study and any other explanation you 
may require.  If you decide that your relative/friend would want to continue to take 
part, you will be asked to sign a consent form. 
 
General 
 
If you need an interpreter, one can be provided. 
 
Participation 
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Participation is entirely voluntary (your choice).  Your relative/friend does not have to 
continue to take part in this study, and if you choose for them not to continue to take 
part this will not affect any future care or treatment that they receive.   
 
If you do agree for them to continue to take part they are free to withdraw from the 
study at any time, without having to give a reason and this will in no way affect their 
health care. Participation in this study will be stopped should any harmful effects 
appear or if the doctor feels it is not LQWKHSDUWLFLSDQW¶VEHVWLQWHUHVWVWRFRQWLQXH 
 
About The Study 
 
What are the aims of the study? 
We are working to identify ways to quickly and easily diagnose inflammation, 
infection, metabolic and kidney dysfunction in critically ill patients.  There are 
currently blood and sputum tests available to diagnose some of these conditions, 
however they are not always as accurate as we would like and it can take some time to 
receive results. The area of critical illness is dynamic, with rapid changes in a patLHQW¶V
condition, therefore it is important to find rapid methods to detect problems in order to 
allow earlier treatment which might be more effective.  For this reason we are trying 
to develop breath tests and blood tests which might be quicker and more accurate than 
our current tests. 
 
Your relative/friend has been selected to take part because they have a condition 
requiring sedation, intubation and mechanical ventilation in the Intensive Care Unit.  
We are comparing people undergoing elective surgery with patients in the Intensive 
Care Unit to look at differences in levels of breath and blood markers of inflammation, 
infection, kidney and metabolic dysfunction, and levels of sedative drugs. 
 
We will be measuring several substances in breath, including acetone, hydrogen 
sulphide, hydrogen cyanide, 2-Aminoacetophenone, trimethyamine, dimethylamine 
and ammonia.  We believe these substances are higher in the breath of people with 
critical illness because they have increased metabolic demands due to infection and 
inflammation and a degree of kidney dysfunction.  In addition we are measuring levels 
of sedative and painkilling drugs in the breath to look into the properties of these 
drugs and whether breath samples may help to determine the level of sedation.  A 
blood sample will be taken for substances including glucose, ketones, hydrogen 
sulphide, renal function, white cell count and C-reactive protein (a marker of 
inflammation).  Blood samples will be taken to look accurately at the oxygen level, as 
is routine on the Intensive Care Unit. No samples that are taken will be stored and all 
samples will be disposed of as per New Zealand standards. 
 
How were participants selected for this study, and who selected them? 
We are studying patients in the Intensive Care Unit who are sedated, intubated and 
ventilated, most with high blood sugar levels and some with evidence of lung changes 
on chest x-ray or kidney dysfunction.   
 
We are contacting people in the Intensive Care Unit.  The Intensive Care specialists 
and nurses at Christchurch Hospital are helping identify people who may wish to take 
part. 
 
Where will the study be held? 
In the Intensive Care Unit, Christchurch Hospital. 
 
What is the time span for the study? 
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Participants will have breath and blood samples taken prior to and once a day whilst 
on insulin therapy, or until treatment for lung disease has been stopped, in order to 
compare these results with the results collected from elective surgical patients.   
 
What will happen during the study? 
Breath samples will have been taken from the airways either via a syringe connected 
to a T-piece within the respiratory circuit, or by passing a suction catheter into the 
airways and sucking a sample into a syringe.  It will be necessary to continue to take 
samples on a daily basis until treatment is finished. Arterial blood samples will have 
been taken from an arterial catheter (a small tube that has been inserted into the artery 
in the wrist) and will be taken daily in those subjects who also have breath samples 
taken on a daily basis.  The arterial catheter will already be present for ongoing 
management by the Intensive Care Unit team. Urine samples will be taken and 
analysed as per ICU protocol, including for urinary creatinine level. 
 
Benefits Risks And Safety 
 
What are the benefits of the study? 
There are no benefits to participating in the study.   
What are the risks and/or inconveniences of the study? 
Collection of exhaled breath when a patient is intubated is a similar process to 
suctioning sputum from the airways.  There are no identified significant risks or side 
effects.  
Blood tests taken from the arterial line will not cause any extra risk or discomfort. 
There will be no payment made for participation in this study. 
 
Compensation 
 
The Upper South A Regional Ethics Committee has certified that this clinical trial is 
being conducted principally for the benefit of the manufacturer or distributor of the 
medicine or item in respect of which this trial is being carried out.  This means that if 
you suffer injury as a result of your participation, you will not be eligible for cover by 
ACC.  Compensation however, will be provided by Syft Technologies Limited in 
DFFRUGDQFHZLWKWKH³1HZ=HDODQG5HVHDUFKHG0HGLFLQHV,QGXVWU\50,*XLGHOLQHV
on Clinical Trials ± Compensation for injury resulting from participation in Industry 
6SRQVRUHG&OLQLFDO7ULDOV´ 
 
These RMI Guidelines are only guidelines and until your claim is assessed by the 
insurers of Syft Technologies Limited it cannot be said with any certainty exactly 
what type or amount of compensation you will receive if you suffer injury as a result 
of your participation, or exactly what sort of injury will be covered.  However the 
guidelines require that compensation must be provided by Syft Technologies Limited 
where the injury you suffer is serious and not just temporary and is one caused by the 
trial medicine or item or where you would not have suffered injury but for your 
inclusion in this trial. The guidelines also require that the compensation you receive 
must be appropriate to the nature, severity and persistence of your injury.  This means 
that you will be likely to receive some compensation from Syft Technologies Limited 
unless your injury is minor or temporary.  However, you might not receive 
compensation from Syft Technologies Limited if your injury was caused solely by you 
or by the negligence of the research staff of institution. 
 
In the event of a dispute over the cause of the injury or level of compensation, Syft 
Technologies Limited will accept the decision of a New =HDODQGPHGLFDO³UHIHUHH´DV
agreed to by yourself and Syft Technologies Limited. 
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Advocacy 
 
If you have any queries or concerns regarding your rights, or those of your 
relative/friend as a participant in this study, you may wish to contact a Health and 
Disability Advocate.  This is a free service provided under the Health and Disability 
Commissioner Act. 
 
Telephone (NZ Wide): 0800 555-050 
Free Fax (NZ Wide): 0800 2787-7678 
E-mail: advocacy@hdc.org.nz 
 
For Maori Health support:  Nga Ratonga Hauora Maori Health Service based at 
Christchurch Hospital campus when available will endeavour to provide awhi/support 
to turoro/patient and whanau/family while they are involved in study participation.  
Please contact Tahu Potiki Stirling, Pouarahi Roopu / Team Leader of Nga Ratonga 
Hauora Maori and Chairperson of Te Komiti Whakarite. Telephone: (03) 364-0640, 
ext 88797. 
 
Confidentiality 
 
No material which could personally identify your relative/friend will be used in any 
reports on this study.   
Records and information about the study and the results will be kept at the Canterbury 
Respiratory Research Group offices, in locked rooms, for 15 years. 
 
Results 
 
7KLVVWXG\ZLOOEHZULWWHQXSDVSDUWRI'U6WXUQH\¶VDFDGHPLFWKHVLVRYHUVHHQE\WKH
University of Nottingham, UK.  We plan to publish the results of this research in 
international medical journals.  No data which might identify your relative/friend will 
be published. 
 
Statement Of Approval 
 
This study has received ethical approval from the Upper South A Ethics Committee.  
The General Manager of Christchurch Hospital has given permission for this study to 
be carried out. 
 
Who To Contact 
 
Please feel free to ask questions about the study ± further information can be obtained at 
any time from the following researchers: 
 
Dr Sharon Sturney, Principal Investigator, Ph: (03) 364-1157 
Dr Michael Epton, Director, Canterbury Respiratory Research Group, Ph: (03) 364-1157 
Dr Geoff Shaw, Intensive Care Specialist, Ph: (03) 364-0640 
Julie Cook, Research Nurse, Ph: (03) 364-1157 
 
Who to contact in an emergency (24 hours) 
Business Hours: Canterbury Respiratory Research Group,  
 Ph: (03) 364-1157 
After Hours: Dr Sharon Sturney,  
 Ph: 021 023 20985 
 
Thank you for taking the times to read this information 
Canterbury Respiratory Research Group 
Canterbury Respiratory Services 
Christchurch Hospital 
Private Bag 4710 
Christchurch 
 
Telephone:  (64) (3) 364-1157 
Facsimile:  (64) (3) 378-6299 
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Participant Study Number:________________  
 
Consent Form for Intensive Care Patients 
For use after urgent enrolment 
Statement by relative/friend/family/whanau 
(Version 3, 7 October 2011) 
 
Exhaled Breath in Critical Illness 
 
Principal Investigator 
 
Name: Dr Sharon Sturney, Research Fellow, 
  Canterbury Respiratory Research Group 
 
Address: Canterbury Respiratory Services 
 Christchurch Hospital 
 Private Bag 4710 
 Christchurch 
 
Phone: (03) 364-1157 
 
Request for an Interpreter 
 
English I wish to have an interpreter Yes No 
Deaf I wish to have a NZ sign language interpreter Yes No 
Maori E hiahia ana ahau ki tetahi kaiwhakamaori / kaiwhaka 
pakeha korero 
Ae Kao 
Samoan 2XWHPDQD¶RLDLDLVHID¶DPDWDODXSX Ioe Leai 
Tongan 2NXRXILHPD¶XKDIDNDWRQXOHD Io Ikai 
Cook Island Ka inangaro au i tetai tangata uri reo Ae Kare 
Fijian Au gadreva me dua e vakadewa vosa vei au Io Sega 
Niuean Fia manako au ke fakaaoga e taha tagata fakahokohoko 
kupu 
E Nakai 
 
¾ I have read and I understand the Information Sheet dated 7 October 
2011 for relatives/friends of people taking part in the study designed to 
develop new techniques for breath testing in intubated and ventilated 
patients, looking into markers of inflammation, infection, metabolic and 
renal dysfunction and anaesthetic drug levels, by testing breath and 
blood samples.  I have had the opportunity to discuss this study.  I am 
satisfied with the answers I have been given. 
 
¾ I have had the opportunity to use family/whanau support or a friend to 
help me ask questions and understand the study. 
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SDUWLFLSDQW¶VQDPHZRXOG
have chosen and consented to participate in this study if he/she had 
been able to understand the information that I have received and 
understood. 
 
¾ I understand that taking part in this study is voluntary and that my 
relative/friend may withdraw from the study at any time if he/she 
wishes.  This will not affect his/her continuing health care. 
 
¾ I understand that his/her participation in this study is confidential and 
that no material which could identify him/her will be used in any 
reports on this study. 
 
¾ I understand that the investigation will be stopped if it should appear 
harmful to my relative/friend. 
 
¾ I understand the compensation provisions for this study. 
 
¾ I know whom to contact if I have any questions about the study. 
 
¾ I consent to the researches collecting samples of breath and blood and 
testing it as part of this study.  I understand that any blood samples 
taken during this study cannot be returned. 
 
¾ I consent to the researches doing a breath analysis as part of this 
research. 
 
¾ I know whom to contact if my relative/friend has any side effects to the 
study or if anything occurs which I think he/she would consider a 
reason to withdraw from the study. 
 
¾ This study has been given ethical approval by the Upper South A Ethics 
Committee.  This means that the Committee may check at any time that 
the study is following appropriate ethical procedures. 
 
¾ I believe my relative/friend would agree to an auditor approved by the 
8SSHU 6RXWK $ (WKLFV &RPPLWWHH UHYLHZLQJ P\ UHODWLYH¶VIULHQG¶V
relevant medical records for the sole purpose of checking the accuracy 
of the information recorded for the study. 
 
 
I/my relative/friend would like a copy of the results 
of the study. 
  Yes   No 
 
I believe my relative/friend would agree to his/her 
GP being informed of his/her 
  Yes   No 
participation in this study. 
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Signed:       Date:       
  
Printed name:       
  
Relationship to 
participant: 
      
  
Address for results:       
 
 
I confirm that if the participant becomes competent to make an informed 
choice and give an informed consent, full information will be given to him/her 
as soon as possible, and his/her participation will be explained.  If the 
participant makes an informed choice to continue in the study, written consent 
will be requested and if the participant does not wish to continue in the study, 
he/she will be withdrawn. 
 
Using language that is understandable and appropriate, I have discussed this 
VWXG\ ZLWK WKH SDUWLFLSDQW¶V UHODWLYHIULHQG  , KDYH RIIHUHG WR DQVZHU DQ\
questions and have fully answered such questions.  I believe that they 
understands my explanations and have freely given informed consent. 
 
   
 
________________________________ _____________________________ 
Printed Name of Individual Conducting Signature of Individual Conducting 
Informed Consent Discussion Informed Consent Discussion 
___________ 
Date 
 
Dr Sharon Sturney, Principal Investigator, Ph:  (03) 364-1157 
Dr Michael Epton, Director, Canterbury Respiratory Research Group 
Ph:  (03) 364-1157 
Dr Geoff Shaw, Intensive Care Specialist, Ph:  (03) 364-0640 
Julie Cook, Research Nurse, Ph:  (03) 364-1157 
 
 
(If applicable at a later stage) 
 
I                                                   (participant) having been fully informed about 
this study agree to continue taking part in it. 
 
Signed:       Date:       
 (Participant)   
 
Thank you for taking the time to read this Consent Form and thank you in advance 
for your help with this study 
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Appendix B: Ethics Approval 
 
Upper South A Regional Ethics Committee 
c/- Ministry of Health 
Montgomery Watson Building 
6 Hazeldean Road 
Christchurch 
Phone: (03) 974 2304 
Email: uppersoutha_ethicscommittee@moh.govt.nz 
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24 August 2011  
 
Dr Sharon Sturney 
Canterbury Respiratory Research Group 
Canterbury Respiratory Services 
Private Bag 4710 
Christchurch 
 
Dear Dr Sturney 
 
Ethics ref: URA/11/07/032 (please quote in all correspondence) 
Study title: Measurement of exhaled volatile organic compounds in 
critical illness measured via Selected Ion Flow Tube - 
Mass Spectometry (SIFT-MS) and Gas Chromatography 
Mass Spectroscopy (GCMS-MS) 
Investigators:  Dr S Sturney, Dr M Epton, Ms M Storer, Ms J Cook,  
Ms F McCartin, Dr G Shaw, A/Prof R Kennedy, Prof S 
Chambers, Dr J Pickering, Prof M Bhatia 
 
This study was given ethical approval by the Upper South A Regional Ethics Committee. 
 
Approved Documents 
x Information sheet and consent form for elective surgical patients, version 2 dated 
26/07/11 
x Information sheet and consent form for intensive care patients, version 2 dated 
26/07/11 
x Information sheet and consent form for intensive care patients (relative/friend/whanau) 
version 2 dated 26/07/11 
 
This approval is valid until 31 December 2013, provided that Annual Progress Reports are 
submitted (see below). 
 
Access to ACC  
For the purposes of section 32 of the Accident Compensation Act 2001, the Committee is 
satisfied that this study is not being conducted principally for the benefit of the 
manufacturer or distributor of the medicine or item in respect of which the trial is being 
carried out.  Participants injured as a result of treatment received in this trial will therefore 
be eligible to be considered for compensation in respect of those injuries under the ACC 
scheme.  
 
Amendments and Protocol Deviations 
All significant amendments to this proposal must receive prior approval from the 
Committee.  Significant amendments include (but are not limited to) changes to:  
 the researcher responsible for the conduct of the study at a study site 
 the addition of an extra study site 
 the design or duration of the study 
 the method of recruitment 
 information sheets and informed consent procedures. 
 
Upper South A Regional Ethics Committee 
c/- Ministry of Health 
Montgomery Watson Building 
6 Hazeldean Road 
Christchurch 
Phone: (03) 974 2304 
Email: uppersoutha_ethicscommittee@moh.govt.nz 
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Significant deviations from the approved protocol must be reported to the Committee 
as soon as possible. 
 
Annual Progress Reports and Final Reports 
The first Annual Progress Report for this study is due to the Committee by 31 July 2012.  
The Annual Report Form that should be used is available at 
www.ethicscommittees.health.govt.nz.  Please note that if you do not provide a progress 
report by this date, ethical approval may be withdrawn.   
 
A Final Report is also required at the conclusion of the study.  The Final Report Form is 
also available at www.ethicscommittees.health.govt.nz.   
 
Requirements for the Reporting of Serious Adverse Events (SAEs) 
SAEs occurring in this study must be individually reported to the Committee within 7-15 
days only where they: 
 are unexpected EHFDXVHWKH\DUHQRWRXWOLQHGLQWKHLQYHVWLJDWRU¶VEURFKXUHDQG 
 are not defined study end-points (e.g. death or hospitalisation), and 
 occur in patients located in New Zealand, and  
 if the study involves blinding, result in a decision to break the study code. 
 
There is no requirement for the individual reporting to ethics committees of SAEs that do 
not meet all of these criteria.  However, if your study is overseen by a data monitoring 
committee, copies of its letters of recommendation to the Principal Investigator should be 
forwarded to the Committee as soon as possible.   
 
Please see www.ethicscommittees.health.govt.nz for more information on the reporting of 
SAEs, and to download the SAE Report Form. 
 
Statement of compliance 
The committee is constituted in accordance with its Terms of Reference.  It complies 
with the Operational Standard for Ethics Committees and the principles of international 
good clinical practice. 
 
7KHFRPPLWWHHLVDSSURYHGE\WKH+HDOWK5HVHDUFK&RXQFLO¶V(WKLFV&RPPLWWHHIRU
the purposes of section 25(1)(c) of the Health Research Council Act 1990. 
 
We wish you all the best with your study. 
 
Yours sincerely 
 
Alieke Dierckx 
Administrator 
Upper South A Regional Ethics Committee 
Uppersoutha_ethicscommittee@moh.govt.nz  
25 October 2011 
 
Upper South A Regional Ethics Committee 
c/- Ministry of Health 
Montgomery Watson Building 
6 Hazeldean Road 
Christchurch 
Phone: (03) 974 2304 
Email: uppersoutha_ethicscommittee@moh.govt.nz 
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Dr Sharon Sturney 
Canterbury Respiratory Research Group 
Canterbury Respiratory Services 
Private Bag 4710 
Christchurch 
 
Dear Dr Sturney 
 
Ethics ref: URA/11/07/032 (please quote in all correspondence) 
Study title: Measurement of exhaled volatile organic compounds in 
critical illness measured via Selected Ion Flow Tube - 
Mass Spectometry (SIFT-MS) and Gas Chromatography 
Mass Spectroscopy (GCMS-MS) 
Investigators:  Dr S Sturney, Dr M Epton, Ms M Storer, Ms J Cook,  
Ms F McCartin, Dr G Shaw, A/Prof R Kennedy, Prof S 
Chambers, Dr J Pickering, Prof M Bhatia 
Amendments 
- To change the consenting process for Phase 3 of the study from prospective to 
delayed consent 
- To allow data obtained from deceased participants to be used without consent 
from family/whanau 
 
The above amendments were discussed at the meeting of the Upper South A 
Regional Ethics Committee on 17 October 2011. The committee thanks you for 
participating in the meeting by teleconference. 
 
The FRPPLWWHH¶VGHFLVLRQVUHJDUGLQJWKHDPHQGPHQWVDUHDVIROORZV 
x The change in consenting process in Phase 3 from prospective to delayed 
consent is approved 
x The proposal to use data from deceased participants without delayed consent 
from family/whanau is not approved. 
 
If you have any queries, please do not hesitate to contact me. 
 
Yours sincerely    
 
Alieke Dierckx 
Administrator 
Upper South A Regional Ethics Committee 
Uppersoutha_ethicscommittee@moh.govt.nz  
 268 
 
 269 
 
Appendix C. Inspired and mean exhaled volatile concentrations using the four breath collection methods described in Chapter 3. 
Subject Inspiratory concentration 
(ppb) 
Mean concentration of breath 
from T-piece after tidal 
breathing (ppb) 
Mean concentration of breath 
from airways after tidal 
breathing (ppb) 
Mean concentration of breath 
from T-piece after 
recruitment-style breath (ppb) 
Mean concentration of breath 
from airways after 
recruitment-style breath (ppb) 
Acetone H2S HCN Acetone  H2S HCN Acetone H2S HCN Acetone H2S HCN Acetone H2S HCN 
1 38.7 0.760 0.769 6750 2.21 1.71 6813 2.05 1.70 5993 1.86 0.888 6423 1.89 1.49 
2 54.6 0.961 0.755 2977 1.27 0.917 4057 1.67 1.10 - - - - - - 
3 32.5 1.06 0.788 362 0.892 0.679 449 1.26 0.667 322 0.950 0.661 465 0.900 0.741 
4 41.1 1.21 0.901 261 0.915 0.868 540 1.07 0.964 697 0.812 0.718 963 1.10 0.686 
5 50.7 0.774 1.02 689 1.37 2.12 938 2.12 1.86 619 1.13 1.29 946 1.88 1.38 
6 116 0.634 0.807 4060 2.60 1.92 4983 2.71 2.06 4543 1.61 1.27 4887 2.16 1.92 
7 22.6 0.420 0.760 3470 1.08 1.02 4350 1.22 1.13 3467 1.02 0.806 4253 0.975 0.936 
8 51.5 0.727 1.08 3360 1.45 0.977 - - - 3243 1.16 1.05 - - - 
9 43.4 1.58 0.899 8940 1.63 1.21 12067 1.66 - - - - - - - 
10 82.2 0.847 0.893 4637 2.44 2.28 6016 2.66 2.22 4787 1.96 1.45 5613 2.56 2.10 
11 97.1 0.868 0.880 1743 0.881 0.787 2233 0.910 0.832 1787 0.68 0.744 2377 0.793 0.845 
12 52.8 0.597 0.662 722 0.673 0.821 948 0.657 0.862 515 0.73 0.768 900 0.702 0.954 
13 110 1.44 1.13 10157 4.18 2.53 11620 4.69 2.43 8663 2.56 1.56 11300 3.68 2.55 
14 107 0.933 0.766 1011 1.08 0.813 - - - 931 1.10 0.827 - - - 
15 291 0.800 0.972 11733 4.04 4.17 12700 4.20 3.23 9053 2.90 2.61 13733 4.04 5.13 
16 89.6 0.866 0.830 13167 3.96 6.86 14367 4.49 8.06 11933 3.83 5.64 15500 4.45 9.44 
17 150 1.62 1.14 - 1.82 - 722 1.81 6.26 661 1.45 - 734 1.21 5.24 
18 265 1.26 1.30 9780 2.87 2.32 7763 2.90 2.25 8470 2.06 1.63 9910 2.34 1.80 
19 61.2 0.997 0.861 11133 3.02 2.85 11157 3.44 3.04 7360 1.58 1.19 10633 2.87 2.31 
20 175 0.859 0.836 27800 4.05 13.2 35367 3.75 18.2 20500 3.91 9.80 28800 3.60 14.1 
                
Median 71.7 0.867 0.871 4060 1.73 1.71 5500 2.09 2.06 4005 1.52 1.19 5250 2.03 1.86 
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Appendix D. Comparison of patient demographics and ventilation data from Chapters 4 and 5/6. 
 Healthy 
controls 
(n=26) 
ICU patients Significance of 
difference 
(p value) 
  All (n=32) Pulmonary 
infiltrates 
only (n=28) 
HC v A HC v PI 
Subject demographics      
Age years (±SD) 53 (±19) 61 (±16) 61 (±16) 0.079 0.092 
Male/Female 9/17 20/12 17/11 - - 
Smoking status n (smoker/ex-smoker/non-
smoker) 
2/6/18 13/8/11 12/6/10 - - 
Ventilation parameters  Day 1 Day 1   
VT ml (IQR) 500 
(450-500) 
455 
(390-500) 
445 
(360-485) 
0.033 0.0080 
RR breaths/min (IQR) 10 (10-10) 18 (16-22) 20 (16-22) <0.0001 <0.0001 
MV L/min (IQR) 5 (4.5-5.1) 8.8 (7.5-9.9) 8.8 (7.4-9.9) <0.0001 <0.0001 
PetCO2 mmHg (IQR) 38 (35-40) 38 (32-43) 40 (33-43) 0.92 0.78 
        ICU, Intensive Care Unit; HC, healthy controls; A, all; PI, group of patients with pulmonary infiltrates on chest radiograph; 
        SD, standard deviation; VT, tidal volume; RR, respiratory rate; MV, minute ventilation; PetCO2, end-tidal partial pressure of  
        carbon dioxide; IQR, interquartile range. 
 
